

























Novel Approaches to Cancer Therapy 
 
1. Allosteric inhibitors of the Ras-activating 
exchange factor Sos 
 
2. Inhibition of interferon regulatory factor 4 
(IRF4) with drug-like-small-molecules as a 
useful therapy in lymphoid cancers 
 
3. FragLites: Developing new approaches to 
asses druggability and hit finding 
  
4. MDM2-PROTACS for the Androgen 
















CHAPTER 1:	 NOVEL APPROACHES TO CANCER THERAPY 17 	
1.1	 Cancer	 17	
1.2	 Cancer Impact	 18	
1.3	 Hallmarks of Cancer	 21	
1.4	 Cancer Chemotherapy	 24	
1.5	 Drug Discovery nowadays	 27	
1.5.1	 The	development	of	a	Drug	Discovery	project	 27	
1.5.2	 Tool	Compounds	or	Chemical	Probes	 28	
1.6	 Fragment-based drug discovery (FBDD)	 29	
1.7	 Biophysical Assays for validation of hits and lead compounds	 29	
CHAPTER 2:	 INTRODUCTION TO ALLOSTERIC INHIBITORS OF THE RAS-
ACTIVATING EXCHANGE FACTOR SOS 30 	
2.1	 A Ras History	 31	
2.2	 Ras Functions	 39	





2.5	 GAP proteins and GTPase Reaction	 44	
2.6	 Is Ras Druggable?	 46	
2.6.1	 Targeting	Ras	directly	 46	
2.6.2	 New	and	alternative	approaches	to	target	Ras	 56	
2.7	 Future Perspectives	 59	
CHAPTER 3:	 PROJECT RATIONALE 60 	
3.1	 Research Plan	 66	
3.1.1	 Optimization	of	compound	(11)	and	(12)	 66	
CHAPTER 4:	 RESULTS AND DISCUSSION 69 	
CHAPTER 5:	 BIOLOGICAL ASSAYS 82 	
CHAPTER 6:	 CONCLUSIONS AND FUTURE WORK 88 	
3	
	
CHAPTER 7:	 INTRODUCTION TO INHIBITION OF IRF4 WITH DRUG-LIKE 
SMALL MOLECULES AS A USEFUL THERAPY IN LYMPHOID CANCERS 89 	
7.1	 Transcription Factors and cancer	 89	
7.1.1	 IRF	family	 89	
7.1.2	 IRF-4	and	cancer	 91	
7.2	 Transcription factors as drug targets	 95	
7.3	 Current Approaches to inhibit IRF4 for multiple myeloma malignancies	 96	
7.3.1	 Lenalidomide	 96	
7.3.2	 Bortezomib	combined	with	lenalidomide	 97	
CHAPTER 8:	 PROJECT RATIONALE 100 	
8.1	 Structural Biology and Hit Discovery	 103	
CHAPTER 9:	 RESULTS AND DISCUSSION 110 	
9.1	 Methodology	 110	
9.2	 Targets synthesized	 110	
9.2.1	 Pyridazinones	 110	
9.2.2	 Acrylamides	 118	
CHAPTER 10:	 BIOPHYSICAL ASSAYS AND CONCLUSIONS AFTER HTS AND 
SAR FOCUSED ON THE DNA BINDING DOMAIN (DBD) 121 	
CHAPTER 11:	 FRAGMENT-BASED SCREENING BY SPR FOCUSED ON THE 
DNA BINDING DOMAIN (DBD) 124 	
CHAPTER 12:	 DISCUSSION AND RESULTS OF THE NEW CHEMICAL SERIES
 128 	
CHAPTER 13:	 BIOPHYSICAL ASSAYS AFTER FBS AND SAR FOCUSED ON 
THE DNA BINDING DOMAIN (DBD) 134 	
CHAPTER 14:	 CONCLUSIONS AND FUTURE WORK 141 	
CHAPTER 15:	 FRAGLITES. DEVELOPING NEW APPROACHES TO ASSESS 
DRUGGABILITY AND HIT FINDING AT EARLIER STAGES 143 	
15.1	 Improvements in the scientific methodology to speed-up the drug discovery process	 143	
CHAPTER 16:	 PROJECT RATIONALE 150 	
CHAPTER 17:	 RESULTS AND DISCUSSION 154 	
4	
	
CHAPTER 18:	 CONCLUSION AND FUTURE WORK 161 	
CHAPTER 19:	 INTRODUCTION TO MDM2 PROTACS FOR THE ANDROGEN 
RECEPTORS AS A PROSTATE CANCER TREATMENT 162 	
19.1	 PROTACs: Inducing protein degradation	 162	
19.1.1	 Background	 162	
19.1.2	 Mechanism	of	action	 164	
19.2	 Alternative approaches to protein degradation	 167	
19.3	 Androgen Receptors and PROTACs	 186	
19.3.1	 The	case	of	androgen	receptor	(AR)	and	flutamide	 186	
19.4	 MDM2 as an E3 ligase ligand	 189	
19.4.1	 MDM2	biology	 189	
19.4.2	 MDM2	inhibitors	 190	
CHAPTER 20:	 PROJECT RATIONALE 191 	




CHAPTER 21:	 RESULTS AND DISCUSSION 195 	





CHAPTER 22:	 BIOLOGICAL ASSAYS 207 	





22.2	 Western blot analysis (flutamide as control)	 212	
22.2.1	 Addition	of	PROTACs	LNCap	cells:	 213	
22.2.2	 Addition	of	PROTACs	to	VCap	cells:	 213	














CHAPTER 23:	 CONCLUSIONS AND FUTURE WORK 221 	
CHAPTER 24:	 EXPERIMENTAL AND ANALYSIS 224 	
24.1	 Safety	 224	
24.2	 Solvents and Reagents	 224	
24.3	 Chromatography and Equipment	 224	
24.4	 Analytical Techniques	 224	
CHAPTER 25:	 GENERAL EXPERIMENTAL 226 	
25.1	 Synthesis of (15) and (17) and derivatives:	 226	
25.2	 Synthesis of (54) and derivatives:	 244	
25.3	 Synthesis of (80) and derivatives	 256	
25.4	 Synthesis of (85) and derivatives	 259	
25.5	 Synthesis of (86) and derivatives	 265	
25.6	 Synthesis of FragLites derivatives	 271	
25.7	 Synthesis of flutamide precursor	 275	
25.8	 Synthesis of (132)	 276	















The work contributing to this thesis was conducted between October 2015 and September 
2019 in the Medicinal Chemistry laboratories, Bedson Building, Northern Institute for Cancer 
Research, Newcastle University, Newcastle upon Tyne, NE1 7RU.  
 
All the research presented in this thesis is original in context and does not include any 
material or ideas previously published or presented by other authors except where due 
reference is given in the text. Any figures included without reference were generated using 
ChemDraw or Microsoft Office and were drawn from knowledge.  
 
No part of this thesis has been previously submitted for a degree, diploma or any other 



























I would like to thank my primary PhD supervisor, Ian R. Hardcastle for his support and 
encouragement over the past four years. He has been an excellent menthor both academically 
and emotionally and I am eternally grateful for his guidance during my PhD. I would also 
like to thank my other supervisors, Prof. Mike J. Waring, Prof. Bernard Golding and Dr. 
Celine Cano for their invaluable knowledge and expertise and continued enthusiasm during 
my project. I would like to thank all the people I have been privileged to work with in the lab 
at the Bedson Building and at the Paul O’Gorman Building. I would also like to thank Julie 
Tucker and Duncan C. Miller, who were a continual support and provided invaluable 
biological and chemical knowledge during my thesis. 
 
I would also like to thank co-workers at the NICR for their continued help with the 
bioscience, Prof. Martin Noble and Prof. Steve Wedge for all their help with structural 
biology and Anita Wittner and Daniel J. Wood for conducting cell-based assays. 
 
Finally, I would like to thank Dr. Leonelo Forti Sampietro for his guidance and support, my 
close friends and family, particularly my mother for her support throughout my thesis and all 
my life. Also, to Anxela for always being there to help when things were not going as good as 
























Allosteric inhibitors of the Ras-activating exchange factor SoS 
SoS protein is responsible for keeping Ras, a key molecular switch involved in cell division, 
turned on. In many cancers a mutation in the Ras protein can permanently lock the molecular 
switch into the ‘on’ position, leading to enhanced cell division. This problem is especially 
relevant to pancreatic cancer, which has a particularly high prevalence of mutant Ras driven 
tumours (90%). Inhibiting the ability of SoS to catalyse nucleotide exchange on Ras has the 
potential to afford a means of targeting oncogenic Ras signalling. 
 
In preliminary studies, we have identified small molecule compounds that bind to an 
unprecedented site on SoS itself and have the potential to inhibit Ras activation via a novel 
allosteric mechanism. Currently, we are exploring and modifying the structure of this small 
molecule to achieve a more potent and drug-like compound. 
 
Figure A1; Outline chemical strategy for chemical optimization 
 
Small-molecule inhibitors of interferon regulatory factor 4 (IRF4) 
Interferon regulatory factor 4 (IRF4) is a transcription factor that has been shown to regulate 
the survival of several aggressive lymphoid malignancies. It appears to be a master-regulator 
of gene transcription in myeloma, influencing cellular survival, proliferation, metabolism and 
differentiation. siRNA knockdown of IRF4 by only 40 – 60% is lethal to myeloma cells. The 
possibility of inhibiting IRF4 with drug-like small-molecules could be a useful therapy in a 
number of aggressive lymphoid cancers. 
 
High Throughput Screen using Fluorescence Polarization assay for the IRF4 DNA Binding 
Domain and a fragment-based screen using SPR and NMR were undertaken. 7 hits were  
 
Fig. 3. Bin ing site for 2 in SOScat. The left-hand side of the site is formed by residues 
from the Rem domain, while a pocket in the CDC25 domain forms the right-hand part 












Fig. 5. Project ti eline. 

























obtained from both screens and 63 close analogues were synthesised to explore SAR and 
address physicochemical properties.  
 
Figure A2; Hits obtained after HTS and FBS 
 
FragLites: Bifunctional Halogenated Fragments 
Identification of ligand binding sites on proteins is of critical importance for chemical 
biology and drug discovery applications. We describe an efficient and comprehensive 
approach to mapping interaction sites on a protein using a designed set of bifunctional 
halogenated fragments that express hydrogen-bonding pharmacophore doublets. These 
fragments are capable of seeking out productive polar interactions and can be identified 
unambiguously by X-ray crystallography by the anomalous scattering of their halogen 
substituent.   
 
Soaking this set of compounds with CDK2 elucidated previously identified binding sites and 
also new ones, which can be used as starting points for fragment growing and drug design. 
 
Figure A3; Overview of Fraglite binding events to CDK2 
10	
	
MDM2-PROTACS for the Androgen Receptors (AR) 
PROTACS (proteolysis targeting chimeric molecules) have been recently disclosed as 
chemical tools to target specific proteins for destruction by the proteasome. PROTACS 
comprise a ligand for an E3 ligase protein that may be a peptide or small molecule, and a 
ligand for the target protein. The advent of highly potent and specific ligands for MDM2 (E3 
ligase) offers the opportunity to develop MDM2-PROTACS. Several compounds were 
designed to target the Androgen Receptor via Flutamide using two different MDM2 ligands 
and a broad variety of linkers (Figure 4).  
 
Figure A4; PROTAC molecule divided by functionalities (in pink: AR inhibitor, in blue: MDM2 
inhibitor, in black: linker) 
 
We have demonstrated the activity of MDM2 PROTACS for degradation of the AR and 
confirmed the importance of the linker length in different in vitro assays. The influence of the 
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Chapter 1: Novel approaches to cancer therapy 
1.1 Cancer 
Cancer is a group of complex genetic diseases characterised by alterations in normal cell 
growth and function resulting in uncontrolled proliferation.1 Over 100 types of cancer and 
over 200 subtypes of tumours affect humans in different organs and tissues.2 Most of these 
cancers are named by the organ or cell type where they originated. 
 
Cancer malignancies are caused by alterations in the DNA sequence after several genetic (or 
epigenetic) mutations happen in a somatic cell. These can lead to stimulation of oncogenes, 
which instead of regulation will cause proliferation and subsequent survival of tumour cells. 
In many cases the loss (or under-expression) of suppressor genes involved in the inhibition of 
proliferation and apoptosis will happen in parallel.3 Exogenous factors can accelerate or 
promote the appearance of cancer (e.g.: life-style and environmental factors such as alcohol 
abuse; smoking or sedentary routines are known to induce cancer). Other risk factors to take 
into account are endogenous factors, which may involve inherited genetic mutations and 
hormones (Figure 1). It is also known that age is the biggest risk factor and should be 
considered when we analyse the prevalence of the disease in developed societies.4 Half of all 




















1.2 Cancer Impact  
Cancer has an immense impact on public health across the world. Since 1990, the world has 
experienced an increase in life expectancy and therefore the incidence of cancer and its 
mortality has increased similarly. Lifestyles and behaviours associated with cancer including 
smoking, physical inactivity, and diet are widespread in developing countries and the 
incidence and mortality rates show significant regional variability (Figure 2). 
																		 															
 




Cancer has become the second leading cause of death in the world following heart disease. 
An increase of 33% in cancer cases over the previous decade has provoked an estimated of 
17.5 million new cancer cases and 8.7 million deaths in 2015. Of all the different cancer 
types, tracheal, bronchus and lung (TBL) cancers are the most prevalent of the list with 1.6 
million deaths. In women, breast cancer is the most frequently reported (28% of total 
incidence), and is the leading cause of cancer death. In men, prostate cancer is the most 
commonly reported, comprising 17% of total new cancer cases with 1.6 million cases.  
 
Since the 1980s, a steady increase has been observed in the number of cancer cases, and 
according to a study conducted by Cancer Research UK (CRUK) in 2015, half of British 
people will develop cancer at some point in their lives. In 2015, breast, prostate, lung and 




Figure 3, Share of population with cancer by age in the UK 
 
However, there are reasons for optimism; the ten-year survival rate has doubled since the 
1980s. In addition, overall cancer death rates in the UK have declined by 15% since 1990 






Figure 4; Cancer death rates (per 100000) age-standardized from all cancer types8 
 
Advances in our understanding of cancer and the processes through which cells progress into 
a tumor state have yielded therapeutic drugs for the disease. Analysing the 5-year survival 
rate over the last 4 decades (indicating the percentage of people who lived longer than five 




 Figure 5; Average five-years survival rates from common cancer types, 1970-77 to 2007-13 
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Despite these significant improvements there are still a number of specific cancers, such as 
lung and pancreatic cancers, for which not enough advances have been made. More research 
is needed to achieve new therapeutic agents. 
1.3 Hallmarks of Cancer 
During the past 30 years, the complicated mechanisms by which cancer is driven have been 
deeply studied and the conclusions published in a great research effort. We know that 
tumorigenesis is a multi-step pathway and that these steps reflect several genetic mutations 
exquisitely synchronized that drive the conversion of normal cells into cancerous cells. 
  
In 2000, Hanahan and Weinberg published a comprehensive review in which they described 
six acquired capabilities or physiological changes known as the hallmarks of cancer.9 The 
number was increased to ten in a more recent review.10 Most tumour types in humans share 
the distinct features presented in these studies, allowing them to survive, proliferate and 





Figure 6; Hallmarks of cancer12	
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This study provided an important overview of the basic physiology of a mutant cell and the 
progressive transformations that they induce in their immediate environment. These 
hallmarks are described below:  
Sustaining proliferative signalling 
Cell growth and proliferation is controlled by growth factors that pass the information inside 
the cell via trans-membrane receptors. These growth factors can be diffusible, extracellular 
matrix components or cell-to-cell adhesion/interaction molecules. In the case of cancer cells, 
there is a developed independence from exogenous signals. Cancer cells can proliferate 
through alternative pathways (upstream or downstream) like creating their own growth 
factors or becoming hyper-responsive to the environment via over-expression of epidermal 
growth factor receptor. Structural mutations in the receptor proteins can also induce hyper-
responsiveness, which contribute to growth and proliferation of cancer cells without 
exogenous control.  
Evading growth suppressors 
Quiescence and normal tissue homeostasis keep the balance between growth factors and 
antiproliferation factors. These factors include several tumour suppressor genes such as pRb 
(retinoblastoma-associated) or p53, which limit cell growth and division. These genes are 
frequently found mutated in many types of cancer cancers, resulting in inactivation of 
antiproliferation mechanisms and therefore, cancer cells can evade the antigrowth signals.  
Resisting cell death 
There are two main apoptotic pathways: the intrinsic and the extrinsic. In the intrinsic 
pathway cells respond to internal signals (DNA damage or oncogene expressed proteins), 
while external signals (hormones or cytokines) activate the extrinsic pathway. Proteases 
involved in these pathways can lead to destruction of cells by phagocytes. There are several 
mechanisms by which cancer cells resist apoptosis, one of the most studied is the over-
expression of proteins involved in suppressing apoptosis.  
Enabling replicative immortality 
Before going into a non-proliferative state (senescence) cells have a limited number of cycles 
of cell division. This is determined by the telomeres, which are essential to protect the 
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chromosomes against instability through the prevention of chromosomal degradation. The 
length of telomeres decreases with each phase of DNA replication until it becomes 
completely degraded, triggering a crisis mode and causing apoptosis. Telomerase is a DNA 
polymerase that extends telomeric DNA, enhancing the replicative potential of cells. Tumour 
cells acquire unlimited replicative potential due to over-expression of the telomerase enzyme.  
Inducing angiogenesis 
Tumour cells have the ability to establish their own vascular system in a process called 
angiogenesis. Thanks to this tumour, cells can obtain nutrients and oxygen. Vascular 
endothelial growth factor (VEGF) is the most potent factor that initiates angiogenesis in the 
surroundings of the tumour and within.  
Invasion and metastasis 
Metastasis is the ability of tumour cells to invade neighbouring tissues and spread through the 
body via the lymphatic and blood circulatory system. E-cadherin is a protein that promotes 
the adhesion of an individual cell to other cells in the surrounding area and is down regulated 
in tumours, which allows metastatic processes to happen by the development of secondary 
malignant growths that are distant from the primary site of cancer. 
Genome instability and mutations  
To maintain genome integrity and to counteract DNA damage, cells have developed DNA-
damage response (DDR) pathways. These pathways allow cells to detect DNA damage and 
activate cell cycle arrest for DNA damage repair. If the damage cannot be repaired, the DDR 
pathways will lead the cell to apoptosis and prevent the propagation of the damage. 
Malfunctioning DDR pathways lead to damaged DNA replication, which leads to genome 
instability and causes progression to cancer. The inactivation of tumour suppressor genes can 
occur through epigenetic mechanisms such as DNA methylation and histone modifications. 
Tumour-promoting inflammation 
Tumour-associated inflammatory states are driven by cells of the immune system. Some of 
which serve to promote tumorigeneses. Inflammatory cells can release reactive species (e.g. 
reactive oxygen radicals (ROS)), which cause DNA damage and can lead to genomic 
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instability. Inflammatory cells also provide bioactive molecules such as growth factors, 
resulting in sustained proliferative signalling.  
Deregulation of cellular energetics 
The modification of cellular energy metabolism is necessary to support sustained neoplastic 
growth and proliferation. Normal cells utilise glucose to produce energy through glycolysis in 
the presence of oxygen thanks to the mitochondria. In the absence of oxygen, normal cells 
rely on anaerobic glycolysis. Regardless of the availability of oxygen, cancer cells can 
upregulate their glucose metabolism by increasing aerobic glycolysis. Mutations affecting 
enzymes related to metabolic processes (e.g. p53) are known to reprogram cancer metabolism 
as well. 
Avoiding immune destruction  
The immune system can recognise and eliminate emerging tumours. In order to escape from 
attack and elimination by immune cells, cancer cells can be enabled with several mechanisms 
providing this ability. For example, secreting immunosuppressive factors, which prevent 
natural killer cells from eliminating tumour cells.  
 
These Hallmarks are cellular mechanisms by which cancer cells differ from a normal cell. 
From a therapeutic point of view, all the different strategies followed by cancer cells offer us 
an opportunity to disrupt the tumorigenic process via Cancer Chemotherapy. 
1.4 Cancer Chemotherapy 
The traditional treatments for cancer are radiotherapy or surgery. In the case of surgical 
treatment, removing the tumour could solve the problem, whereas by the application of X-
rays we try to kill cancer cells and shrink the tumour. The success of both approaches 
depends on early diagnosis, in general are not successful against invasive cancers. The 
introduction of chemical compounds as a viable therapeutic approach has come to be known 
as chemotherapy. This strategy started in the 1950s with nitrogen mustard11 (Figure 7-
compound 1), to treat non–Hodgkin's lymphoma. In the following years, new DNA-
alkylating agents were introduced, including orally administered drugs like chlorambucil12 




Figure 7; Nitrogen mustard derivative (1) and Chlorambucil (2) 
 
In 1965, the combination chemotherapy was hypothesized by James F. Holland, Emil 
Freireich and Emil Frei by following the same principles of antibiotic therapy. A multidrug 
approach is followed in most cases where different mechanisms of actions can work together 
and overcome resistance mechanisms or bypass pathways that help cancer cells to survive.13 
Cytotoxic cancer therapy 
In general, chemotherapeutic drugs and macromolecules cannot target proteins in an entirely 
selective process, leading to cytotoxicity and cell death. Cancer cells use normal cells in their 
neoplastic activity, and a huge number of normal cells are directly involved in the replicating 
process that can be affected by chemotherapy. The damage provoked in these cells result in 
side-effects that in general lead to nausea, vomiting and hair loss. Furthermore, cytotoxic 
treatment also leads to drug resistance as result of new mutations in the tumour cells. These 
new mutations are the most common reason for treatment failure. The often necessary large 
doses to cover all organs and achieve a therapeutic efficacy against tumour cells cause more 
side-effects, and faster acquired resistance has led to new strategies directing drug 
accumulation in cancerous cells. One of these strategies involves designing compounds that 
exploit processes in tumour physiology that are not present in healthy cells.  
 
Despite the limitations of traditional cytotoxic chemotherapy, it is still the treatment of choice 






Figure 8; Common cytotoxic agents used in the treatment of cancer 
 
Targeted cancer chemotherapy 
 
In the past twenty years we have seen great developments in the field of chemotherapy. 
Thanks to a better understanding of cancer progress and evasion of our immune system, new 
targeted cancer therapies like monoclonal antibodies and small molecule inhibitors are 
emerging. By targeting growth factors, signalling molecules, cell-cycle proteins and 
processes involved in apoptosis and angiogenesis, which are crucial for tumourigenesis, we 
can be more specific between cancer cells and healthy cells. Also, targeted therapies are 
administered at the optimal effective dose rather than at the maximum tolerated dose, which 





1.5 Drug Discovery nowadays 
1.5.1 The development of a Drug Discovery project 
Drug discovery is a long and expensive process. It takes an average of 12–15 years and about 
$1 billion to produce a new drug (Figure 9).16    
 
 
Figure 9; Drug discovery stages 
 
The initial step is to identify a target and validate it, so we can treat a specific protein or a 
biochemical pathway to affect the disease. This step can be approached by bioinformatics, 
biochemical in vivo and in vitro experimental models, genetic interaction and functional 
screening, including knockdown or using chemical probes. Once the biological target is 
validated, the next stage is to identify hit molecules with activity against the target. This 
process can include high-throughput screening (HTS), where a library of thousands of 
compounds is screened, fragment based-screening (FBS), virtual screening, or structure-
based design. 
 
After hit identification, the hit-2-lead (H2L) stage is carried out by running systematic 
structure-activity relationship (SAR) studies. The purpose is to determine the core structure 
(pharmacophore) and the modifications that will affect the potency and selectivity of the 
compound. If successful, a lead compound will be obtained. Structure-based drug design 
strategies using molecular modelling and technologies like X-ray crystallography and NMR 
will guide medicinal chemists to develop the SAR rationally.  
 
Lead compounds are further optimised during the lead optimisation campaign using a range 
of in vitro and in vivo ADMET (absorption, distribution, metabolism, elimination, 
toxicology) assays to improve the properties of the candidate drug.  
 
Finally, one or a few compounds are progressed to pre-clinical stage to assess in vivo 














1.5.2 Tool Compounds or Chemical Probes 
Tool compounds, also known as probes, are potent, selective and cell-permeable small 
molecules that play an essential role in the target validation stage. The genomic era has 
yielded an increasing number of potential druggable targets (an estimated 5,000-10,000) with 
a possible therapeutic effect. Chemical tools are necessary to validate a specific strategy by 
clarifying the relationship between a therapeutic target and the biological response. These 
tools allow researchers to explore if a specific target modulation by small molecules can lead 
to a novel drug.  
 
Different biophysical and biochemical techniques can successfully identify a specific 
chemical probe or tool compound. However, the successful application of these probes 
remains challenging, and we can often find several examples in the literature where chemical 
probes have been misused. Only high quality chemical probes generate meaningful biological 
data. It is difficult for the research community to keep well informed about the most 
appropriate chemical probe and some initiatives have appeared like a Chemical Probe Portal 
(Figure 10).17   
 
 




In addition, chemical probes need to be soluble and stable in water, have good cell 
permeability, show evidence of target binding and be able to modulate a biological response. 
Also, it is desirable that the probe is available and pure for researchers.  
1.6 Fragment-based drug discovery (FBDD) 
The past few decades have witnessed technological advances that can accelerate the pace of 
drug development.  
 
For many years, HTS campaigns were the most used methodologies in drug discovery for 
identification of novel hits. HTS involves in vitro screening of a large number of structurally 
diverse compounds (300–500 Da) in a highly automated process. HTS has been successfully 
applied and has facilitated the development of highly potent and specific inhibitors but, 
despite of its proved efficiency, suffers from several drawbacks: 
 
• The time and cost associated with the HTS process is high. 
• The efficiency tends to decline with increasing size of a library.  
• Not able to identify suitable starting points for targeting protein-protein interactions 
(PPIs).  
 
In contrast to HTS, FBDD relies on obtaining structural information to rationally design or 
grow small molecules. The relatively low cost of a fragment library and the rapid and 
efficient identification of hit fragments has created great expectations for this technique. HTS 
and the development of FBDD will be further explained in Chapter 15 (FragLites). 
 
1.7 Biophysical Assays for validation of hits and lead compounds 
Several biochemical and biophysical techniques, including NMR, X-ray crystallography, 
surface plasmon resonance (SPR), isothermal titration calorimetry (ITC), thermal shift and 
fluorescence correlation spectroscopy-based assays have been developed to validate the hits 
obtained by different screening techniques. Each of these assays has advantages and 
disadvantages, and usually are complementary to each other to afford optimal outcomes. 




Chapter 2: Introduction to allosteric inhibitors of the Ras-activating 
exchange factor Sos18 
There is constant communication between cells in our body. The signals they receive and 
their environment determine when they proliferate, differentiate or die. Our cells 
communicate with each other using messengers (hormones, growth factors, chemokines) that 
can deliver information by interacting with other cells. Many of these messengers are too big 
to cross cell membranes and for this, there is a mechanism called signal transduction. This 
allows membrane receptors to transmit the messages from the surface to the nucleus via 
proteins inside the cell.  
The mutation of these proteins can alter the original message, meaning that the cell nucleus 
will receive the wrong information. This can be the cause of many diseases, among them 
cancer. For this reason, the genes that code for signal transduction proteins, activation of 
which leads to cancer, are known as oncogenes.  
Through expression of the Ras proteins, the Ras oncogenes are responsible of delivering 
signals from the cell surface through receptor tyrosine kinases (RTKs). Ras signaling 
activates several pathways effecting mitogenic functions (cell division and proliferation). The 
constitutive activation of these signals through mutation of Ras genes is implicated in many 
cancer types. Importantly, half of all colon cancers and 90% of pancreatic carcinomas harbor 
activating Ras mutations. Ras employs a bound guanine nucleotide to create a switch to 
toggle between “on” and “off” states. In the “off” state, Ras is bound to GDP, but an 
interaction with a guanine nucleotide exchange factor (GEF) such as Sos (Son of Sevenless) 
can make Ras change its conformation and liberate the GDP, after that, and because the 
concentration of GTP in the cell cytosol is much higher than GDP, Ras binds to GTP. This 
causes a change in the structure of the protein, which initiates the cascade of mitogen-
activated protein kinases (MAPKs) (and others) which then can phosphorylate a final target 
(a transcription factor) delivering the message to the nucleus of the cell. To deactivate itself 
again, Ras proteins hydrolyze GTP to GDP assisted by GTPase-activating proteins (GAPs), 




Figure 11; RAS-RAF-MEK-ERK signaling cascade 
If Ras suffers certain mutations, the regulation of this mechanism will be disrupted. If Ras is 
always activated (switched “on”) the message will be delivered continuously, leading to 
continuous expression of proteins and progression to cancer. 
2.1 A Ras History19 
Ras was identified during the studies of acutely transforming retroviruses isolated from mice, 
rats, cats, monkeys, chickens and turkeys. These viruses have the ability to cause the 
formation of sarcomas and transform cells in culture with high oncogenic properties.20 
During the 1960s discoveries of the Harvey murine sarcoma21 and lately of the Kirsten 
murine sarcoma viruses22 provided the basis for establishing the human H-Ras and K-Ras 
oncogenes respectively. Later in the 1970s Scolnick et al.23,24 performed studies determining 
the cellular origin of the viral H-Ras and K-Ras genes, and the proteins encoded by those that 
bind to GDP and to GTP.25 In these studies was also found that Ras proteins are associated to 
the inner cell membrane. It was not until the 1980s that a third transforming human Ras gene 
32	
	
was discovered in neuroblastoma-derived DNA and was designated as N-Ras. The three 
human Ras genes share 82-90% overall sequence identity. Residues 1 – 164 comprise the G 
domain that contains six conserved sequence motifs shared with other Ras superfamily and 
GTP-binding proteins. These motifs are involved in binding either phosphate/Mg2+ or the 
guanine base of GDP and GTP.26, 27 
One of the crucial discoveries made by Scolnick was that Ras proteins are preferentially 
bound to GTP when overexpressed28 and, as a consequence of the discovery of mutational 
activated Ras genes in human cancer in 1982, a huge research effort has ensued since then to 
elucidate the function of Ras protein and the relationship between mutated Ras and cancer. 
Most of this effort has been focused not only on the complex biochemical mechanisms ruling 
the action of the Ras proteins, but also on the structure of the proteins and its molecular 
switch that toggles from “on” to “off” depending on being bound to GTP or GDP 
respectively. The clear goal since that moment (and still nowadays) is to develop anti-Ras 
drugs for the treatment of cancer. 
The complexity of this target led to an immense amount of work and research, which resulted 
in several discoveries in the Ras field that can be applied at the same time in other areas of 
science. Thanks to Ras proteins and their mechanisms, many new, and nowadays 
fundamental, concepts related to cancer in a molecular level were discovered.29 Remarkably, 
the understanding of biochemical mechanisms related to signal transduction was better 
understood, and this gave insights in how the cell responds to extracellular stimulation. 
Furthermore, the recently discovered “on-off switches” for different signaling cascades also 
helped with the elucidation of canonical pathways for signal transduction.30 
Ras proteins are also the founding members of the large family of GTPases, regulators of 
many of the basic cellular mechanisms.31 The human family of these versatile regulators 
could be divided in relation to their sequence identity into different branches: Ras, Rho, Rab, 
Arf and Ran.32 The confusing nomenclature of small GTPases comes from the tradition of 





Figure 12; Ras superfamily proteins (numbers indicate total members per family) 
More recently, thanks to the sequencing of the human genome, it was possible to identify all 
the genes encoding Ras-related small GTPases,14,15 fueling the speculation of other members 
being involved in cancer disorders. The research showed that many Ras superfamily proteins, 
despite not being mutated, are critical contributors to oncogenic growth.33 Ras homologue 
enriched in brain (Rheb) was found to be an activator of m-TOR and also to be activated 
downstream of the signaling cascade associated to PI3K.34 Other members of the Ras 















































































Regarding the importance of Ras genes in relation to cancer, one of the paramount 
discoveries was the high frequency of Ras mutations found in colon,35,36 lung,37 and 
pancreatic 38 cancers, three of the four most deadly cancers and with the worst prognosis for 
patients. Not all the isoforms are likely to be mutated. Mutations are found mainly in K-Ras 
(85%) and less commonly in N-Ras (12%) and H-Ras (3%). Interestingly, mutations in the 
different isoforms often happen in the same residues. Missense mutations in H-Ras, K-Ras 
and N-Ras happen mainly in three residues, G12, G13 and Q61. The most commonly mutated 




Figure 13; Distribution of Ras missense mutations in cancer39 
 
In 1987 it was confirmed by mouse models that Ras mutation can cause cancer but needs 
cooperating genetic events. This requirement is also true in human colon and pancreatic 
cancers, and the accumulation of cooperative genetic mutations was also observed.  
 
Thanks to current advances in sequencing technology, the tremendous genetic complexity of 



































pancreatic cancer42 and glioblastoma43,44 it was observed that most of cancers happen through 
a combination of very frequent mutations of specific genes in cooperation with the mutation 
of a set of less commonly mutated genes specific of each type of cancer. Interestingly, it has 
also been observed that about 15-20 driver mutations contribute in general to cancer 
progression.  
 
As we can see in Figure 14, in the case of colorectal cancer, colonic epithelial cells undergo a 
transition from normal to malignant state. This transformation is driven by specific genetic 
events, including inactivation of tumor suppressors (APC, SMAD4 and TP53) and activation 
of the K-Ras oncogene.45 Also in Figure 14, in the case of pancreatic ductal adenocarcinoma 
(PDAC), K-Ras gene mutations are present in 90% of patients. In PDAC cancer, progression 
of the activating point mutation in the K-Ras oncogene occurs early. Inactivation of the 
p16/INK4A gene occurs at an intermediate stage, and inactivation of the TP53, 
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The ability of viral Ras proteins to bind GDP or GTP gave the first clues to understand their 
mechanisms of action and their biochemical roles.46 This information prompted the idea that 
Ras proteins may be binary switches regulated by GDP and GTP.47  
 
With the finding that the mutant version of the Ras protein is impaired approximately 10 fold 
in its capacity for hydrolyzing GTP, it was assumed that the aberrant function in cancer cells 
could be associated with preferential binding to GTP.48,49,50 Despite the confirmation of this 
hypothesis, it was again the cooperation with another protein that established the full picture. 
Trahey and McCormick51 discovered in 1987 that the GTPase activating proteins (GAPs) 
activity was responsible for a 300 fold acceleration of the hydrolysis of GTP bound to normal 
Ras, but not to tumor-associated mutant Ras proteins. Later, in 1990 studies regarding a 
tumour suppressor protein involved in neurofibromatosis type I,52,53 showed the existence of 
a different Ras-GAP, neurofibromin (Nf1).54 This discovery led to the search and 
identification of more Ras-GAPs.55 These findings, together with the established idea that the 
GTP-bound form of Ras is the activated state, concluded that the key biochemical defect of 
mutant Ras proteins is GAP insensitivity, resulting in impaired GAP-stimulated GTP 
hydrolysis that turns into persistent accumulation of the active GTP-bound Ras protein. 
 
The crystal structure of H-Ras provided insights into how Ras functions as a GDP/GTP-
regulated switch. Future structural determinations of Ras complexed with GAPs, GEFs and 
Ras-interacting domains of effectors revealed the complex mechanism of the switch.56 
 
Another important step in the understanding of the role of Ras signal transduction was to 
locate Ras downstream of EGFR and other RTKs located on the cell surface. The first 
evidence to support it was that EGFR stimulation increased Ras-GTP binding.57  
 
Further studies in C.elegans and Drosophila confirmed the linkage between Ras and EGFR 
with the discovery of Grb2. Several studies showed that Grb2, through SH2 domains, 














Figure 15; Conservation of Raf-MEK-ERK cascade downstream of Ras58 
 
Sos is a guanosine exchange factor (GEF) that induces a conformational change in Ras by 
forming a complex. This structural change allows deactivated Ras to liberate GDP and 
associate to GTP to become activated Ras59, 60 The complex Grb2:Sos, in association with 
activated EGFR, promotes Ras activation by the displacement of the cytosolic Sos to the 
inner membrane. The location of Ras was supported by studies showing that membrane-
targeted Sos activates Ras.61 This observation was fundamental to understand an important 
concept in signal transduction: “Regulation of subcellular location is an important 
mechanism to regulate the function of signaling protein”.  
 
In 1993, after a deep exploration of Ras signaling in Drosophila62 and in C.elegans63 together 
with information on the biochemistry of Ras proteins determined in mammalian cells, 
identified Raf serine/threonine kinases as proteins that bind preferentially to activated Ras-



























active form of Ras. This association, together with previous studies supporting Ras- and Raf-
dependent activation of the ERK1 and ERK2 Mitogen-activated protein kinases (MAPKs) 
and the ability of Raf to activate MEK1 and MEK2,64 defined the Raf-MEK-ERK protein 
kinase cascade downstream of Ras.65 The conservation of the Raf-MEK-ERK cascade 
downstream of Ras in both Drosophila and C.elegans, suggested that the map of the Ras 
effector signaling cascade was achieved; however, other Ras effectors were found.66  
 
By 1994, the p110 catalytic subunits of class I-PI3K were also recognized as validated Ras 
effectors67 (Figure 16). 
 
 
Figure 16; Ras effector pathways implicated in Ras-mediated oncogenesis68 
 
A structural property was found to be common to most of the Ras effectors, the presence of a 
Ras-binding domain (RBD) that promotes association of the effector with GTP-bound 
Ras.69,70 
Most of the Ras superfamily proteins have very well-conserved and related isoforms that 
differ from each other in their “variable” membrane targeting domains rather than in their 
“constant” G domains. Therefore, Ras activity is not only controlled by its GDP/GTP cycle 
(concept discovered in 198471), but also by the C-terminus of Ras associating with the 
membrane. Ras proteins must be in the right location to become activated. The importance of 
the location explains that Ras proteins are synthesized as soluble precursors, which then 
undergo several steps of post-translational modification, facilitating their transit to the plasma 
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membrane where they are activated by GEFs, inactivated by GAPs and interact with effectors 
to transmit their signals downstream.  
 
In 1980, an important study using electron microscopy confirmed the presence of H-Ras at 
the inner leaflet ofthe cell membrane.72 In 1989 it was determined that Ras proteins are 
modified by farnesylation,73,74 and that this modification is an obligatory first step to allow 
palmitoylation. Without farnesylation at a very specific residue (Cys 186), Ras proteins 
become cytosolic. In contrast, Ras proteins that are farnesylated but do not undergo 
subsequent processing steps are located to endomembranes. The location of Ras proteins 
when not processed was not clear and it was not until 1999 when Philips et al.75 showed that 
H-Ras and N-Ras trafficked through the Golgi apparatus on the way to the membrane.  
Originally there was a general acceptance that all the Ras isoforms were identical in 
biological function and the study of H-Ras dominated the scene. This bias towards H-Ras 
was due to the availability of H-Ras expression vectors, mutant proteins and easy 
crystallization. But in recent years it has been proved that the most common mutation in 
human cancers is present in the K-Ras and N-Ras genes, shifting the research towards K-Ras 
in particular. 
2.2 Ras Functions76 
The main function of Ras is to convert GTP to GDP, functioning as a GTPase. Ras functions 
as a “binary molecular switch”, toggling between “ON” and “OFF” states, based on whether 
it is bound to GTP or GDP respectively (Scheme 1).77 
	
Scheme 1; Ras GTP/GDP cycle regulation by GEFs and GAPs	
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The function of the switch involves the exchange of GDP for GTP by GEFs, turning the 
switch to the “ON” state. This should be reversible and to turn the switch to the “OFF” state 
GTP is hydrolysed by Ras to GDP. This process is very slow and is accelerated by GTPase 
activating proteins (GAPs). 
2.3 The structure of the G Domain 
The G domain of the Ras protein has the fundamental function of binding the nucleotide and 
hydrolysing GTP to GDP. This domain has a universal and well conserved structure for all 
the GNBPs and a universal switch mechanism, which consists of six-stranded β sheets and 
five helixes located on both sides. The most important contributions to binding are made by 
the interactions of the nucleotide base with the N/TKXD motif (where X is any amino acid) 
and of the β,γ-phosphates with the conserved P-loop (phosphate-binding loop).78 Specificity 
for guanine is due to an Asp side chain (from the NKxD motif), which forms a bifurcated H 
bond with the base, and to a main chain interaction of an invariant Ala (146) with the guanine 
oxygen (Figure 17). 
 
Figure 17; Ribbon plot of the G domain generated using MoE (PDB ID: 3GFT) 
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Structures of the subunit of heterotrimeric G proteins like Gt , Gi, and Gs, and several Ras-
related proteins like Rap, Ral, Rac, Rho, Cdc42, Arf, Arl, Rab and Ran have been also 
determined.79, 80, 81 
2.3.1 The Structural Changes of the switch 
Whereas the GDP-bound proteins show variations in their structures, the GTP bound forms of 
the G domain are remarkably similar.  
The trigger for the conformational change is universal. In the GTP-bound form, there are two 
hydrogen bonds from γ-phosphate oxygens to the main chain NH groups of the invariant 
Thr35 and Gly60 residues in switch I and II, respectively. The conformational change could 
be described as a loaded-spring mechanism where release of the γ-phosphate after GTP 
hydrolysis allows the two switch regions to relax into the GDP-specific conformation (Figure 
18). 
 
Figure 18; The universal switch mechanism76 (Reprinted with permission from AAAS) 
2.3.2 Moving out the nucleotide, GEF reaction 
GEFs help by accelerating the release of GDP from Ras, which is slow by nature. This is a 
multistep process involving several fast reactions. This action could be summarized as a 
binary protein-nucleotide complex that leads to another binary nucleotide-free complex via a 
ternary GNBP-nucleotide-GEF intermediate. These reactions come to an end by binding 
phates with the conserved P loop (phosphate-
binding loop), the GXXXXGKS/T motif
(Fig. 1A) (5). Specificity for guanine is due to
an Asp side chain (from DXXG), which
forms a bifurcated H bond with the base, and
to a main chain interaction of an invariant Ala
(from the SAK motif ), Ala146 in Fig. 1A with
the guanine oxygen, which for steric reasons
would not tolerate the adenine amino group.
Structures of the ! subunit of heterotrimeric
G proteins like Gt!, Gi!, and Gs!, and sev-
eral Ras-related proteins like Ras, Rap, Ral,
Rac, Rho, Cdc42, Arf, Arl, Rab and Ran have
been determined, as well as those of the
protein synthesis factors EF-Tu, EF-G, IF2,
and the antiviral human guanylate-binding
protein GBP1 (hGBP1) (1–3, 6–8). The eas-
iest way to compare these structures is to
consider the G domain of the Ras protein
with 166 residues as the minimal signaling
unit and to describe the others as variations
on this canonical structure (Fig. 1B). The G
domains of the signal recognition particle
SRP and its receptor SR show a divergent
topology of the " sheet in addition to an
extension and insertion, whereas tubulin and
its bacterial homolog FtsZ are structurally not
related to the G-domain proteins.
The Ras-related Rho proteins contain an
!-helical insertion of about 13 amino acids,
whereas Arf, Arl, and Sar1 proteins contain
an NH2-terminal extension necessary for in-
sertion into and interaction with the mem-
brane. Ran has an elongated COOH-terminal
element crucial for its function in nuclear
transport (9, 10). G! proteins with a molec-
ular mass of 40 to 45 kD have several exten-
sions to and insertions into the G domain, one
of which constitutes an independently folding
!-helical domain (Fig. 1B), whereas the oth-
ers are mostly loops. The entire hGBP1 pro-
tein consists of a 300-residue extended G
domain with many extra secondary structural
elements and a COOH-terminal coiled-coil
domain (8). Elongation factor Tu (EF-Tu),
initiation factor 2 (IF2/eIF5B) (7), and elon-
gation factor G (EF-G) have two, three, and
four additional domains, respectively (Fig.
1B).
Many GNBPs are posttranslationally
modified by hydrophobic groups on NH2- or
COOH-terminal extensions of the G domain.
These modifications, such as prenylation and
myristoylation, are important for membrane
targeting and are crucial for biological func-
tion (11). Structural information is available
only for the prenylated Cdc42-RhoGDI (gua-
nine nucleotide–dissociation inhibitor) com-
plex (12); in the other crystal structures, the
extension is either absent or not visible (13).
The Conformational Switch
Because structures in both the GDP- and
GTP-bound form have been described, we
can define the requirements of the molecular
switch. Structural differences are usually sub-
tle but may turn out to be quite large in some
cases. They are confined primarily to two
segments, first observed in Ras, which are
called the “switch regions” (14). These re-
gions usually show an increase flex bility in
x-ray structures and in studies using nuclear
magnetic resonance (NMR) and electron
paramagnetic resonance (15, 16).
Furthermore, whereas the GDP-bound
proteins show a large variation in structural
details, the GTP-bound forms of the G do-
main are remarkably similar (2, 3) (Fig. 2).
Most important, the trigger for the conforma-
tional change is most likely universal. In the
triphosphate-bound form, there are two hy-
drogen bonds from #-phosphate oxygens to
the main chain NH groups of the invariant
Thr and Gly residues (Thr35/Gly60 in Ras) in
switch I and II, respectively. The glycine is
part of a conserved DXXG motif, the threo-
nine is also involved in binding Mg2$ via its
side chain (Fig. 1A). The conformational
change can best be described as a loaded-
spring mechanism where release of the
#-phosphate after GTP hydrolysis allows the
two switch regions to relax into the GDP-
specific conformation (Fig. 3). The extent of
the conformational change is different for
different proteins and involves extra elements
for some proteins. Strictly speaking, the ex-
tent of the switch regions needs to be deter-
mined for each protein separately from the
corresponding structures. In Ras they involve
residues 32 to 38 for switch I and 59 to 67 for
switch II.
The canonical switch mechanism is mod-
ified in many ways. Ras, Rap, Rho, Rac, and
Rab show minor changes involving only the
switch I and II region. Upon going from the
GDP- to the GTP-bound form, Ran experi-
ences a large conformational change in
switch I with unfolding of an extra " strand
and a dramatic relocation of the COOH-ter-
minal extension, the so-called C-terminal
switch (9, 10, 17). An even more dramatic
change upon triphosphate binding involves
the change in register of two " strands rela-
tive to the rest of the sheet in switch I of Arf
nd the detac men and membrane insertion
of the NH2-terminal helix, the so-called N-
terminal switch (18, 19). G! proteins use an
extra structural element for the transition,
which correspondingly is called switch III.
Nevertheless, all of these structural changes
are thought to be triggered by the release of
the spring, which in the biosynthesis factors
transduces the conformational changes to
other domains. In the case of IF2/eIF5B, a
molecular lever is vealed that transfers the
structural change over a distance of 90 Å
Fig. 2. Canonical GTP conformation of GNBPs. Superimposition of a selection of Ras-related
proteins on the G domain show the switch I and II regions to be much more divergent in the
GDP-bound form. Extra elements in the structures of Rho, Arf, and Ran are highlighted. The
COOH-terminus of Ran is in red, the Rho insert in magenta and the Arf NH2-terminal helix in blu .
Fig. 3. Schematic diagram of the universal
switch mechanism where the switch I and II
domains are bound to the #-phosphate via the
main chain NH groups of the invariant Thr and
Gly residues, in what might be called a loaded
spring mechanism. Release of the #-phosphate
after GTP hydrolysis allows the switch regions
t relax into a different conform tio .
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GTP, which is predominant in the cell. The fact that the cycle can start again makes GEFs act 
as a catalysts to unbalance a specific equilibrium82 (Scheme 1).  
The complexes formed between GEFs and their GNBPs have several features in common, 
suggesting mechanistic similarities. The GEFs can interact with both switch I and II regions, 
and more importantly, insert residues close to the P loop and the Mg2+-binding area. This 
results in a conformational change that inhibits the binding of phosphates and Mg2+. Mg2+ in 
this case plays an important role, however studies showed that the β-phosphate-P loop 
interaction is the most important interaction for binding of the nucleotide. The structural 
change in the P loop is probably the reason for the decreased affinity towards GTP. Mg2+ is 
pushed out of its position by elements of switch II itself (see Ala59) or from residues of the 
GEF. The residues of the P-loop suffer a conformational change and the lysine associated to 
those is oriented now to the carboxylates of Glu62. Switch I is pushed out, and switch II pulls 
toward the nucleotide-binding site (Figure 19). 
 
 
Figure 19; GEF:GNBP interaction76 (Reprinted with permission from AAAS) 
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2.3.3 Son of Sevenless (Sos)83 
Sos is a major member of the GEF family84 and it is a multidomain enzyme with a Ras 
Exchanger Motif (Rem) domain and a Cdc25 domain that are both essential for Ras GTPase 
activation and signalling (Figure 20).  
 
Figure 20; Ribbon plot of SoS:Ras complex generated using MoE (PDB ID: 1BKD); Sos N-domain 
(blue), Sos catalytic domain (green); Ras Switch I and II (orange and magenta), P-loop (red), 
conserved regions among Ras family exchange factors (cyan) 
Cdc25 is the catalytic site, where Ras-GDP binds. The Rem domain is an allosteric site. 
Binding of Ras-GTP to the distal allosteric site results in a ternary complex 
Ras(GDP):Sos:Ras(GTP) which increases Ras exchange activity.85  
The formation of the Ras-Sos complex causes drastic changes in Switch I, which is removed 
from the binding site, breaking a network of direct and water-mediated interactions between 
Switch I and the nucleotide, as well as impeding binding of the Mg2+ ion and phosphate.86 
The backbone of Switch II is compressed, helping to occlude the Mg2+ ion and interrupting 
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the phosphate binding side chains (Figure 21). 
 
Figure 21; Change in Switch I causing liberation of GDP after interaction with Sos is highlighted 
(Generated using MoE); a) Ras (white ribbon) - GDP analogue (stick representation) interactions 
(PDB ID: 5P21) to b) Ras (white ribbon) -Sos interactions (PDB ID: 1BKD) 
Sos mediates nucleotide dissociation from the ternary complex and the formation of the new 
complex, Ras-Sos is disrupted when GDP or GTP binds to Ras. GTP and GDP bind with 
similar affinity, but intracellular GTP concentration is over 10 times that of GDP, resulting in 
an innate preference for the GTP bound form.  
2.4 Effectors 
The effectors of the GTP-binding proteins will be molecules that can interact (or interact 
more tightly) to GTP bound proteins than to GDP bound proteins. This implies that the 
effector binding mode will involve the switch regions of G proteins as these regions are the 
ones in contact with the different nucleotides. 
The Ras-binding domain (RBD) of the Raf protein kinase (Ras effector) is a very small 
domain with a ubiquitin fold, which binds to Ras by forming a GTP sensitive interprotein β 
sheet between the two molecules.87 This binding domain is contained in many other proteins, 
most of them with similar fold and function.  
2.5 GAP proteins and GTPase Reaction 
The GTPase reaction is found to be very slow for all GNBPs, and for most biological 
processes is required to be complete within minutes after GTP is loaded. For this, GAP 
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proteins are necessary, and work in assistance of Ras forming a complex. The speed of 
hydrolysis changes dramatically: 
• GTP hydrolysis in water takes 200 days 
• GTP hydrolysis by Ras takes 30 min 
• GAP assisted GTP hydrolysis by Ras takes 50 ms88 
Structures of RasGAP and RhoGAP in complex with their respective GNBPs in the presence 
of AlFx (AlF3 or AlF4
-), show that GAPs supply a so-called arginine finger into the active 
site.89 There are some common principles in the mechanism of GAP action on Ras, Rho, and 
G proteins (Figure 22).  
 
Figure 22; “GAP:G-domain” interaction. This figure was prepared with Molscript.90 Ras- RasGAP 
(yellow), Rho- RhoGAP (red), Rac- ExoS (cyan), and Gi-RGS (magenta); catalytic water (W). All in 
the presence of GDP and aluminium fluoride compounds (AlF4- or AlF3) 
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2.6 Is Ras Druggable?91 
Although the direct targeting of Ras is a very challenging goal due to its rounded surface and 
lack of potential druggable sites, some potential pockets on the surface of K-Ras have been 
found, allowing the use of computational approaches92, 93 to find small molecules inhibitors. 
2.6.1 Targeting Ras directly 
Low-affinity inhibitors 
Initially the compounds were designed to compete with GTP for the binding site on Ras,94 
some compounds were found to bind close to the region of switch II, however all of these 
initial series had a hydroxylamine group, which is highly toxic and has poor metabolic 
properties due to instability. On top of that the potency of those is very low. 
Another type of compounds was found to inhibit the formation of the dimeric complex 
Ras:Raf. These compounds are based in the non-steroidal anti-inflammatory drug sulindac 
sulphide.  The most potent of those compounds (IND12), is a selective inhibitor for the 
proliferation of Ras-transformed-cells, but lacks potency and has many side effects (Figure 
23).95 
 
Figure 23; IND 12 
In a yeast two-hybrid screen for compounds that could potentially inhibit the Ras-Raf 
interaction, small molecules (like MCP1-Figure 24) were discovered that inhibited Raf 
activation in cancer cells.96 Again, the compounds are not potent enough. Structural 
information on how they bind has not yet been obtained but could be a starting point for 




Figure 24; MCP1 was the product of a yeast screening 
Zn2+ cyclen (Figure 25) was shown to bind to Ras and block the interaction with Raf,97 but 
this molecule has no selectivity for Ras due to its chelating nature. The side effects limit any 
further development. 
 
Figure 25; Zn2+ cyclen 
Despite of all these problems, these low-affinity inhibitors revealed the existence of pockets 
in Ras that could be used to disrupt the interaction with its main effector, Raf, with a small 
molecule and therefore inhibit the signaling cascade. 
GEF inhibitors 
The Ras GTP/GDP cycle is regulated negatively by GAPs and positively by GEFs (Scheme 
1, page 39). The most studied and prominent Ras GEF is Sos, which forms a complex with 2 
Ras proteins (Ras:catSos:Ras) using 2 binding sites (allosteric and catalytic).98  
A peptide based on the α-H helix of Sos, the region that can bind to Ras (HBS3 peptide-
Figure 26) was found to bind very closely to the Switch I and Switch II regions. After this 
discovery, the research for a new peptide with good pharmacokinetic properties started. The 
resulting pseudo-peptide bound to GDP-bound Ras and inhibited the Ras activation which 
therefore regulated the ERK-MAPK signaling, however the peptide was again not potent 




Figure 26; The HSB3 peptide is a mimic of the Sos α-H helix that interacts with H-Ras99 
In 2012 two compounds were reported to bind to K-Ras after fragment based screenings by 
two different groups. Genentech could identify a compound named as DCAI, which binds to 
a pocket located between the α2 helix and β sheets of K-Ras (Figure 27).                       
 
Figure 27; K-RasG12D GDP bound to DCAI (PDB ID: 4DST)100 
DCAI inhibited Sos-mediated nucleotide exchange by blocking the interaction between Ras 
and Sos, and inhibited Ras activation in cells, but again very weakly (IC50 = 340 µM). At the 
same time another group in Vanderbilt, discovered several compounds using NMR-based 
fragment screen. The most potent was named VU0460009,101 which binds to the same cleft as 




Figure 28; X-Ray structure of K-RasG12V-GDP bound to VU0460009 (PDB ID: 4EPY) 
This pocket cannot be observed in the ligand free form of K-Ras, it is only with the 
conformational change induced by binding of the compounds that this pocket becomes 
available. This new conformation inhibited the Sos-mediated nucleotide exchange by 
blocking the Ras-Sos complex formation but like many other compounds, these new small 
molecules weakly bind K-Ras. The improvement of these compounds is very challenging and 
it is not sure if the mechanism of action would be valid with mutated Ras proteins.  
Recent publication for the inhibition of the GEF (Sos)102 
The identification of a potent small molecule inhibitor with the capacity to disrupt the 
interaction between K-Ras and Sos was undertaken via a dual approach:  
1) Fragment screen to identify inhibitors via K-Ras-Sos complex stabilization. 
2) A High-throughput Screen (HTS) designed to search for inhibitors of the enzymatic 
Sos nucleotide exchange activity, via binding either to K-Ras or to Sos. 
 
For the first approach the aim was to identify molecules able to stabilize the interaction 
between K-Ras and Sos and drive the complex to a dead-end. An NMR fragment screen for 
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binders of the complex was performed to identify potential stabilizers (Figure 29). 
 
Figure 29; a) Screening cascade; b) example spectra for (8) 1D proton spectrum (blue) and STD-
NMR spectrum with K-RasG12C-Sos1 complex (red), K-RasG12C_C118S (green), and Sos1cat (purple)102 
 
A library of 3000 fragments was screened by STD-NMR yielding 310 single fragment hits. 
The hits found were subjected to K-Ras and Sos screens. Of the 97 “complex exclusive” 
fragments (fragments binding exclusively to the K-RasG12C:Soscat complex)	 42 were 
unambiguous and selected for crystallization. Soaking of the 42 fragments gave 13 co-crystal 
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structures that showed binding to a mainly hydrophobic pocket on Sos located adjacent to K-
Ras.  
 
Of the different fragments identified, compound (8) stabilized K-RasG12C-Soscat complex in 
three different assays: In the 2D NMR assay, this was indicated by the reduction of signals 
for 15N-labeled K-RasG12C upon addition of (8). In the SPR assay, addition of (8) increased 
the amount of K-RasG12C binding to immobilized Soscat. In the interaction assay, (8) addition 
resulted in an increased homogeneous time-resolved fluorescence (HTRF) signal. (8) 
interacts with Sos via a π- π interaction with Phe890 and forms two hydrogen bonds to 
Tyr884 and Asp887; moreover, the aminomethyl group forms a cation-π interaction with 
Tyr884 (Figure 30). 
 
 
Figure 30; Co-crystal structure of (8) bound to K-RasG12C–Soscat. Overall complex with location of 
the fragment binding site (yellow box); Inset is the area in the yellow box enlarged, showing hydrogen 
bonds as thin dashed lines and cation–π interaction as a thick dashed line102 
 
Attempts of SAR exploration on (8) were conducted but no significant improvements were 




For the second approach, an HTS with a developed enzymatic assay was undertaken with a 
Bayer library of over 3 million compounds (Figure 31) identifying compound (9). 
 
 
Figure 31; a) Quantifying the Sos-mediated loading of a fluorescently labeled GTP analogue onto K-
RasG12C, which results in an increased HTRF signal; b) Monitoring the SOS1-catalyzed HTRF signal 
decrease by the deloading of a fluorescently tagged GDP analogue preloaded onto K-RasG12C. (K-Ras 
reference compound (R2) is a direct K-Ras inhibitor) 
 
A thermal shift assay was also used to confirm initial hits and to analyse the interaction of the 
small molecules with K-Ras or Sos. Compound (9) stabilized Sos, but not K-Ras (wild type 
or mutant). ITC also confirmed a strong enthalpy driven binding (-14.1 kcal/mol). Further 
SAR exploration of compound (9) yielded compound (10), with an IC50 of 21 nM. Co-
crystallization with (10) revealed, unambiguously, that only the (R)-enantiomer (10) had 





Figure 32; Hydrogen bonds shown as thin dashed lines, cation–π interaction as a thick dashed line 
 
 
Thanks to this work a cell-active and selective inhibitor of Sos with a 21 nM potency was 
reported for the first time. Compound (10) could be used for future investigations of the Ras-
Sos interaction in vitro. Further improvement of the pharmacokinetic profile of the ligand are 
being undertaken for viable in vivo experiments. 
 
Inhibiting Raf-1 binding 
 
One compound was found to have the ability to inhibit the Ras-Raf interaction by binding to 
the Ras binding domain (RBD) known as Raf-1103 after a computer docking screen of a 
virtual library, and then a second compound was also found after a similarity search. These 
compounds named Kobe derivatives decreased the phosphorylation of downstream proteins 
in the Ras pathway and more importantly inhibited the allosteric Ras binding site of Sos. 
Unfortunately, these molecules contain a thiosemicarbazide, which should be replaced in 




Figure 33; NMR-derived structure of K-RasT35S-GNP bound to Kobe-2601 (PDB ID: 2LWI) 
These compounds also lack potency to be a viable treatment and again are proposed as a 
scaffold for optimization. 
Mutant-specific inhibitors 
In a recent approach, first published by Shokat et al., compounds have been designed that 
covalently bind the specific mutant K-RasG12C. These inhibitors were discovered by screening 
a library of small molecules with GDP-bound K-RasG12C using a tethering approach. The 
most active compound is Shokat compound 16. The design and synthesis of analogues was 
performed with the help of X-ray structures of co-complexes.  Crystallographic studies reveal 
the formation of a new pocket beneath the effector binding switch-II region. Binding of these 
inhibitors to K-RasG12C disrupts switch-I and switch-II, changing the nucleotide preference to 





Figure 34; X-Ray structure of K-RasG12C-GDP bound to Shokat compound 16 (PDB ID: 4M22) 104 
 
These studies show that a specific mutation can be specifically targeted reducing the toxicity 
of the therapeutic treatment. 
 
Ras-GDP induced stabilization 
 
Recently, Gray et al. prepared a GDP analogue with an electrophile attached (SML-8-73-1-
Figure 35) that binds to a cysteine of mutant K-RasG12C in the presence of 1 mM 
concentrations of GDP and GTP.105 It was presumed that “GDP-bound Ras-like” 
conformation would induce an inactive K-Ras conformation. As a proof-of-concept the idea 





Figure 35; SML-8-73-1 
2.6.2 New and alternative approaches to target Ras106  
All the experiences that have been previously described, together with the lack of a well-
defined hydrophobic pocket(s), led to the idea that Ras may be not tractable.107 This 
contributed to the pursuit of viable therapeutic treatments targeting proteins that promote Ras 
membrane interaction, effector signaling, synthetic lethality or Ras-dependent 
metabolism.108,109 
Farnesyl transferase inhibitors (FTIs) 
The protein association with the inner part of the membrane is crucial for the Ras oncogenic 
activity, therefore post-translational modifications that modulate this association could be 
useful for the development of Ras drugs that disrupt its membrane association.110 Ras 
proteins are initially cytosolic; the first post-translational modification111 is 
farnesyltransferase-catalyzed covalent addition of a farnesyl moiety to a cysteine residue. 
The second, in the surface of the endoplasmatic reticulum, is a proteolytic removal of three 
amino-acids by Ras converting enzyme 1 (RCE1) and the last modification is done by 
isoprenylcysteine carboxyl methyltransferase (ICMT), which facilitates a methyl group 
transfer to the C-terminal amino acid to prevent plasma membrane repulsion. Extra 
modifications together with the addition of palmitate fatty acid, promote Ras association to 
the plasma membrane.  
An intense search was done during the 1990’s to try to disrupt the Ras association to the 
membrane by inhibiting the process described above in different stages. 
Two inhibitors (lonafarnib and tipifarnib) advanced to phase III clinical trials but showed no 
efficacy, because the protein is able to find alternative ways to be post-translationally 
modified and associated to the membrane. In recent years the interest for inhibitors of the 
membrane association has been revisited and one of the most interesting targets identified is 
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the prenyl binding protein phosphodiesterase δ (PDEδ). A solubilizing factor that facilitates 
the transport of Ras proteins within the cell through the cytosol.112  
Initially it was thought that PDEδ would overcome the weaknesses of FTIs, but the amount of 
side effects produced from PDEδ inhibition is too high. 
Targeting downstream effector signaling  
Blocking effector signaling is one of the most pursued anti-RAS strategies, however, with at 
least 11 catalytically effector families, the key question is: which effectors to target, and if 
concurrent inhibition of several effectors is necessary in the probable case that the cell would 
be able to bypass a single disruption in the signaling cascade. 
The first Raf inhibitors (vemurafenib and dabrafenib) are now approved for B-Raf-mutant 
melanomas. When these inhibitors were evaluated in Ras-mutant cancer cells, a paradoxical 
activation of ERK signaling was observed. This activity was determined to be driven by 
mutant Ras–dependent formation of B-Raf - C-Raf heterodimers.113  Because the first-
generation of Raf inhibitors are only B-Raf selective, they paradoxically cause activation of 
C-Raf and thereby activation of MEK-ERK signaling. This observation led to the 
development of second-generation pan-Raf inhibitors (LY3009120 and PLX8394), which do 
not activate the MAPK pathway in the presence of a Ras mutation.114, 115 
Potent and highly selective inhibitors of MEK1 and MEK2 have also been developed. 
Unfortunately, these inhibitors have shown limited efficacy in Ras-mutant cancers, in part 
because of loss of ERK-mediated feedback inhibitory mechanisms.116 
Although increased ERK signaling drives cancer growth, aberrantly high ERK activation can 
be growth-inhibitory. Therefore, feedback inhibition mechanisms are initiated by ERK 
phosphorylation of components upstream of MEK (like C-Raf or B-Raf), dampening flux 
through the cascade. Consequently, upon MEK inhibition of ERK, increased flux through Raf 
and MEK can overwhelm the inhibitor block, leading to ERK reactivation. Cancer-associated 
MEK mutations have also been described that render these cancers insensitive to MEK 
inhibitors. These unanticipated consequences of MEK inhibition have prompted the 
development of inhibitors of ERK, with several candidates now under clinical evaluation. 
The PI3K-AKT-mTOR pathway serves as a highly complementary role for the Raf-MEK-
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ERK cascade. Resistance to ERK- MAPK pathway inhibitors can be mediated by PI3K-
AKT-mTOR activation. Inhibition of components of both pathways has shown enhanced 
antitumor activity in mouse models. However, these combinations have not demonstrated the 
same activities in clinical trials, in part because of toxicities not seen in mouse studies.108  
Recently, Rigosertib has been reported to have an unanticipated activity, acting as a Ras 
mimetic to occupy the Ras-binding site in Raf and Ras association domains of Ras 
effectors.117 However, another recent study reported that rigosertib affinity for Ras-binding 
and Ras association domains may not be sufficient to block Ras effector signaling. Studies 
showed that the observed reduction in ERK was due to an indirect mechanism of inhibition of 
Sos and Raf.118 
Synthetic lethal interaction partners of mutant Ras  
Another indirect approach for targeting mutant Ras is based on the concept of synthetic 
lethality.119 Synthetic lethal interaction partners for mutant Ras are genes whose functions are 
essential in Ras-mutant but not wild-type Ras cells.  
In 2009, several groups reported the identification of synthetic lethal interactors of mutant 
Ras, including several protein kinases (e.g., STK33 and TBK1). However, these interactors 
failed to demonstrate a functional linkage with mutant Ras. To date, the search for synthetic 
lethal interactions of mutant Ras has been unsuccessful.120 
Targeting Ras-regulated metabolic processes  
One of the 10 hallmarks of cancer is the need for cancer cells to reprogram energy and 
nutrient metabolism to support their elevated proliferative state.121 These increased needs are 
met by reprogramming various metabolic processes to recycle intracellular fuel sources or to 
scavenge extracellular components. 
Oncogenic Ras is known to drive macropinocytosis, an endocytic process in which cells use 
their plasma membrane to internalize nutrients.122 There are no pharmacologic inhibitors that 
selectively block macropinocytosis, but EIPA [5-(N-ethyl-N-isopropyl)amiloride], an 
inhibitor of Na+/H+ exchange, was reported to inhibit this process and thereby impair PDAC 
tumor formation in vivo. Although the elevated macro-pinocytotic activity in PDAC is Ras-
dependent, the effector signaling mechanisms driving this activity remain poorly understood. 
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Another route used by oncogenic Ras-driven cancer cells to generate what is required for cell 
proliferation is autophagy. During this process, the cell degrades unneeded intracellular 
components, providing a supply of amino acids, lipids, and nucleic acids. Chloroquine 
inhibition of lysosomal acidification prevented tumorigenic growth in mice.123 Chloroquine 
(Figure 36) is a nonspecific inhibitor of autophagy and can also inhibit macropinocytosis. The 
related approved drug, hydroxychloroquine, is now under clinical evaluation for PDAC 
(clinicaltrials.gov identifier, NCT01506973-Phase II studies). 
 
Figure 36; Chloroquine 
Mutant Ras has been linked to increased glucose metabolism and the use of glucose 
metabolites into nucleotide and lipid biosynthetic pathways,124 also Ras-mutant PDAC is 
characterized by increased dependency on glutamine for NADPH (nicotinamide adenine 
dinucleotide phosphate, reduced form) production to maintain redox balance125 but none of 
these strategies have been studied yet. 
2.7 Future Perspectives  
Despite the challenging history of Ras drug discovery, there is renewed optimism that the 
goal will be achieved in a reasonably not too far future. It is thought that it will not be a 
simple therapy that will be effective in all Ras-mutant cancers. The function of mutant Ras is 
greatly affected by cell type and genetic environment.   
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Chapter 3: Project Rationale 
In normal cells the GEF activity of Sos is tightly regulated through interactions with Ras, but 
also by the allosteric modulation of GTP-bound active Ras at an allosteric binding site close 
to the catalytic Ras binding site present in Sos. Activating mutations in Ras (K-Ras is the 
most frequently mutated isoform in cancer) short-circuit Sos-mediated activation, as their 
intrinsic and GTPase-activating protein (GAP)-catalyzed GTP hydrolysis is impaired, leaving 
them in a perpetually GTP-loaded state.  
It was previously assumed that mutant Ras-driven tumorigenesis would be insulated from the 
effects of inhibition of any up-stream activating factor, including Sos. However, recent 
evidence suggests that this may be too simplistic an interpretation, and that mutant Ras in fact 
co-opts wild-type Ras isoforms through allosteric activation of Sos in order to achieve and 
maintain cellular transformation.126, 127  
It remains in serious doubt if any of these strategies could yield a potent compound for a 
potential therapy and we can conclude that the functional output of Ras proteins depends on 
their GTP-binding status that is dictated by the counteracting actions of guanine nucleotide 
exchange factors (GEFs) and GTPase activating proteins (GAPs).  
In the absence of oncogenic mutations that compromise the response of Ras to the action of 
GAPs, the amount of GTP-bound Ras molecules is thought to be controlled by the action of 
GEFs. The Ras-specific GEF Son of Sevenless, has a key role in regulating Ras activity by 
catalysing the exchange of GTP for GDP128. The presence of an allosteric site on Sos that 
interacts preferentially with Ras-GTP has been previously reported. This interaction 
augments the catalytic activity of Sos by affecting conformational changes that release it 
from its autoinhibited state.129 
As oncogenic Ras proteins are constitutively bound to GTP, their interaction with the 
allosteric site on Sos would be favoured. Accordingly, it is plausible that the occupation of 
the allosteric site on Sos by oncogenic Ras would lead to the enhancement of Sos-mediated 
activation of wild-type (WT) Ras.  Accordingly, with this observation 2 different approaches 
have emerged: 
 
1) Fesik approach (Scheme 2): It has been observed by X-Ray crystallography studies 
that aminopiperidine indole ligands, found after an HTS campaign, bind to the ternary 
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complex (Ras:Sos:Ras) in a sub-pocket of the CDC25 catalytic site. These ligands act 
as agonists, therefore inducing high concentrations of Ras-GTP in the cell. This can 
paradoxically disrupt the signaling cascade acting in a biphasic mode: low 
concentrations of ligand would induce the production of phosphorylated downstream 
effectors (MEK, ERK), but a high concentration of ligand can enhance the 
concentration of phosphorylated ERK up to a point where Sos can be also 
phosphorylated at a serine residue (Ser-1178), disrupting the interaction with GRB2 
and therefore creating a cytosolic phosphorylated quaternary complex which cannot 
drive tumorigenesis anymore (Scheme 2).130  
 
Scheme 2 
The questions that would remain unanswered with this approach are:  
• Why can we not see this phosphorylation happening when tumorigenesis is taking 
place as phosphorylation is also upregulated? 
• Why would the system be stable?  
Regarding the latter question it could be theorized that once the concentration of 
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phosphorylated ERK decreases after disruption of tumorigenesis, the quaternary complex will 
not form and the cycle would re-start. 
2) Bar-Sagi approach: On the observation that wild type Ras recruits mutant type Ras 
(permanently bound to GTP as GAPs activity is impaired) to form a catalytically 
activated ternary complex (Ras:Sos:Ras), it has been also proposed to disrupt this 
association by ligands that can expand the cleft between the allosteric site (Rem 
domain) and the catalytic site (CDC25), then the ability of Sos to recruit mutant Ras 
will be impaired, and therefore tumorigenesis disrupted (Scheme 3).88 
 
Scheme 3 
Based on the observations by Bar-Sagi et al. that mutant K-Ras is dependent on the Sos-
mediated activation of mutant-type Ras, we hypothesize that inhibition of Sos’s ability to 
catalyze nucleotide exchange on wild-type Ras has the potential to target oncogenic Ras 
signaling. 
In preliminary studies, we have identified small molecule compounds that bind to an 
unprecedented site on Sos itself and have the potential to inhibit Ras activation via a novel 
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Figure 37, X-ray structure of compound with Soscat:Ras (catalytic site) complex can confirm binding 
As we can see in the previous figure, the binding site spans the cleft between CDC25 (where 
catalytic Ras binds) and Rem domains of Sos (where allosteric Ras binds). We can see a 
mixed polar/apolar site, giving us opportunities for enhancing the affinity. 
We seek to establish this as a viable mechanism to treat Ras mutant pancreatic tumors and 
pave the way for future drug discovery strategies. 
Preliminary Data 
To identify compounds that bind to Sos, we conducted a small-scale biophysical binding 
screen of a 960-compound library, using a thermal melting (Tm-shift, thermofluor) assay to 
detect compounds that would bind to the catalytic domain of Sos (CDC25). From this screen, 




Figure 38; 960-compound library screened against Soscat using ‘Tm-shift’ assay 
Compound (11), that induced a Tm shift of 1.3°C, was selected for further characterization. 
The compound was co-crystallized with H-Ras:Sos complex, showing the binding site of (11) 
(Figure 39). 
 
Figure 39; Complex of (11) (green) with binary Ras:Sos. Soscat (red), ’catalytic’ Ras (blue), Ras 




Preliminary supporting data – Breeze/Waring 
 
 
Fig. 1. Complex of 1 (green) with binary Ras:SOS. SOScat in red, ’catalytic’ Ras in 
blue; approximate binding site of ’allosteric’ Ras shown in orange for illustration, but 
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2D protein-observed NMR using 15N-2H-labelled Soscat
 
confirmed specific binding of (11) to 
Sos and yielded a Kd of ~400 µM. Soaking of (11) into crystals of Soscat with H-Ras bound at 
the catalytic site (Ras:Sos) revealed that the compound binds in a hitherto unreported and 
unique binding site spanning the “cleft” between CDC25 and Rem domains of Sos. The outer 
edges of this cleft form the allosteric Ras binding site, via which activated Ras potentiates the 
catalytic activity of Sos in a positive feedback loop. 2DNMR titrations of 15N, 2H-Soscat
 
previously saturated with H-Ras:GTPγS (GTPγS: a non-hydrolyzable analogue of GTP) with 
(11) revealed an apparent Kd of ~1.2 mM, compared with 400 µM in the absence of Ras. The 
decrease of measured binding affinity of (11) to Sos complexed with Ras at both its allosteric 
and catalytic sites, supports the hypothesis that (11) competes for the binding of Sos allosteric 
site with Ras. This could be rationalized through comparison of the structure of binary 
Ras:Sos bound to (11) with structures of the ternary complex of Sos with Ras bound at both, 
the catalytic and allosteric sites (ternary Ras:Sos:Ras). (11) would clash sterically with 
“allosteric” Ras via its salicylate group (Figure 40). 
 







Figure 40; 1H-15N NMR of Sos shows Kd (affinity) of ~400 µM, Repeating experiment in presence of 
GTP-Ras weakens Kd to 1.2 mM, suggesting binding at the allosteric site 
 
The close analogue (12) (Figure 41) has also been solved in the binary Ras:Sos complex 
crystal system and, as expected, adopts the same binding mode; however, the affinity data 
O Sos + H-Ras  
    (no compound) 
 
O 1mM compound 
 
O 4mM compound 
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suggests a slightly better interaction with a Kd of 1 mM in the presence of Ras-GTP.  
 
Figure 41 
The binding site for (11) and its close analogue (12) is predominantly hydrophobic in nature, 
and the ligands make only a single polar H-bond contact between the benzoylamino carbonyl 
and a εH-N of His700. However, examination of the site clearly indicates a number of other 
potential polar interactions that were exploited through relatively minor modifications to the 
existing scaffold and/or accessed with more significant changes. 
3.1 Research Plan 
The ligand efficiency of the hits we have identified for the novel binding site on Sos is 
modest (around 0.18 KJ/mol), yet clear potential exists to access additional energetically 
favorable interactions via appropriate modifications or scaffold changes.  
3.1.1 Optimization of compound (11) and (12) 
Initially, a small set of analogues of the primary hit (11) was synthesized. We had a number 
of design concepts that we explored to exploit additional polar and non-polar interaction 
potential in and adjacent to the binding site of (11). Different biophysical assays that are well 
established in the Alexander L. Breeze lab (Tm shift and/or microscale thermophoresis 
(MST), surface plasmon resonance (SPR) and bi-dimensional 1H-15N TROSY-HSQC and 1H-
13C-methyl HMQC-NMR)131 were used to measure the affinities of these analogues and 
confirm binding to the allosteric Ras binding site of Soscat. Initial analogues have been 





Figure 42; Binding site for (12) in Soscat. The left-hand side is formed by residues from the Rem 
domain, while a pocket in the CDC25 domain forms the right-hand part of the cavity  
Firstly, the existing lead was modified to optimize its contacts and interactions to try to 
enhance potency by growing the existing structure towards areas of the protein which have 
the potential for making further productive interactions (Figure 43).  
 
Figure 43; Outline chemical strategy for chemical optimization 
It can be seen from the structure that the acidic group does not make interactions with the 
protein; this is supported by the observation that the acid and phenol motifs can be transposed 
without significant loss of activity of (11) and (12). Addition of N-heterocycles (indazolones, 
isoindazolones and aminoindazoles) replacing the aminosalicylic group was also proposed.  
The existing hydrogen bonding interaction made by the central amide group was tuned 
electronically by manipulating the electronics of the aryl rings. Structures of this type are 
likely to suffer from compromised solubility by the formation of strongly hydrogen bonded 
 
 
Fig. 3. Binding site for 2 in SOScat. The left-hand side of the site is formed by residues 
from the Rem domain, while a pocket in the CDC25 domain forms the right-hand part 












Fig. 5. Project timeline. 

























Fig. 3. Binding site for 2 in SOScat. The left-hand side of the site is formed by residues 
from the Rem domain, while a pocket in the CDC25 domain forms the right-hand part 












Fig. 5. Project timeline. 

























arrays in the crystalline state; hence, in order to avoid possible solubility issues, methylation 
of one or both amides, was explored.  
In the crystal structure, the second amide ring can be seen to adopt a non-coplanar 
configuration with respect to the amide, hence it is likely that potency could be enhanced by 
the addition of a substituent ortho- to the amide.  
Finally, the cyclopropyl group occupies a lipophilic pocket within the protein; the fit of the 
molecule within this pocket was explored by the modification of the cyclopropane ring. The 
second amide appears not to make productive interactions and so alternative, less polar 
linking groups were explored. This could increase the potency and provide additional vectors 
for growing the compounds towards hydrophobic sub-pockets of the protein.  
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Chapter 4: Results and Discussion 
For the design and synthesis of the analogues, a common intermediate was synthesized and 
derivatized, this strategy gave us a convergent synthesis and the opportunity to save time and 
synthetic steps. For this, para-amino benzoic acid was treated with Na2CO3 in dry THF, then 
cyclopropylcarbonyl chloride was added and the mixture was stirred for 16 hours at room 
temperature, affording compound (13) in 44% yield after purification. Compound (13) was 
used as the common intermediate (Scheme 4). 
 
Scheme 4; i) Cyclopropylcarbonylchloride, Na2CO3, THF, r.t., 16h 
The scale up of this compound facilitates the access to most of the analogues. The initial 
exploration was designed for the salicylic acid moiety, which is the terminal phenyl ring. 
Also, amide methylation was performed for solubility improvement (Figure 44). 
 
Figure 44; Regions of the molecule of choice for exploration 
The exploration performed via the common intermediate (13) was carried out to understand 
the importance of the substituents in the terminal phenyl ring. Elucidation of their most 
productive position for interactions can help us in building potency. Both substituents or just 
one of them were removed, leaving the hydroxy or the carboxy groups in positions 4 or 5 of 
the phenyl ring. For this exploration, several amide couplings were performed using 
intermediate (13) and different anilines. HATU was used as coupling agent after treating 
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compound (13) with DIPEA in dry DMF and with the subsequent addition of the aniline. The 
reactions stirred for 16 hours at room temperature. The yields obtained were very variable 
depending on the para-substituent of the amino group of the aniline and its electron donating 
or withdrawing properties (Scheme 5). 
 
Scheme 5; ii) Aniline, HATU, DIPEA, DMF, r.t., 16h 
After the synthesis of the analogues shown in the previous scheme, it was noted that the 
solubility of these compounds was very challenging. Specially for those with a carboxy group 
in the terminal phenyl ring, which could be purified by washing with DMSO in a sintered 
funnel. The different analysis performed were done in hot DMSO to avoid precipitation of 
the analogues.  
The solubility issues that we can see in our molecules are ascribed to the polyamide stacking 
properties of the compounds that we are handling. The amides will interact with each other 
creating very insoluble solid compounds (Figure 45). 
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Figure 45; Putative H-bonding repeat interactions 
It was theorized that the methylation of one of the amides could disrupt the interaction of the 
carbonyl group of one molecule with the hydrogen of the amide of the next. To synthesize the 
new derivative a new synthetic route was designed. To avoid methylation of the acid present 
in the terminal phenyl ring, the pathway was started with methyl 4-aminobenzoate. The 
aniline was reacted with cyclopropylcarbonyl chloride after treatment with Na2CO3 in dry 
THF. The reaction was stirred for 16 hours at room temperature affording the desired 
intermediate in 95% yield. Then, compound (21) was treated with sodium hydride (60% in 
mineral oil) in dry THF at 0oC and subsequently reacted with iodomethane to afford 
compound (22) after 16 hours, allowing the reaction to warm to room temperature and 
affording compound (23) in 95% yield. The methylated intermediate (23) was hydrolyzed 
under basic conditions yielding acid (23) in quantitative yield. Finally, an amide coupling of 
intermediate (23) with 5-amino-2-hydroxybenzoic acid gave us the desired product (24) 
(Scheme 6). 
 
Scheme 6; i) Cyclopropylcarbonyl chloride, Na2CO3, THF, r.t., 16h; ii) Iodomethane, NaH (60%), 
THF, r.t., 16h; iii) 2M NaOH, H2O, r.t., 16 h; iv) Aniline, HATU, DIPEA, DMF, r.t., 16h 
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Additionally, the presence of a new heterocycle derivatives on the terminal phenyl ring could 
give an improvement in potency if the molecule fits in the appropriate way in the pocket. 
This approach gave us also the opportunity to try different functional groups. Indolinones, 
isoindolinones and aminoindazoles were synthesized. For the synthesis of indolinones and the 
isoindolinone, similar chemistry to the one shown in previous schemes was used. 
Intermediate (13) was reacted with the appropriate 4-amino isoindolinone/4-amino 
indolinone after treating compound (13) with HATU in the presence of DIPEA in dry DMF 
(Scheme 7). The yields of these amide couplings slightly improved (31-52%) after changing 
the solvent to DMF, which was crucial for better solubility of the aminoisoindolinone and 
aminoindolinones. 
 
Scheme 7; Amide coupling reaction for the derivatization of a common intermediate 
We were also interested in the synthesis of aminoindazoles as these molecules also had a 
hydrogen bond acceptor mimicking the carboxylate group. The synthesis of these compounds 
was completely different to the synthesis shown in previous schemes. A fluoronitrile 
intermediate was used to ring close the aminoindazoles using hydrazine hydrate. 4-amino-2-
fluorobenzonitrile was very deactivated due to presence of a nitrile in para position to the 
amino group and the amide coupling was not successful. In the case of 5-amino-2-
fluorobenzonitrile the amide coupling was successful but with a low yield (52%). Compound 
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(28) showed multiplicities in the 13C resonances due to coupling to 19F. This intermediate was 
also used for testing. Part of intermediate (28) was treated with hydrazine monohydrate at 
60oC for 24 hours yielding the desired aminoindazole (29) in 39% yield (Scheme 8).  
 
Scheme 8; Different strategies for the synthesis of aminoindazoles 
An exploration with MoE of different compounds allowed us to find a potential new 
interaction from an aminomethyl moiety in two different ways with two different glutamine 
residues. On one side, the nitrogen of the amino group is acting as a hydrogen bond acceptor 
with the hydrogens of the carbamate moiety of a glutamine, and on the other side the same –
NH2 from our ligand is acting as a hydrogen bond donor with a carbonyl of an amide moiety 
of a different glutamine (Figure 46 – blue circle).  
 
Figure 46; Putative amino group interactions highlighted (PDB ID: 3RSJS) 
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For the synthesis of the new target, the amino group of the 4-aminomethyl-benzoic acid was 
protected. The reaction was performed with trifluoroacetic anhydride in DCM at 0oC for 16 
hours to give us compound (30). Then the protected intermediate crude product was treated 
with thionyl chloride to give the acyl chloride (31), which was reacted with 5-amino-2-
hydroxybenzoic acid in dry THF for 16 hours at room temperature yielding compound (32) in 
65% yield over three steps. Subsequent deprotection of compound (32) in a mixture of 
NH3/H2O (1:9) at 80oC for 16 hours gave us the desired product (33) (Scheme 9). 
 
Scheme 9; i) (CF3CO)2O, pyridine, DCM, 0oC to r.t., 16h; ii) SOCl2, 70oC, 16h; iii) 2-hydroxy-4-
amino carboxylic acid, THF, r.t., 16h; iv) NH3:H2O (1:9), Dioxane, 90oC, 16h 
In the case of the 2-hydroxy-5-aminobezoic regioisomer, the lack of aniline nucleophilicity 
resulted in extremely poor yields, this lack of reactivity led us to focus our efforts on the 2-





Unfortunately, compound (33) lacked enough solubility for biological testing. NMR spectra 
were obtained by adding TFA to improve the solubility. However, it was decided to 
synthesize a series of analogues of this compound to try to explore several substituents in the 
same position of the compound. All the compounds were synthesized by preparing the acyl 
chloride with thionyl chloride and reacting the crude intermediate after evaporation with 4-
aminosalicylic acid in dry THF for 16 hours (Scheme 11). The synthesis of these 
intermediates was done by Shaun R. Stevens and me. 
Scheme 11; i) SOCl2, 70oC, 16h; ii) 4-aminosalicylic acid, THF, r.t., 16h 
As mentioned before, the solubility of the molecules was very problematic and in some cases 
the molecules synthesized could not be tested. For this reason, it was decided to make further 
modifications of the parent compound trying not to lose (or improve) the potency and 
solubility.  
To make the compounds more soluble we attempted to disrupt the hydrogen bonding capacity 
of the compounds by methylation of the amide bonds as done before with compound (24) 
(Scheme 8), or introducing greater 3 dimensionality,132 leading to low packaging energies. 
For this purpose, it was proposed to saturate one of the benzene rings. Accordingly, 
analogues in which the terminal phenyl ring was replaced with cyclohexyl moiety were 
explored. The synthesis procedure was similar to that used for previous compounds. After 
preparation of the acyl chloride with thionyl chloride at 80oC, the crude intermediate (38) was 
reacted with 4-aminosalicylic acid in dry THF at room temperature for 16 hours, affording 




Scheme 12; i) SOCl2 (solvent), 80oC, 16h; ii) THF, r.t. 16h 
Gratifyingly, the solubility of this compound improved compared to previous analogues. 
Compound (39) was soluble in methanol and DMF, which made the analysis of this 
compound easier. 
This information encouraged us to start working with this structure and to synthesize new 
analogues based on the cyclohexyl moiety. To understand how our new molecules would 
bind to the designated pocket, different isomers were synthesized exploring the cis- (Scheme 
13) and trans- isomers (see Scheme 14). For both isomers duplicated signals due to presence 
of chair conformers were observed in the NMR analysis (see general experimental).  
The synthetic procedure started with an amide coupling of the Boc-protected 
aminocyclohexanoic acid with 4-aminosalicylic acid after treatment with HATU in the 
presence of DIPEA in dry THF. After 16 hours stirring at room temperature, intermediate 
(40) was obtained in 8% yield. Then, this intermediate was treated with 2M HCl in THF at 
room temperature for 16 hours affording compound (41) in quantitative yield. The 
deprotected intermediate was then reacted with cylcopropylcarbonyl choride in dry THF for 




Scheme 13; i) HATU, DIPEA, THF, r.t., 16h; ii) aq. 2M HCl, THF, r.t., 16h; iii) 
cyclopropylcarbonyl chloride, THF, r.t., 16h 
In the case of the trans- isomer, the Boc-protected version of the starting material was not 
commercially available, and we decided to try to start the synthesis directly with the 
deprotected 4-aminocyclohexanoic acid. The amide coupling with 4-aminosalicylic acid was 
performed with HATU as a coupling agent yielding intermediate (43). This compound has 
solubility issues due to the high polarity of the molecule and its zwitterionic properties 
(Scheme 14).  
 
Scheme 14; i) HATU, DIPEA, THF, r.t., 16h 
To try to amend this problem a new synthetic route was proposed to decrease polarity and 
obtain a compound more likely to be soluble in organic solvents. The protection of the 
carboxylate group of (45) avoids the formation of a zwitterionic compound.  
For this, 4-aminocyclohexanoic acid was treated with HBTU in the presence of TEA in dry 
THF to then perform an amide coupling with cyclopropane carboxylic acid to give compound 
(44) in 23% yield. This intermediate was treated with EDCI.HCl in the presence of DIPEA in 
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dry DMF and reacted with methyl 5-amino-2-hydroxybenzoate to afford compound (45) in 
52% yield. Then, compound (45) was hydrolyzed under basic conditions to give the desired 
product (46) in 92% yield (Scheme 15). 
 
Scheme 15; i) Cyclopropanecarboxylic acid, HBTU, TEA, THF, r.t., 6h; ii) EDCI.HCl, DMAP, 
DMF, methyl 5-amino-2-hydroxybenzoate, r.t., 48h; iii) 2M NaOH, THF, 80oC, 5h 
Unfortunately, the solubility of the cis- and trans- isomers was not as improved as we hoped. 
Despite being soluble in methanol and DMF in the laboratory, the biological assays were not 
possible according to the biologists and new approaches were explored.  
To try to disrupt the planarity of our molecules and then improve the solubility, another 
reported approach is the modification of the dihedral angle involved in the amide couplings. 
For this purpose, introduction of substituents in ortho-position to the carboxamide was 
explored by Harry Shrives (Figure 47).  
 




We were happy to see that a methoxy substituent improved significantly the solubility of the 
compound. At this stage it was theorized that 2 different events could be happening in our 
molecule to favor solubility: 
a) The steric hindrance between the methoxy group and the carbonyl group of the amide 
favors twisting the central aromatic ring out of the plane of the amide (Figure 48-a). 
b) It could be theorized that our compound is forming a new hydrogen bond. The lone 
pair of the oxygen and the hydrogen of the amide bond interact, and this hydrogen 
bond disrupts the polyamide structure and favors solubility (Figure 48-b). 
 
Figure 48; a) Orthogonal-inducing effect by steric hindrance; b) Hydrogen bonding by methoxy 
group 
To confirm which event is enhancing the solubility of our compound we thought that the 
methylation in ortho- position of the carboxamide (Figure 49) should also twist the central 
aromatic ring out of the plane. The absence of a hydrogen bond acceptor would discard the 
“b) approach” as responsible for the improvement of solubility, at least in this particular case. 
 
Figure 49; Rotation of the dihedral angle by steric hindrance of the alkyl group 
For further improvements of solubility and disruption of the polyamide structure, it was also 
theorized that the replacement of the central benzyl ring could be positive. To achieve a 
three-dimensional structure the synthesis of a cubane derivative was proposed. 
(1s,2R,3s,4r,5S,6r,7R,8S)-4-((tert-butoxycarbonyl)amino)cubane-1-carboxylic acid was 
reacted with 4-aminosalicylic acid after treatment with HATU in the presence of DIPEA in 
dry DMF for 16 hours at room temperature, yielding the desired intermediate in 20% yield. 
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Then, compound (48) was treated with TFA in DCM for 4 hours at room temperature, 
affording the Boc-deprotected compound (49). This intermediate was treated with TFA in 
DCM at room temperature for 4 hours affording compound (49). The intermediate was 
reacted with cyclopropylcarbonyl chloride in dry THF, the mixture stirred at room 
temperature for 16 hours yielding the desired compound (50) (Scheme 16). 
 
Scheme 16; i) 5-Aminosalicylic acid, TEA, HATU, DMF, r.t., 16h; ii) TFA, DCM, r.t., 4h; iii) 
Cyclopropylcarbonyl Chloride, TEA, THF, r.t. 16h 
 
Regarding the solubility observed in the laboratory, the studies performed indicated that the 
disruption of the polyamide π-stacking can improved the solubility of our compounds by 
following four different strategies: 
1. The methylation of one of the amides also disrupts the polyamide stacking improving 
solubility (Scheme 8 – Compound (24)) 
 
2. The introduction of a three-dimensional moiety was achieved by the saturation of one 
of the benzene rings (Scheme 12, 13, 15 – Compound (39), Compound (42), 
Compound (46)) or by the introduction of a cubane (Scheme 16 – Compound (50)) 
 
3. Introduction of an ortho-substituent (Figure 45 – Compound (47)) in the terminal 
phenyl ring close to the ketone, twisting the aromatic ring out of the amide plane. In 
the case of introducing a methoxy group the same event might be occurring, but 
hydrogen bonding by the oxygen’s lone pair with the amide’s hydrogen is also 




4. Removal of the right-hand side amide bond and introduction of different substituents 
also improved solubility (Scheme 13 – Compound (36), Compound (37)) 
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Chapter 5: Biological Assays 
Unfortunately, the improvements observed in solubility in the laboratory, showing promising 
solubility in methanol and/or DMF, were not always confirmed by the biologists during the 
different biophysical assays. In most of the cases, the compounds precipitated during the 
biological assays under the conditions used: Tris 100 mM, sodium formate 4.5 M, 5% 
glycerol, pH 8; or Hepes 100 mM, Sodium Formate 4.5 M, 5% glycerol, pH 7.5. Testing our 
compounds to direct the improvement in potency of the inhibitors was very challenging. 
Several biophysical studies were trialed by Sebastien Cardon at Leeds University (under the 
supervision of Alexander Breeze) yielding different outcomes. The solubility of the different 
compounds synthesized in different biophysical assays is summarized below (Table 1). 
 



































Table 1; Solubility of the compounds in the assays trialled (soluble, partially soluble, not soluble) 
 
• Protein X-Ray crystallography: 
 
To monitor and characterize the protein-ligand interactions by X-ray crystallography the 










































expressed in mycobacterium tuberculosis (TB) at 37oC. Protein expression was induced by 
isopropyl β-D-1-thiogalactopyranoside (IPTG) (180 rpm/ overnight). 
 
After the purification of the complex several conditions were trialled, making variations on 









Figure 50; a) 12 mg/ml; b) 10 mg/ml; c) 8 mg/ml 
 
Of all the compounds synthesized, only the hit compounds were soluble and some of them 
partially soluble ((33) and (47)) in the soaking conditions (Tris 100 mM, sodium formate 4.5 
M, 5% glycerol, pH 8). Unfortunately soaking the compounds in crystal for X-Ray diffraction 
of the protein-ligand complex cannot guide us in the search of a more potent compound due 
to insolubility issues.  
 
• Protein Observed-NMR assay: 
 
For protein observed NMR the expression of labelled 2D,15NSoscat is necessary. The 
experiments were performed in 250 mL of D2O + 5 g/L of 2D,15Nceltone powder. The 
preculture of the protein was expressed in TB and then treated with labelled media in D2O. 
Finally, the protein was purified by Ni2+ NTA affinity column. TROSY-NMR experiments 
were performed using a frequency of 950 MHz by increasing gradually the ligand 
concentration (300 µM, 1 mM, 3 mM, 5 mM). The observation of NMR shifted signals in the 
aminoacids of the allosteric site gave us information to extrapolate Kd’s for the different 
ligands. However, the solubility of compounds was still a liability and only a few ligands 






Figure 51; NMR shifts of the 2D,15NSoscat binding site (amino-acids 11, 68, 83 and 90) for compounds 
Ref. 24314-Compound (15), Ref. 24315-Compound (17), Ref. 24883-Compound (36) and Ref. 
24916-Compound (18) 
 
The NMR shifted signals can be observed in several of the allosteric site amino-acids, the 
same information can be also pictured with all the amino-acids present and extrapolating Kd’s 
for each of the most perturbed signal, the information is summarized in Figure 52, 53, 54 and 
55: 
 
Figure 52; NMR shifted signals for the amino-acids present in the allosteric site of Sos upon addition 




Figure 53; NMR shifted signals for the amino-acids present in the allosteric site of Sos upon addition 






Figure 54; NMR shifted signals for the amino-acids present in the allosteric site of Sos upon addition 






Figure 55; NMR shifted signals for the amino-acids present in the allosteric site of Sos upon addition 
of (37) 
 
Regarding the affinity of our ligands to the allosteric site, with the results that we have so far 
only a few conclusions can be made. The cyclopropyl amide moiety is not strictly necessary 
for affinity, when this group was substituted by a methoxy group or a nitrile the potency 
slightly dropped, suggesting the introduction of a (cyclopropylmethoxy)benzene or a 
(cyclopropylnitrile)benzene (Figure 52 and 53). 
 
ITC and SPR assays were also run, but the lack of solubility and the low affinity of our 





Chapter 6: Conclusions and Future Work 
The development (or choice) of a different biophysical technique with less demanding 
solubility conditions could give us information about the affinity of the ligands explored. For 
this, a lower concentration of ligand was proposed for future SPR trials.  
 
Obtaining the crystal structure for (H-Ras:Soscat) with soluble ligands can give us useful 
information for future explorations. The orientation of the ligands binding the protein, and 
rationalizing which substituents are necessary for binding could lead future explorations. 
 
Also, the application of the FragLite library (see Chapter 15) by soaking the FragLites into 
protein crystals can give us valuable insights about the different binding pockets of our 
protein. 
 
Unfortunately, without more information about the affinity of our ligands for the allosteric 





Chapter 7: Introduction to inhibition of IRF4 with drug-like small 
molecules as a useful therapy in lymphoid cancers 
7.1 Transcription Factors and cancer 
7.1.1 IRF family 
Interferon Regulatory Factors (IRFs) are proteins with the ability to block (repressor) or 
promote (activator) the expression of interferons (IFNs). IFNs are a class of cytokines, i.e. 
molecules used by cells to communicate with each other to trigger the immune system and 
eradicate pathogens. A virus-infected cell releases viral particles that can infect nearby cells, 
however, the infected cell can prepare neighboring cells against a potential infection by the 
virus by releasing IFNs. The way to prepare this response is done via motifs found in 
pathogens such as viral glycoproteins, lipopolysaccharides (bacterial endotoxin), bacterial 
flagella or viral RNA. These motifs can trigger the interferon response by binding to 
transmembrane receptors of cells, which can initiate several signaling pathways such as MAP 
kinases, PI3-K or Jak-STAT.133 The final step of the signaling cascade is performed by a 
Transcription Factor (in the case of IFN an Interferon Regulatory Factor). IRFs can bind 
specific sequences of DNA and control the rate of transcription from DNA to messenger 





Figure 56; Transcription factor promoting RNA synthesis 
 
Since the discovery of the first IRF transcription factor, the IRF family of proteins has grown 
remarkably in number and also in the diversity of functions related to them. Despite being 
originally defined for their relationship with viruses (notoriously Kaposi’s sarcoma) and IFNs 
induced activation of gene expression, it is now established that the IRF proteins have a great 
impact in our immune responsiveness, cell growth regulation and hematopoietic 
development.  
 
The IRFs can be classified into four groups, those that activate (IRF-1 and ISGF3γ), those 
that repress (IRF-2, ICSBP), those that both activate and repress (IRF-4) and those that may 
activate or repress (IRF-3) transcription of target genes. All members of this family share 
significant homology in the N-terminus part (115 aminoacids) which comprises the DNA 
binding domain (DBD); through this DBD the IRFs bind similar DNA motifs termed 
Interferon Stimulated Response Element (ISRE; found in most IFN-inducible gene 
promoters), Interferon Consensus Sequence (ICS) or Interferon Regulatory Factor Element 
(IRF-E). 
 
Studies characterizing IRF-expressing cell lines and IRF knockout mice reveal that each 
member of the IRF family performs different roles in cellular processes such as pathogen 
91	
	
response and cytokine signalling but can be also involved in cell growth regulation and 
hematopoietic differentiation. Its overexpression has been also related to cancer 
malignancies. 
7.1.2 IRF-4 and cancer 
Interferon Regulatory Factor 4 (Figure 57), also known as MUM, was found to be associated 
with sensitivity of skin to sun exposure, it has a strong presence in blue eyed, brown haired 
and freckled people and it is implicated in several types of leukaemia. 
 
Figure 57; IRF4 Ribbon-3D structure, PDB ID: 2DLL 
 
IRF4 is also closely related to several immune malignancies:  
• Recent studies have shown that B-Cell chronic lymphocytic leukaemia (B-CLL) is the 
most common form of leukaemia in the Western world.135 Absence of IRF4 
expression is the highest relative risk among the factors analysed in determining the 
probability of death in patients with B-CLL. Patients without IRF4 expression had 
significantly worse overall survival than did those with IRF4 expression.136 The 
overexpression or lower expression of IRF4 in the different types of diffused large B 
cell lymphoma has been demonstrated to be of paramount importance, however the 
pathogenesis and its direct relation with IRF4 is still not completely defined.137 
• The overexpression of IRF4 is not confirmed to be involved in the Hodgkin and Reed 
Sternberg (HRS) cells, however some studies have linked the viability of these cells to 
the expression of IRF4.138  




• In chronic myeloid leukaemia IRF4 is shown to be under-expressed, however the role 
of IRF4 in the disease is not characterized yet.140 
• IRF4 is associated with multiple myeloma (MM) leukaemia, and it has been 
commonly shown to be overexpressed without genetic alterations in a majority of 
multiple myeloma cases. The precise mechanism for pathogenesis of multiple 
myeloma in presence of high levels of IRF4 is mediated by an auto-regulatory loop 
established between IRF4 and c-MYC during B cell activation. Genetic abnormalities 
of MYC upregulate its expression in myeloma, thereby augmenting IRF4 expression. 
In normal plasma cells, Blimp-1 represses MYC, but this control circuit is abrogated 
in myeloma (Figure 58). 
 
Figure 58; IRF4 and MYC autoregulatory loop during normal B cell activation 
 
Despite functioning as a tumour suppressor gene in early B-cell development, IRF4 is a well-
established oncogene in multiple myeloma, with oncogenic implications extending to certain 
adult lymphomas and leukaemias.141,142,143 IRF4 appears to be a master-regulator of gene 
transcription in myeloma, influencing cellular survival, proliferation, metabolism and 




Figure 59; IRF4 Master Regulator in Multiple Myeloma 
 
siRNA knockdown of IRF4 by only 40-60% is lethal to myeloma cells, and therefore termed 
“non-oncogenic addiction”. The possibility of inhibiting IRF4 is considered a highly 
attractive therapeutic strategy since IRF4 gene deletion results in mice that are phenotypically 
normal suggesting a therapeutic window. 
 
To successfully inhibit IRF4 we need to understand how this transcription factor binds to 
DNA. The structure of IRF4 and its mechanism to interact with DNA have been widely 
studied.144 It is known that the Ets (E26 transformation-specific or E-twenty-six) and IRF 
transcription factor families contain structurally divergent members, which have evolved to 
cooperatively assemble on composite Ets-IRF DNA elements to regulate gene expression in 
the immune system.  
 
PU.1 is a hematopoietic Ets family transcription factor. Together PU.1 and IRF-4 
cooperatively bind to composite elements found in the DNA promoters and enhancers of B-
lymphoid and myeloid genes. 
 
The interaction of PU.1 and IRF-4 involves two protein-protein interactions (Figure 60).  
1. The Ets (E26) and IRF DNA binding domains 
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2. The phosphorylated PEST region of PU.1 and an autoinhibitory domain in IRF-4. 
 
 
Figure 60; X-Ray Structure of ternary complex145; The PU.1 Ets domain (red) and IRF-4 DNA 
binding domain (blue) are accommodated on opposite faces of the DNA (gold). 
 
Whereas PU.1 binds independently to its recognition site in DNA with high affinity, IRF-4 
interacts weakly with template DNA in the absence of PU.1. The reduced affinity of IRF-4 
for its binding site can be explained by its structurally diverged IRF-4 domain and by the 
presence of a C-terminal autoinhibitory domain.  
 
It has been proposed that recruitment of IRF-4 DNA bound to PU.1 involves cooperative 
interaction between the Ets and IRF DNA binding domain (DBDs) as well as relief of 
autoinhibition, which is mediated by the interaction of the phosphorylated PEST region in 
PU.1 with the C-terminal regulatory domain of IRF-4.  
 
In previous structure determinations done via co-crystallization of a ternary complex using 
murine PU.1, mouse IRF-4 and DNA fragments, the structure revealed that PU.1 and IRF-4 
bind to opposite faces of DNA in a head-to-tail orientation. A continuous van der Waals 




Figure 2. Protein and DNA Structure
(A) An overview of the PU.1/IRF-4/DNA ter-
nary complex. The PU.1 Ets domain (red) and
IRF-4 DNA binding domain (blue) are accom-
modated on opposite faces of the DNA (gold).
The residues involved in direct protein-pro-
tein interactions are drawn at the back of the
DNA. The figure was generated with program
MOLMOL (Koradi et al., 1996).
(B) PU.1 and IRF-4 bend the DNA into an “S
shape.” PU.1 binds primarily to the top half
of the DNA, while IRF-4 binds primarily to the
bottom half (c.f., Figure 2A). The DNA was
analyzed with the program arcFit (Slickers et
al., 1998).
(C) A continuous van der Waals surface ex-
tends between PU.1 and IRF-4. The surface,
computed with program GRASP (Nicholls et
al., 1991), is colored according to electro-
static properties, where red to blue spans
!10 to "10 kT in electrostatic potential. The
view corresponds to a 180# rotation about the
DNA axis, compared to that in (A).
equivalent loop in IRF-4, it drapes over the DNA rather by !5.1 Å, as compared to regular B-DNA. This distor-
tion in the DNA is critical in positioning the two DNAthan extending outward from it. Also, like most helix-
turn-helix proteins (Harrison and Aggarwal, 1990), the binding domains close together for protein-protein inter-
actions across the central minor groove.PU.1 recognition helix ($3) lies in the major groove in
an orientation perpendicular to the DNA axis, whereas
the IRF-4 recognition helix ($3) is tilted in the major Cooperative Protein-Protein Interactions
A continuous van der Waals surface can be drawn fromgroove with its axis almost parallel to the DNA sugar-
phosphate backbone. PU.1 to IRF-4 (Figure 2C), across the minor groove, that
is visually reminiscent of bipartite DNA binding by theThe DNA contorts into an unusual S shape due to
opposing bends (Figures 2A and 2B). PU.1 bends the Oct-1 POU domain (Klemm et al., 1994). Together,
!320 Å2 of solvent-accessible surface area is buried atDNA by !29.9#, while IRF-4 bends it in the opposite
direction by !30.3#. These bends are slightly greater the heterodimer interface, corresponding to the 20- to
40-fold measured cooperativity between the two DNAthan the values observed when PU.1 and the IRF-4-
related protein IRF-1 bind independently to DNA (!24# binding domains (Brass et al., 1999). Residues Arg222
and Lys223 in PU.1 extend across the minor groove likeand !26#, respectively). Because of the opposing bends
in the DNA, the net bend is !0# (Figure 2B). However, a pair of “pliers” to grip Asp117 in IRF-4 (Figure 3A).
This electrostatic hold is augmented by van der Waalsdespite this lack of a cumulative bend, the PU.1 and
IRF-4 binding sites are displaced laterally by as much contacts between the aliphatic portion of the Arg222




Figure 61; Computed with program GRASP146; Surface colored according to electrostatic properties, 
red to blue spans -10 to +10 kT in electrostatic potential.  
Summarizing, IRF4 is composed by a DNA Binding Domain (N-terminal), which weakly 
binds to DNA, and by an Interferon Association Domain (C-terminal), which binds to PU.1. 
If we can interfere with the association of IRF4 with DNA, the function of the interferon 
regulatory factor as a transcription factor could be disrupted and potentially benefit cancer 
patients with IRF4 overexpression. Both association domains are relevant and potential 
tractability could offer an interesting therapeutic window.  
7.2 Transcription factors as drug targets 
Transcription factors could be considered as the most direct targets for treating cancer. The 
amount of signaling proteins affected in cancer is considerably higher than the number of 
oncogenic transcription factors identified, therefore an effective anti-transcription factor-drug 
could be useful for several upstream proteins.  
 
Three main groups of transcription factors are known to be relevant in cancer: 
1. Steroid receptors (estrogen receptors in breast cancer for example or androgen 
receptors in prostate cancer). 
2. Resident Nuclear Proteins (usually activated by serine kinase cascades).147 
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3. Latent cytoplasmic factors (usually activated by receptor-ligand interaction at the cell 
surface). 
 
Despite the expectation that inhibition of the interaction between DNA-binding proteins with 
DNA is difficult, intense screening campaigns for this purpose are being undertaken from 
academia and industry.148 In fact, even if the specific DNA binding of a specific transcription 
cannot be disrupted, the interruption of functions of the transcription factor could still give us 
the desired pharmacological effects.  
7.3 Current Approaches to inhibit IRF4 for multiple myeloma malignancies  
In general, only considering patients affected by MM, the 3-year survival rate decreases from 
82.5% to 50.4% in patients with low and high IRF4 expression respectively.149 Thus IRF4 is 
a target for antitumour drugs to treat multiple myeloma malignancies that has been already 
investigated. Research focused on the disruption of IRF4 overexpression has yielded 2 
molecules with inhibitory activity and 2 different mechanism of action: lenalidomide and 
bortezomib. 
7.3.1 Lenalidomide 
Lenalidomide is an orally active compound with immunomodulatory and antiproliferative 
agent characteristics with several uses for haematological disorders, non-Hodgkin lymphoma 
and MM.150 It is sometimes used in combination with the corticosteroid dexamethasone in 
MM patients, however a low dose of dexamethasone generally results in a superior overall 
survival.151 These results indicated that dexamethasone adds toxicity and may limit some of 
the beneficial effects. Lenalidomide success relies on the inhibition of the proliferation of 
MM cells and immunomodulation against tumour cells. To inhibit the proliferation of MM 
cells lenalidomide has been proven to upregulate apoptosis via inhibition of CDK2, 4 and 6 
activity which leads to retinoblastoma (RB1) hypophosphorylation and cell cycle arrest. In 
the case of MM patients RB1 is predominantly expressed in the phosphorylated form. 
Regarding the immunomodulatory actions, lenalidomide can downregulate cytokines (such as 
IL-6) and therefore reduce the expression of IRF4 present in cells. 
 
Lopez-Girona, A. et al. (2011)152 studied the association between IRF4 and MYC. It was 
confirmed that lenalidomide treatment decreased the amount of IRF4 and MYC proteins 
bound to the specific sites of IRF4 and c-MYC genes suggesting that lenalidomide interferes 
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with IRF4/MYC auto-regulatory loop which affects the proliferation of cells. These results 
support the hypothesis that IRF4 plays an important role in the inhibition of the cell cycle and 
proliferation of MM cells and that lenalidomide can interfere with the association with MYC 
rather than inhibiting the association with DNA. In the same study it was also established 
with a panel of MM cell lines with different sensitivity to lenalidomide that there is a 
relationship between IRF4 levels and lenalidomide efficacy. An overall survival analysis 
done on samples from 154 well-characterized MM patients confirmed a significantly shorter 
overall survival for patients with high IRF4 expression. Without any treatment median 
overall survival was 42 and 83 months in patients with high and low IRF4 expression 
respectively (Figure 62-A). Among patients treated with lenalidomide, there was no longer 
any significant difference in overall survival between patients with high or low expression of 
IRF4 (Figure 62-B). The importance of high IRF4 expression was even more important for 
patients treated with non-lenalidomide strategies (Figure 62-C). 
 
Figure 62; Treatment influence in patients with variable IRF4 expression: A) patients with no 
treatment, B) Patients treated with lenalidomide, C) Patients treated with other strategies 
7.3.2 Bortezomib combined with lenalidomide153 
In the case of Mantle cell lymphoma (MCL), which leads to aberrant overexpression of 
cyclin D1, conventional chemotherapy induces remission but unfortunately relapses within a 




Bortezomib is a first in class proteasome inhibitor of 26S proteasome and induces response 
rates of 30% to 50% in patients with relapsed disease independently of their sensitivity to 
prior treatment. However, more than half of all MCL patients are resistant or develop 
resistance to bortezomib. The mechanism for resistance is not yet understood but an increased 
expression of IRF4, among other things, has been pointed to by in vitro approaches. 
 
In a recent attempt to establish if lenalidomide could reverse MCL resistance to bortezomib 
in vivo, mice inoculated with REC-1 cells (MCL cell line that develops resistance) were 
assigned to four different treatment arms (i/v administered): 
1. Bortezomib (0.15 mg/kg) twice per week. 
2. Lenalidomide (50 mg/kg) daily. 
3. A combination of both agents. 
4. Equal volume of vehicle (saline). 
In the case of administration of bortezomib the size of the tumour was not affected. When 
administration of lenalidomide was done a 45% of reduction of the tumour size was observed 
when compared to the vehicle and finally the reduction of the tumour size was enhanced with 
the addition of bortezomib to lenalidomide, reaching a 37% and 67% tumour decrease when 
compared with lenalidomide and vehicle arms respectively (Figure 63). 
 
 
Figure 63; Mice were inoculated with REC-1 cells as previously described and began treatment at 
day 9 post-inoculation with 50 mg/kg lenalidomide, 0.15 mg/kg bortezomib, both agents or equal 





Further histological analysis of the tumour confirmed a stronger reduction in the mitotic 
index by the combination therapy (Figure 64). Left panel, intra tumour glucose uptake was 
evaluated in representative mice injected intravenously with an IR800-labeled 2-deoxy 
glucose probe 24 h prior killing, and visualized with an Odyssey infra-red scanner (Li-Cor, 
Lincoln, NE, USA). Right panel, relative fluorescence quantification by means of the Image 
Studio software (Li-Cor) shows markedly reduced glucose uptake in tumour masses from 
mice receiving lenalidomide or the lenalidomide–bortezomib combination, when compared 
with either vehicle- or bortezomib-treated animals. 
 
 
Figure 64; Infrared Scanner showing tumour volumes (blue to red: increase in glucose uptake) 
 
After analyzing the in vivo studies previously described with spontaneous or acquired 
resistance to proteasome inhibitor it was proved that drug-resistant MCL cell lines have 
increased tumourigenic properties in vivo, and that the increased aggressiveness of these 
tumours is directly related to the expression of a plasmacytic differentiation program, IRF4 
being the major regulator.  
 
The evidence suggests that MYC upregulation would be present in bortezomib-resistant 
tumours thanks to the overexpression of IRF4 which downregulation can be achieved through 
administration of lenalidomide. This surprising combination of drugs offers potential 
opportunities for the treatment of MCL patients with resistance to bortezomib. 
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Chapter 8: Project Rationale 
Multiple myeloma is the second most common haematological malignancy, and responsible 
for 2% of all deaths from cancer. Despite novel therapies for multiple myeloma becoming 
available (including bortezomib and lenalidomide), the outlook remains poor. High risk 
patient median survival is < 2-3 years, for this reason tool compounds for IRF4 could be of 
great benefit to the field and would be used by many investigators worldwide. 
The hypothesis of our project relies on the inhibition of interferon regulatory 4 (IRF4) with 
drug-like small-molecules as a possible therapy for multiple myeloma. IRF4 inhibitors can be 
discovered by screening and optimization through structure guided medicinal chemistry.  
A small-molecule inhibitor of IRF4 would be expected to have a significant impact in the 
treatment of several cancers including myeloma and lymphomas, immunosecretory disorders 
and autoimmune disorders. It would also provide clinical proof of concept for the targeting of 
transcription factors – a previously unexploited approach.  
A crystal structure for the C-terminal “IAD” (interferon association domain) of murine IRF4 
has been previously reported (Figure 65). In the same article, small angle X-ray scattering 
(SAXS) data for full-length IRF420-132 are also presented and used to derive the full-length 








With this information, reproducible crystals of a mutant of the IRF4 DNA-binding domain 
(IRF420-132 E45A E46A K47A C99S) have been obtained in Newcastle University (E = 
Glutamate, K = Lysine, C = cysteine) by Dr. Julie Tucker (NICR). 
 
 The crystals tend to grow as clusters of plates, some of which are comprised of multiple 
layers (Figure 66). 
 
 
Figure 66; Crystals of IRF420-132 E45A E46A K47A C99S grown from 0.2 M NaCl, 20 % PEG3350, 
0.1 M HEPES, pH 7.5 
 
Unfortunately, the diffraction quality of these crystals is inconsistent, with some showing 
diffraction to better than 2.4Å on an in-house rotating anode X-ray source, whilst others show 
only ~3 Å diffraction at a synchrotron source (DIAMOND Light Source, Oxford).  The 
crystals belong to at least two different space groups (C2221 and P212121), even though they 
look very similar to the eye under the microscope.  The two space groups occur in the same 
drop under the same conditions. A subset of the crystals shows a form of twinning called “ 
order-disorder” twinning.  
 




1- Crystals must diffract consistently and ideally to high resolution better than 2.5 Å 
2- Must be reproducible 
3- Have binding sites/surfaces accessible for fragment binding 
4- Be tolerant to high concentrations of co-solvent (DMSO) and compound 
5- Be stable in a buffer compatible with compound solubility and binding 
 
Due to these restrictions alternative crystallisation conditions were tried, and also some 
alternative protein variants were synthesised and tested. Finally, mutation of cysteine 99 to 
serine, to generate the quadruple mutant IRF4 (20-132 [E45A E46A K47A C99S]), led to the 
development of a highly reproducible, well diffracting crystal system suitable for screening 
(Figure 67).  
A) B)  
Figure 67; X-ray structure (IRF4); A) Ribbon diagram; B) DBD surface showing possible binding 
sites 
 
The obtention of these crystal systems can used for several purposes, such as: 
• The completion of a model, analyzing accessible surfaces and crystal contacts 
• Comparing our structure with the NMR structure of the ternary complex of IRF4 with 
PU.1 and DNA and DNA binding domains of other members of the IRF family 
• Fully exploit the structure through pocket finding and docking 
• Characterise hits from the HTS 













A number of constructs spanning the IRF4 DBD variously tagged so as to facilitate the 
development of a variety of assays (including FP, SPR and NMR) as well as crystallisation 
have been generated at Newcastle University. Protein observed NMR (in collaboration with 
the University of York), isothermal titration calorimetry (ITC) and differential scanning 
fluorimetry (DSF) methods have been used to measure DNA binding to the recombinant 
human IRF420-132.  
8.1 Structural Biology and Hit Discovery 
Initially a fluorescence polarization assay using fluorescently labeled DNA oligomers to 
characterize a variety of combinations of DNA sequences and IRF4 fragments was developed 
(Figure 68).  
 
Figure 68; Fluorescence Polarization Assay; A) Tagging of fluorophore labelled DNA duplex with 
Tagged IRF4; B) Four different candidate molecules showing a decreased detection of fluorescence 
due to binding with previously IRF4 tagged-fluorophore labelled DNA for our 4 hits 
A high throughput screening was carried out at CRT-DL (Cristina Alli, Fabrice Turlais, 
Suzanne Grooby, Cambridge) using IRF420-132 with a C-terminal hexahistidine tag and a 
TAMRA-labelled 12mer DNA duplex in a fluorescence polarisation (FP) assay format.  The 
assay had been developed at NICR (Judith Reeks, Mathew Martin) based on similar assays 
and validated using unlabelled DNA duplex to compete off labelled DNA duplexes. Cysteine 
99 within the IRF4 DNA binding domain lies close to the interface with DNA. Covalent 
derivatisation of Cys99 with bulky thiol-reactive compounds (S399272, 024957) was shown 
to abolish the signal in the FP assay, suggesting steric hindrance of DNA binding, and further 




The current FP assay shows a lower than ideal signal-to-noise ratio with the Maximum 
(Protein + DNA duplex) and Minimum (DNA duplex alone) signals differing by ~1.25 fold.  
Further optimisation of assay parameters with the aim of improving the signal-to-noise ratio 
to a value ≥ 2.5 were carried out.   
 
This work included testing: 
• Different combinations of IRF4 construct (e.g. GST-tagged IRF4 instead of 
His-tagged IRF4) with DNA duplex (e.g. 21-mer instead of 12-mer). 
• Alternative fluorophores (e.g. Fluorescein instead of TAMRA), and possibly 
alternative fluorophore attachment points (currently 3’ to ensure close spatial 
proximity of fluorophore and IRF4 binding site on the duplex (Figure 69). 
• A range of buffers (e.g. Tris instead of HEPES), [NaCl], pH. 
• The effect of additives (e.g. detergent, glycerol). 
• The effect of temperature (e.g. 4oC instead of room temperature). 
 
 
Figure 69; Design of fluorophore and biotinylated DNA duplexes for the IRF4 FP and SPR assays 
 
Unfortunately, the FP assay could not be improved and the initial HTS hits were used for 
future exploration.  
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Four hits were selected from the initial output ((51), (52), (53) and (54)) (Figure 70), re-
purchased and subjected to HPLC purification and/or re-synthesized in house.   
 
Figure 70; Hits selected after screening 
 
The four hits were characterised in the FP assay at NICR, and shown to increase the FP 
signal, suggesting that they displace DNA from IRF4. Different attempts with different 
techniques, explained in the following pages, were performed to confirm the hits. At the same 
time an SAR exploration of the parent compounds (51) and (54) was undertaken. 
 
Herein we present a summary of further biophysical assays performed to confirm the hits: 
• Isothermal titration calorimetry (ITC). It is typically used as a secondary screening 
technique in HTS. ITC is particularly useful as it gives not only the binding affinity, 
but also the thermodynamics of the binding. This thermodynamic characterization 
allows for further optimization of compounds (Figure 71). 
 
 
Figure 71; Basics of ITC experiments 
 
ITC was used to assess the direct binding of the four hits to the IRF4 DNA binding domain 
(GPLGS-IRF420-132-LERPHRD). Poor solubility of the compounds in aqueous buffer 
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supplemented with 2% DMSO limited the maximum concentration that could be achieved in 
the titrations.  The solubility of compound (52) was so low that a reverse titration was 
performed with a lower concentration of compound in the sample cell and a higher 
concentration of protein in the syringe.  Data for this compound were not measured at 10oC 
as the compound solubility was further reduced at this low temperature. The data obtained 
showed no evidence for the binding of NCL-00022363 (Compound (51)), NCL-00022472 
(Compound (52)), or NCL-00022474 (Compound (53)) under the conditions used, whilst the 
data for NCL-00022473 (Compound (54)) was inconclusive (Figure 72).  
 
Figure 72; Data were measured using an iTC200 instrument (GE-Healthcare, located in ICaMB, 
Catherine Cookson building) with the indicated concentrations of protein and compound 
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• MicroScale thermophoresis (MST). Is based on the directed movement of particles in 
a microscopic temperature gradient. Any change of the hydration shell of 
biomolecules due to changes in their structure/conformation results in a relative 
change of the movement along the temperature gradient and is used to determine 
binding affinities. MST allows measurement of interactions directly in solution 
without the need of immobilization to a surface (immobilization-free technology). 
Preliminary investigation of the behaviour of 3’-fluorescein labelled 21-mer DNA 
duplex was carried out using the microscale thermophoresis instrument 
(NanoTemper) available in the CBCB (Baddiley-Clark Building). A sample of DNA 
duplex in FP assay buffer was measured. Whilst demonstrating that a good signal 
could be obtained, the data showed that aggregation of the DNA was likely occurring 
under the conditions used. Use of a detergent in the assay buffer was suggested by the 
MST technical support (Astrid Sitte) who helped with the measurements, but no 
improvement was observed. 
 
• Nuclear Magnetic Resonance Spectroscopy. Measurements have been carried out on 
the 700 MHz NMR instruments (Bruker) in York (Pedro Aguiar, Jennifer Potts) and 
in Newcastle (Corinne Wills, William McFarlane).  A number of different techniques 
have been used to assess direct binding of compounds to the IRF4 DNA binding 
domain. In York, two ligand observed methods were employed; saturation transfer 
difference (STD) and WaterLOGSY.  Unfortunately, due to the small size of the IRF4 
DNA binding domain (13 to 15 kDa depending on the protein batch used), the nuclear 
Overhauser transfer effects (nOe) would not be expected to be strong enough to 
provide a good signal in these experiments at the protein concentrations employed (up 
to 10 µM). Also, critical control experiments for the WaterLOGSY experiments were 
not carried out, such that aggregation of the compound under the experimental 
conditions cannot be ruled out.  Although these experiments have not so far provided 
evidence for direct binding of the compounds to IRF4, neither have they completely 
ruled this out. 
 
In Newcastle, preparatory work to assess direct binding of compound by monitoring 
the chemical shift of the methyl protons in the IRF4 protein 1H spectrum was 
performed.  An initial DMSO titration experiment shows that the IRF4 DNA binding 
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domain can tolerate at least 10 % DMSO without loss of signal (Figure 71). Binding 
of compound to the protein should impact directly on the environment of methyl 
groups in amino acids within the compound binding site (i.e. leucine, methionine, 
threonine, alanine, valine, isoleucine), thus causing a chemical shift.  Alternatively, 
binding may cause a change in the overall protein conformation, which will alter the 
environment of methyl groups distal to the binding site.  Monitoring the methyl 
groups is therefore a highly sensitive method of detecting binding. The DC50 values 
for compound (51) and (54) as measured in the FP assay at NICR are in the 30-100 
µM range and unfortunately no ligand binding events were detected as we can see in 
the lack of chemical shift of the methyl protons (Figure 73) for compound (54) under 
any conditions. 
 
Figure 73; Titration of DMSO into IRF4 monitored by 1H NMR. Methyl proton shifts are not visible 
at around -1.0 ppm 
 
• Differential Scanning Fluorimetry (DSF). Changes in the protein and/or DNA duplex 
melting temperature (Tm) can be used to monitor the binding of compounds. This 
technique has already been used in the IRF4 project, both to assess binding of DNA 
duplex to the DNA binding domain, and to screen a small library of fragments 
provided by CRT.  The Tm shifts observed, including those for DNA binding, were 
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very small (< 3oC), such that the signal-to-noise is very low. The results are not 
reliable. 
 
As a conclusion, none of the techniques that we tried were able to confirm any of the parent 
compounds as active. 
 
In the case of the ITC experiments we can observe some activity for compound (54) when the 
assay is tested at 25oC. Future analogues of this hit will be synthesized and further assays in 
the same conditions could give us some insights in the result previously obtained. 
 
Also, in our effort to try to find compounds more suitable for the different techniques applied 
we decided to pursue an exploration on the scaffolds obtained during Hit Finding. The SAR 
conducted is presented in the following chapter. 
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Chapter 9: Results and Discussion 
9.1 Methodology 
The first goal of the project was to develop robust synthetic methods for the target 
compounds. With the appropriate synthetic approach we were able to produce a series of 
analogues that can improve the potency of the compounds and establish a structure activity 
relationship. After the HTS several compounds were identified, of those the pyridazinone and 
acrylamide series were chosen for further exploration (Scheme 17). 
Scheme 17; Target compounds; A) Pyridazinone series B) Acrylamide series 
9.2 Targets synthesized 
Our present effort is a follow up on HTS hits, for compound (54)155 (Pyridazinones), and for 
(51)156 (Acrylamides).  
9.2.1 Pyridazinones 
Pyridazinone compounds have been studied as potential targets for the development of 
treatments of proliferative diseases such as lung cancer.  
 
Pyridazine and its derivatives have been known for almost a century but have received not 
enough attention until recently due to the discovery of medicinally useful natural products.157 
Today, the pyridazinone nucleus and its 3-oxo derivative (2H-pyridazin-3-one) moieties have 
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been recognized as versatile pharmacophores. This key subunit is part of many biologically 
active substances with a broad range of biological and pharmaceutical activities like 
cardiotonic agents158 or as a treatment of neuropathic pain.159 
 
The strategy followed initially to identify new candidates with improved properties was the 
exploration of parent compound (54). The exploration was undertaken by synthesizing 
analogues modifying the benzoic acid moiety (positions R) and the substituents on the 
pyridazinone ring (position R2) (Scheme 18).  
 
 
Scheme 18; Derivatization of the structure of the parent compound 
These two different series of targets were divided between me and Shaun R. Stevens. Here 
we present the work carried out to synthesize the R2 analogues. 
9.2.1.1 Pyridazinone variations 
Several derivatives have been synthesized changing the substituents of the pyridazinone ring 
system. A classical approach was used initially for targets (54) and (55) (Figure 74). 
 
Figure 74; Pyridazinone ring derivatives 
 
Traditionally, these compounds have been obtained by acid-catalyzed cyclocondensation 
reaction of N-arylhydrazine with various 1,4-difunctionalized compounds. The reactions are 




Scheme 19; Aryl hydrazine and 1,4-difunctional hydroxyfuranone reacted at 65oC for 16 hours 
 
For target (57) two different approaches were carried and both produced the desired target 
(Scheme 20). In the first approach (Scheme 20-a) to synthesize the compound of interest an 
adaptation of the classic approach was used. 2,3-Dimethylmaleic anhydride was treated with 
lithium tri-tert-butoxyaluminium hydride in THF-Et2O at room temperature for 6 hours to 
afford our 1,4-difunctionalized compound (58). Subsequent treatment with 4-
hydrazinobenzoic acid did not gave the desired target (57).  
 
In the second approach and as a more convergent synthetic pathway, compound (54) (Scheme 
20-b) was used as starting material, after treatment with aluminium trichloride and palladium 
tetrakis in toluene at reflux temperature (100oC) the desired target (compound (57), Scheme 
20-b) was obtained. In this case the yield was superior and for our interests the synthetic 
route is more convergent. 
 
 
Scheme 20; a) i) Li(tBuO)3Al-H, r.t.; THF; ii) aryl hydrazine, EtOH-H2O, HAc; 60oC; b) i) AlMe3, 




For target (56) (Figure 74) an initial approach was developed using an Ullmann condensation 
as a final step for obtaining the desired target (Scheme 21). 
 
 
Scheme 21; i) K2CO3, EtOH, reflux; ii) NH4HCO2, EtOAc; iii) Ullmann condensation or Chan-Lam 
coupling 
 
After a wide exploration of different catalysts, bases, solvents and aryl halides, the approach 
using pyridazin-3(2H)-one (60) was finally abandoned due to lack of reactivity of the 
pyridazinone (60) as a nucleophile (Table 2). 
Substrate Ligand Catalyst Base Solvent Results 
	 	





































































Cu(OAc)2 pyridine DMF 
0% by 
LCMS 
Table 2; (Ullmann condensation and Chan-Lam attempts) 
 
A new approach was tried and found to be successful (Scheme 24). In this approach 
trifluoro(furan-2-yl)-borane potassium salt (61) was prepared from furan-2-ylboronic acid 
and 4-cyanobenzenediazonium fluoride (62) was prepared from 4-aminobenzonitrile. These 
two compounds were slowly mixed together in water at 5o C and after 30 minutes the reaction 
went to completion. After the intermediate compound 4-(6-oxopyridazin-1(6H)-
yl)benzonitrile (63) was isolated and hydrolyze in acidic conditions the desired target 
molecule (56) (Scheme 22) was obtained. 
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Scheme 22; i) KHF2, MeOH, 0oC to r.t; ii) tBuONO, BF(OEt)3, DCM, -15oC to r.t; iii) H2O, 5oC to 
r.t.; iv) H2SO4/H2O (6:4), r.t. 
9.2.1.2 Pyridone and Pyrimidinone variations 
To obtain more information regarding the functions of the heteroatoms in the pyridazinone 
ring we synthesized a new series of compounds with different heterocycles. Nitrogen in 
position 2 of the pyridazinone ring was moved and deleted (Figure 75). 
 
Figure 75; Pyridone and pyrimidinone ring derivatives 
 
To synthesize compound (66) 4,6-dichloropyrimidine was treated with conc. HCl in dioxane. 
The mixture was stirred at 70oC for 6 hours affording compound (67) in 57% yield after 
purification. The pyrimidinone (67) was then reacted with 4-(ethoxy)benzene boronic acid 
under Chan-Lam conditions affording intermediate (68) in 62% yield. The hydrolysis of this 
intermediate under acidic conditions gave us the desired compound (66) in 11% yield after 
purification (Scheme 23-a). To synthesize compound (64), 2-amino-4-chloropyridinewas 
treated with H2O2 in conc. HCl at 0oC, affording compound (69) in 27% yield after 
purification. The intermediate was reacted with sodium nitrite in HCl to afford the desired 
pyridinone (71) in 16% yield after purification. Compound (71) was then reacted with 4-
iodobenzonitrile under Ullman conditions affording the desired compound (72) in 16% yield 
after purification. The hydrolysis of compound (72) under acidic conditions gave us the 
116	
	
desired compound (64) in 7% yield after purification (Scheme 23-b). To make compound 
(65) 2,4-dichloropyridine was treated with sodium acetate in acetic acid to afford pyridinone 
(73) in quantitative yield. The intermediate was reacted with ethyl 4-iodobenzoate under 
Ullman conditions to give (74) in 35% yield after purification. Hydrolysis of compound (74) 
gave the desired product (65) in 53% yield after silica purification (Scheme 23-c). 
 
Scheme 23; a) i) HCl/H2O (1:9) in Dioxane; ii) 4-(Ethoxy)benzene boronic acid, Cu(OAc)2, pyridine 
in DCM; iii) H2SO4/H2O (6:4); b) i) H2O2 in HCl; ii) NaNO2 in HCl; iii) 4-Iodobenzonitrile, 8-
Hydroxyquinoline, CuI, K2CO3 in DMSO; iv) H2SO4/H2O (6:4); c) i) NaOAc/ HAc; ii) Ethyl 4-
iodobenzoate, K3PO4, CuI, N,N-Dimethylethylenediamine in dioxane; iii) LiOH.H2O in THF 
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Further to these analogues Shaun R. Stevens prepared compounds by growing the left-hand-
side moiety and making variations in the same benzene ring. These compounds will be shown 
together with the FP assays at the end of this section. 
9.2.1.3 Sulfonamide variations 
After several issues with the solubility in DMSO of our compounds affecting its reactivity 
and having not only poor yields, but also many problems in the reliability of the biological 
assays, it was decided to substitute the carboxylic group in the benzylic ring for a new series 
of sulfonamide analogues (Figure 76). 
 
 
Figure 76; Sulfonamide derivatives 
 
Our approach to synthesize these compounds was similar to that used in section 9.2.1.1 using 
a different hydrazine compound as starting material, this gave us access to the sulfonamide 
compounds. A common intermediate (78) was synthesized and used as precursor of the final 
target in the three different final targets (Scheme 24). 
 
 
Scheme 24; Synthesis of common intermediate (78) for synthesizing sulfonamide derivatives 
Once intermediate (78) was synthesized the derivatization for the different final targets was 
performed as described in the following scheme. Intermediate (78) was treated with thionyl 
chloride and the sulfonyl chloride crude intermediate was then reacted with morpholine, 




Scheme 25; a) i) SOCl2 in DMF; ii) Addition of morpholine; b) SOCl2 in DMF; ii) Addition of N-
methly piperazine; c) i) SOCl2 in DMF; ii) Addition of N-Boc-piperazine; iii) H2SO4/H2O (6:4) 
9.2.2 Acrylamides 
For the parent compound (51) several analogues were synthesized.  Shaun R. Stevens was 
focused in modifying the THF moiety (left-hand side of the molecule) and I synthesized 






Figure 77; Derivatization on position 2 of the aniline 
9.2.2.1 Acid variations 
Several derivatives were synthesized with different substituents in position 2 of the initial 
aniline. The main purpose of these variations was to, on top of improving the potency of the 
scaffold, work with compounds with better solubility to obtain information in the assays. It 
was believed that the removal of the carboxylic group in exchange for more lipophilic groups 
would improve the solubility in DMSO but little or no improvement was observed (Scheme 
26). 
 




We have used the same synthetic pathway for our desired targets in the three different 
analogues. (Compounds (80), (81) and (82)) (Scheme 29). (E)-3-(furan-2-yl) acrylic acid was 
used as starting material in all our cases, after treatment with oxalyl chloride to give the 
intermediate acyl chloride, which after treatment with the appropriate aniline compounds 
gave the desired targets (Scheme 27). 
 
















Chapter 10: Biophysical Assays and Conclusions after HTS and SAR 
focused on the DNA Binding Domain (DBD) 
The hits obtained via high throughput screening (HTS) were not confirmed by the initial FP 
assay, which shows a lower than ideal signal-to-noise ratio with the Maximum (Protein + 
DNA duplex) and Minimum (DNA duplex alone) signals differing by ~1.25 fold.  
 
Some compounds were at or, above or below, this maximum and minimum making the 




Figure 78; The millipolarisation (mP) versus concentration of compound results for representative 
analogues of the parent compounds 
 
Most active compounds shown in previous Figure are light orange and dark blue (both 
compound (57)) and dark purple and green (both compound (83)-Synthesized by Shaun R. 




Figure 79; Most active compound after first initial FP assays 
 
 
Figure 80; The millipolarisation (mP) versus concentration of compound results for representative 
analogues of the parent compounds 
 
Most active compounds shown in previous Figure are orange and dark blue (both compound 





Figure 81;	Most active compounds after first initial FP assays 
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A further optimisation of this assay parameters with the aim of improving the signal-to-noise 
ratio to a value ≥ 2.5 was carried out in order to confirm our hits and to provide us, in 
combination with other methods ((Isothermal titration calorimetry (ITC), MicroScale 
thermophoresis (MST), Nuclear Magnetic Resonance Spectroscopy, Differential Scanning 
Fluorimetry (DSF)) with reliable tools and information to evaluate the activity of the different 
compounds synthesized and also of the parent compounds.  
 
Unfortunately, none of the methods tried provided us with any useful information and this 
approach was abandoned. With the hope to obtain additional hit matter a Fragment Based 




Chapter 11: Fragment-Based Screening by SPR focused on the DNA 
Binding Domain (DBD) 
Additional Hit Finding was done via “Fragment based screening” with the human DNA 




Figure 82, IRF4 domains 
 
The advantage of fragment-based screening (FBS) is the possibility of start an exploration 
with smaller compounds and build new molecules with more degrees of freedom while not 
abandoning the “drug-like space”.  
 
The fragmentation of drug leads into smaller fragments, has been used to simplify the 
computational analysis of ligand binding and to map pharmacophoric elements required for 
high-affinity binding. The concept of FBS relies on the optimization of each unique 
interaction in the binding site and subsequent building of a single molecule that should give 
us a compound with a binding affinity that is the addition of the individual affinities. 
However, even the most advanced computational algorithms cannot make a perfect prediction 
of the affinity for each single fragment so, to effectively use fragments in drug design, an 
experimental method is required to rapidly and reliably screen thousands of low-molecular-
mass test compounds for weak (millimolar range) binding to the target protein. Two-
dimensional, isotope-edited nuclear magnetic resonance (NMR) spectroscopy is well suited 
to this purpose and is considered the main method as NMR chemical shifts tend to be 
sensitive to ligand binding. In our case, a fragment-based screening was undertaken using 
human DNA binding domain crystals. A subset of the Astex fragment library was used with 
no hits obtained due to very low ligandability.  
 
After this exploration a new approach, fragment screening by SPR, more efficient towards 
the detection of very weakly binding hits was undertaken. The SPR experiment is based on 
the detection of variations in the refractive index upon binding of the ligand to the surface. 
The variation of the signal is proportional to mass of bound ligand (Figure 83). 
 





Figure 83; SPR experiment160  
 
The SPR experiment was performed at Glasgow University (Figure 80 and Table 3) 
affording: 
• 13 SPR hits out of 1041 fragments (Beatson library) + 3 fragments from Newcastle 
screened (1.25 %) 
• 3 out of 13 SPR hits confirmed by NMR (23 %) (STD and WaterLogsy) 
 
Hits are categorized in: 
 





Specific (fast kon/koff) 5 2 40 
Specific/non-specific  
(fast kon/slow koff) 
2 0 0 
Non-specific (slow kon/koff) 6* 1 17 
 
Table 3; SPR and NMR hit finding 
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The specificity of the ligand towards the target can be measured by the response curves. The 




 SPECIFIC / NON-SPECIFIC
    NON-SPECIFIC 
 
Figure 84; Shapes of general curves for the 3 different hit types by SPR 
 
To confirm the binding site of our compounds and the affinity of those for the DNA binding 
domain (DBD), the different analogues were soaked into crystals of IRF4 DBD. The different 
compounds were dispensed directly into crystallisation drops using Echo: 
• 25 or 50 nL of 100 mM stock in DMSO 
• Final concentration of the compounds ≥ 5 to 10 mM 
• Soaked for 16 hours – 5 days 
 
The data collected at ESRF or Diamond Light Source is summarized below: 
• Resolution range 2 to 2.6 Å 
• Auto-processed using Global Phasing software pipeline 






























































There are several reasons for a lack of electron density; for example: 
• Binding site is not present in the crystal 
- Binding pocket occluded by crystal contacts 
- Protein conformation different in crystal than solution 
- Mutations undertaken to form the crystal destroyed the binding site 
• Compound does not bind or binds weakly in soak buffer 
• Potency/solubility ratio is too low 
 
Despite not having conclusive results a further exploration of the hits obtained was 
undertaken relying mainly on the SPR analysis. 
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Chapter 12: Discussion and Results of the new chemical series 
After the fragment-based screening different analogues of the parent compounds identified 
were synthesized. Herein is reported the synthesis of the parent compounds (85) and (86) and 
its analogues (Figure 85). 
 
Figure 85; Hits categorized as Tier 1 after fragment-based screen 
 
In both cases the synthesis of the parent compounds and its analogues was undertaken by 
Stephen H. Hobson, Shaun R. Stevens and me. After obtaining the parent compound (85) 
several analogues were proposed (Figure 86). 
 
 




The methodology used to synthesize the parent compound was also used for derivatization 
(Scheme 29). 
 
Scheme 29; Methodology used to synthesize the parent compound and its analogues. i) 1) NaNO2, 
conc. HCl; 2) SnCl2, H2O; ii) 5-Chloro-2-pentanone, EtOH, HOAc  
 
The aniline is initially dissolved in conc. HCl and then sodium nitrite in H2O is added to the 
reaction maintaining the temperature of the stirred mixture below 50C during the addition. 
Subsequently the SnCl2 in conc. HCl is added to form the hydrazine compound 93. The 
hydrazine is then treated with 5-chloro-2-pentanone and acetic acid in methanol to give the 
desired products (85), and (88). Regarding compound (88) stability issues were detected and 
the product was registered but not further tested nor investigated as the molecule was not 
stable as a solid or in solution. Decomposition was always observed if position 4 of the indole 
is not substituted with any atom different to hydrogen. In the case of (89) a different synthetic 
route was used due to quaternization of the primary amine after trying to methylate the parent 
compound (85) with iodomethane and using as a base sodium hydride (NaH (60%)). The 
pathway to synthesize (89) was via Fischer indole synthesis (Scheme 30). 
 
Scheme 30; Methodology used to synthesize (89); i) 1) NaNO2, (c) HCl; 2) SnCl2, H2O; ii) acetone, 
ZnCl2; iii) MeI, NaH(60%), THF; iv) POCl3, DMF; v) CH3NO2, NH4OAc; vi) LiAlH4, THF 
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To synthesize compound (87) a different synthetic pathway was used due to lack of 
availability of the commercial hydrazine (Scheme 31). 
 
Scheme 31; Synthesis of (87); i) t-Butyl Carbazate, CuI, Cs2CO3, DMF; ii) AcOH, 5-Chloro-2-
pentanone, DMF 
 
The Boc-hydrazine (98) was formed by treatment with t-butyl carbazate, copper (I) iodide 
and Cs2CO3, the intermediate was directly used without any further purification in the next 
step to finally synthesize the desired product (87). 
 
For the structure activity relationship exploration of the ethanamine substituent in position 3 
of the indole a synthetic pathway similar to the one used for the synthesis of the parent 
compound (85) was used. The parent compound was then used as a common intermediate in 
a convergent synthesis to obtain the 3 new analogues via amide couplings (Scheme 32). 
 




To synthesize compound (86) different attempts relying in a 4-bromo-2-aminothiazole 
intermediate were attempted (Scheme 33). 
Scheme 33; i) Propionyl chloride, pyridine, dioxane; ii & iii) nBuLi, ZnCl2, THF, Et2O; iv & v) 
Pd(PPh3)4, Na2CO3, DMF, H2O 
 
Unfortunately, the attempts to synthesize this compound were not successful and a new 
pathway was followed (Scheme 34). 1-(Pyridin-2-yl)ethan-1-one was treated with bromine in 
aq. HBr affording compound (101). Condensation of the intermediate with thiourea gave 
compound (102), which was subsequently treated with propionyl chloride to yield the desired 
product (86). 
 
Scheme 34; i) Br2, aq. HBr; ii) Thiourea, EtOH; iii) Propionyl chloride; pyridine; Dioxane 
 
New analogues were explored by making modifications in the alkyl chain of the amide (right-
hand side) and in the pyridinyl moiety (left-hand side) (Figure 87). 
 
Figure 87; SAR exploration proposed for aminothiazoles 
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An initial exploration was undertaken by varying the alkyl chain lengths of the amide and by 
substituting it with a phenyl and a pivaloyl group. The synthesis of the different molecules 
was done via the same synthetic procedure proposed in Scheme 36. Using compound (86) as 
a general intermediate and different acyl chlorides or anhydrides in the last step of the 
synthesis gave 4 new analogues in a facile and short synthetic route (Figure 88). 
 
Figure 88; Derivative analogues for aminothiazole series 
The exploration of the aminothiazole structure was extended to the pyridinyl substituent, in 
this case the position of the nitrogen in the ring was modified and the pyridinyl moiety was 
also substituted for a para-tolyl (see Figure 85 left-hand side). The synthesis of the new 
analogues was undertaken using the same approach shown in Scheme 36. In this case the 
synthesis was not convergent because no common intermediate can be used for all the targets. 





Scheme 35; i) Br2, aq. HBr; ii) Thiourea, EtOH; iii) Propionyl chloride; pyridine; Dioxane 
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Chapter 13: Biophysical Assays after FBS and SAR focused on the DNA 
Binding Domain (DBD) 
 
After the fragment-based screening different analogues of the parent compounds were 
synthesised (by Shaun R. Stevens (SRS), Stephen Hobson (SH) and me (highlighted with * in 
Table 3) or purchased and tested by SPR (Table 4). 
























































































































































































Table 4; Structure-Activity relationship exploration for the 3 different HITS obtained by SPR 
Fragment based screening (code = active, interference, inactive) 
 
SPR analysis of the different scaffolds obtained by FBS were performed. A summary of the 









































Figure 97; Compound SRS-16 NTA; Ni2 2 and 4 His8-His8-IRF4-C99S (BeatsonAnaloguesDR) 
 
 
Unfortunately, the binding of the compounds synthesized was very weak in the best cases 












Chapter 14: Conclusions and Future Work 
In conclusion, none of the new compounds synthesized with the most promising SPR results 
were confirmed by any of the NMR techniques performed (WaterLogsy or STD) or by any 
biophysical technique. By the terms established as part of our collaboration with Astex 
Pharma it was concluded that no further work based on these screening results would be 
financed. From our scientific point of view the lack of confirmation of the hits left us without 
any solid conclusion.  
 
In the future if a new assay can be developed where the hits obtained can be confirmed it 
would be interesting to re-test all the compounds synthesized during this thesis. Future efforts 
must be focused in the development of a functional assay that can allow the scientist an 
robust development of initial hit matter. 
 
With these results in hand and all the data collected previously, it was decided that no further 
experiments or structural exploration would be fruitful with any of the hits obtained by HTS 
or FBS unless a functional assay is developed. 
 
Further experiments with the IRF4 Association Domain (IAD) could be performed in the 
future. In this approach “Fragment based screening” with human IRF4 association domain 
(IAD) crystals could be used. The ligandability of this binding site is predicted to be stronger 
and subsequently easier to confirm by different experiments (SPR, STD, WaterLogsy or X-
ray crystal structures), giving us a better opportunity to develop a functional assay. However, 
the need for a functional assay for the DBD is still there, it would be a great contribution for 
future research conducted for IRF4 projects. If the assay is developed it should be applied to 












At the end of the project our main conclusion was that we could not confirm binding to the 
DBD of IRF4 by any of the hits found after HTS or FBS or by any of the analogues 
synthesized and explored in the laboratory during my PhD.  
 
None of the compounds shown here showed significant binding to the DBD of transcription 
factor IRF4 or in case of binding to the target it could not be confirmed by any technique.  
 
This result was very disappointing from a scientific point of view but new questions came to 
our minds: 
• “Could we save time and money to ourselves in future projects by NOT spending 
more time than necessary in undruggable targets?” 
• “Could we map the interactions of a ligand to the protein in a facile and fast way?” 
It is often not apparent from the outset whether it will be possible for a small molecule (or 
subset of molecules) to bind to a given site with sufficient affinity to modulate its function. 
As a result, many drug discovery projects are initiated against chemically intractable targets.  
To try to assess druggability in a facile, faster and reliable way a new method is described in 
the following section of this thesis: FragLites 
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Chapter 15: FragLites. Developing new approaches to assess druggability 
and hit finding at earlier stages 
	
Drug discovery is characterized, among other things, by drug attrition, which could be 
described as the high failure rates associated with pharmaceutical development. Despite of 
the technological advances and increase in research and development efforts, the number of 
truly innovative medicines approved (1st in class) is not increasing accordingly. Low 
productivity of NMEs can be tackled in many ways, from an organizational point of view or a 
scientific point of view. 
 
From an organizational point of view, it was theorized that an increased workload in the pre-
clinical stages would lead to more drugs being successful in the clinical stages. The way 
companies have improved productivity is related to an increase in the chances of success in 
the clinic by focussing on better rationale for targets and compounds. 
15.1 Improvements in the scientific methodology to speed-up the drug discovery 
process 
In the last decades (especially since the 1990s) the genomics have dominated the way new 
biological targets (usually proteins) are discovered to be the key regulators in the 
development of a disease. The modulation or suppression of the activity of these targets gives 
us a rationale base for drug discovery. This approach takes us to a target-centric strategy, 
where different biological hypotheses can be tested and used as starting points for molecule 
identification.161 
 
Several methods have been developed to find drugs that interact with the desired biological 
target. One of the most widely used is High-throughput screening (HTS). This method has 
been tremendously potentiated by robotics (Figure 98) to conduct millions of chemical tests 
where a researcher can quickly identify active compounds that interact with a particular 





Figure 98; A robot arm handles multiple assay plates 
 
Recent advances in automation and drop-based microfluidics allowed this technique to 
effectively test 100 million reactions in 10 hours but these methods are still very expensive to 
implement. However, traditional HTS is increasingly utilized in academia thanks to the 
growing availability of compound sets. At the same time, many companies specialized in 
these services offer the possibility of outsourcing HTS campaigns, making HTS the leading 
paradigm of small molecule drug discovery.  
 
During the 1990s several flaws associated with HTS campaigns were known, the most 
important liability was the tendency to obtain as hits with very high lipophilicity and drug-
unlike properties. To avoid these issues drug-like criteria (like the Lipinski rule of five162) 
was developed for the design of the screening libraries. Nowadays, target-focused compound 
collections can be found if we already have a starting point. Screening libraries can also be in 
silico designed. 
 
However, the lack of success of HTS for some specific targets, gave a steady impulse to the 
creation of new techniques like Fragment Based Drug Discovery (FBDD), which 
development started with the “SAR by NMR” by the Abbott group in 1996.163 In this paper, it 
is described how a linked-fragment approach, where ligands are treated as building blocks 
with independent binding to different parts of the target, can yield a final drug with optimized 
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affinity for the protein. Binding is determined by the observation of 15N-1H-amide chemical 
shift changes in a 2D 15N-heteronuclear single-quantum correlation (15N-HSQC) spectra. 
Once a lead molecule is identified the binding is optimized to its site, then the process is 
repeated for a ligand in an adjacent pocket. Then the two fragments are linked together with 
the right orientation so the affinity of the new (and larger) ligand should be improved 
(Scheme 36). 
 
Scheme 36; Outline of the SAR by NMR method (Reprinted with permission from AAAS) 
 
Over the last 20 years we have seen increasing acceptance and use of the fragment-based 
approach. The key of FBDD is that it does not only rely on Ligand Efficiency as the 





In the early 2000’s emerged the rule of three.164 A useful rule to define a fragment for the 
construction of libraries for lead generation, fragment hits must have: 
1. Molecular weight of < 300 
2. ClogP < 3  
3. Hydrogen bond donors and acceptors < 3  
 
To study the development of fragment-based drug discovery and the impact on drug 
discovery Johnson et al. have published a mini-perspective article summarizing hit to lead 
development (2015-2017), nature of the screening methods used, and the target classes 
involved in these hits. An analysis of the distribution of target classes thanks to these 
articles, shows that there was an increase in the development of antagonists of protein-
protein interactions (specially for bromodomains) (Figure 99), which represent a target with 
X-ray crystallography availability. About three quarters of the campaigns target enzymes, 
and around one quarter of the examples specifically targeted kinases. In the last three years, 
only one GPCR and no ion channels have been reported. These data reflect the difficulty in 
developing FBDD without high resolution X-ray structures. 
 
 




The choice of screening method is highly relevant. Biochemical assays are the most 
commonly used screening technique (5 out of 7 kinases, 8 out of 11 for the rest of enzymes, 
only 2 out of 11 protein-protein interactions) (Figure 100). In the later years there was an 
increase in the number of virtual screens, probably derived from the improvements in the 
techniques and the increased availability of structural information. HTS can also be 
integrated with FBDD (deconstruction of HTS hits), and these approaches are potentially 
complementary. We can use an initial fragment collection for screening (FBDD), then 
analyse the results and rationalize the selection of compounds for a new screening by HTS 
containing the appropriate sub-structural features.165 In addition to the rational 
deconstruction of hits derived from HTS, a fragment obtained by FBDD can be merged with 
a hit obtained by HTS. 
 
 
Figure 100; Distribution of screening method for the F2L examples along with the total 
 
The articles published by Johnson et al. state the importance of structural information for 
fragment optimization. In 21 out of 30 campaigns a crystal structure was available. 
 
X-Ray crystallography is the most sensitive of the biophysical techniques used for fragment-
screening experiments. The lack of theoretical lower limit on the affinity of fragments 
detectable is the main advantage, with the practical limitations being compound solubility 
and crystal robustness. This provides us reliable detection of compounds with a dissociation 
constant Kd ≤ 5 mM. Furthermore, the use of crystallography as a screening technique has 
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other advantages like specific structural information on the interaction between fragment hit 
and target at the earliest stage, providing fast and efficient assessment of hits in terms of 
their medicinal chemistry tractability and in terms of synthetic vectors that can help in the 
optimization.  
 
A disadvantage is the low throughput of X-ray crystallography. Different methods have been 
described allowing the power of X-ray based screening to be fulfilled as a highly viable 
component of drug-discovery. One of the more recent methods was developed by Astex and 
is called “Pyramid™”. In this approach, high throughput crystallography is coupled with 
other biophysical techniques, such as NMR, resulting in an integrated fragment-based 
discovery platform.166 
 
The Pyramid screening idea is based on “automated protocols for rapid X-ray data 
collection”. The method requires the soaking of crystals with fragments of interest, followed 
by X-ray data collection, processing, and refinement of the ligand-free complex to 
potentially reveal the difference in electron density associated with the bound ligand. The 
electron density is then interpreted, fitted, and the complex further refined to give the final 
protein–ligand structure (Scheme 37).  
 
Scheme 37; Flow-chart for a crystallographic fragment-screening experiment 
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The Astex’s Core Fragment Set was created as a general-purpose library (1,000 fragments 
approximately), which aims to cover wide chemical space and be suitable for screening 
against different targets. The rationale for the library creation is based on the idea that 
“drug-fragment space” can be effectively sampled with a relatively small number of 
compounds based on scaffolds and functional groups commonly found in drug molecules. 
 
Fragments are screened by soaking the ligand of interest into pre-formed protein crystals, 
with a high concentration solution of ligand in mother liquor for enough time. Another 
possibility is to co-crystallize the complex in situ. Effectively, a separate crystallization 
method is needed for each compound and the process gets even more complicated if for each 
compound, different crystallization conditions are needed. 
Unfortunately, this method will give us a large library of compounds to be tested and 
experimental methods such as fragment screening by X-ray crystallography cocktailing are 
still time consuming. Moreover, to adequately cover chemical space, it is required the testing 
of a sufficient numbers of compounds, such that a druggability assessment using 
conventional fragments requires a comparable investment to running a full fragment screen. 
For this reason, there is scope to further improve FBDD screening, especially regarding the 











Chapter 16: Project Rationale 
Since the anomalous signals from native atoms are relatively weak, it is normally 
advantageous to add heavier atoms to protein crystals either through incorporation during 
protein expression,167 co-crystallization as a binding partner168 or soaking into previously 
formed crystals.169 During an X-ray crystallographic small-molecule fragment screening 
campaign targeting HIV-1 reverse transcriptase bound to a non-nucleoside reverse 
transcriptase (NNRTI) drug, (rilpivirine), 4-bromopyrazole was found to bind to 15 sites and 
4-iodopyrazole in 21 (Figure 101). 
 
Figure 101; Locations of 4-bromopyrazole are shown as light pink spheres 
In general, to have sufficient affinity, size and shape to be detected by X-ray crystallography, 
compounds typically need to have molecular weights > 200. It has been theorized that the 
promiscuous nature and detection of molecules like 4-bromopyrazole or 4-iodopyrazole is 
due to electrostatics. Density functional theory calculations revealed that the electronegative 
nitrogen atoms in the pyrazole ring enhance the polarization of the halogen atom in both, 




Table 5; Computed electrostatic surfaces for 4-Iodopyrazole, 4-Bromopyrazole and related analogues 
The promiscuous binding of 4-bromopyrazole and 4-iodopyrazole allows the ordered binding 
of Br and I atoms, respectively, at many sites around a target protein and both bromine and 
iodine scatter X-rays with strong anomalous signal when appropriate wavelengths are used. 
While in typical non-crystallographic screenings the present promiscuous binding would be 
undetectable, in the case of crystallographic fragment screening it is possible to see how the 





Figure 102; 4-Bromopyrazole and 4-iodopyrazole binding sites. (a)-(f) Two binding sites with the 
clearest electron density for the compounds are depicted for each protein: (a, b) influenza 
endonuclease, (c, d) proteinase K and (e, f) RT-rilpivirine. Electrostatic potential surfaces are shown. 
Potential electrostatic interactions are depicted as blue dashes with interatomic distances shown 
The unambiguous detection of this anomaly makes possible the detection of the exact 
location of these small fragments. Usually, a fragment is considered a molecule with a 
molecular weight of < 300, and when the libraries are designed in order to be able to detect 
our fragments the molecular weight usually varies between 200-300. 4-Bromopyrazole 
(molecular weight is 144) is smaller than this. The possibility of detecting these small 
fragments in an electron density map gives us the possibility to explore more chemical space 
with smaller libraries, and directly test small binding motifs in our targets. 
A structure-based assessment of druggability could be achieved more efficiently and provide 
guidance into the likely pharmacophores and chemotypes that would bind to the target 
protein. In addition, the ability to map a protein for all potential sites of ligand interaction 
could be provided, identifying opportunities for allosteric inhibitors, with great potential to 
tackle resistance mechanisms, both alone and in combination with orthosteric ligands. It 
would be advantageous to develop a method that can quickly assess the druggability of a 
target in an efficient way, without consuming a large amount of time and resources.  
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To generate evidence that these problems can be addressed, a set of very simple fragments 
expressing common pharmacophoric interacting groups was designed to identify productive 
binding sites using X-ray crystallography. The set consists of 31 fragments, which express 
the combination of two binding hydrogen bonding groups (donors and acceptors) separated 
by 1 to 4 bonds and incorporating a bromine atom for visibility in the electron density map. 
Also, the combination of two polar groups should confer water solubility and allow high 
concentrations of these molecules for crystallography studies (Table 6). 
 
 
Table 6; Design of fragments and matching with pharmacophore doublet 
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Chapter 17: Results and Discussion 
To test the library and to validate our concept, initial testing was done in a protein for which 
druggability is established and potent ligands are known. Cyclin-dependant kinase 2 (CDK2) 
is a protein that has been explored recently in our group by Celine Cano et al.170 and the 
existence of several allosteric sites on top of the orthosteric has been previously shown.171 
 
Each of the FragLites from our library was soaked into CDK2 protein. The anomalous signal 
generated from our fragments allowed us to detect 9 of the 31 fragments in 6 different sites. 
Fragments 1, 2, 7, 13, 14, 16 and bound the orthosteric site with fragment 31 binding in an 
adjacent pocket. The orthosteric site was successfully identified thanks to the highest 
frequency of binding. The Fraglites library also identified known and new allosteric sites. Of 
the 5 detected allosteric sites, fragment 4 interacts in the lower region of the C-terminal lobe 
on the C-helix side. Another allosteric site was observed with fragment 6 at the very bottom 
of the C-lobe. The other sites were all identified by fragment 31 at the N-terminal lobe below 
the hinge region and in the pocket close to the cyclin binding region (Figure 103). 
 
 
Figure 103; Overview of Fraglite binding events to CDK2 (white ribbon), depicting the sites 
identified by our Fraglite library (yellow) 
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Fragment 1 was found to bind in 2 different modes, in one case with the pyrazole-2-nitrogen 
accepting a hydrogen bond from the backbone of Leu83 and in the other case with the 2-
nitrogen accepting a H-bond from Leu83 and the NH forming a H-bond with the backbone 
carbonyl of Glu81 (Figure 104). 
 
 
Figure 104; Interaction of fragment 1 with the ATP pocket 
 
Fragments 2, 7, 13 and 14 showed very similar interactions (Figure 105-a) and fragment 16 
bound to the ATP site through a halogen mediated interaction (Figure 105-b). 
 
 
Figure 105; a) Fragment 7 forming donor-acceptor paired interaction with the NH and carbonyl of 
Leu83, b) Fragment 16 bound via halogen mediated interaction 
 
It was also found that fragment 31 (2-methoxy-4-bromophenyl) acetic acid also bound to the 
hinge in an adjacent pocket, with the carboxylate interacting with the backbone NH and 
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sidechain hydroxyl of Thr14 and the amino group of Lys129, in addition a π-cation 
interaction with Lys33 was also observed (Figure 106). 
 
 
Figure 106, Fragment 31 bound to the hinge in an adjacent pocket 
 
The hit rate obtained was surprisingly high and it was compared with Pan-Dataset Density 
Analysis (PanDDA) algorithm (state of the art statistical approach for detecting weak binding 
events in electron density maps172). PanDDA analysis was performed on 31 FragLite crystal 
datasets and could not identified the sites unveiled by FragLites 16 and 14 and several 
binding events found for FragLite 31. 
 
In addition to showing the location of binding sites, the Fraglites also identify the specific 
hydrogen bonding motif that makes the productive interaction, unambiguously identified due 
to the adjacent anomalous signal.  This information can be used for optimization. The 
established 3-point hinge binding pharmacophore for CDK2 can be derived from the overlaid 
Fraglite signatures, and new molecules can be designed by merging adjacent or overlaid 
Fraglites (Figure 107. 
 
Figure 107; 3-point pharmacophore derived from 2 FragLites binding to the hinge 
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Molecules with the same binding motif were trialed to test their affinity with CDK2. 
Fragments 32 and 33 made the three suggested interactions by the binding motif proposed. 
Fragment 33 showed increased affinity by isothermal calorimetry (ITC) (Figure 108). 
 
Figure 108; a) 2,6-diaminopyridine 32 fulfilling the 3-point pharmacophore and making the 
predicted interactions, b) 4-iodo-6-aminopurine 33 making the predicted interactions, showing 
binding with a measurable a Kd by ITC 
 
The orientation of fragment 31 binding in the ATP pocket gave us insights in how to grow 
the molecule. New molecules were designed with no additional screening. The structure of 
fragment 31 was explored in one case, tethering an aniline with a pyrimidine moiety, with 
two nitrogen atoms available as hydrogen bond acceptors (compound (115)) and in the other 
case tethering the aniline with pyridine, which has a combination of two binding hydrogen 
bonding groups (donors and acceptors) (compound (117)). 
 
For the synthesis of compound (115) an SNAr displacement of 4-bromopyrimidine with (3-
aminophenyl)acetic acid was performed. The mixture stirred at 80oC for 3 hours affording the 
desired compound in 10% yield after purification (Scheme 38). 
 
 




In the case of compound (117) a copper catalysed etherification of 4-bromo-2-
methoxypyridine with methyl (4-hydroxyphenyl)acetate was undertaken, the reaction was 
stirred for 24 hours at 120oC yielding the desired product (116) in 37% yield after 
purification. The intermediate was demethylated with 5 equivalents of pyridine hydrochloride 




Scheme 39; i) methyl (4-hydroxyphenyl)acetate (1.5 eq.), 3,4,7,8-tetramethylphenanthroline (cat.), 
CuI (cat.), Cs2CO3, toluene, 110° C, 24h; ii) pyridine hydrochloride (5 eq.), 180° C, 6h 
 
The crystallization showed both compounds binding in a predictable way to the hinge region, 
with very similar interactions to those shown by fragments (13), (7) and the carboxylate (31). 
The overlay of these structures with the new compounds is shown in Figure 109. 
 
 
Figure 109; a) Overlay of (115) (grey carbon atoms), indicating orientation of the hinge motif, and 
31 (cyan carbon atoms) as they bind to the CDK2 ATP pocket, b) Linked aminopyrimidine (117) 
binding to CDK2 and forming interactions with the hinge and Thr14, overlay shows the alignment of 
34 (grey) with the original FragLites 13 and 31 (cyan) 
 
Fragment 33 was also expanded using the fraglite map, combining this fragment with 
carboxylate 31 affording two different biaryl compounds. For the synthesis of compound 
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(120), a standard method to achieve displacements at C-6 position of purines utilises a 6-
chloropurine as starting material and proceeds via an intermediate with trialkyl ammonium as 
leaving group. The production of 6-trialkyl ammonium purine species is well described in the 
literature using DABCO.173 Compound (120) was synthesized by SNAr displacement after 
DABCO treatment of a DHP diprotected 6-chloro-9H-purine-2-amine with methyl 2-(3-




Scheme 40; i) dihydropyran (10 eq.), aq. 2M HCl (cat.), DCM, r.t., 16h; ii) DMSO, DABCO (2 eq.), 
r.t., 3h; iii) 1) methyl 2-(3-hydroxyphenyl)acetate (1.33 eq.), DBU (1.1 eq.), DMF, 65° C, 72h; 2) aq. 
2M HCl, THF, r.t., 4h 
 
In the case of compound (123) (Scheme 41) a Suzuki-Myaura coupling was performed 
directly in the DHP diprotected 6-chloro-9H-purine-2-amine and followed by acidic 




Scheme 41;	 i) dihydropyran (10 eq.), HCl (2M, cat.), DCM, r.t., 16h; ii) ethyl 2-(3-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetate (2.5 eq.), K2CO3 (2.5 eq.), Pd(PPh3)4 (0.05 eq.), 
DMF:H2O (1:1), 140° C, 20', MW hv; iii) aq. 2M HCl, THF, r.t., 2h 
 
The 2 biaryl compounds (120) and (123) were soaked in CDK2 crystals. Both compounds 




Figure 110; Linked pyridone biarylether (120) (grey) binding with the acid making comparable 
interactions to fragment 31 (cyan) 
 
 
Figure 111; Linked biarylether (123) (grey) binding to CDK2 making comparable interactions to 






Chapter 18: Conclusion and Future Work 
Mapping the different binding sites of CDK2 with our Fraglite set was highly efficient. The 
orthosteric site was successfully identified as the principal binding site for several fragments. 
The different allosteric sites previously reported were also identified and a new one was also 
reported. 
 
The efficacy of the Fraglite set for mapping CDK2 was high and with no need for a large and 
time-consuming screening campaign. The different crystal structures obtained during our 
investigation gave us key structural information about the location of the fragment binding 
and its orientation. These findings allowed us to design further analogues with combined 
structural motifs, which yielded a final compound (123) with concentration-dependent 
binding (measured by ITC; Kd = 50 µM and a LE = 0.3). These results confirm the efficacy 
of the FragLite mapping approach to grow lead molecules shortening the screening process 
and without the synthesis of a large number of analogues. 
 
For the future development of this strategy, new proteins should be explored in order to 
confirm the applicability of the FragLite mapping approach to other systems, and with the 
consequent optimization of a FragLite library. These findings will be shown in future 









Chapter 19: Introduction to MDM2 PROTACS for the androgen receptors 
as a prostate cancer treatment 
19.1 PROTACs: Inducing protein degradation 
19.1.1 Background174 
The classical small-molecule drug discovery approach relies on the occupation of a binding 
site in the target protein that produces a different structure. This change affects the protein 
function, and therefore a modification in the specific biological response of our target should 
occur (i.e. occupancy-driven strategy). At the same time, in order to achieve the desired 
biological response consistently, we have to consider the necessity of maintaining enough 
concentration of drug in our body to sustain target occupancy in vivo, which increases the risk 
of side effects.175 An event-driven strategy to induce protein degradation is an alternative 
approach with different characteristics in which the target protein is tagged for elimination 
(Table 7). 
 
Occupancy-driven strategy Event-driven strategy 
Stoichiometric activity Sub-stoichiometric activity 
Binding to active site required Potential to target undruggable proteome 
Site occupancy to block function Restoration of function requires re-synthesis 
Specificity defined by binding Added layer of specificity 
Table 7; Main differences of different medicinal chemistry approaches 
One example of an event-driven strategy is the PROTACs (Proteolysis Targeting Chimeras) 
methodology but is not the only technique with event-driven characteristics. Other methods, 
like RNAi (RNA interference) can modulate the intracellular protein concentration, but very 
often engages off-target mRNA leading to side-effects.176,177,178 We are also witnessing the 
dawn of CRISPR-Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats). This 
technology is able to directly modify the genome and find a way to a specific “gene 
knockout”, but its full potential is yet to be discovered.179, 180, 181 
Novel approaches based on PROTACs take advantage of the cellular quality control systems 
to selectively degrade target proteins and have advantages over traditional strategies 
(occupancy-driven strategy). These advantages include the capacity to target a broad range of 
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proteins that traditionally have been considered undruggable.182,183 Thanks to the genomic 
revolution many proteins have been identified to be directly associated to different types of 
cancer diseases,184,185,186 but a lack of binding pockets for ligands which could potentially 
modulate the structure and the biological response associated to those187 make this part of the 
proteome undruggable. With this regard, small-molecule-induced protein degradation can be 
considered a more interesting strategy. The hetero-bifunctional PROTACs consist of a ligand 
for the recruitment of E3 ligases, a linker, and a ligand to bind to the targeted protein, thus 
PROTACs have potential to eliminate “undruggable” protein targets, such as transcription 
factors and non-enzymatic proteins.  
 
The approach is not limited to physiological substrates of the ubiquitin-proteasome system 
and, at the same time, inducing protein degradation can compensate for protein 
overexpression that often happens after loss of protein function due to inhibition. The 
consequent loss of therapeutic potential and pharmacological efficacy of our drug188 is not a 
problem when the consistent degradation of the targeted protein takes place. Also, PROTACs 
can be advantageous to avoid resistance mechanisms that appear when druggable targets are 
recognized to have undruggable scaffolding roles.189, 190, 191, 192, 193, 194 A very interesting 
example is EGFR (epithelial growth factor receptor), a receptor which independently of 
its kinase activity, maintains the basal intracellular glucose level, thereby 
preventing cells from undergoing autophagic death.195 It has also been proved that the 
attachment of an E3 ligase ligand via a linker to a known inhibitor can add layers of 
selectivity to our warhead. The choice of linker and E3 ligase ligand are crucial for the 
formation of the ternary complex of our PROTAC with the target protein and the E3 ligase,196 
so degradation of the protein is dependent on the structure of the PROTAC.  Also, recent 
evidence suggests that the action of PROTACs is catalytic, after degradation of one target 
protein the same PROTAC molecule can re-engage and degrade further proteins, which can 
reduce drug exposure and undesirable side effects.197 
 
In summary, this new approach shifts the paradigm from inhibition of the protein to removing 
it by degradation. This gives us the opportunity of exploring a central challenge in biology, 
which is to understand, in a reliable way, the functions of a protein within the cell and the 
consequence of its removal. At the same time, the methodology allows us to control the 
protein expression levels without the need for genetic intervention. 
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19.1.2 Mechanism of action 
The proteolysis targeting chimeras (PROTACs) are heterobifunctional molecules which 
recruit a specific protein target to an E3 ubiquitin ligase, resulting in the target’s 
ubiquitination and degradation (also known as chemical knockdown). We can describe the 
way PROTACs work as the hijacking of the proteolysis machinery of the cell in which the 
target is tagged via poly-ubiquitin chains (for ubiquitin see Figure 112). 
 
Figure 112; Ubiquitin is a regulatory protein that may be linked to other proteins; PDB ID: 1UBI 
The “Ubiquitin-Proteasome Pathway” (UPS) consists on the conjugation of one or more 
ubiquitin molecules to other proteins for degradation by the 26S proteasome (Scheme 42). 
 
Scheme 42; Ubiquitin-Proteasome Pathway198 
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When discovered, the UPS was considered the first “natural” mechanism for the targeted 
destruction of misfolded proteins. The mechanism is based in a rationally designed enzymatic 
cascade that leads to the attachment of ubiquitin via covalent bonds to a lysine of the targeted 
protein.  
 
The cascade (Scheme 43-a) is initiated by ubiquitin-activating enzyme (E1),199 which forms a 
reactive thioester through an ATP-dependent process. The ubiquitin is then passed to 
ubiquitin-conjugating enzyme (E2),200 again via formation of a reactive thioester. The last 
step of the cascade (Scheme 43-b) is performed by the ubiquitin ligase enzyme (E3),201 which 
specifically recognizes a specific target protein and catalyses the transfer, induced by 
proximity, of ubiquitin from the E2 protein to the targeted protein via a lysine residue present 
in the surface of the protein to be tagged and subsequently degraded. 
 
Scheme 43; a) Ubiquitin is first conjugated to the E1, then passed to the E2 protein; b) The E3 
protein is responsible for substrate recognition, and transferral of the ubiquitin onto the substrate 
 
The specificity of the E3 ligase ligand for different proteins is very important for the 
degradation and management of protein levels in the cell. Several are usually considered for 




To regulate the concentration of proteins, the different E3 ligases recognize several specific 
binding motifs in the different targets. For example, the Von-Hippel-Lindau (VHL) E3 ligase 
binds to a core hydroxylated proline residue on hypoxia-inducible factor 1α (HIFα)202, 
another example is the β-transducing repeat-containing protein (βTRCP) that binds 
specifically to phosphorylated residues on NFκB inhibitor-α (IκBα) and β-catenin.203 For the 
purpose of PROTACs a variety of E3 ligase ligands are commonly used (e.g., cereblon ligand 
(CRBN), VHL ligand and βTRCP ligand). These act as substrate recognition subunits in 
multisubunit cullin-ring E3 ligase (CRL) complexes.204, 24 Also Mouse Double Minute 2 
homologue (MDM2) forms homo- or hetero-oligomeric E3 ligase complexes for productive 
ubiquitination.205, 206  
 
As ubiquitin has seven lysines, substrate-linked ubiquitin can be further modified to produce 
unique polyubiquitin chains, which are recognized by the 26S proteasome, which will induce 
degradation of the tagged protein.  
 
Summarizing, the PROTACs concept could be described with 3 main aspects (Scheme 44): 
• Targeting a ubiquitin ligase to recognise a protein of your choice 
• Bringing the protein you are interested in into close proximity to an ubiquitin ligase 
• A bivalent PROTAC ligand is used to reversibly bind the target to the E3 ligase and 




Scheme 44; Main steps of the PROTACs strategy 
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19.2 Alternative approaches to protein degradation 
19.2.1 HSP90 inhibitors 
Induced protein degradation is not a completely new concept. The inhibitors of the molecular 
chaperone heat shock protein 90 (HSP90) entered clinical trials in 1999. The drug with the 
ability to bind HSP90 and subsequently degrading client proteins was under big expectations 
due to the discovery of upregulation of the chaperone as a consequence of interaction with 
cancer cells to drive proliferation and survival pathways.207 All the different drugs designed 
target the ATP-binding domain208,209, 210 leading to the degradation of HSP90 client 
proteins.211,212 The antiproliferative effects of these compounds is related to destabilization of 
the Raf-1 protein, one of the client proteins of HSP90, resulting in inhibition of MAPK. After 
more than 30 clinical trials and a wide exploration associated to HSP90 binders, none has 
achieved approval from the FDA. Then main reason is its poor pharmacokinetic profile, 
mainly associated to the hepatotoxic benzoquinone moieties present in the ligands (Figure 
113).213, 214, 215 On top of that HSP90 target proteins associate with more than half of the 
human kinome and attempts to achieve selective degradation have been extremely 
challenging.216 
	
Figure 113; Geldanamycin (left hand-side) and its derivatives 
19.2.2 Selective hormone receptor degraders (SERDs & SARDs) 
The estrogen receptors (ER) are nuclear hormone receptors that are suitable for modulation 
with small-molecule drugs. After binding to the hormones (estrogens), the ER dimerises and 
translocates from the cytosol to the nucleus where it binds to DNA to activate transcription. 
The proteins expressed after estrogen signalling have a great influence on the cardiovascular, 
musculoskeletal, immune and reproductive systems in males and females. It has also been 
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proved that ER signalling has a clear contribution to breast cancer and its progression, and 
this type of carcinomas are responsive to hormone deprivation therapy (Figure 114).  
 
 
Figure 114; Activation and translocation of the estrogen receptor (ER) to the nucleus to activate 
transcription (E2 = oestradiol) 
 
Depending on several factors, selective estrogen receptor modulators (SERMs) act as 
antagonists or agonists, being an antagonist in breast tissue but an agonist in the uterus, 
enhancing in the last case the risk of endometrial cancers.217 Tamoxifen is a SERM,218 and 
this drug is used to treat breast cancer but with a small increased risk in the development of 
uterine cancer. On top of that, a long term estrogen deprivation could lead to pharmacological 
resistance due to compensatory feedback signalling and/or mutations in the estrogen receptor, 
which impair the pharmacological efficacy of tamoxifen making necessary the intervention of 
a new treatment. 
 
Following the strategy of induced degradation via destabilization of the protein, fulvestrant 
modifies the structure of the ER creating a larger hydrophobic surface due to the presence of 
an alkylsulfinyl moiety (Figure 115, thus activating the degradation of the receptor219 by 




Figure 115; Fulvestrant with alkylsulfinyl moiety highlighted 
 
Fulvestrant has lower risk of endometrial cancer220 and, despite several pharmacokinetic 
issues, is the only FDA-approved selective estrogen receptor degrader (SERD) for ER-
positive metastatic breast carcinomas after development of resistance to tamoxifen. Newer 
generations of fulvestrant are under investigation.221 The limited success of this drug was still 
encouraging, and the same strategy was investigated with androgen receptors (ARs) in 
prostate cancer, to develop selective androgen receptor degraders (SARDs).  
 
As a nuclear hormone receptor, the AR responds to mainly two hormones, testosterone and 
5α-dihydrotestosterone (5α-DHT).  For this reason prostate cancer is dependant on AR 
signalling, thus antiandrogen therapy with flutamide or bicalutamide has demonstrated good 
results.222 Again, resistance is developed, leading to castration resistant prostate cancer 
(CRPC)223 via overexpression or amplification of the ARs.224 Much work is being undertaken 
and there are several clinical trials ongoing (including PROTACs from Arvinas225), but at the 
moment no known SARDs are available in the market. 
 
As a conclusion, inducing ER and AR degradation is a very interesting approach that remains 
active. Targeting the degradation of either receptor not only fights the compensatory 
upregulation associated to inhibition of a function but could also disrupt resistance 
mechanisms. Moreover, the transformation of an antagonist into an agonist via mutation of 
the receptor should not be a problem for an induced degradation strategy. At the same time, 
high systemic exposure associated to classic drugs could be reduced due to the catalytic 
nature of the PROTACs. 
19.2.3 Hydrophobic tagging (HyT) 
This strategy consists of a heterobifunctional molecule, one end able to be bound to the 
protein of interest (POI) and the other end able to bind the cell quality control mechanism 
through hydrophobic moieties,226 which induce protein destabilization. One proposal for the 
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mode of action is that the hydrophobic tag destabilizes the protein of interest, thereby 
recruiting endogenous chaperones to the unfolded protein. The protein is then shuttled to the 
proteasome for degradation. An alternative proposal is that chaperones recognize the 
hydrophobic tag directly and mediate proteasomal degradation of the tagged protein (Figure 
116). 
 
Figure 116; PROTACs strategy using hydrophobic moieties 
 
In 2012 it was proved that Boc3Arg (Figure 117) can induce protein degradation by targeting 
glutathione-S-transferase (GST) through the covalent inhibitor etacrynic acid.227  
 
 
Figure 117; Boc3Arg 
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An alternative hydrophobic tagging method was discovered using adamantane (Figure 
118).228 This approach is also based on a bifunctional molecule, one end engages the cell 
quality control mechanism via a hydrophobic moiety, and the other end binds to the protein 
of interest.229 
 
          
Figure 118; Adamantane Moiety 
 
Recently the hydrophobic technology (HyT) has been expanded to ARs. A high affinity 




Figure 119; SARD279 
 
The HyT shows the scope and possibilities of modular post-translational protein knockdown 
by targeting proteins traditionally considered undruggable. The main weakness of this 
method is that the hydrophobic moieties can potentially bind to human serum proteins having 
as a result the loss of free drug available to induce degradation. Furthermore, it is still not 
clear if the degradation is induced by the hydrophobic moiety (Boc3Arg or Adamantane) or 
by the induced destabilization of the protein itself leading to self-degradation without 
proteasome intervention, however both of these approaches would work. By contrast, 
PROTACs that induce proximity-induced ubiquitynation of a targeted protein via E3 ligase 
ligands are already in several clinical trials and showing more promising in vivo 
performances and better pharmacokinetic profiles. 
19.2.4 Peptide-based PROTACs 
The first peptide-based PROTAC was reported in 2001.232 A bifunctional molecule with the 
ability to harness the ubiquitin-proteasome system (UPS) by recruiting an E3 ligase to the 
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protein of interest, and leading to ubiquitination, and consequently degradation of the protein 
was described (Figure 120). 
 
Figure 120; Representation of a peptide-based PROTAC strategy 
 
The peptide-based PROTACs have at one end a phosphopeptide (E3 ligase ligand) portion of 
NF-κB inhibitor-α(IκBα). This peptide recruits the F-box protein β-transducin repeat-
containing protein (βTRCP), a component of the S-phase kinase-associated protein 1 
(SKP1)–cullin 1– F-box E3 ligase complex (SCFβTRCP). On the other end, in a similar way to 
other PROTACs, the enzyme inhibitor ovalicin (protein ligand), covalently binds to the target 
protein, methionine aminopeptidase 2 (MetAP2).233 
The potencies of these PROTACs were not high enough (micromolar range) and cellular 
permeability was extremely low; moreover, the dependency on IκBα phosphorylation for E3 
ligase recruitment was limited by the action of cellular phosphatases, therefore improvements 
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were needed. The crucial one was the switch to a smaller peptidic E3 ligase ligand fragment 
in which phosphorylation is not required for functioning. The E3 ligase ligand Von Hippel-
Lindau (VHL) (Figure 121) recognizes the E3 ligase hypoxia-inducible factor 1α (HIF1α).234, 
235 
 
           Figure 121; 1st generation VHL ligand236 
With this new E3 ligase ligand in hand a new PROTACs era started. As a first example, a 
PROTAC targeting AR comprised DHT linked to the HIF1α peptide fragment237 was 
developed and proved to lead to AR depletion in HEK293 cells (Figure 122-a). Analogous 
PROTACs for ER degradation using ER inhibitors were positively tested, reducing 
proliferation of breast cancer cell lines238 in vitro (Figure 122-b). 
	
Figure 122; a) Peptide-based PROTAC for AR, b) Peptide-based PROTAC for ER 
However, the potencies of peptidic PROTACs are very low, remaining usually in the 
micromolar range in the best cases and showing pharmacokinetic issues like poor cell 
penetration. Having these problems in mind a new type of PROTACs was to be developed.  
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19.2.5 All Small-Molecule PROTACs 
Considering the cellular problems of peptide-based PROTACs and its limitations an 
important effort was done focused on the generation of all small-molecule PROTACs.  
 
In 2008 the synthesis of a PROTAC based on Nutlin-3a (Figure 123) to recruit E3 ligase 
mouse double minute 2 (MDM2)239 to target the AR240 showed an induced AR degradation of 
10 µM concentration in cells. The first “all small molecule” made the bifunctional strategy 
much more drug-like, especially from a pharmacokinetic point of view. These results had 
implications for the potential study and treatment of various cancer types with increased 
androgen receptor levels. 
 
Figure 123; Flutamide (AR ligand) in pink, nutlin-3a (MDM2 ligand) in blue 
 
The potency was lower than with the peptidic VHL ligand but newer generations of E3 ligase 
ligands have been developed with increased potency241 and improved pharmacokinetic 
profiles. 
19.2.6 The case of SNIPERs 
Based on the same approach for protein degradation, another type of small molecule-based 
PROTAC called SNIPER (specific and non-genetic inhibitor of apoptosis proteins (IAPs)-
dependent protein eraser) was reported by the Hashimoto group in 2010. Using bestatin 
(Figure 124) ester to recruit the E3 ligase cellular IAP1 (cIAP1)242 the degradation of cellular 
retinoic acid binding protein I (CRABPI) and CRABPII was achieved. However, bestatin was 
not specific and these esters induced the polyubiquitination and subsequent degradation of the 
recruited E3 ligase cIAP1 reducing the efficiency of this technology and showing the first 




Figure 124; CRABPII inhibitor (protein ligand) in pink, bestatin (cIAP ligand) in blue 
19.2.7 Halo-PROTACs 
To overcome some of the pharmacokinetic handicaps related to PROTACs, a new idea was 
proposed. Introducing a label in the protein of interest with a HaloTag and then using 
ChloroPROTAC that can react with the HaloTag creates a covalent bond into the cell. With 
this method we can avoid the use of poorly permeable compounds and build our PROTAC 
inside the cell (Scheme 45).243 
 
Scheme 45; (POI = protein of interest; VHL (Von Hippel Lindau protein) = E3 ligase ligand) 
19.2.8 New directions identifying a replacement for the HIF-1α  
A replacement for the HIF1α peptide fragment to provide an alternative E3 ligase for the all-







µM),244 and after structure-activity studies a new E3 ligase ligand with Kd = 185 nm was 
yielded.  
 
The improved ligand enabled the synthesis of two VHL-based small-molecule PROTACs, 
which were described in 2015, with nanomolar potency for ERRα and RIPK2 (Figure 
125).245 In vivo degradation was achieved at 40% knockdown approximately in heart, kidney 
and tumour xenografts. The same studies demonstrated that PROTACs can induce multiple 
rounds of target ubiquitylation showing catalytic activity. 
 
Figure 125; a) Receptor-interacting serine/ threonine kinase 2 ligand (RIPK2) and b) ER ligand 
(ERR-alpha) in pink; VHL ligand in blue 
19.2.9 Cereblon derivatives 
In 2010 another PROTAC system based on a different small-molecule E3 ligase ligand 
moiety was developed. Handa and colleagues identified cereblon (CRBN) as the primary 
target of thalidomide analogues246. In 2014, the Kaelin and Ebert groups discovered that 
different phthamilides, such as pomalidomide (Figure 126) or lenalidomide, induce 
degradation of the lymphoid transcription factors Ikaros family zinc finger 1 and 3 (IKZF1 





Figure 126; Pomalidomide (CRBN ligand) 
19.2.10  The catalytic nature of PROTACs 
In 2015 two “all small” PROTACs were reported. In one case using Cereblon as an 
innovative E3 ligase ligand for BET domain protein Brd4249 (Figure 127) and in the other 
using VHL.250 These molecules demonstrated the catalytic nature of PROTACs in vivo, 
which was subject of controversy. 
	
Figure 127; Pomalidomide (CRBN-based E3 ligase ligand) in blue and Brd4 inhibitor in pink 
 
It has been recently confirmed by a comprehensive real-time degradation and recovery 
profiles for targets quantifying degradation rates, maximal levels of degradation (Dmax) and 
time frame at Dmax. These studies also showed that the ternary complex stability has a direct 
relation with the capacity of the PROTAC for degradation.251 
19.2.11  Added layers of selectivity 
In 2015, Alessio Ciulli reported a study where the induced degradation strategy provides 
selectivity towards a specific bromodomain. The Bromo- and Extra-Terminal (BET) proteins 
BRD2, BRD3, and BRD4 play master roles in the transcription regulation and epigenetics 
and are associated to the development of cancer diseases. The pan-BET selective 
bromodomain inhibitor JQ1 lacks selectivity and limits the scope of the inhibitor. By 
tethering JQ1 to a ligand for the E3 ubiquitin ligase VHL, the PROTAC was unexpectedly 
selective to BRD4.252  
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19.2.12  First crystal structure of the 3ary complex 
In 2016 Alessio Ciulli published the first crystal structure of the key ternary complex ligase-
PROTAC-target species (Figure 128). Its structural elucidation remained elusive until then 
and can be a key for future structure-based-design PROTACs. The results elucidate how 
PROTAC-induced de novo contacts dictate preferential recruitment of a target protein into a 
stable and cooperative complex with an E3 ligase for selective degradation.253 
 
 
Figure 128; Crystal structure of the 3ary complex 
19.2.1 The importance of the linker 
The importance of the linker has been highlighted as a major contributor of the different 
conformations that the PROTAC can adopt in space. The influence of the linker, and 
consequently, the flexibility and shape of the molecule produced has an influence in the 
activity of the PROTAC binding the two targets of interest (protein and E3 ligase) and 
creating the ternary complex.254  
In 2017 Craig Crews published a study with a rational identification of a degrader targeting a 
serine/threonine TANK-binding kinase-1.255 This article states that the progression to a potent 
PROTAC have generalized key structural elements associated with degradation activities 
which can be rationalized.  
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A new study in 2019 demonstrated that with the right linker tethering position and the 
appropriate linker length several E3 ligase ligands can be used successfully for 
degradation.256 
19.2.2 Challenges and opportunities ahead 
PROTACs technology is having a great impact in the development of molecules able to 
induce degradation. To date, this approach has been mostly used to target druggable proteins, 
however the ability to degrade transcription factors and scaffolding proteins would increase 
the current target drug space and give access to new therapeutic strategies.  
However, there are potential problems with PROTACs. As we can clearly see, this approach 
will always use molecules with very high molecular weights, also these are likely to have 
many Hydrogen Bond Donors and Acceptors (HBD and HBA) and a high Polar Surface Area 
(PSA). As a consequence, the cell penetration is challenging but the potency of these 
compounds might be increased by the catalytic nature of ligands.  
19.2.3 From initial concept to industry 
The Craig Crews research group has been focused in controlled proteostasis. In 2001 Crews 
developed, in collaboration with Ray Deshaies, the concept of PROTACs. 12 years later, in 
2013, Crews founded Arvinas. The company, which main business is the development of 
PROTACs to treat cancer and other diseases, partnered with Merck and Genentech in 2015 to 
develop PROTAC-based drugs. In 2018 Arvinas signed a $830M plus deal with Pfizer, the 
pact centers on the discovery and development of PROTACs across multiple disease areas. 
The promise of induced protein degradation is very attractive for industry257 (Figure 129) and 
has led to the creation of companies focused on this technology (Arvinas was launched in 




Figure 129; Timeline of protein-induced degradation. Events related to estrogen receptors (ER) in 
blue, PROTACs technologies in red, hydrophobic tagging (HyT) in green, companies in yellow 
Recently, Arvinas has announced that a PROTAC-based drug candidate had advanced into 
phase I clinical trial in 2017260 for mCRPC. Currently there are no drugs in the market based 
on PROTACs. The success of these clinical trials can pave the way for a new generation of 
therapeutic drugs based in a completely new approach. 
19.2.4 Recently reported MDM2 induced degradation via PROTACs as a viable 
treatment for leukaemia 
PROTACs is a very recent and promising technology and important papers have been 
reported while this thesis was in preparation. In a recent publication by Shaomeng Wang et 
al.261 was reported an MDM2 induced degradation strategy based in PROTACs that achieves 
complete and durable tumour regression in vivo and was reported as a new class of anticancer 
agent. This publication is a nice example of the successful development of a PROTAC, and it 
will be summarized here to illustrate the potential of this strategy. 
 
In the studies reported here, an MDM2 inhibitor (MI-1061) was used as a small molecule 
ligand. After studying the co-crystal structure (Figure 130) the solvent exposed area of the 
ligand, with a carboxylic acid on the phenyl ring, was proposed as the tethering site for the 
design of the bivalent compound. MI-1061 was tethered with different linkers to two 
different E3 ligase ligands for Cereblon: thalidomide and its derivative lenalidomide (Table 8 
and 9).  
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found to induce 
ER degradation 
PROTAC technology is 
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Arg HyT is 
used to degrade 
GST and DHFR
A potent VHL 
inhibitor is 
identi ed and 
co-crystallized 
with VHL
Lenalidomide is discovered 
to bind to CRBN and 
induce degradation of 
IKZF  and IKZF3
C4 Therapeutics 
launches in Boston, 
USA, to further develop 
PROTAC technology
Rule of five
The rule of five is a widely used 
guideline to predict the 
likelihood of poor absorption 
or permeability characteristics 
for small molecules. It is based 
on upper limits for 
physicochemical properties of 
the compounds, including 
molecular mass (for which 
500 Da is the cut-off).
Degrons
Peptide segments recognized 
by the cellular quality control 
system that influence the 
degradation rate of the 
full-length protein.
challenging pharmacological properties, tolerability 
and the lack of a clear clinical indication; however, given 
the volume and range of ongoing clinical trials, HSP90 
inhibitors may still find their way to the market. With 
the approval of fulvestrant, SERDs and SARDs remain 
another promising class of drugs that can address mech-
anisms of resistance arising from a traditional inhibitor 
approach. However, bioavailability and systemic expo-
sure remain a challenge for this class of drugs. In addi-
tion, these small-molecule approaches are not broadly 
applicable to other targets.
In theory, HyT technology can be applied to a broad 
range of targets, but the unknown mechanism of HyT 
might limit the adoption of the technology. By contrast, 
the PROTAC technology offers a modular approach to 
sub-stoichiometric targeted protein degradation, which 
only requires accessible surface lysines to be present on 
the target protein in order to harness the UPS (BOX 3). 
However, PROTACs are not considered to be traditional 
‘small’ molecules, as they do not conform to Lipinski’s 
rule of five178 owing to their relatively large molecular 
mass. Unfortunately, this larger size of PROTACs pro-
vides more opportunity for metabolic modification of 
the compounds. First-pass metabolism could limit the 
oral delivery of PROTACs, yet a lower bioavailability 
might not significantly hinder PROTAC efficacy given 
the sub-stoichiometric nature of the technology when 
using non-covalent ligands. In regard to future clinical 
application, the potencies achievable in cell culture as 
well as the efficacies observed in tumour xenografts are 
e couraging.
As the field of PROTAC-mediated target protein 
degradation matures, the idea of additional specific-
ity could be explored further: is it possible to achieve 
tissue- or disease-specific induced protein degradation 
by utilizing tissue- or disease-specific E3 ligases? Small-
molecule screens have already identified several candi-
date E3 ligase inhibitors that can potentially be used as 
recruiting ligands179–182, and our laboratory has found 
that different E3 ligases provide different degradation 
profiles71. A more thorough understanding of E3 ligase 
tissue expression could potentially offer an increased 
therapeutic window with an appropriate E3  ligase -
recruiting PROTAC. Similarly, subcellular localization 
and regulation f E3 ligases could offer opportunities 
for conditional removal of target proteins183: perhaps an 
E3 ligase localized to the nucleus would permit condi-
tional degradation of activated nuclear receptors while 
sparing the cytoplasmic population. In addition, as 
suggested by studies with peptidic phosphoPROTACs, 
perhaps developing ‘state-specific’ protein ligands will 
permit conditional protein knockdown; on the other 
end of the PROTAC, one can also imagine a conditional 
unmasking of the E3 ligase-recruiting ligand by either 
chemical or optical means to permit temporal and 
spatial control of target degradation analogous to the 
endogenous system of cryptic degrons. The concept of 
increased specificity is only the tip of the iceberg for this 
emerging technology.
Finally, PROTAC technology could have its bigg st 
impact via the development of degrader molecules capable 
of targeting the undruggable r teome. Despite the rec nt 
Figure 3 | Timeline of the induced protein degradation field. Selected events related to selective oestrogen 
receptor (ER) degraders are highlighted in blue, proteolysis-targeting chimaera (PROTAC) technology in red, 
hydrophobic tagging (HyT) in green, and biotechnology company launches in yellow. βTRCP, β-transducin 
repeat-containing protein; AR, androgen receptor; cIAP1, cellular inhibitor of apoptosis protein 1; CRABP, cellular 
retinoic acid-binding protein; CRBN, cereblon; DHFR, dihydrofolate reductase; ERBB3, erythroblastosis 
oncogene B3; GST, glutathione-S-transferase; HSP90, heat shock protein 90; IKZF, Ikaros family zinc finger; MDM2, 
mouse double minute 2 homologue; MetAP2, methionine aminopeptidase 2; VHL, von Hippel–Lindau.
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Figure 130; Modelled structure of MI-1061 in complex with MDM2 
 
In the case of thalidomide (Table 8) a compound where the MDM2 inhibitor and the E3 
ligase ligand are directly linked to examine the importance of the linker (Table 8-entry w-3) 
was investigated. The analysis shows that compound w-3 failed to achieve acceptable levels 
of inhibition compared to other compounds. Changing the linker to different lengths and the 
introduction of ethylene glycols instead of alkyl chains (w-9, w-10) has an impact in the 
inhibition of cell growth. 
 
Compound No. Linker IC50 (nM) cell growth inhibition 















It is also known that modifications on the Cereblon binding portion of the degrader molecule 
can significantly change the levels of induced degradation of the protein. Exchanging 
thalidomide for lenalidomide (Table 9) gave new compounds (w-11, w-12) with improved 
IC50 values. The rigidification and shortening of the linker was also investigated with 









CO 29 8 
w-12 
 
CH2 5 5 
w-14 
 
CH2 1.5  
w-15 
 
CH2 3.9  
 
Table 9; MDM2 Degraders with Modifications of the tethering to the CRBN Ligand Portion 
 
The analysis of the co-crystal structure of CRBN E3 ubiquitin ligase complexed with 
lenalidomide shows the possibility of tethering the linker in 3 different positions (Figure 
131), this is very important for the development of PROTACS as the formation and stability 
of the 3ary complex can vary substantially, and the different possibilities must be explored. 




Figure 131; PDB ID: 4CI2 
 
Different E3 ligases can target the same protein, and the specificity of those for a specific 
target is hard to predict and may vary depending on each PROTAC’s design. For this reason 
several E3 ligase ligands are usually trialled in a given project. In addition to CRBN/Cullin 
4A E3 ligase complex, the von Hippel-Lindau protein (VHL-1)/cullin 2 E3 ligase system was 
also explored. The synthesis of several analogues gave compounds with good potencies but 
considerably inferior to the ones previously synthesized series. Therefore, after an analysis of 
all the data collected, the most promising compounds w-13 (MD-222) and w-14 (MD-224) 
were selected for further evaluation.  
 
To confirm degradation of MDM2 and subsequent accumulation of p53 in a dose dependant 
manner, Western blotting analysis were conducted in leukaemia cell lines. Both (w-13) MD-
222 and (w-14) MD-224 induced degradation in different cell lines, with effective depletion 




Figure 132; Western blotting analysis for MDM2 (green box) and p53 levels (blue box) after 
treatment with MDM2 inhibitors MI-1061 and the MDM2 degraders MD-222 and MD-224, (RS4;11 
cell line in fig. 129-A and MV4;11 cell line in fig. 129-B) 
 
One experiment generally used to confirm degradation upon addition of PROTACs is based 
on blocking the CRBN/Cullin 4 E3 ligase complex upon addition of an excess of 
lenalidomide. Western blotting analysis shows that lenalidomide actually blocks MDM2 
degradation (green box) and accumulation of p53 protein (blue box) is induced despite the 





Figure 133; Western blotting analysis of both MDM2 degraders in presence of lenalidomide excess. 
MDM2 degradation in the presence of PROTACs (green box) and accumulation of p53 (blue box) 
 
We can also verify the PROTACs activity with the addition of a proteasome inhibitor. In the 
case that the cell degradation machinery is impaired the PROTACs cannot induce 
degradation and only MDM2 inhibition patterns should be observed. After preincubation with 
proteasome inhibitors MG-132 and PR-171 or a neddylation inhibitor, MDM2 degradation is 
inhibited in a dose dependant manner (Figure 134-green box).  
 
 
Figure 134; Western blotting analysis of MDM2 (green box) and p53 proteins in RS4;11 cells 
 
After several analysis in different leukemia cell lines and p53 (wild type and mutant), and 
having very promising pharmacodynamics data, MD-224 was tested in vivo in comparison 




Figure 135; In vivo antitumor activity of MI-1061 and MD-224 in the RS4;11 xenograft model in 
mice  
 
The MDM2 inhibitor effectively retards tumour growth, but MD-224 can achieve more 
potent activity with significant tumour volume loss and no signs of toxicity or weight loss. 
 
MD-224 effectively induces inhibition of cell growth and is >10-100 times more potent than 
the MDM2 inhibitor used as positive control (MI-1061). This compound is highly efficacious 
and will be further evaluated as a potential new therapy for the treatment of human 
leukaemia.	
19.3 Androgen Receptors and PROTACs 
19.3.1 The case of androgen receptor (AR) and flutamide 
The Androgen receptors (AR) is a member of the nuclear receptor superfamily and they are 
transcription factors ligand-dependant. ARs are activated by binding of endogenous 
androgens (mainly DHT), regulate several processes in the male reproductive system. They 
play a significant role in the development of prostate cancer and castration resistant prostate 
cancer (CRPC). Mechanisms of resistance can emerge to antagonists of the AR (like 
flutamide, enzalutamide, bicalutamide or apalutamide (Figure 136)) by mutations that convert 
these antagonists into agonists.262 A mutation of the AR is believed to be responsible for 
metastatic prostate cancer (mPCa) cells ability to survive through mechanisms which rely on 




Figure 136; Different Androgen Receptor inhibitors (ARi) 
 
There are several known androgen receptor variants (ARVs), ARF876L is driven by 
enzalutamide and ARW741L/C and ARH874Y/ART877A are known to be driven by 
flutamide. These ARVs along with AR amplification provide prostate cancer cells a 
mechanism for Androgen Deprivation Therapy (ADT) evasion (Scheme 46) and currently, 
the reduction of available androgen/testosterone/dihydrotestosterone (DHT) by chemical or 
surgical means is the only way to fight prostate cancer. 
 
Scheme 46; Evasion strategy through Androgen receptor variants (ARVs) of ADT 
 
Intensive studies have been carried to produce analogues of the available antagonists 
(flutamide (Figure 137), 263 bicalutamide, enzalutumide, apalutamide, etc…) to overcome 
188	
	
resistance. Also innovative lines of research are under development like nicotinamide 
derivatives as a novel type of nonsteroidal AR antagonists, or curcumin natural pigment 
analogues, which have shown antiandrogenic activity.  
 
Figure 137; Previous analogues of flutamide 
 
A series of nonsteroidal ligands based on flutamide were synthesized by Marhefka et al.264 as 
2nd generation ligands for the AR. These ligands were designed initially to eliminate 
metabolic sites with fast metabolism and low activity. Thanks to this research, more potent 
compounds with improved pharmacokinetic properties were discovered, by changing the 
sulfur-linked compounds to oxygen-linked compounds (Table 10). 
 
 X R Ki (nM) Relative Activity 
DHT - - 0.27 100 
R-2 S NHC(O)CH3 4.90 ± 0.20 50 
S-5 O F 6.11 ± 0.19 43.40 ± 2.60 
R-5 O F 225 ± 15 N.D. 
S-6 O NHC(O)CH3 3.98 ± 0.70 92.92 ± 7.00 
S-7 O C(O)CH3 36.6 ± 2.4 9.67 ± 1.50 
S-8 O C(O)CH2CH3 6.07 ± 0.14 75.41 ± 11.50 
S-9 O Cl 9.56 ± 0.66 64.01 ± 11.20 
S-10 O Br 11.64 ± 0.36 17.02 ± 2.90 
S-11 O I 29.96 ± 2.69 16.00 ± 2.90 
S-12 O CH3 34.77 ± 3.50 8.95 ± 2.50 
S-13 O OCH3 13.69 ± 0.68 17.40 ± 3.30 
S-14 O NHC(O)OC(CH3)3 336 ± 71 4.43 ± 1.30 
S-17 NH F 7.96 ± 0.43 21.33 ± 2.22 
 
Table 10; Ki and in vitro activity of 2nd generation nonsteroidal AR ligands (Marhefka et al.) 
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19.4 MDM2 as an E3 ligase ligand 
19.4.1 MDM2 biology 
MDM2 is a protein and an E3 ligase that has several roles inside cells. One of its most 
studied functions is to control the levels of the transcription factor p53, which is achieved by 
MDM2 forming an auto regulatory feedback loop by virtue of the ability of p53 protein to 
activate the MDM2 gene and therefore MDM2 protein expression. MDM2 is a 491 amino 
acid protein that contains a deep hydrophobic binding site. For binding between MDM2 and 
p53, a triad of amino acids (Phe19, Trp23 and Leu26) in p53 binds to a shallow cleft in 
MDM2. Binding between p53 and MDM2 is driven essentially by hydrophobicity, with 
multiple Van der Waals interactions formed (Figure 138).265 
 
Figure 138; MDM2 bound with the p53 turn II (49 –54) peptide. The residues of p53 peptide are 
represented in a ball and stick mode with nitrogen atoms in blue and oxygen atoms in red266 
MDM2 is a RING E3 ligase, so it can be used as a target for a PROTACs strategy. As we 
have described, the active site of MDM2 has been studied by identifying the key interactions 
between p53 and MDM2, but also importantly, recent studies have shown that there is a 30 
aminoacid acidic region of MDM2 that is critical for binding to the E2 ligase and promote 
ubiquitination.267 Several inhibitors for MDM2 have been developed with thorough structural 
characterization of its interactions, these inhibitors are available for PROTACs development. 
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19.4.2 MDM2 inhibitors 
The first group of small molecules developed to target the E3 ligase MDM2 are called 
Nutlins. These ligands can displace p53 from MDM2 with IC50 values in the range of 100-
300 nm. Through crystal structure determination it was found that the Nutlin compounds 
successfully bind to the p53 pocket in MDM2 with its cis-imidazoline structure allowing a 
halophenyl group to sit in the Trp23 and Leu26 pocket (Figure 139). 
 
 
Figure 139; MI-219 (Nutlin) in complex with MDM2 and superpositioned to the MDM2– p53 
crystal structure. MI-219 is shown in ball and stick representation268 
 
This cis-imidazoline (Figure 140) provided a strong scaffold for further exploration of the 
molecule and to direct binding towards the MDM2 binding site.269 
 
 
Figure 140; Nutlin-3 compound used for the synthesis of PROTACs270 
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Chapter 20: Project Rationale 
The main objective of this project is to synthesize innovative PROTACs for the androgen 
receptors (ARs) that could be used as chemical probes for future anti-cancer treatments 
focused on prostate cancer.	
20.1 Design of a hetero-functional molecule 
As we already know a PROTAC is divided in three parts and the design will be rationalized 
for each one of these parts: 
20.1.1 E3 ligase ligand 
MDM2 is an E3 ligase and is overexpressed in around 20% of cancer cells. The advent of 
potent and specific ligands for MDM2 offers the opportunity to develop an optimised 
MDM2-based PROTAC. A considerable number of small molecule inhibitors of this specific 
protein-protein interaction have been reported and successfully entered clinical trials.271, 272, 
273, 274 
 
The participation of several research groups and pharmaceutical companies have provided us 
with a broad spectrum of inhibitors of which a pyrazolopyrrolidine scaffold reported by the 
Novartis was selected to be used as the E3 ligase ligand.  
 
The design and characterization done to achieve this new inhibitor is remarkable and based 
on previous experience of Novartis for this particular interaction.275, 276, 277 The initial design 
relies on the occupancy by appropriate moieties of three essential pockets of the N-terminal 
domain of MDM2 which will recognize the residues of the transactivation domain of p53 
(Phe19, Trp23 and Leu26).278 For a successful design, a strategy based on “the central valine” 
concept was followed. This strategy is based on the use of a planar and unsaturated core 
moiety that interacts through Van der Waals interactions with a valine residue (V93) which 
occupies the central position of the p53 binding pocket of MDM2 (Figure 138; red arrow). 
Once this core is in the right position it provides with a suitable tool to successfully use the 
three sub-pockets present in p53.279 A five-membered lactam ring, when fused to an aromatic 
ring is flat and able to project two exit vectors to the Phe19 pocket of MDM2 (Figure 141; 
magenta arrows). For this purpose, several analogues with different hydrophobic substituents 
in position 3 of the pyrazole ring were designed, of those the isopropyl gave the best potency.  
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A feature of the Leu26 sub-pocket pharmacophore was previously identified in different 
series of inhibitors. The π-π stacking interaction between a chlorophenyl ring of the ligand 
and residue H96 (Figure 141; orange arrow) must be parallel for high efficiency.111, 112 
 
 
Figure 141; Crystal structure of MDM2 in complex with the pyrazolopyrrolidine (PDB ID: 5LN2) 
 
It was speculated that the compounds could be binding with a conformational energy penalty. 
Modelling experiments elucidated that the introduction of two methyl groups causing steric 
hindrance would be adequate to avoid the conformational penalty (Figure 142) associated to 
the leucine and tryptophan sub-pockets. 
 
Figure 142; Calculated (ab initio) lowest energy conformations 
 
After synthesizing a series of analogues exploiting the top exit vectors of the core moiety, it 
turned out that only one variation of this type, attachment of an ortho-methoxyphenyl group, 
produced a significant increase in potency. The appropriate diastereoisomer of the inhibitor 
(Novartis-3) showed a great final potency (Figure 143) with an IC50 value of 0.13 nM in the 
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TR-FRET assay. An amino solubilizing chain replacing the methyl group in ortho position of 
the meta-chlorophenyl group was introduced to obtain a co-crystal by increasing the 
solubility of the compound. This modification gives us key information about the tethering 
position for the linker. 
 
Figure 143; IC50 values (nM) for the different isomers of the MDM2 inhibitor 
 
To avoid disruption on the binding mode of the E3 ligase ligand with MDM2 (E3 ligase) the 
linker will be placed in a solvent exposed part of the E3 ligase ligand. The crystal structure 
(Figure 144) shows the dimethyl-aminoethyl substituent is exposed to the solvent, and it 









20.1.2 Andogen Receptor Inhibitor 
To bind to the androgen receptors (AR) we use the most potent version of flutamide 
(androgen receptors inhibitor) that has been reported so far.  
The fact that this molecule has been already reported in the literature as part of a functional 
PROTAC (Figure 145) is very encouraging.280 
 
Figure 145; AR degrader reported by C. Crews et al. (flutamide in pink and E3 ligase ligand in blue) 
20.1.3 Linker exploration 
Polyethylene glycols (PEGs) will be used as linkers, different linker lengths should be 
synthesized and trialed. Also, the moiety that will tether the linker with both ligands will be 
explored, using an amide moiety, a triazole or both, one in each end of the linker. 
Predicting the right linker length is not possible and several must be explored to find the 
optimal length and nature for our PROTAC. 
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Chapter 21: Results and Discussion 
21.1 Methodology and Synthesis	
PROTACs are hetero-bifunctional molecules and the synthesis will be divided in three 
independent pathways (Figure 146).  
 
 
Figure 146; Molecule divided by functionalities. Three different synthetic pathways will be designed 
21.1.1 Part A: flutamide 
Part A of the molecule, and common to all the different targets synthesized, will be flutamide, 
a known inhibitor of the ARs. We will use the best analogue studied and synthesized up to 
date (127). The synthesis of Part A of the molecule starts with the amide coupling of 4-nitro-
3-(trifluoromethyl)aniline (124) and  (2R)-3-bromo-2-hydroxy-2-methylpropanoic acid. To 
do this coupling reaction an acyl chloride was prepared by using thionyl chloride and 
subsequent addition of the aniline (124) to afford compound (125). Then the molecule was 
treated with sodium hydride at 0oC in anhydrous tetrahydrofuran and then stirred at room 
temperature for 6 hours to yield compound (126). The epoxide was treated with potassium 
carbonate in acetone and then reacted with N-Boc-4-aminophenol to give us the Boc-
protected desired product, which was treated with a mixture of TFA/DCM (1:1) to finally 






Scheme 47; i) (2R)-3-bromo-2-hydroxy-2-methylpropanoic acid, SOCl2, DMF, 0oC to r.t., 5h, ii) 
NaH(60%), THF, 0oC to r.t., 6h, iii) a) K2CO3, acetone, 65oC, 48h, b) TFA/DCM (1:1), r.t., 8h 
21.1.2 Part B: E3 ligase ligand 
Part B of the molecule is the MDM2 inhibitor synthesized by Novartis. The necessity of 
including a functional group that will allow us the attachment of a linker to finally build our 
PROTAC molecule was taken into account. In order to have a suitable and reactive end in 
this part of the molecule a terminal alkyne was planned for a future reaction with an azide via 
click chemistry. Thus, a modified version of the MDM2 inhibitor was designed (Scheme 48 – 
Modified MDM2 inhibitor). 
 
Scheme 48; Modified version of the MDM2 inhibitor for click chemistry (Cu catalysed) 
 
The synthesis of Part B of the molecule starts with the treatment of the nitrophenol (128) with 
potassium carbonate and subsequent reaction with propargyl bromide to give compound 
(129). Then the intermediate was subjected to a reduction with SnCl2.2H2O in Ethanol under 
acidic conditions (conc. HCl) to yield compound (130) as a mixture with the dehalogenated 
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starting material, which was separated by flash column chromatography. With compound 
(130) in hand a reaction with 4-chloro-2-methyl benzaldehyde and ethyl 5-methyl-2,4-
dioxohexanoate in acetic acid was performed at 80oC for 20 hours to give us the desired 
intermediate (131). Further treatment of this intermediate with 2-methoxyphenyl hydrazine 
hydrochloride in ethanol, using conc. HCl as a catalyst, finally gave us the modified version 
of the MDM2 inhibitor (132) (Scheme 49). 
 
Scheme 49; i) Propargyl bromide, K2CO3, DMF, 0oC to r.t. 16h, ii) SnCl2.2H2O, EtOH, conc. HCl, 
iii) 4-chloro-2-methyl benzaldehyde, ethyl 5-methyl-2,4-dioxohexanoate, acetic acid, 80oC, 20h, iv) 2-
methoxyphenyl hydrazine hydrochloride, ethanol, conc. HCl (catalytic), 80oC, 48h 
21.1.3 Part C: linker 
Part C of the molecule is the linker. In this case we used PEG linkers with different lengths. 
The nature of the moiety to bind the linker to the different ligands was explored, using amide 





Figure 147; PROTACs to be synthesized (variations of the linker type and length)) 
 
The synthesis of part C of the molecule starts with the different polyethylene glycols and the 
addition of para-toluenesulfonyl chloride to mono-tosylate one end of the molecule to give 
intermediate (133). To avoid di-tosylation the number of equivalents of p-TsCl goes only up 
to 0.45 equivalents. After the mono-tosylation a reaction with sodium azide in DMF was 
performed affording the desired compound (134) (Scheme 50). 
 
Scheme 50; i) p-TsCl, TEA, DCM, r.t., 16h; ii) NaN3, DMF, r.t., 16h 
21.1.4 Tethering of the different parts 
To link all the different parts of the potential PROTAC a synthetic route was planned 
(Scheme 51). As a first step, the linker with a terminal azide (134) was reacted with the 
modified version of the MDM2 inhibitor (132) under click conditions to give (135). This 
intermediate was oxidized using Chromo Jones conditions to give (136). Coupling the acid 
with the aniline of flutamide (127) to give the desired PROTAC (137) was attempted under a 
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range of conditions (Table 11).  
 
Scheme 51; i) (134), (+)-Na-L-ascorbate, CuI(I), THF, 110oC, 1h, MW irradiation, ii) Chromo Jones 
sol. acetone, 0oC to r.t., 3h, iii) see table 5, (127), r.t. to 80 oC, 16h 
 
Compounds Coupl. Agent Base Conditions Conversion 
(136) and (127) HATU DIPEA Increasing Temperature and 
addition of crown ether 
0% by LCMS 
(136) and (127) HBTU DIPEA Increasing Temperature and 
addition of crown ether 
0% by LCMS 
(136) and (127) EDCI.HCl Et3N Increasing Temperature and 
addition of crown ether 
0% by LCMS 
(136) and (127) SOCl2 Et3N Increasing Temperature and 
addition of crown ether 
0% by LCMS 
 




Unfortunately, the amide coupling between compound (136) and the aniline of compound 
(127) did not work. It was theorized that the nature of the linker could act as crown ether, 
coordinating with cations present in the reaction, but the addition of different crown ethers 
did not improve the outcome of the reaction. 
 
A new strategy reversing the amide coupling was designed to try to synthesize the desired 
PROTAC molecule. For this new approach a different linker was synthesized. The tosylation 
of the polyethylene glycol is achieved with an excess of p-TsCl to give (138). Then a 
treatment with an excess of NaN3 gave (139), then a Staudinger reaction gave (140) (Scheme 
52). 
 
Scheme 52; i) p-TsCl, TEA, DCM, r.t., 16h; ii) NaN3, DMF, r.t., 16h, iii) Ph3P, DCM, H2O (cat.), 
r.t., 5h 
In this case, we did not rely on an amide coupling reaction. Instead, a α-carbonyl halide SN2 
reaction was performed (Scheme 53- step ii) before the click reaction, which provided us 
with the desired PROTAC (Scheme 53 – step iii). 
Scheme 53; i) Chloroacetyl chloride, K2CO3, acetone, r.t., 4h; ii) (140), K2CO3, DMF, 80oC, 8h, iii) 
(132), Na ascorbate, Cu(I)I, TBTA, 100oC, 1h, MW irradiation 
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Unfortunately, the presence of an epimeric mixture (Figure 148) gave us very unusual 
splitting patterns and duplicated signals in the 1H-NMR (Figure 149-a) and also in the 13C-
NMR (Figure 149-b). The presence of both compounds was confirmed by HRMS. 
	
Figure 148, Circled groups with unusual splitting signals detected by NMR 
 
 





Figure 149-b; 13C-NMR, signals from 15 – 35 ppm for isopropyl and aromatic methyl group 
A new PROTAC with a different linker length and, at the same time, with a different moiety 
attaching the linker to the flutamide and to the E3 ligase was also designed. For this, we used 
a di-azide as a linker and two click reactions were performed to join the two ligands and the 
linker. In one end with a new version of flutamide, functionalized with an alkyne (146) and 
on the other end the MDM2 inhibitor (132). 
For the synthesis of the new linker a di-tosylation followed by treatment with excess of 
sodium azide was performed to yield (145) (Scheme 54). 
 
Scheme 54; i) p-TsCl, TEA, DCM, r.t., 16h; ii) NaN3, DMF, r.t., 16h 
For the synthesis of the new version of flutamide, compound (127) was used to perform an 




Scheme 55; i) Propiolic acid, EDCI.HCl, TEA, THF, r.t., 16h 
The click chemistry was performed first with compound (146) and then with compound (145) 
using similar conditions in both cases (Scheme 58). To try to entropically minimize the 
formation of homo-bivalent compounds in the first step (Scheme 56-step i) an excess of 
linker was used. 
 
Scheme 56; i) (139), Na ascorbate, Cu(I)I, TBTA, 100oC, 1h, MW irradiation; ii) (146), Na 
ascorbate, Cu(I)I, TBTA, 100oC, 1h, MW irradiation 
Again, the presence of an epimeric mixture (see Figure 148) gave us very unusual splitting 
patterns and duplicated signals in the 1H-NMR (Figure 150-a) and also in the 13C-NMR 




Figure 150-a; 1H-NMR, (0.8 – 1.2 ppm) for isopropyl group and (1.9 – 2.3 ppm) for aromatic methyl 
group 
 
Figure 150-b; 13C-NMR, signals from 15 – 35 ppm for isopropyl and aromatic methyl group 
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As the linker chemistry proved to be challenging an additional PROTAC was also developed 
with a less potent version of flutamide. In this case the primary alcohol of an ethylene glycol 
linker was used as a nucleophile to open the cyclopropoxy ring present in compound (126) 
(Scheme 57) with the use of sodium hydride to deprotonate the terminal alcohol of the linker. 
 
Scheme 57; i) (135) (n = 2), NaH (60%), THF, 0oC to r.t., 16 h 
The presence of an epimeric mixture (see figure 148) should gave us unusual splitting 
patterns and duplicated signals in the 1H-NMR (Figure 151-a) and 13C-NMR (Figure 151-b), 
but in this case the spectrum was well defined.  
 









Chapter 22: Biological Assays 
The PROTACs were submitted for testing. The results are summarized in this chapter. The 
compounds selected to be tested with different AR cell lines are classified below: 
 
Compound Label Structure (AR inhibitor-E3 ligase ligand) 
NCL-00023900 PROTAC 1 Flutamide-isoindolinone (MDM2 ligand) 
(149) PROTAC 2 Flutamide-pyrazolopyrrolidine (MDM2 ligand) 
(143) PROTAC 3 Flutamide-pyrazolopyrrolidine (MDM2 ligand) 
(148) PROTAC 4 Flutamide-pyrazolopyrrolidine (MDM2 ligand) 
547-244-1 PROTAC 5 Apalutamide derivative-pomalidomide (cereblon ligand) 
Table 12; PROTACs to be tested with different AR cell lines 
 
For structure of PROTAC 1 see Figure 149-b, for structure of PROTAC 2 (compound (149)) 
for structure of PROTAC 3 (compound (143)) and for PROTAC 4 (compound (148)). 
PROTAC 5 is not related to the previous compounds but also targets the androgen receptor 
and is based on Cereblon as an E3 ligase instead of MDM2 so we can compare a new E3 
ligase ligand targeting the same protein, see Figure 152-a. 
 
Figure 152; a) Cereblon-based PROTAC 5; b) MDM2-based PROTAC 1 (*confidential structure) 
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The aim is to test the effects of the PROTACs on a panel of PCa cell lines with defined 
androgen receptors status upon addition of DHT and each of the PROTACs by Western blot 
analysis. In this case, the plating was done using several types of cell lines summarized in the 
table below: 
 
Cell line AR mutation Androgen 
Responsive 
Prostate Specific Antigen 
(PSA) 
LNCaP Mutation in AR ligand binding 
domain 
Positive Expresses PSA 
mRNA/protein 
VCap Express wild type AR and low 
levels of AR- V7 
Weakly Expresses PSA 
CWR22Rv1 Express mutant (H874Y) AR and 
AR variants 
Weakly Secretes low levels of PSA 
 
AR-EK 
CRISPR modified CWR22Rv1 to 





Secretes low levels of PSA 
Table 13; Different AR cell lines and their properties 
During the analysis the levels of AR, PSA and FKBP-5 (binding protein for the role of 
regulation and tumourigenesis) were monitored. α-tubulin was used as positive control for the 
analysis.  
Also, one of the ways to confirm that the activity of our PROTACs is based in degradation 
rather than straightforward inhibition could be the addition of a proteasome inhibitor but also 
the confirmation of the “hook effect”. The fundament of this effect is that the proportion of 
target protein degraded would be reduced at high concentrations of PROTAC. Due to binding 
of the target by the PROTAC as a binary complex and, at the same time, binding of the E3 
ligase by the PROTAC also as a binary complex, the formation of the ternary complex is not 






Figure 153; Hook effect (Sainan, An et al., 2018) 
22.1 Western blot analysis (enzalutimade as control) 
The results and conclusions obtained after Western Blot Analysis are summarized below: 
22.1.1 Addition of PROTACs LNCap cells 
 
Figure 154; Western blot analysis of LNCap cells upon addition PROTACs 
 
• In the case of the AR we can see a subtle reduction in PROTACs 2 (blue box) and 5 
(purple box). For PROTAC 5, the reduction is similar to that observed for 
enzalutamide (green box). For PROTACs 1, 3 and 4 the level of AR shows a subtle 
increase in the levels of AR without DHT suggesting a possible weak agonistic 
activity. Unfortunately, the results observed are inconclusive. The differences in 
signals are extremely weak and the assumptions made here are not definite. Further 
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testing should be implemented specially in the case of AR for consistent 
interpretation. 
• The observation of PSA expression levels gives us similar information, but in this 
case the intensity of the signals is slightly more reassuring. As we can see the PSA 
expression levels for PROTACs 1, 3 and 4 is enhanced in the absence of DHT 
addition, suggesting again a possible agonistic activity. For PROTACs 2 (blue box) 
and 5 (purple box) the reduction in the PSA signal upon addition of DHT is very 
subtle but consistent with the expression levels of androgen receptors, suggesting 
possible degradation or simple inhibition. 
• FKBP5 levels are clearly reduced for PROTAC 5 (purple box), and subtly reduced for 
PROTAC 2 (blue box). Again, PROTACs 1, 3 and 4 suggest some weak agonistic 
activity due to the results observed in the absence of DHT. 
• As a general conclusion, because LNCap Cells are androgen responsive with mutated 
androgen receptors, enzalutamide should not be as effective as an antagonist due to 
the mutation of the androgen receptor. In the case of flutamide,281 agonistic activity is 
observed for mutated androgen receptors, and the fact that some agonistic activity is 
observed reflects that our PROTAC is based on flutamide, these results would suggest 
that flutamide engages the mutated androgen receptor with agonistic activity and that 
the PROTAC is not producing degradation. 
22.1.2 Addition of PROTACs to VCap cells: 
 
 
Figure 155; Western blot analysis of VCap cells upon addition PROTACs 
 
• The results of the Androgen Receptor are inconclusive. 
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• In the case of the PSA expression levels we can see a subtle decrease after addition of 
PROTACs 2 (blue box) and 5 (purple box). PSA expression levels are similarly 
reduced after addition of enzalutamide. For PROTACs 1, 3 and 4 again a weak 
agonistic activity can be suggested from the results in the absence of DHT. 
• Results obtained for FKBP5 showed a great reduction on the expression levels for the 
protein upon addition of DHT for PROTAC 5, similar to the result observed for 
enzalutamide. 
• As a general conclusion, we know that androgens directly regulate FKBP5 via an 
interaction between the androgen receptor and a distal enhancer located downstream 
of the transcription start site in the fifth intron of the FKBP5 gene.282 Unfortunately, 
this result by itself cannot confirm degradation of the androgen receptors, specially in 
this case, where no change is observed in the expression levels of androgen receptor. 
A weak agonistic activity can be inferred again for PROTACs 1 and 3, ruling out 
degradation, but the results are not conclusive. 




Figure 156; Western blot analysis of CWR22Rv1 cells upon addition PROTACs 
 
• In the case of the androgen receptors and its variant, the results are not conclusive. As 
we can see, almost the same level of AR and ARV expression is observed, with or 
without DHT addition in the control experiment. In the case of PROTAC 3 a weak 
agonistic activity could be suggested. 
• PSA cannot be interpreted. 
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• FKBP5 expression levels remained almost constant during our experiments, no 
conclusion can be obtained with these results. 
• Inconclusive, no interpretation can be made with these results in hand. 
 
22.1.4 Addition of PROTACs to AR-Vs in AR-EK cells: 
 
 
Figure 157; Western blot analysis of AR-EK cells upon addition PROTACs 
 
 
• PROTACs (1 to 5) or flutamide are unable to target the proteins. Levels are constant 
during the assays. Further repetition of the assay should be implemented. 
• Inconclusive results. 
 
22.2 Western blot analysis (flutamide as control) 
In order to compare flutamide based PROTACs with flutamide itself a series of experiments 
were performed with the androgen receptor inhibitor as a control.  For the immunoblotting 










22.2.1 Addition of PROTACs LNCap cells: 
 
 
Figure 158; Western blot analysis of LNCap cells upon addition PROTACs 
	
• In the case of PROTAC 2 we can see a reduction in the level PSA in the absence of 
DHT, suggesting that is the only PROTAC without an agonistic activity as we can see 
in the rest of them. 
22.2.2 Addition of PROTACs to VCap cells: 
 
 
Figure 159; Western blot analysis of VCap cells upon addition PROTACs 
 
• Results for AR and ARV are inconclusive. 
• Very subtle reduction of PSA levels for PROTAC 2 (blue box).  
• Antagonistic activity could be assumed for PROTACs 2 (blue box) and 3 with the 
reduction of PSA expression levels observed but the further experimentation would be 




22.3 Testing the hook effect  
PROTACs 2 and 5 will be re-tested for the hook effect as the most promising compounds 
form the previous tests, engaging the androgen receptors without an agonistic effect 
(enzalutamide as control) and showing weak agonistic activity (flutamide as control).  
22.3.1 Addition of enzalutamide in LNCaP and VCaP cells 




Figure 160; Western blot analysis of LNCap and VCap cells upon addition of enzalutamide (0.25 
µM to 10 µM) 
 
• The hook effect is not observed upon addition of enzalutamide. 
 
As the most promising compounds from previous tests PROTAC 2 and 5 were tested in 











Figure 160; Dose-effect of PROTAC 5 in LNCaP and VCaP cells 
 
 
• In the case of LNCaP cells a slight increase in the expression of androgen receptors 
levels is observed, suggesting the presence of the hook effect. 
• With the increase in PROTAC 5 we can see a decrease in the PSA levels for both cell 
lines but no presence of the Hook Effect is observed. 
• Results with androgen receptors expression levels and PSA expression levels are not 


















Figure 161; Dose-effect of PROTAC 5 in LNCaP and VCaP cells 
 
 
• Very subtle decrease of the level of PSA in LNCaP cells is observed. No presence of 
hook effect. 
• In the case of the VCaP cells a reduction of AR and PSA levels is observed but no 
presence of Hook Effect can be confirmed. 
 
Finally, a combination effect of PROTAC 2 with nutlin-3a was proposed. According to the 
research performed John Lunec,283 5 µM of nutlin-3a could inhibit LNCaP proliferation by 
50% with subsequent accumulation of MDM2 in the cell as a result of a positive feedback 
loop induced by the high levels of p53 in the cell which activates the expression of MDM2 by 






22.3.4 Addition of PROTAC 2 and Nutlin-3a to LNCaP cells: 
 
Figure 162; Addition of PROTAC 2 and Nutlin-3a to LNCaP cell 
 
• In the case of the combination between Nutlin-3a and PROTAC 2 no further 
degradation of PSA or androgen receptors is observed in the combination experiment. 
The expression levels of androgen receptors in the control experiment are similar 
upon addition of DHT, suggesting that the experiment was not conducted properly. 
Results are inconclusive. 
22.3.5 Addition of PROTAC 2 and Nutlin-3a to VCaP cells 
 
Figure 163; Addition of PROTAC 2 and Nutlin-3a to VCaP cell 
 
• AR and PSA levels are reduced in two PROTAC 2 groups and also in the 
combination group, but no remarkable difference is observed. 
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22.4 Cell proliferation assays 
To test whether any of our PROTACs could influence the proliferation of PCa cell lines, cell 
proliferation assays were carried. The results are summarized below: 
22.4.1 PROTAC 1 cell proliferation assay 
 
Figure 164; Cell proliferation assay in LNCaP cells for PROTAC 1 (x-axys = cell number) 
 
 
• The proliferation is reduced upon PROTAC 1 addition, with or without DHT addition. 
22.4.2 PROTAC 2 cell proliferation assay 
 
Figure 165; Cell proliferation assay in LNCaP cells for PROTAC 2 (x-axys = cell number) 
 







22.4.3 PROTAC 3 cell proliferation assay  
 
 
Figure 166; Cell proliferation assay in LNCaP cells for PROTAC 3 (x-axys = cell number) 
 
• The proliferation is reduced upon PROTAC 3 addition, with or without DHT addition. 
22.4.4 PROTAC 4 cell proliferation assay 
 
Figure 167; Cell proliferation assay in LNCaP cells for PROTAC 4 (x-axys = cell number) 
 












Figure 168; Cell proliferation assay in LNCaP cells for PROTAC 5 (x-axys = cell number) 
 
 
As a general conclusion, all the PROTACs reduced the proliferation of LNCaP cells 
compared to the control groups. Among them, PROTAC 2 and 3 had the greater effects in 










Chapter 23: Conclusions and Future Work 
The results of the biological assays were not conclusive. Further experimentation is required 
to assess if the cell proliferation assays were slightly successful because of induced 
degradation rather than simple inhibition, or cytotoxic effects. Addition of a proteasome 
inhibitor should be used to block the degradation of androgen receptors. 
 
The fact that a cereblon-based PROTAC was relatively active compared to MDM2-based 
PROTACs confirms the tendency found in recent literature. Using thalidomide or VHL-based 
E3 ligase ligands could give us better chances of synthesizing successful PROTACs. Also, 
the optimisation of the linker (nature and length), and the nature of the moiety tethering the 
E3 ligase ligand and the linker should be considered. 
 
The hook effect proved to be elusive and a proteasome inhibitor strategy to confirm 
degradation should be implemented to avoid inconclusive results. For this strategy, the 
addition of the proteasome inhibitor would tell us if the lower expression levels of androgen 
receptors are the consequence of inhibition by the flutamide molecule contained in our 
PROTACs rather than degradation. If the 26S proteasome is inhibited the levels of androgen 
receptor expression should be not affected by the PROTAC. 
 
The enzymatic process to efficiently ubiqutinylate a protein with the subsequent degradation 
can be harnessed and used to our purpose but in practice a complex development of events 
must happened. The failure of any of these can ruin our strategy and among the different 
steps for degradation of the targeted protein things can go wrong in several of those:284 
1. The agent that brings in close proximity the cell degradation machinery and the 
protein must access the cell and PROTACs are usually large molecules with poor 
permeability. 
2. The population of ternary complex must be sufficient to allow subsequent steps. 
Thermodynamics of this complex are hard to predict. A low population would not 
enable enough degradation and overpopulation can lead to the hook effect. 
3. For the transfer of ubiquitin to the targeted protein the ternary complex must have an 
appropriate conformation, so the transfer of ubiquitin is directed to an appropriate 
receptor site, usually a lysine, so the rate of ubiquitin transfer is faster than the 
lifetime of the ternary complex. 
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4. At the same time, the speed of ubiquitination must overcome the action of 
deubiquitinase enzymes. 
5. The ubiquitin chain formed in the targeted protein must be recognizable and 
accessible for the proteasome for degradation to happen. Different chain 
lengths/topologies can result in different responses. 
6. Finally, the induced degradation rate must overcome the de novo synthesis of the 
targeted protein in order to ensure that the levels of the protein are diminished by 
degradation by PROTACs inside the cell. 
 
Future work should be focused in the exploration of new E3 ligase ligands to target the 
androgen receptor. The use of MDM2 based PROTACs has not been optimised and new 
“degron” moieties will be tested.  
 
The use of different linker lengths has shown to be critical for the design of a successful 
PROTACs and should be considered for future explorations. 
 
PROTACs are a very promising strategy for the development of new therapeutic agents. In 
the following decades we will see the introduction of these molecules in the market by 
pioneers like Arvinas. The possibility of overcoming resistance and the capacities of these 
molecules to act as chemical probes can give the scientific community new insights about the 
functions of proteins within cells and the possibility to re-explore already known warheads 
that could be still active despite of new mutations developed in the targeted protein.  
 
However, the lack of a rational design for the linker and the choice of an appropriate E3 
ligase ligand depending on the targeted protein are the current handicaps of this emerging 
approach. The advent of more sophisticated computational chemistry approaches for the 
design of highly complex entities (like PROTACs) could give medicinal chemists new tools 
and the key to a faster approach to develop these heterobifunctional molecules. In the 
meantime, large amounts of manpower for the synthesis of large libraries with different 
linkers and E3 ligase ligands analogues are still necessary. Having said that, strategies 




The fact that Arvinas and C4-Therapeutics have several clinical trials ongoing should make 
us feel optimistic about the future of this strategy that mixes a deep understanding in biology 





Chapter 24: Experimental and Analysis 
24.1  Safety 
All procedures were carried out in line with the School of Natural Sciences Safety Policy. 
COSHH risk assessments were completed before starting any practical work. 
24.2  Solvents and Reagents 
Chemicals were purchased from Sigma-Aldrich, Alfa Aesar, Apollo Scientific and 
Fluorochem and used without further purification. SureSeal™ or Acroseal™ bottles of 
anhydrous solvents were purchased from Sigma-Aldrich or Acros, respectively. Deuterated 
solvents used for the determination of NMR spectra were purchased from Sigma-Aldrich. 
24.3  Chromatography and Equipment 
Purifications by column chromatography were carried out using a Biotage SP4 automated 
flash system with UV monitoring at 298 nm and collection at 254 nm. Grace Resolv pre-
packed flash cartridges were used in most cases for normal phase separations. Reveleris pre-
packed NH silica cartridges and Reveleris C18 silica cartridges were also used where stated. 
Semi-preparative HPLC was carried out by Dr. Lauren Molyneux and Dr. Stephen Hobson 
using an Agilent 1200 HPLC system with a binary pump, autosampler, fraction collector and 
diode array detector, controlled by Agilent ChemStation software. 
Where stated, reactions were carried out under microwave irradiation in sealed microwave 
vials with the use of a Biotage Initiator Sixty with a robotic sample bed. Reactions were 
irradiated at 2.45 GHz, and were able to reach temperatures between 60 and 250 oC. Heating 
was at a rate of 2-5 oC/s and the pressure was able to reach 20 bar. 
24.4 Analytical Techniques 
Melting points were measured using a Stuart Scientific SMP3 apparatus. FTIR spectra were 
measured using a Agilent Cary 630 FTIR as a neat sample. UV spectra were recorded on a 
Hitachi U-2800A spectrophotometer and were performed in ethanol. HRMS were provided 





LC-MS analyses were conducted using a Waters Acquity UPLC system with PDA and 
ELSD. When a 2 min gradient was used, the sample was eluted on Acquity UPLC BEH C18, 
1.7µm, 2.1 x 50mm, with a flow rate of 0.6 ml/min using 5-95% 0.1% HCOOH in MeCN. 
Analytical purity of compounds was determined using Waters XTerra RP18, 5 µm (4.6 × 150 
mm) column at 1 ml/min using either 0.1% aq. ammonia and MeCN or 0.1% aq. HCOOH 
and MeCN with a gradient of 5-100% over 15 min. 
 
1H NMR spectra were obtained using a Bruker Avance III 500 spectrometer using a 
frequency of 500 MHz. 13C and 19F NMR spectra were acquired using the Bruker Avance III 
500 spectrometer operating at a frequency of 125 MHz, and 470 MHz, respectively. The 
abbreviations for spin multiplicity are as follows: s = singlet; d = doublet; t = triplet; q = 
quartet, quin = quintet, sept = septet and m = multiplet. Combinations of these abbreviations 
are employed to describe more complex splitting patterns (e.g. dd = doublet of doublets) and 





Chapter 25: General Experimental 
25.1 Synthesis of (15) and (17) and derivatives: 
 
General procedure A for (14), (15), (16), (17), (18), (19) and (20) 
 
4-(Cyclopropanecarboxamido)benzoic acid (13) 
 
To a suspension of para-aminobenzoic acid (2 g, 14.6 mmoles) and Na2CO3 (3.1 g, 29.2 
mmoles) in anhydrous THF (15 mL) was added dropwise cyclopropane carbonyl chloride 
(1.3 mL, 14.6 mmoles) under N2 atmosphere at room temperature, the mixture was stirred for 
16 hours, then evaporated in vacuo to give a pale yellow oil. The crude product was diluted in 
water and the pH adjusted to 2 after adding 2M HCl. The precipitate formed was filtered 
through a sintered funnel and dried in a vacuum oven for 16 hours affording a pale white 
solid (1.23 g, 44%). mp 320-321oC; UV λmax (EtOH)/nm 273.0; IR υmax/cm-1 3281, 3015, 
2667, 2541, 1677, 1650, 1523, 1421; LCMS (ESI)- m/z = 189.1 [M – H2O]-; 1H NMR (500 
MHz, DMSO-d6) δ 12.67 (1H, s, -CO2H), 10.51 (1H, s, -NH-3), 7.88 (2H, d, J = 8.7 Hz, H-1, 
H-1’), 7.70 (2H, d, J = 8.7 Hz, H-2, H-2’), 1.82 (1H, p, J = 6.2 Hz, H-4), 0.83 (4H, d, J = 6.2 
Hz, -CH2-5, -CH2-5’); 13C NMR (126 MHz, DMSO) δ 172.6, 167.4, 143.8, 130.9 (x2), 125.3, 
118.6 (x2), 15.2, 8.0 (x2); HRMS calc. for C11H11NO3 [M-OH]: 189.0790, found 189.0788 
4-(Cyclopropanecarboxamido)-N-phenylbenzamide (14) 
 
To a stirred solution of 4-(cyclopropanecarboxamido)benzoic acid (0.17 g, 0.8 mmoles), 
HATU (0.38 g, 1 mmol) and DIPEA (0.35 mL, 2.5 mmoles) in DMF (5 mL) was added 
dropwise aniline (0.08 mL, 0.9 mmoles) under N2 atmosphere at room temperature, the 
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mixture was stirred for 16 hours, then evaporated in vacuo. The residue was taken up with 
EtOAc (20 mL), washed with brine, dried (Na2SO4), filtered and evaporated in vacuo to 
afford a yellow oil. Chromatography (SP4, EtOAc in Petrol, eluting 5-40%) gave a pale white 
solid (105 mg, 61%). mp 280-281oC; LCMS (ESI)- m/z = 279.0 [M - H]-; UV λmax (EtOH)/nm 
286.2; IR υmax/cm-1 3275, 1645, 1596, 1517, 1438, 1406; 1H NMR (500 MHz, DMSO-d6) δ 
10.49 (s, 1H, H-8), 10.11 (s, 1H, H-9), 7.93 (d, J = 8.8 Hz, 2H, H-1, H-1’), 7.77 (dd, J = 8.5, 
1.0 Hz, 2H, H-5, H-5’), 7.73 (d, J = 8.8 Hz, 2H, H-2, H-2’), 7.35 (dd, J = 8.5, 7.5 Hz, 2H, H-
6, H-6’), 7.09 (tt, J = 7.5 Hz, 1.0 Hz, 1H, H-7), 1.87 – 1.77 (m, 1H), 0.89 – 0.77 (m, 4H); 13C 
NMR (125 MHz, DMSO-d6) δ 172.5, 165.3, 142.7, 139.8, 129.4, 129.1 (x2), 129.0 (x2), 
123.9, 120.8 (x2), 118.6 (x2), 15.2, 8.0 (x2); Analytical HPLC purity: 100% (CH3CN [0.1% 
formic acid]); HRMS calc. for C17H16N2O2 [M+H]+ 281.1285, found 281.1200 
4-(Cyclopropanecarboxamido)-N-(4-hydroxyphenyl)benzamide (16) 
 
To a stirred solution of 4-(cyclopropanecarboxamido)benzoic acid (0.2 g, 0.97 mmoles), 
HATU (0.45 g, 1.2 mmol) and DIPEA (0.41 mL, 2.9 mmoles) in DMF (5 mL) was added 
portionwise 4-aminophenol (0.128 g, 1.2 mmoles) under N2 atmosphere at room temperature, 
the mixture was stirred for 16 hours, then evaporated in vacuo. The residue was taken up with 
EtOAc (20 mL), washed with brine, dried (Na2SO4), filtered and evaporated in vacuo to 
afford a yellow oil. Chromatography (SP4, C18, CH3CN [0.1% formic acid] in water [0.1% 
formic acid]; eluting 20-80%) gave a white solid (5 mg, 2%). Rf 0.39 (C18, CH3CN [0.1% 
formic acid] in water [0.1% formic acid] (45:55)); mp 292-293oC; LCMS (ESI)- m/z = 295.1 
[M - H]-; UV λmax (EtOH)/nm 287.4; IR υmax/cm-1 3289, 1638, 1609, 1510, 1434, 1408; 1H 
NMR (500 MHz, DMSO-d6) δ 10.49 (1H, s, H-8), 9.89 (1H, s, H-9), 9.28 (1H, br s, -OH), 
7.90 (2H, d, J = 8.6 Hz, H-2, H-2’), 7.71 (2H, d, J = 8.6 Hz, H-1, H-1’), 7.51 (2H, d, J = 8.8 
Hz, H-5, H-5’), 6.73 (2H, d, J = 8.8 Hz, H-6, H-6’), 1.82 (1H, p, J = 6.5 Hz, H-4), 0.92 – 0.69 
(4H, m, -CH2-3, -CH2-3’); 13C NMR (125 MHz, DMSO-d6) δ 172.5, 164.8, 154.1, 142.5, 
131.3, 129.6, 128.9 (x2), 122.7 (x2), 118.6 (x2), 115.4 (x2), 15.1, 7.9 (x2); Analytical HPLC 




5-(4-(Cyclopropanecarboxamido)benzamido)-2-hydroxybenzoic acid (15) 
 
General procedure A: Using 4-(cyclopropanecarboxamido)benzoic acid (0.2 g, 0.97 
mmoles) affording a pale white solid (190 mg, 57%). mp 300-301oC; LCMS (ESI)- m/z = 
339.2 [M - H]-; UV λmax (EtOH)/nm 286.2; IR υmax/cm-1 3264, 1652, 1607, 1523, 1449, 1408; 
1H NMR (500 MHz, DMSO-d6) δ 10.49 (1H, s, H-8), 10.10 (1H, s, H-9), 8.26 (1H, d, J = 2.7 
Hz, H-7), 7.93 (2H, d, J = 8.8 Hz, H-2, H-2’), 7.87 (1H, dd, J = 8.9, 2.7 Hz, H-5), 7.72 (2H, 
d, J = 8.8 Hz, H-1, H-1’), 6.95 (1H, d, J = 8.9 Hz, H-6), 1.82 (1H, p, J = 5.6 Hz, H-4), 0.89 – 
0.74 (4H, m, -CH2-3, -CH2-3’); 13C NMR (125 MHz, DMSO-d6) δ 172.5, 172.2, 165.1, 
157.8, 142.7, 131.4, 129.2, 129.0, 128.97 (x2), 122.2, 118.6, 117.4, 113.0, 15.1, 7.9 (x2); 
Analytical HPLC purity: 98.4% (CH3CN [0.1% formic acid]); HRMS calc. for C18H16N2O5 
[M+H]+ 341.1132, found 341.1093 
4-(4-(Cyclopropanecarboxamido)benzamido)-2-hydroxybenzoic acid (17) 
 
General procedure A: Using 4-(cyclopropanecarboxamido)benzoic acid (0.2 g, 0.97 
mmoles) affording a pale yellow oil. Chromatography (SP4, MeOH [0.1% formic acid] in 
DCM, eluting 1-15%) gave a pale white solid which was triturated in dry MeOH (5 mg, 2%). 
LCMS (ESI)- m/z = 339.2 [M - H]-; UV λmax (EtOH)/nm 291.8; IR υmax/cm-1 3319, 1661, 
1592, 1513, 1458; 1H NMR (500 MHz, DMSO-d6) δ 10.52 (1H, s, H-8), 10.31 (1H, s, H-9), 
7.93 (2H, d, J = 8.8 Hz, H-2, H-2’), 7.74 (3H, d, J = 8.8 Hz, H-1, H-1’, H-6), 7.52 (1H, d, J = 
1.8 Hz, H-7), 7.32 (1H, dd, J = 8.7, 1.8 Hz, H-5), 1.82 (1H, p, J = 6.0 Hz, H-4), 0.89 – 0.79 
(4H, m, -CH2-3, -CH2-3’); 13C NMR (125 MHz, DMSO-d6) δ 172.6, 165.8, 162.7, 162.5, 
143.0, 131.2, 129.3 (x2), 128.9, 118.6 (x2), 111.4, 107.3, 15.2, 8.0 (x2); Analytical HPLC 




Methyl 4-(cyclopropanecarboxamido)benzoate (21) 
 
To a stirred solution of 4-methyl-aminobenzoate (3 g, 20 mmoles) and DIPEA (5.6 mL, 40 
mmoles) in DCM (20 mL) was added dropwise cyclopropanecarbonyl chloride (1.8 mL, 20 
mmoles) at 0oC under N2 atmosphere, the mixture was warmed slowly to room temperature 
and stirred for 16 hours. The mixture was treated with saturated aqueous solution of NaHCO3 
and extracted with DCM (x3), the combined organic layers were washed with brine, dried 
(Na2SO4), filtered and evaporated in vacuo affording a yellow oil. Chromatography (SP4, 
C18, MeOH [0.1% NH3] in water, eluting 25-95%) gave a colourless oil (1.1 g, 25%). UV 
λmax (EtOH)/nm 275.0; IR υmax/cm-1 3303, 3008, 2949, 2423, 2364, 1713, 1649, 1601, 1539, 
1511, 1452, 1409; LCMS (ESI)- m/z = 218.2 [M - H]-; 1H NMR (500 MHz, Methanol-d4) δ 
7.95 (2H, d, J = 8.9 Hz, H-2, H-2’), 7.68 (2H, d, J = 8.9 Hz, H-1, H-1’), 3.88 (3H, s, -CH3), 
1.82 – 1.75 (1H, m, H-3), 1.00 – 0.93 (2H, m, -CH2-4), 0.91 – 0.85 (2H, m, -CH2-4’); 13C 
NMR (126 MHz, Methanol-d4) δ 173.8, 166.8, 143.3, 130.1 (x2), 124.7, 118.6 (x2), 51.0, 
14.3, 6.9 (x2); HRMS calc. for C12H13NO3 [M- MeO-] 189.0970, found 189.0701 
Methyl 4-(N-methylcyclopropanecarboxamido)benzoate (22) 
 
To a stirred solution of methyl 4-(cyclopropanecarboxamido)benzoate (1 g, 4.9 mmoles) in 
anhydrous THF (20 mL) was added portionwise (60%) NaH (0.25 g, 6.2 mmoles) at 0oC 
under N2 atmosphere. The mixture stirred for 30 minutes and then iodomethane (0.38 mL, 6.2 
mmoles) was added dropwise. The mixture was allowed to warm to room temperature slowly 
and was stirred for 16 hours. The mixture was treated with saturated aqueous solution of 
NaHCO3, extracted with DCM (x3) and the organic layers were combined, washed with 
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brine, dried (Na2SO4), filtered and evaporated in vacuo to afford a yellow oil. 
Chromatography (SP4, C18, MeOH [0.1% NH3] in water [0.1% NH3], eluting 20-80%) 
affording a pale yellow oil (1.0 g, 95%). UV λmax (EtOH)/nm 261.8; IR υmax/cm-1 3008, 2951, 
1717, 1651, 1601, 1430; LCMS (ESI)- m/z = 232.3 [M - H]-; 1H NMR (500 MHz, 
Chloroform-d) δ 8.09 (2H, d, J = 8.4 Hz, H-1, H-1’), 7.36 (2H, d, J = 8.4 Hz, H-2, H-2’), 
3.93 (3H, s, -CH3-6), 3.33 (3H, s, -CH3-5), 1.41 (1H, tt, J = 8.0, 4.6 Hz, H-3), 1.05 (2H, dt, J 
= 6.9, 3.3 Hz, -CH2-4), 0.67 (2H, dq, J = 6.9, 3.7 Hz, -CH2-4’); 13C NMR (125 MHz, 
Chloroform-d) δ 173.4, 166.3, 148.4, 130.9 (x2), 128.8, 127.0 (x2), 52.3, 37.3, 12.9, 8.8 (x2) 
4-(N-Methylcyclopropanecarboxamido)benzoic acid (23) 
 
To a stirred solution of methyl 4-(N-methylcyclopropanecarboxamido)benzoate (1 g, 4.3 
mmoles) in anhydrous THF (10 mL) was added 2M NaOH in water (10 mL). The mixture 
was stirred at room temperature for 16 hours, 2M HCl was added to pH=2 and extracted with 
EtOAc (x3), the combined organic extracts were dried (Na2SO4), filtered and evaporated in 
vacuo affording a pale white solid. Chromatography (SP4, C18, MeOH [0.1% NH3] in water 
[0.1% NH3] eluting 5-95%) to give a colourless oil (0.94 g, 99.99%). LCMS (ESI)- m/z = 
203.2 [M – H2O]-; UV λmax (EtOH)/nm 272.5; IR υmax/cm-1 3018, 2931, 1737, 1716, 1686, 
1665, 1645, 1619, 1493, 1482; LCMS (ESI)- m/z = 203.2 [M – H2O]-; 1H NMR (500 MHz, 
Methanol-d4) δ 8.13 (2H, d, J = 8.3 Hz, H-1, H-1’), 7.50 (2H, d, J = 8.3 Hz, H-2, H-2’), 3.94 
(3H, s, -CH3-5), 1.56 – 1.43 (1H, m, H-3), 0.88 – 1.03 (2H, m, H-4), 0.84 – 0.68 (2H, m, H-
4’); 13C NMR (125 MHz, Methanol-d4) δ 175.6, 167.6, 149.5, 132.0 (x2), 130.4, 128.4 (x2), 
52.8, 37.8, 13.7, 9.2 (x2); HRMS (ESI+) [M+H]+m/z Calc. for C12H13NO3 [M - OH] 
203.0946, found 203.0940 




General procedure A: Using 4-(N-methylcyclopropanecarboxamido)benzoic acid (0.25 g, 
1.2 mmoles) affording a pale yellow oil. Chromatography (SP4, MeOH [0.1% NH3] in water 
[0.1% NH3], eluting 5-40%) gave a pale white solid (5 mg, 1%). mp 238-239oC; LCMS 
(ESI)- m/z = 336.9 [M – H – H2O]–; UV λmax (EtOH)/nm 289.2; IR υmax/cm-1 3264, 1673, 
1635, 1488, 1434, 1392, 1280, 1214, 1123, 1010; 1H NMR (500 MHz, Methanol-d4) δ 8.23 
(1H, d, J = 2.6 Hz, H-1), 8.05 (2H, d, J = 8.4 Hz, H-5, H-5’), 7.76 (1H, dd, J = 8.9, 2.6 Hz, 
H-3), 7.51 (2H, d, J = 8.4 Hz, H-4, H-4’), 6.95 (1H, d, J = 8.9 Hz, H-2), 3.33 (3H, br s, -CH3-
6 ), 1.56 – 1.44 (1H, m, H-7), 0.99 – 0.93 (2H, m, -CH2-8), 0.78 – 0.69 (2H, m, -CH2-8’); 13C 
NMR (126 MHz, Methanol-d4) δ 175.7, 173.2, 167.7, 160.3, 148.3, 135.2, 131.2, 130.6, 
130.2 (x2), 128.5, 124.4, 118.4 (x2), 113.7, 37.9, 13.7, 9.1 (x2);	Analytical HPLC purity: 
99.2% (CH3CN [0.1% formic acid]); HRMS calc. for C19H18N2O5 [M+H]+ 355.1289, found 
355.1221 
4-(4-(Cyclopropanecarboxamido)benzamido)benzoic acid (18)  
 
General procedure A: Using 4-(cyclopropanecarboxamido)benzoic acid (0.2 g, 0.97 
mmoles) affording a yellow oil. Chromatography (SP4, C18, CH3CN [0.1% formic acid] in 
water [0.1% formic acid]; eluting 5-60%) gave a pale white solid (2 mg, 1%). mp 238-239oC; 
LCMS (ESI)- m/z = 322.7 [M – H – H2O]–; UV λmax (EtOH)/nm 291.8; IR υmax/cm-1 3269, 
1646, 1515, 1408; 1H NMR (500 MHz, DMSO-d6) δ 12.74 (1H, s, -CO2H), 10.52 (1H, s, -
NH-7), 10.39 (1H, s, -NH-8), 7.95 (2H, d, J = 8.7 Hz, -H-4, H-4’), 7.92 (4H, m, H-1, H-1’, 
H-2, H-2’), 7.75 (2H, d, J = 8.7 Hz, H-3, H-3’), 1.83 (1H, p, J = 6.0 Hz, H-5), 0.94 – 0.78 
(4H, m, -CH2-6, -CH2-6’); 13C NMR (126 MHz, DMSO-d6) δ 130.6 (x2), 129.3 (x2), 119.8 
(x2), 118.6 (x2), 15.2, 8.0 (x2) (7 missing carbons); Analytical HPLC purity: 100% (CH3CN 








To a stirred solution of 4-(cyclopropanecarboxamido)benzoic acid (0.18 g, 0.88 mmoles), 
HATU (0.4 g, 1.1 mmol) and DIPEA (0.37 mL, 2.6 mmoles) in anhydrous DMF (5 mL) was 
added portionwise 3-aminophenol (0.12 g, 1.1 mmoles) under N2 atmosphere at room 
temperature. The mixture was stirred for 16 hours and then evaporated in vacuo. The residue 
was taken up with EtOAc (20 mL), washed with brine, dried (Na2SO4), filtered and 
evaporated in vacuo affording a yellow oil. Chromatography (SP4, C18, MeOH [0.1% formic 
acid] in water [0.1% formic acid]; eluting 20-80%) gave a pale white solid. (5 mg, 2%). mp 
250-251oC; UV λmax (EtOH)/nm 285.0; IR υmax/cm-1 3535, 3364, 3279, 1640, 1606, 1518, 
1444, 1407, 1308, 1185; LCMS (ESI)- m/z = 295.3 [M – H]–; 1H NMR (500 MHz, DMSO-d6) 
δ 10.48 (1H, s, H-9), 9.97 (1H, s, H-10), 9.38 (1H, s, -OH-11), 7.91 (2H, d, J = 8.6 Hz, H-6, 
H-6’), 7.72 (2H, d, J = 8.6 Hz, H-5, H-5’), 7.35 (1H, br s, H-1), 7.15 (1H, d, J = 7.9 Hz, H-2), 
7.10 (1H, t, J = 7.9 Hz, H-3), 6.49 (1H, d, J = 7.9 Hz, H-4), 1.82 (1H, p, J = 6.6 Hz, H-7), 
0.90 – 0.77 (4H, m, -CH2-8, -CH2-8’); 13C NMR (126 MHz, DMSO-d6) δ 172.5, 165.3, 
157.9, 142.6, 140.8, 129.6, 129.5, 129.1 (x2), 118.6 (x2), 111.5, 111.1, 107.9, 15.1, 7.9 (x2); 
Analytical HPLC purity: 95.1% (CH3CN [0.1% NH3]); HRMS calc. for C17H16N2O3 [M+H]+ 
297.1234, found 297.1380 
3-(4-(Cyclopropanecarboxamido)benzamido)benzoic acid (20) 
 
General procedure A: Using 4-(cyclopropanecarboxamido)benzoic acid (0.4 g, 2.0 mmoles) 
affording a pale yellow oil. Chromatography (SP4, C18, CH3CN [0.1% formic acid] in water 
[0.1% formic acid]; eluting 5-55%) gave a pale white solid (21 mg, 3%). mp: 318-319oC; UV 
λmax (EtOH)/nm 285.0, 508.6; IR υmax/cm-1 3278, 1683, 1640, 1591, 1521, 1407; LCMS 
(ESI)- m/z = 307.3 [M – H2O – H]–; 1H NMR (500 MHz, DMSO-d6) δ 12.98 (1H, s, -CO2H), 
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10.50 (1H, s, H-9), 10.29 (1H, s, H-10), 8.42 (1H, s, H-1), 8.04 (1H, d, J = 7.9 Hz, H-2), 7.96 
(2H, d, J = 8.7 Hz, H-6, H-6’), 7.74 (2H, d, J = 8.7 Hz, H-5, H-5’), 7.67 (1H, d, J = 7.9 Hz, 
H-4), 7.47 (1H, t, J = 7.9 Hz, H-3), 1.94 - 1.73 (1H, m, H-7), 1.02 – 0.77 (4H, m, -CH2-8, -
CH2-8’); 13C NMR (125 MHz, DMSO-d6) δ 172.6, 167.7, 165.5, 142.9, 140.0, 131.7, 129.3, 
129.2, 129.0, 124.8, 124.7, 121.5, 118.6, 15.2, 8.0 (x2); Analytical HPLC purity: 98.1% 
CH3CN [0.1% NH3]; HRMS calc. for C18H16N2O4 [M+H]+ 325.1183, found 325.1111 
General procedure B for (27), (25) and (26) 
4-(Cyclopropanecarboxamido)-N-(3-oxoisoindolin-5-yl)benzamide (27) 
 
To a stirred solution of 4-(cyclopropanecarboxamido)benzoic acid (0.2 g, 0.97 mmoles), 
HATU (0.45 g, 1.2 mmol) and DIPEA (0.41 mL, 2.9 mmoles) in DMF (5 mL) was added 
portionwise 6-aminoisoindolin-1-one (0.17 g, 1.2 mmoles) under N2 atmosphere at room 
temperature. The mixture was stirred for 16 hours, then filtered through a sintered funnel and 
washed with EtOAc (5 mL). The precipitate formed was collected and dried in a vacuum 
oven for 16 hours affording a white solid (160 mg, 49%). mp 366-367oC; LCMS (ESI)- m/z = 
334.3 [M – H]–; UV λmax (EtOH)/nm 285.2; IR υmax/cm-1  3255, 3188, 3070, 1664, 1598, 
1523, 1451, 1407; 1H NMR (500 MHz, DMSO-d6) δ 10.55 (1H, s, H-9), 10.32 (1H, s, H-10), 
8.58 (1H, s, H-11), 8.18 (1H, d, J = 1.8 Hz, H-1), 7.96 (2H, d, J = 8.9 Hz, H-5, H-5’), 7.94 
(1H, dd, J = 8.3, 1.8 Hz, H-2), 7.75 (2H, d, J = 8.9 Hz, H-4, H-4’), 7.54 (1H, d, J = 8.3 Hz, 
H-3), 4.34 (2H, s, -CH2-8), 1.92 – 1.79 (1H, m, H-6), 0.96 – 0.72 (4H, m, -CH2-7, -CH2-7’); 
13C NMR (126 MHz, DMSO-d6) δ 172.6, 170.4, 165.5, 142.9, 139.5, 139.3, 133.5, 129.1 
(x2), 124.2, 124.0, 118.6 (x2), 114.7, 45.1, 15.1, 8.0 (x2) (1 missing carbon); Analytical 








General procedure B: Using 4-(cyclopropanecarboxamido)benzoic acid (0.2 g, 0.97 
mmoles) affording a white solid (100 mg, 31%). mp 343-344oC; LCMS (ESI)+ m/z = 336.1 
[M + H]+; UV λmax (EtOH)/nm 297.6; IR υmax/cm-1 3263, 3201, 1652, 1605, 1522, 1432; 1H 
NMR (500 MHz, DMSO-d6) δ 10.51 (1H, s, H-9), 10.38 (1H, s, H-10), 8.41 (1H, s, H-11), 
8.12 (1H, d, J = 1.7 Hz, H-1), 7.95 (2H, d, J = 8.8 Hz, H-5, H-5’), 7.79 (1H, dd, J = 8.3, 1.7 
Hz, H-2), 7.75 (2H, d, J = 8.8 Hz, H-4, H-4’), 7.63 (d, J = 8.3 Hz, H-3), 4.37 (2H, s, -CH2-8), 
1.93 – 1.76 (1H, m, H-6), 0.91 – 0.75 (4H, m, -CH2-7, -CH2-7’); 13C NMR (126 MHz, 
DMSO-d6) δ 172.6, 170.2, 165.7, 145.6, 142.9, 142.7, 129.2 (x2), 129.1, 128.0, 123.6, 120.1, 
118.6 (x2), 115.0, 45.4, 15.2, 8.0 (x2); Analytical HPLC purity: 97.6% (CH3CN [0.1% formic 
acid]); HRMS calc. for C18H16N2O4 [M+H]+ 336.1343, found 336.1277 
4-(Cyclopropanecarboxamido)-N-(2-oxoindolin-5-yl)benzamide (26) 
 
General procedure B: Using 4-(cyclopropanecarboxamido)benzoic acid (0.2 g, 0.97 
mmoles) affording a white solid (169 mg, 52%). mp 337-338oC; LCMS (ESI)+ m/z = 336.1 
[M + H]+; UV λmax (EtOH)/nm 291.2; IR υmax/cm-1 3259, 1730, 1684, 1630, 1604, 1524, 
1444, 1407; 1H NMR (500 MHz, DMSO-d6) δ 10.46 (1H, s, H-9), 10.32 (1H, s, H-10), 9.98 
(1H, s, H-11), 7.91 (2H, d, J = 8.7 Hz, H-5, H-5’), 7.72 (2H, d, J = 8.7 Hz, H-4, H-4’), 7.66 
(1H, d, J = 1.9 Hz, H-1), 7.51 (1H, dd, J = 8.4, 1.9 Hz, H-2), 6.78 (1H, d, J = 8.4 Hz, H-3), 
3.50 (2H, s, -CH2-8), 1.87 – 1.77 (1H, m, H-6), 0.88 – 0.77 (4H, m, -CH2-7, -CH2-7’); 13C 
NMR (126 MHz, DMSO) δ 176.8, 172.5, 165.0, 142.6, 140.1, 133.7, 129.5, 128.9 (x2), 
126.3, 120.3, 118.6 (x2), 118.2, 109.2, 36.5, 15.1, 7.9 (x2); Analytical HPLC purity: 98.8% 






To a stirred solution of 4-(cyclopropanecarboxamido)benzoic acid (0.2 g, 0.97 mmoles), 
HATU (0.45 g, 1.2 mmol) and DIPEA (0.41 mL, 2.9 mmoles) in anhydrous DMF (5 mL) was 
added portionwise 5-amino-2-fluorobenzonitrile (0.13 g, 0.97 mmoles) under N2 atmosphere 
at room temperature. The mixture was stirred for 5 days, then diluted with EtOAc (20 mL) 
and washed with brine (x3), dried (Na2SO4), filtered and evaporated in vacuo affording a 
yellow oil. Chromatography (SP4, EtOAc in Petrol, eluting 1-50%) to give a white solid (85 
mg, 27%). Rf 0.82 (silica, EtOAc in Petrol (40/60)); mp 297-298oC; LCMS (ESI)+ m/z = 
322.4 [M - H]-; UV λmax (EtOH)/nm 287.6; IR υmax/cm-1 3342, 3299, 2240, 1684, 1643, 1591, 
1522; 1H NMR (500 MHz, DMSO-d6) δ 10.52 (1H, s, H-8), 10.45 (1H, s, H-9), 8.28 (1H, dd, 
J = 5.7, 2.6 Hz, H-1), 8.07 (1H, dq, J = 8.8, 2.6 Hz, H-3), 7.94 (2H, d, J = 8.6 Hz, H-5, H-5’), 
7.75 (2H, d, J = 8.6 Hz, H-6, H-6’), 7.54 (t, J = 8.8 Hz, H-2), 1.83 (1H, p, J = 6.1 Hz, H-6), 
0.92 – 0.77 (4H, m, -CH2-7, -CH2-7’); 13C NMR (126 MHz, DMSO-d6) δ 172.6, 165.6, 
159.7, 157.7, 143.1, 136.9, 129.2 (x2), 128.5, 128.04, 127.98, 124.5, 118.7 (x2), 117.5, 117.3, 
114.5, 100.3, 100.2, 15.2, 8.0 (x2); 19F NMR (471 MHz, DMSO-d6) δ -115.0; Analytical 




To a stirred solution of N-(3-cyano-4-fluorophenyl)-4-(cyclopropanecarboxamido)benzamide 
(0.65 g, 0.2 mmoles) in dry EtOH (1.5 mL) and anhydrous THF (0.5 mL) was added 
236	
	
hydrazine monohydrate (12 µL, 0.4 mmoles) under N2 atmosphere at room temperature. The 
mixture was stirred at 60oC for 24 hours. After observing starting material by LCMS 
hydrazine monohydrate (48 µL, 3.2 mmoles) was added. The mixture was stirred at 60oC for 
3 days, then filtered through a sintered funnel, washed with EtOH (5 mL) and the precipitate 
formed was collected and dried in a vacuum oven for 16 hours affording a pale brown solid 
(26 mg, 39%). mp 357-358oC; LCMS (ESI)+ m/z = 334.1 [M - H]-; UV λmax (EtOH)/nm 
270.2; IR υmax/cm-1 3445, 3264, 1638, 1594, 1534, 1495, 1456, 1410; 1H NMR (500 MHz, 
DMSO-d6) δ 11.32 (1H, s, H-10), 10.47 (1H, s, H-8), 10.03 (1H, s, H-9), 8.08 (1H, d, J = 2.0 
Hz, H-2), 7.95 (2H, d, J = 8.6 Hz, H-5, H-5’), 7.73 (2H, d, J = 8.6 Hz, H-4, H-4’), 7.42 (1H, 
dd, J = 8.9, 2.0 Hz, H-3), 7.21 (1H, d, J = 8.9 Hz, H-1), 5.27 (2H, s, -NH2), 1.83 (1H, p, J = 
7.0 Hz, H-6), 0.94 – 0.75 (4H, m, -CH2-7, -CH2-7’); 13C NMR (126 MHz, DMSO-d6) δ	
172.5, 165.0, 149.7, 142.5, 139.4, 129.9, 129.6, 128.9 (x2), 122.6, 118.6 (x2), 114.1, 112.9, 
109.6, 15.1, 7.9 (x2); Analytical HPLC purity: 100% (CH3CN [0.1% formic acid]); HRMS 
calc. for C18H17N5O2 [M+H]+ 336.1455, found 336.1370 
2-Hydroxy-5-(4-((2,2,2-trifluoroacetamido)methyl)benzamido)benzoic acid (32) 
 
To a stirred solution of 4-(aminomethyl)benzoic acid (0.5 g, 3.3 mmoles) in dry DCM (15 
mL) was added trifluoroacetic anhydride (1.2 mL, 6.6 mmoles) under N2 atmosphere at 0oC. 
The mixture was stirred for 30 minutes then anhydrous pyridine (0.11 µL) was added 
dropwise under N2 atmosphere at 0oC and the mixture stirred for 2 hours, then evaporated in 
vacuo. The residue was dissolved in thionyl chloride (5 mL) and stirred at room temperature 
for 3 hours. The mixture was evaporated in vacuo and the residue dissolved in anhydrous 
THF (5 mL) and 5-amino-2-hydroxybenzoic acid (760 mg, 4.96 mmoles) in anhydrous THF 
(5 mL) was added dropwise at 0oC under N2 atm, stirred at room temperature for 16 hours, 
then diluted with saturated aqueous solution of NaHCO3, extracted with EtOAc (x3), the 
combined organic extracts were dried (Na2SO4), filtered and evaporated in vacuo affording a 




5-(4-(Aminomethyl)benzamido)-2-hydroxybenzoic acid (33) 
 
To a stirred solution of 2-hydroxy-5-(4-((2,2,2-
trifluoroacetamido)methyl)benzamido)benzoic acid (0.83 g, 2.17 mmoles) in anhydrous 
dioxane (5 mL) was added dropwise 10 mL of a mixture NH3/H2O (1:9). The mixture was 
stirred at 80oC for 16 hours and evaporated in vacuo affording a yellow oil. Chromatography 
(SP4, C18, CH3CN [0.1% NH3] in water [0.1% NH3], eluting 5-75%) to give a pale black 
solid (5 mg, 1%). Rf 0.61 (C18, CH3CN [0.1% NH3] in water [0.1% NH3] (45:55)); mp 277-
278oC; IR υmax/cm-1 3393, 3254, 2116, 1630, 1532, 1477, 1428, 1375, 1340, 1312, 1239; 1H 
NMR (500 MHz, DMSO-d6) δ 8.26 (1H, d, J = 2.6 Hz, H-3), 8.12 (1H, s, H-7), 7.98 (2H, d, J 
= 8.2 Hz, H-4, H-4’), 7.84 (1H, dd, J = 8.9, 2.6 Hz, H-2), 7.58 (2H, d, J = 8.2 Hz, H-5, H-5’), 
6.98 (1H, d, J = 8.9 Hz, H-1), 4.11 (2H, s, -CH2-6); 13C NMR (126 MHz, DMSO-d6) δ 171.7, 
165.3, 163.4, 159.2, 158.9, 158.6, 158.3, 157.7, 137.5, 135.0, 130.9, 129.3, 129.2 (x2), 128.3 
(x2), 122.5, 117.6, 112.8, 42.2 (+1 drop of TFA for solubility); Analytical HPLC purity: 
88.5% (CH3CN [0.1% formic acid]); HRMS calc. for C15H14N2O4 286.0954, found 286.1178 
5-(4-Cyanobenzamido)-2-hydroxybenzoic acid (37) 
 
A mixture of 4-cyanobenzoic acid (0.28 g, 1.9 mmoles) in thionyl chloride (5 mL) and 
anhydrous DMF (catalytic) was stirred at 80oC under N2 atmosphere for 16 hours. The 
mixture was evaporated in vacuo and the residue redissolved in anhydrous THF (5 mL), then 
4-amino-2-hydroxybenzoic acid (0.29 g, 1.9 mmoles) in anhdrous THF (5 mL) was added 
dropwise and subsequently triethylamine (1.33 mL, 9.5 mmoles). The mixture was stirred at 
room temperature for 48 hours, then treated with saturated aqueous solution of NaHCO3, 
extracted with EtOAc (x3), the combined organic extracts were dried (Na2SO4), filtered and 
evaporated in vacuo affording a pale yellow oil. Chromatography (SP4, C18, CH3CN [0.1% 
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formic acid] in water [0.1% formic acid], eluting 5-55%) gave a white solid (75 mg, 14%). Rf 
0.76 (C18, CH3CN [0.1% formic acid] in water [0.1% formic acid] (45:55)); mp 261-262oC; 
UV λmax (EtOH)/nm 236.4, 318.2; IR υmax/cm-1 3388, 2232, 1982, 1668, 1619, 1549, 1492; 1H 
NMR (500 MHz, DMSO-d6) δ 10.46 (1H, s, H-6), 8.27 (1H, d, J = 2.7 Hz, H-1), 8.11 (2H, d, 
J = 8.6 Hz, H-4, H-4’), 8.03 (2H, d, J = 8.6 Hz, H-5, H-5’), 7.88 (1H, dd, J = 8.9, 2.7 Hz, H-
3), 6.99 (1H, d, J = 8.9 Hz, H-2); 13C NMR (126 MHz, DMSO) δ 172.0, 164.3, 158.1, 139.2, 
132.9 (x2), 130.8, 129.0, 128.9 (x2), 122.5, 118.8, 117.6, 114.3, 113.1; Analytical HPLC 
purity: 97.8% (CH3CN [0.1% formic acid]); HRMS calc. for C15H11N2O4 [M+H]+ 283.0713, 
found 283.0991 
5-(4-(1-H-Imidazol-2-yl)benzamido)-2-hydroxybenzoic acid (35) 
 
A mixture of 4-(1-H-Imidazol-2-yl)benzoic acid (0.18 g, 0.96 mmoles) in thionyl chloride (5 
mL) and anhydrous DMF (catalytic) was stirred at 80oC under N2 atmosphere for 16 hours. 
The mixture was evaporated in vacuo and the residue redissolved in THF (5 mL), then 4-
amino-2-hydroxybenzoic acid (0.15 g, 0.96 mmoles) in anhydrous THF (5 mL) was added 
dropwise. The mixture was stirred at room temperature for 16 hours, then was treated with 
saturated aqueous solution of NaHCO3, extracted with EtOAc (x3), the combined organic 
extracts were dried (Na2SO4), filetered and evaporated in vacuo affording a pale yellow oil. 
Chromatography (SP4, C18, CH3CN [0.1% formic acid] in water [0.1% formic acid], eluting 
5-50%), to give a white solid (5 mg, 2%). Rf 0.79 (C18, CH3CN [0.1% formic acid] in water 
[0.1% formic acid] (45:55)); mp 291-292oC; UV λmax (EtOH)/nm 310.4, 210.0; IR υmax/cm-1 
3280, 3158, 1631, 1538, 1429; 1H NMR (500 MHz, DMSO-d6) δ 10.21 (1H, s, H-7), 8.24 
(1H, d, J = 2.7 Hz, H-1), 8.11 – 8.03 (4H, m, H-4, H-4’, H-5, H-5’), 7.86 (1H, dd, J = 8.9, 2.7 
Hz, H-3), 7.26 (2H, br s, H-6, H-6’), 6.92 (1H, d, J = 8.9 Hz, H-2); 13C NMR (126 MHz, 
DMSO-d6) δ 172.1, 165.0, 158.2, 134.4, 133.4, 130.8, 128.6 (x2), 128.5, 125.1 (x2), 122.5, 
117.2; Analytical HPLC purity: 98.9% (CH3CN [0.1% formic acid]); HRMS calc. for 




5-(Cyclohexanecarboxamido)-2-hydroxybenzoic acid (39) 
 
A mixture of cyclohexane carboxylic acid (0.18 g, 1.4 mmoles) in thionyl chloride (5 mL) 
and anhydrous DMF (catalytic) was stirred at 80oC under N2 atmosphere for 16 hours. The 
mixture was evaporated in vacuo and the residue redissolved in anhydrous THF (5 mL), then 
4-amino-2-hydroxybenzoic acid (0.194 g, 1.26 mmoles) in anhydrous THF (5 mL) was added 
dropwise and the mixture was stirred at room temperature for 16 hours. Then the mixture was 
treated with saturated aqueous solution of NaHCO3, extracted with EtOAc (x3), the combined 
organic extracts were dried (Na2SO4), filetered and evaporated in vacuo affording a pale 
yellow solid which was triturated in EtOAc and Et2O to give a white solid (15 mg, 4%). mp 
288-289oC; UV λmax (EtOH)/nm 314.6, 254.4, 218.8, 206.2; IR υmax/cm-1 3308; 2927, 2852, 
2455, 2007, 1648, 1580, 1534, 1491, 1444; 1H NMR (500 MHz, Methanol-d4) δ 7.77 (1H, d, 
J = 2.7 Hz, H-1), 7.59 (1H, dd, J = 8.7, 2.7 Hz, H-3), 6.76 (1H, d, J = 8.7 Hz, H-2), 2.34 (1H, 
tt, J = 11.3, 3.3 Hz, H-4), 1.94 – 1.80 (4H, m, -CH2-), 1.74 (2H, dd, J = 9.2, 3.3 Hz, H-CH2-), 
1.54 (2H, qd, J = 12.3, 11.8, 2.5 Hz, -CH2-), 1.38 (2H, qt, J = 12.3, 2.5 Hz, -CH2-), 1.33 – 
1.26 (2H, m, -CH2-); 13C NMR (126 MHz, Methanol-d4) δ 176.0, 158.1, 128.9, 126.1, 123.0, 
118.8, 115.6, 45.6, 29.3 (x2), 25.5, 25.5 (x2); Analytical HPLC purity: 97.2% (CH3CN [0.1% 
formic acid]); HRMS calc. for C18H17N5O2: 263.1158, found 263.1159 
5-((1S,4S)-4-((tert-Butoxycarbonyl)amino)cyclohexane-1-carboxamido)-2-hydroxy 
benzoic acid (40) 
 
To a stirred suspension of HBTU (0.47 g, 1.24 mmoles) and DIPEA (0.45 mL, 2.47 mmoles) 
in anhydrous DMF (2.5 mL) was added tert-butyl[cis-4-
(anilinocarbonyl)cyclohexyl]carbamate (0.3 g, 1.24 mmoles) at room temperature under N2 
atmosphere. The mixture was stirred for 30 minutes and 5-amino-2-hydroxybenzoic acid (189 
mg, 1.24 mmoles) in anhydrous DMF (2.5 mL) was added and then mixture was stirred for 
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16 hours at room temperature. The mixture was treated with saturated aqueous solution of 
NaHCO3, extracted with EtOAc (x3), the combined organic extracts were dried (Na2SO4), 
filtered and evaporated in vacuo to give a brown oil which solidified upon standing and was 
used in the next step without further purification (385 mg, 82%). mp 221-222oC; UV λmax 
(EtOH)/nm 283.4; IR υmax/cm-1 3625, 3404, 3300, 3238, 2981, 2936, 2865, 1657, 1524, 1490, 
1435; 1H NMR (500 MHz, Methanol-d4) δ 9.47 (1H, s, -Ph-O-H), 8.49 – 8.28 (2H, br s, -
CO2H, -NH-4), 7.91 (1H, d, J = 2.7 Hz, H-1), 7.51 (1H, dd, J = 8.7, 2.7 Hz, H-3), 6.75 (1H, 
br s, -NH-6), 6.68 (1H, d, J = 8.7 Hz, H-2), 3.53 – 3.45 (2H, m, H-5), 2.37 – 2.27 (1H, m, H-
5’), 1.88  - 1.77 (2H, m, -CH2-), 1.74 – 1.67 (2H, m, -CH2-), 1.57 – 1.44 (4H, m, -CH2-(x2)), 
1.39 (9H, s, -CH3 (x3)); 13C NMR (126 MHz, Methanol-d4) δ 173.7, 172.2, 158.3, 155.5, 
130.0, 125.7, 122.0, 117.9, 116.2, 77.8, 49.1, 46.7 (x2), 28.8 (x2), 25.0, 19.3; Analytical 
HPLC purity: 98.6% (CH3CN [0.1% NH3]) 
5-((1S,4S)-4-Aminocyclohexane-1-carboxamido)-2-hydroxybenzoic acid hydrochloride 
(41) 
 
To a solution of 5-((1s,4s)-4-((tert-butoxycarbonyl)amino)cyclohexane-1-carboxamido)-2-
hydroxy benzoic acid (0.38 g, 1 mmol) in anhydrous THF (5 mL) was added 2M HCl (10 
mL) and the mixture was stirred at 80oC for 4 hours.The mixture was evaporated in vacuo to 
give a pale brown oil which was used in the next step without further purification (315 mg, 
99.1%). mp 218-219oC; UV λmax (EtOH)/nm 204.8, 254.6; IR υmax/cm-1 3241, 3053, 2923, 
2885, 2654, 1646, 1616, 1524, 1486, 1422; 1H NMR (500 MHz, Methanol-d4) δ 8.23 (2H, br 
s, -NH-4), 8.14 (1H, d, J = 2.7 Hz, H-1), 8.03 (1H, br s, -NH-4), 7.96 (1H, d, J = 2.7 Hz, H-
1), 7.63 (1H, dd, J = 8.9, 2.7 Hz, H-3), 7.58 (1H, dd, J = 8.9, 2.7 Hz, H-3), 7.10 (1H, d, J = 
8.9 Hz, H-2), 6.90 (1H, d, J = 8.9 Hz, H-2), 3.64 – 3.13 (4H, m, -CH2-, H-5, H-5’), 2.96 – 
2.60 (2H, m, -CH2-), 2.21 – 1.55 (8H, m, -CH2-(x2), -NH2 (x2)); 13C NMR (126 MHz, 
Methanol-d4) δ 176.4, 174.7, 171.8, 170.8, 161.8, 158.4, 129.9, 128.7, 124.7, 122.3, 121.5, 
118.7, 116.9, 113.3, 112.1, 61.5, 40.5, 28.8, 26.9 (x2), 24.3 (x2); Analytical HPLC purity: 





hydroxybenzoic acid (42) 
 
Cyclopropane carbonyl chloride (0.27 mL, 3 mmoles) was added dropwise to a solution of 5-
((1s,4s)-4-aminocyclohexane-1-carboxamido)-2-hydroxybenzoic acid hydrochloride (0.315 
g, 1 mmol) in anhydrous THF (5 mL) at room temperature. The mixture was stirred at room 
temperature for 48 hours and then was evaporated in vacuo affording a yellow oil which was 
triturated in MeOH to give a pale white solid (82 mg, 24%). mp 222-223oC; UV λmax 
(EtOH)/nm 326.2, 254.2; IR υmax/cm-1 3266, 2937, 2098, 1723, 1645, 1544, 1485, 1445; 1H 
NMR (500 MHz, DMSO-d6) δ 9.82 (1H, br s, H-4), 8.02 (1H, s, H-1), 7.78 (1H, br s, -NH-6), 
7.63 (1H, d, J = 8.6 Hz, H-3), 6.83 (1H, d, J = 8.6 Hz, H-2), 4.13 (1H, t, J = 6.4 Hz, H-5), 
4.05 (1H, t, J = 6.4 Hz, H-5) 3.66 (t, J = 6.4 Hz, H-5’), 3.44 (1H, t, J = 6.4 Hz, H-5’), 3.17 – 
3.0 (1H, m, -CH2-), 2.68 – 2.56 (1H, m, -CH2-), 2.09 – 1.40 (6H, m, -CH2- (x3)), 0.90 - 0.78 
(3H, m, -CH2-, H-7), 0.79 - 0.71 (2H, m, -CH2-); 13C NMR (126 MHz, DMSO-d6) δ 171.7, 
157.5, 131.4, 127.3, 120.9, 117.3, 63.7, 45.5, 29.2, 27.4, 26.2, 24.6, 14.8 (x2), 7.4 (x3); 
Analytical HPLC purity: 97.9% (CH3CN [0.1% formic acid]) 
 
(1S,4R)-4-(Cyclopropanecarboxamido)cyclohexane-1-carboxylic acid (44) 
 
To a stirred suspension of HBTU (0.87 g, 2.3 mmoles) and triethylamine (0.16 mL, 2.30 
mmoles) in anhydrous THF (5 mL) was added (1r,4r)-4-aminocyclohexane-1-carboxylic acid 
(0.3 g, 2.1 mmoles) at room temperature under N2 atmosphere. The mixture was stirred for 30 
minutes and then cyclopropane carboxylic acid (198 mg, 1.15 mmoles) in anhydrous THF 
(2.5 mL) was added. The mixture was stirred for 6 hours at room temperature and then was 
treated with water, extracted with EtOAc (x3), the combined organic extracts were dried 
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(Na2SO4), filtered and evaporated in vacuo affording a white solid which was triturated in 
EtOAc to give a white solid which was used in the next step without further purification (100 
mg, 23%). 1H NMR (500 MHz, DMSO-d6) δ 12.10 (1H, s, -CO2H), 7.96 (1H, d, J = 7.8 Hz, -
NH-4), 3.46 (1H, dddt, J = 14.5, 10.8, 6.8, 3.4 Hz, H-1’), 2.14 (1H, tt, J = 11.9, 3.5 Hz, H-1), 
1.93 – 1.85 (2H, m, -CH2-), 1.80 (2H, dd, J = 12.6, 2.9 Hz, -CH2-), 1.50 (2H, ddd, J = 12.6, 
7.7, 4.9 Hz, H-3), 1.33 (2H, qd, J = 13.2, 3.1 Hz, -CH2-), 1.17 (2H, qd, J = 12.8, 3.3 Hz, -
CH2-), 0.68 – 0.56 (4H, m, -CH2-6); 13C NMR (126 MHz, DMSO-d6) δ 179.2, 171.1, 53.3, 





To a solution of EDCI.HCl (227 mg, 1.2 mmoles) and DMAP (174 mg, 1.4 mmoles) in 
anhydrous DMF (5 mL) at room temperature under N2 atmosphere was added methyl 5-
amino-2-hydroxybenzoate (79 mg, 0.47 mmoles) in anhydrous DMF (2.5 mL). The mixture 
was stirred at room temperature for 48 hours and then was evaporated in vacuo to give a 
brown solid which was purified through and SCX-2 cartridge and washed with MeOH 
affording a white solid which was used in the next step without furter purification (88 mg, 
52%). 1H NMR (500 MHz, Methanol-d4) δ 7.81 (1H, d, J = 8.6 Hz, H-1), 6.68 (1H, dd, J = 
8.6, 2.2 Hz, H-2), 6.45 (1H, d, J = 2.2 Hz, H-3), 3.78 (3H, s, -CH3), 3.75 – 3.61 (1H, m, H-5), 
2.58 (1H, m, H-5’), 2.29 – 2.17 (2H, m –CH2-), 2.09 – 1.99 (2H, m, -CH2-), 1.71 – 1.60 (2H, 
m, -CH2-), 1.57 (1H, tt, J = 7.9, 4.7 Hz, H-7), 1.43 – 1.27 (2H, m, -CH2-), 0.91 – 0.82 (2H, m, 









hydroxybenzoic acid (46) 
 
2M NaOH (10 mL) was added to a stirred solution of methyl-4-((1r,4r)-4-
(cyclopropanecarboxamido)cyclohexane-1-carboxamido)-2-hydroxybenzoate (88 mg, 0.24 
mmoles) in anhydrous THF (2 mL). The mixture was stirred at 80oC for 5 hours and then was 
evaporated in vacuo affording a white solid. Chromatography (SP4, C18, CH3CN [0.1% 
formic acid] in water [0.1% formic acid]; eluting 40- 95%) gave a white solid (78 mg, 92%). 
mp 232-233 oC; UV λmax (EtOH)/nm 298.8, 264.6; IR υmax/cm-1 2935, 2857, 1554, 1418; 1H 
NMR (500 MHz, Methanol-d4) δ 7.59 (1H, d, J = 8.3 Hz, H-3), 6.14 (1H, dd, J = 8.4, 2.2 Hz, 
H-2), 6.09 (1H, d, J = 2.2 Hz, H-1), 3.73 – 3.58 (1H, m), 2.08 (1H, t, J = 12.2 Hz), 1.96 (4H, 
t, J = 16.8 Hz), 1.60 – 1.43 (3H, m), 1.26 (2H, q, J = 12.9, 12.0 Hz), 0.83 (2H, dt, J = 4.5, 3.1 
Hz, -CH2), 0.72 (2H, dq, J = 7.2, 3.7 Hz, -CH2) (+2 CH3CN); 13C NMR (126 MHz, 
Methanol-d4) δ 183.5, 179.1, 174.0, 162.6, 152.6, 131.4, 108.7, 105.6, 100.2, 46.3, 32.1 (x2), 




hydroxybenzoic acid (48) 
	
To a stirred solution of HATU (70 mg, 0.18 mmoles) and TEA (50 µL, 0.36 mmoles) in 
anhydrous DMF (2.5 mL) was added (1s,2R,3s,4r,5S,6r,7R,8S)-4-((tert-
butoxycarbonyl)amino)cubane-1-carboxylic acid (50 mg, 0.19 mmoles) at room temperature 
under N2 atmosphere. The mixture was stirred for 30 minutes and 5-amino-2-hydroxybenzoic 
acid (10 mg, 0.07 mmoles) in anhydrous DMF (2.5 mL) was added and then mixture was 
stirred for 16 hours at room temperature. The mixture was treated with saturated aqueous 
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solution of NaHCO3, extracted with EtOAc (x3), the combined organic extracts were dried 
(Na2SO4), filtered and evaporated in vacuo to give a brown oil. Chromatography (SP4, C18, 
MeOH [0.1% formic acid] in DCM [0.1% formic acid]; eluting 1- 10%) gave a yellow oil (15 
mg, 20%). 1H NMR (500 MHz, Methanol-d4) δ 7.81 (1H, s, H-1 ), 7.45 (1H, dd, J = 8.8, 2.6 
Hz, H-2), 6.67 (1H, d, J = 8.7 Hz, H-3), 4.04 (3H, s, -CH-4 (x3)), 3.94 (3H, s, -CH-5 (x3)),  
1.36 (9H, s, -CH3 (x3)) 
5-((1s,2R,3s,4r,5S,6r,7R,8S)-4-(cyclopropanecarboxamido)cubane-1-carboxamido)-2-
hydroxybenzoic acid (50) 
 
To a stirred solution of 5-((1s,2R,3s,4r,5S,6r,7R,8S)-4-((tert-butoxycarbonyl)amino)cubane-
1-carboxamido)-2-hydroxybenzoic acid (15 mg, 0.04 mmoles) in dry DCM (2 mL) was 
added TFA (0.2 mL) at room temperature under N2 atmosphere. The mixture was stirred for 4 
hours and then evaporated in vacuo. The residue was dissolved in dry THF (2 mL) and 
trimethylamine (3 µL, 0.19 mmoles) and cyclopranecarbonyl choride (1 µL, 0.04 mmoles) 
was added dropwise at room temperature under N2 atmosphere. The mixture was stirred for 
24 hours at room temperature. The mixture was treated with water, extracted with EtOAc 
(x3), the combined organic extracts were dried (Na2SO4), filtered and evaporated in vacuo to 
give a yellow oil. Chromatography (SP4, C18, MeOH [0.1% formic acid] in DCM [0.1% 
formic acid]; eluting 20- 80%) gave a yellow oil (2.5 mg, 18%). 1H NMR (500 MHz, 
Methanol-d4) δ 7.98 (1H, d, J = 2.3 Hz, H-1), 7.56 (1H, dd, J = 8.9, 2.3 Hz, H-2), 6.78 (1H, d, 
J = 8.9 Hz, H-3), 4.18 – 4.06 (3H, m, -CH-4 (x3)), 4.04 – 3.90 (3H, m, -CH-5 (x3)), 1.51 
(1H, m, -CH-6), 0.82 – 0.71 (2H, m, -CH2), 0.68 (2H, m, -CH2); 13C NMR (126 MHz, 
Methanol-d4) δ 174.6, 172.1, 158.6, 129.5, 128.5, 122.7, 116.6, 66.6, 58.3, 49.6, 44.9, 13.2, 
6.1; Analytical HPLC purity: 94.8114% (CH3CN [0.1% formic acid]) 
25.2 Synthesis of (54) and derivatives: 
 




4-(4,5-Dichloro-6-oxopyridazin-1(6-H)-yl)benzoic acid (54) 
 
To 4-hydrazinobenzoic acid (0.5 g, 3.2 mmoles) in a mixture of EtOH and H2O (1:1) (8 ml : 
8 ml) was added mucochloric acid (0.6 g, 3.2 mmoles) and 0.1 mL of 12M HCl (catalytic 
amount). The mixture was stirred at 65oC for 16 hours and then was filtered through a 
sintered funnel and washed with cold water affording 4-(4,5-dichloro-6-oxopyridazin-1(6H)-
yl)benzoic acid as a yellow solid (0.7 g, 76%). Rf  0.63 (silica, EtOAc/petrol (1:1) + 1 drop of 
acetic acid); mp: 331-332 oC; LCMS (ESI-) m/z= 284.1 [M - H]-; UV λmax (EtOH)/nm 324; IR 
υmax/cm-1: 1690, 1653, 1572, 1428; 1H NMR (500 MHz, DMSO-d6) δ 13.23 (1H, br s, 
CO2H), 8.39 (1H, s, H-3), 8.09 (2H, d, J = 8.6 Hz, H-2, H-2’), 7.72 (2H, s, J = 8.6 Hz, H-1, 
H-1’); 13C NMR (125 MHz, DMSO-d6) δ 167.0, 156.1, 144.8, 137.3, 136.5, 134.6, 131.2, 
130.3 (x2), 126.3 (x2); Analytical HPLC purity: 100% (CH3CN, [0.1% NH3]; HRMS calc. 
for C11H6Cl2N2O3 [M-OH] 267.9806, found 267.9752 
4-(4,5-Dibromo-6-oxopyridazin-1(6-H)-yl)benzoic acid285 (55) 
 
General procedure B: Using mucobromic acid (169 mg, 0.66 mmoles) affording a pale 
yellow solid (105 mg, 58%). Rf  0.68 (silica, EtOAc/Petrol (1:1) + HOAc (1%)); mp: 308-
309oC; LCMS (ESI-) m/z= 372.9 [M - H]-; UV λmax (EtOH)/nm 286.5; IR υmax/cm-1 1691, 
1650, 1561, 1427; 1H NMR (500 MHz, DMSO-d6) δ 13.21 (1H, br s, -COOH), 8.33 (1H, s, 
H-3), 8.07 (2H, d, J = 8.4 Hz, H-2, H-2’), 7.71 (2H, d, J = 8.4 Hz, H-1, H-1’); 13C NMR (125 
MHz, DMSO-d6) δ 167.0, 156.3, 144.9, 138.9, 131.5, 131.4, 131.1, 130.3 (x2), 126.3 (x2); 
Analytical HPLC purity: 99.7% (CH3CN [0.1% formic acid]); HRMS calc. for C11H6Br2N2O3 




4-(4,5-Dimethyl-6-oxopyridazin-1(6-H)-yl)benzoic acid (57) 
 
To a solution of (55) (0.2 g, 0.5 mmoles) and Tetrakis(triphenylphosphine)palladium (31 mg, 
0.03 mmoles) in anhydrous THF (5 mL) was added (1.0 M in hexane) Me3Al (4.3 mL, 4.3 
mmoles) dropwise at room temperature under N2 atmosphere. The mixture was stirred at 
reflux temperature for 1 hour and then was cooled to room temperature and quenched with 3 
N HCl. The mixture was extracted with DCM (x3), the combined organic extracts were 
washed with brine, dried (Na2SO4), filtered and evaporated in vacuo affording a yellow oil. 
Chromatography (SP4, C18, CH3CN [0.1% formic acid] in water [0.1% formic acid], eluting 
5-50%) gave a pale yellow solid (18 mg, 98%). Rf 0.37 (C18, CH3CN [0.1% formic acid] in 
water [0.1% formic acid] (20/80)); mp: 297-298oC; LCMS (ESI-) m/z= 243.1 [M - H]-; UV 
λmax (EtOH)/nm 257.1; IR υmax/cm-1 1688, 1657, 1603, 1430; 1H NMR (500 MHz, DMSO-d6) 
δ 13.13 (1H, br s, -COOH), 8.04 (2H, d, J = 8.4 Hz, H-1, H-1’), 7.94 (1H, s, H-3), 7.70 (2H, 
d, J = 8.4 Hz, H-2, H-2’), 2.22 (3H, s, CH3-5), 2.09 (3H, s, CH3-4); 13C NMR (125 MHz, 
DMSO-d6) δ 140.7, 139.0, 137.0, 130.1 (x2), 125.9 (x2), 16.5, 12.6; Analytical HPLC purity: 
97.9% (CH3CN [0.1% formic acid]); HRMS calc. for C13H12N2O3 [M-OH] 228.0899, found 
228.0841 
Potassium trifluoro(furan-2-yl)borate (61) 
 
To a solution of 2-furanylboronic acid (1 g, 8.9 mmoles) in MeOH (3 mL) at 0oC 2.1 g of 
KHF2 was added portionwise (2.1 g, 26.8 mmoles) under N2 atmosphere. The mixture was 
stirred at 0oC for 1 hour and then the solvent was evaporated in vacuo affording potassium 
trifluoro(furan-2-yl)borate as a yellow solid (1.55 g, 99.99%) that was used in the next step 




4-Cyanobenzenediazonium fluoride (62) 
 
To a solution of 1.9 ml of boron trifluoride ethyl etherate (1.9 mL, 15 mmoles) in anhydrous 
DCM (20 mL) at 0oC was added 4-aminonitrile (1.2 g, 10 mmoles) portionwise under N2 
atmosphere. The mixture was stirred at 0oC for 20 minutes and then cooled down to -15oC for 
the addtion of tert-BuONO (1.5 mL, 12 mmoles) dropwise. The mixture was stirred at -15oC 
under N2 atmosphere for 1 hour and then the mixture was allowed to warm to room 
temperature slowly. The precipitate formed was filtered through a sintered funnel and washed 
with DCM. The filtrate was evaporated in vacuo and gave a pale yellow solid (1.51 g, 
99.99%) which was used in the next step without further purification. 
4-(6-Oxopyridazin-1(6-H)-yl)benzonitrile286 (63) 
 
To a solution of potassium trifluoro(furan-2-yl)borate (1.55 g, 8.91 mmoles) in H2O (10 mL) 
was added 4-cyanobenzenediazonium fluoride (1.51 g, 10.13 mmoles) in H2O (10 mL) at 5oC 
dropwise. The mixture was allowed to warm to room temperature and stirred for 3 hours. The 
mixture was extracted with EtOAc (x3), the combined organic extracts were washed with 
brine, dried (Na2SO4), filtered and evaporated in vacuo affording an orange solid. 
Chromatography (SP4, silica, EtOAc/ Petrol, eluting 10-40%) gave a pale yellow solid (0.2 g, 
80%). Rf 0.28 (silica, EtOAc in Petrol (2:8)); mp 165-166 oC ; LCMS (ESI+) m/z= 198.2 [M + 
H]+; UV λmax (EtOH)/nm: 226.5; IR υmax/cm-1 1698, 1647, 1593, 1566, 1556; 1H NMR (500 
MHz, Methanol-d4) δ 8.13 (1H, dd, J = 3.8, 1.6 Hz, H-4), 8.00 (2H, d, J = 8.7 Hz, H-1), 7.85 
(2H, d, J = 8.7 Hz, H-2), 7.53 (1H, dd, J = 9.5, 3.8 Hz, H-3); 7.13 (1H, dd, J = 9.5, 1.6 Hz, H-
5); 13CNMR (Chloroform-d) δ 159.2, 144.3, 137.0, 132.2, 131.2, 131.1, 125.3, 117.9, 111.3; 
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HRMS calc. for C11H7N3O [M+H]+ 198.0662, found 198.0594; (lit., mp 158-159 oC; LCMS 
(ESI+) m/z= 198 [M + H]+) 
4-(6-Oxopyridazin-1(6-H)-yl)benzoic acid (56) 
 
4-(6-Oxopyridazin-1(6H)-yl)benzonitrile (0.2 g, 1.1 mmoles) was dissolved in a mixture of 
sulfuric acid (60 v/v) in water. The mixture was stirred at room temperature for 16 hours and 
then was extracted with EtOAc (x3), the combined organic extracts were washed with brine, 
dried (Na2SO4), filtered and the solvents evaporated in vacuo affording a yellow oil. 
Chromatography (SP4, C18, CH3CN [0.1% formic acid] in water [0.1% formic acid], eluting 
0-50%) gave a pale yellow solid (80 mg, 33%). Rf 0.67 (CH3CN [0.1% formic acid] in water 
[0.1% formic acid] (20/80)); mp 164-165 oC; LCMS (ESI)+=217.2 m/z [M + H]+; UV λmax 
(EtOH)/nm: 287.8; IR υmax/cm-1 2231, 1661, 1590, 1507, 1415; 1H NMR (500 MHz, 
Methanol-d4) δ 8.10 (1H, dd, J = 3.8, 1.6 Hz, H-4), 7.93 – 7.84 (4H, m, H-1, H-1’, H-2, H-
2’), 7.51 (1H, dd, J = 9.5, 3.8 Hz, H-3), 7.12 (1H, dd, J = 9.5, 1.6 Hz); 13C NMR (125 MHz, 
Methanol-d4) δ 162.0, 146.5, 139.8, 134.0, 133.9 (x2), 132.0, 127.5 (x2), 119.1, 113.0; 
Analytical HPLC purity: 99.7% CH3CN [0.1% NH3]; HRMS calc. for C11H8N2O3 [M+H]+ 
217.0608, found 217.0531 
6-Chloropyrimidin-4(1-H)-one287(67) 
 
To a stirred solution of 4,6-dichloropyrimidine (1 g, 6.7 mmoles) in anhydrous dioxane (10 
mL) was added a mixture of 12M HCl (1 mL) and water (9 mL). The mixture was stirred at 
70oC for 6 hours and then was concentrated in vacuo affording a pink oil. Chromatography 
(SP4, silica, EtOAc in Petrol, eluting 20-70%) gave a pale pink solid (0.5 g, 57%). Rf 0.41 
(EtOAc/Petrol (4:6)); mp 199-200 oC; LCMS (ESI+) [M + H]+ 131.0; 1H NMR (500 MHz, 
Methanol-d4) δ 8.15 (1H, s, H-2), 6.54 (1H, s, H-1); 13C NMR (125 MHz, Methanol-d4) δ 
164.2, 158.3, 151.4, 114.1; (lit., mp 193-194 oC) 
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Ethyl 4-(4-chloro-6-oxopyrimidin-1(6-H)-yl)benzoate (68) 
 
To a stirred solution of 6-chloropyrimidin-4(1H)-one (0.3 g, 1.9 mmoles), 4-(ethoxy)benzene 
boronic acid (0.5 g, 2.3 mmoles) and anhydrous pyridine (0.3 mL, 3.8 mmoles) in anhydrous 
DCM (10 mL) was added copper (II) acetate (0.5 g, 2.7 mmoles). The mixture was stirred at 
room temperature for 24 hours and then was filtered through celite and washed with EtOAc. 
The filtrate was evaporated in vacuo and the residue was taken up with EtOAc, washed with 
water and brine, dried (Na2SO4), filtered and evaporated in vacuo to afford a brown oil. 
Chromatography (SP4, silica, EtOAc in Petrol, eluting 20-55%) gave a yellow oil (0.25 g, 
62%). Rf 0.29 (EtOAc/Petrol (1:9)); LCMS (ESI)+ m/z = 278.0 [M + H]+; UV λmax 
(EtOH)/nm: 268.2; IR υmax/cm-1 1701, 1588, 1530, 1517, 1400; 1H NMR (500 MHz, DMSO-
d6) δ 8.55 (1H, s, H-3), 8.12 (2H, d, J = 8.7 Hz, H-1, H-1’), 7.68 (2H, d, J = 8.7 Hz, H-2, H-
2’), 6.79 (1H, s, H-4), 4.37 (2H, q, J = 7.1 Hz, -CH2-), 1.35 (3H, t, J = 7.1 Hz, -CH3); 13C 
NMR (125 MHz, DMSO-d6) δ 165.4, 159.7, 157.4, 152.4, 140.7, 131.1, 130.4 (x2), 128.1 
(x2), 113.7, 61.6, 14.6; HRMS calc. for C13H11ClN2O3 [M - EtO] 234.0196, found 234.0487 
Ethyl 4-(4-chloro-6-oxopyrimidin-1(6-H)-yl)benzoate (66) 
 
Ethyl 4-(4-chloro-6-oxopyrimidin-1(6H)-yl)benzoate (0.23 g, 0.7 mmoles) was stirred in a 
mixture of H2SO4/H2O (1:5) at 80oC for 16 hours. The mixture was diluted with water (5 mL) 
and extracted with EtOAc (5 mL x6), the combined organic extracts were separated and 
evaporated in vacuo affording a colourless oil (20 mg, 11%). Rf 0.46 (CH3CN [0.1% formic 
acid] in  water [0.1% formic acid], eluting 20-80%); mp 307-308 oC; LCMS (ESI)+ m/z = 
251.1 [M + H]+; UV λmax (EtOH/nm): 224.0; IR υmax/cm-1 3054, 2984, 1821, 2657, 2541, 
2344, 2113, 1996, 1914, 1676, 1575, 1524, 1424; 1H NMR (500 MHz, DMSO-d6) δ 13.21 
(1H, br s, -CO2H), 8.55 (1H, s, H-4), 8.09 (2H, d, J = 8.5 Hz, H-1, H-1’), 7.64 (2H, d, J = 8.5 
Hz, H-2, H-2’), 6.79 (1H, s, H-3); 13C NMR (125 MHz, DMSO-d6) δ 167.0, 159.7, 157.4, 
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152.5, 140.4, 132.0, 130.6 (x2), 128.0 (x2), 113.7; Analytical HPLC purity: 100% (CH3CN 
[0.1% formic acid ]);  HRMS calc. for C11H7ClN2O3 [M+H]+ 251.0218, found 251.0179 
3,4-Dichloropyridin-2-amine288 (69) 
 
To a stirred solution of 2-amino-4-chloropyridine (2.5 g, 19.4 mmoles) in conc. HCl (10 mL) 
was added H2O2 (0.5 mL, 19.4 mmoles) at 0oC. Then the mixture was stirred for 15 minutes 
at this temperature and then at room temperature for 2 hours. Then the mixture was slowly 
poured into a 2M aqueous solution of Na2CO3 and the pH adjusted to 8, then the aqueous 
layer was extracted with EtOAc (x3), the combined organic extracts were washed with brine, 
dried (Na2SO4), filtered and evaporated in vacuo affording a yellow oil. Chromatography 
(SP4, silica, EtOAc in Petrol, eluting 20-80%) gave a yellow oil (0.8 g, 27%). Rf 0.25 
(EtOAc/Petrol (1:4)); mp 105-106 oC; LCMS (ESI)+ m/z = 164.0 [M + H]+; 1H NMR (500 
MHz, DMSO-d6) δ 8.03 (1H, s, H-1), 6.65 (1H, s, H-2), 6.43 (1H, br s, -NH2); (lit., Rf 0.33 
(EtOAc/hexane (1:2)); mp 99-100 oC) 
3,4-Dichloropyridin-2(1-H)-one (71) 
 
To a stirred solution of 3,4-dichloropyridin-2-amine (170 mg, 1.1 mmoles) in conc. HCl (8 
mL) at 0oC was added NaNO2 (150 mg, 2.2 mmoles) portionwise. The mixture was stirred at 
0oC for 1 hour and then at room temperature for 24 hours. The mixture was slowly poured 
into a solution of Na2CO3 in water and the pH adjusted to 9, then the aqueous layer was 
extracted with EtOAc (x3), the combined organic extracts were washed with brine, dried 
(Na2SO4), filtered and evaporated in vacuo affording a yellow oil. Chromatography (SP4, 
silica, EtOAc in Petrol, eluting 20-80%) gave a colourless oil (88 mg, 16%). Rf 0.31 
(EtOAc/Petrol (2/8)); LCMS (ESI)+ m/z = 164.0 [M + H]+; 1H NMR (500 MHz, DMSO-d6) δ 






To a stirred solution of 3,4-dichloropyridin-2(1H)-one (38 mg, 0.2 mmoles), 4-
iodobenzonitrile (58 mg, 0.3 mmoles) and K2CO3 (48 mg, 0.4 mmoles) in anhydrous DMSO 
(1 mL) was added 8-hydroxyquinoline (8 mg, 0.06 mmoles) and copper(I) iodide (13 mg, 
0.06 mmoles) under N2 atmosphere. The mixture was stirred at 130oC for 24 hours and then 
was treated with 20% NH4OH aqueous solution and extracted with EtOAc (x3), the combined 
organic extracts were washed with brine, dried (Na2SO4), filtered and evaporated in vacuo 
affording a yellow oil. Chromatography (SP4, silica, EtOAc in Petrol, eluting 50-95%) gave a 
colourless oil (10 mg, 16%). Rf 0.35 (EtOAc/Petrol (5:95)); ; LCMS (ESI)+ m/z = 265.1 [M + 
H]+; UV λmax (EtOH)/nm: 294.2; IR υmax/cm-1 2300, 2000, 1798, 1610, 1590, 1555, 1407; 1H 
NMR (500 MHz, Chloroform-d) δ 8.12 (1H, s, H-4), 7.64 (2H, d, J = 8.8 Hz, H-1, H-1’), 
7.16 (2H, d, J = 8.8 Hz, H-2, H-2’), 7.08 (1H, s, H-3); 13C NMR (125 MHz, Chloroform-d) δ 
161.0, 156.9, 147.1, 145.0, 134.0 (x2), 126.13, 121.8 (x2), 118.4, 113.7, 108.8; HRMS calc. 
for C12H6Cl2N2O [M+H]+ 264.9930, found 264.9861 
4-(3,4-Dichloro-2-oxopyridin-1(2-H)-yl)benzoic acid (64) 
 
4-(3,4-dichloro-2-oxopyridin-1(2H)-yl)benzonitrile (10 mg, 0.04 mmoles) was stirred in a 
mixture of H2SO4/H2O (6:4) (1 mL) at room temperature  for 16 hours. The mixture was 
extracted with EtOAc (x3) and the combined organic extracts were washed with brine, dried 
(Na2SO4), filtered and evaporated in vacuo affording a yellow oil. Chromatography (SP4, 
C18, CH3CN [0.1% formic acid] in water [0.1% formic acid] eluting 20-80%) gave a yellow 
oil (0.8 mg, 7%); Rf 0.37 (CH3CN [0.1% formic acid] in water [0.1% formic acid], (20:80)); 
LCMS (ESI)+ (m/z) = 266.8 [M + H]+; 1H NMR (500 MHz, Methanol-d4) δ 8.14 (1H, s, H-1), 
7.84 (2H, d, J = 8.8 Hz, H-1, H-1’), 7.21 (1H, s, H-3), 7.12 (2H, d, J = 8.8 Hz, H-2, H-2’); 





To a stirred solution of 2,4-dichloropyridine (1g, 6.8 mmoles) in acetic acid (10 mL) was 
added NaOAc (1.1 g, 13.5 mmoles). The mixture was stirred at 150oC for 24 hours and then 
was concentrated in vacuo affording a yellow solid. The crude product was partitioned 
between EtOAc and water, the organic layer was separated. Then the aqueous layer was 
extracted with EtOAc (x4), the combined organic extracts were washed with saturated 
aqueous solution of NaHCO3, brine, dried (Na2SO4), filtered and evaporated in vacuo to give 
a white solid (0.9 g, 99.99%). mp: 185-186 °C; LCMS (ESI)+ m/z = 130.0 [M + H]+; 1H NMR 
(500 MHz, DMSO-d6) δ 11.86 (1H, s, -NH-), 7.45 (1H, d, J = 7.0 Hz, H-1), 6.45 (1H, d, J = 
2.1 Hz, H-3), 6.27 (1H, d, J = 7.0, 2.1 Hz, H-2); 13C NMR (125 MHz, DMSO-d6) δ 162.1, 
147.0, 137.1, 118.9, 106.8; HRMS calc. for C5H5ClNO [M+H]+ 130.0054, found 130.0082; 
(lit., 184-186 °C; 1H NMR (400 MHz, DMSO-d6) δ 11.82 (br s, 1H, NH), 7.42 (d, 1H, J = 7.0 
Hz), 6.43 (d, 1H, J = 2.1 Hz), 6.25 (dd, 1H, J = 7.0 Hz, J = 2.1 Hz); 13C NMR (100 MHz, 
DMSO-d6) δ 162.1, 147.0, 137.1, 118.9, 106.7; HRMS (ESI+) Calcd for C5H5ClNO [M + 




To a stirred solution of 4-chloropyridin-2(1-H)-one (0.2 g, 1.6 mmoles), ethyl 4-iodobenzoate 
(0.5 g, 1.9 mmoles) and N,N-dimethylethylenediamine (57 mg, 0.7 mmoles) in anhydrous 
dioxane (10 mL) was added copper (I) iodide (62 mg, 0.3 mmoles) and K3PO4 (0.7 g, 3.2 
mmoles). The mixture was stirred at 110oC for 24 hours and then was filtered through celite 
and washed with EtOAc. The filtrate was evaporated in vacuo and then the residue was taken 
up with EtOAc, washed with water, brine, dried (Na2SO4), filtered and evaporated in vacuo 
affording a brown oil. Chromatography (SP4, silica, EtOAc in Petrol, eluting 10%) gave a 
yellow oil (160 mg, 35%). Rf 0.31 (EtOAc in Petrol (1/9)); LCMS (ESI)+ (m/z) = 278.0 [M + 
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H]+; UV λmax (EtOH)/nm: 292.6; IR υmax/cm-1 2900, 2250, 2028, 1771, 1578, 1535, 1517, 
1455; 1H NMR (500 MHz, DMSO-d6) δ 8.09 (1H, d, J = 8.6 Hz, H-1), 7.79 (2H, d, J = 7.4 
Hz, H-5), 7.60 (2H, d, J = 8.6 Hz, H-2), 6.70 (1H, d, J = 2.3 Hz, H-3), 6.50 (1H, dd, J =7.4, 
2.3 Hz, H-4), 4.36 (2H, q, J = 7.1 Hz, -CH2-), 1.35 (3H, t, J = 7.1 Hz, -CH3), 13C NMR (125 
MHz, DMSO-d6) δ 165.5, 160.4, 146.9, 144.2, 139.9, 130.4 (x2), 130.2, 127.7 (x2), 119.2, 
107.8, 61.5, 14.6; HRMS calc. for C14H12ClNO3 [M - EtO] 233.0244, found 233.0487 
 
4-(4-Chloro-2-oxopyridin-1(2-H)-yl)benzoic acid (65) 
 
To a stirred solution of ethyl 4-(4-chloro-2-oxopyridin-1(2-H)-yl)benzoate (0.1 g, 0.4 
mmoles) in anhydrous THF was added LiOH.H2O (60 mg, 0.7 mmoles). The mixture was 
stirred at room temperature for 16 hours and then 0.1 M HCl was added and the pH adjusted 
to 3. The precipitate formed was filtered through a sintered funnel and dried in a vacuum 
oven for 16 hours affording a white solid. (48 mg, 53%). Rf 0.58 (EtOAc in Petrol (10/90) + 1 
drop of acetic acid); mp 301-303oC; LCMS (ESI)+ m/z = 234.0 [M + H – H2O]+; UV λmax 
(EtOH)/nm: 314.2; IR υmax/cm-1 3370, 1650, 1589, 1511, 1408; 1H NMR (500 MHz, DMSO-
d6) δ 8.03 (2H, d, J = 8.3 Hz, H-1, H-1’), 7.78 (1H, d, J = 7.3 Hz, H-5), 7.43 (2H, d, J = 8.3 
Hz, H-2, H-2’), 6.68 (1H, d, J = 2.0 Hz, 6.47 (1H, d, J =7.3 Hz, H-3), 6.47 (1H, dd, J = 7.3, 
2.0 Hz, H-4); 13C NMR (125 MHz, DMSO-d6) δ 167.9, 160.6, 146.7, 144.2, 140.3, 136.5, 
130.3 (x2), 126.7 (x2), 119.1, 107.5; Analytical HPLC purity: 100% (CH3CN [0.1% NH3]); 
HRMS calc. for C12H8ClNO3 [M+H]+ 250.0266, found 250.0199 
4-(4,5-Dichloro-6-oxopyridazin-1(6-H)-yl)benzenesulfonic acid (78) 
 
To 4-hydrazinosulfonic acid (2 g, 10.6 mmoles) in a mixture of EtOH/H2O (1:1) (6 ml) was 
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added mucochloric acid (1.8 g, 10.6 mmoles) and 0.1 ml of 12 M HCl (catalytic). The 
mixture was stirred at 65oC for 16 hours and then was filtered through a sintered funnel and 
washed with cold water affording a pale yellow solid (3,40 g, 99.99%). Rf 0.37 
(EtOAc/Petrol/HOAc (9:90:1); LCMS (ESI)+ m/z = 322.0 [M + H]+; 1H NMR (500 MHz, 
DMSO-d6) δ 8.35 (1H, s, H-3), 7.73 (2H, d, J = 8.5 Hz, H-1 ), 7.51 (2H, d, J = 8.5 Hz, H-2); 
13C NMR (125 MHz, DMSO-d6) δ 156.1, 148.9, 141.3, 137.0, 136.4, 134.4, 126.5 (x2), 125.6 
(x2) 
General procedure C for (75), (76) and (77) 
 
4,5-Dichloro-2-(4-(morpholinosulfonyl)phenyl) pyridazin-3(2-H)-one (75) 
 
To a solution of 4-(4,5-Dichloro-6-oxopyridazin-1(6-H)-yl)benzenesulfonic acid (0.3 g, 0.9 
mmoles) in anhydrous DMF (6 mL) was added 150 µL of  thionyl chloride (0.15 mL, 1.9 
mmoles) dropwise at 0oC. After the complete conversion of the acid to the sulphonyl 
chloride, the mixture was allowed to warm up slowly to room temperature and then 
morpholine (0.4 mL, 4.8 mmoles) was added dropwise. The mixture was treated with 
saturated aqueous solution of NaHCO3 and extracted with EtOAc (x3), the combined organic 
extracts were dried (Na2SO4), filtered and evaporated in vacuo affording a yellow oil that 
solidified upon standing (160 mg, 66%). Rf 0.38 (EtOAc in Petrol (10/90); mp: 199-200oC; 
LCMS (ESI)+ m/z = 391.0 [M + H]+; UV λmax (EtOH)/nm: 316.0; IR υmax/cm-1 2961, 2913, 
2858, 1672, 1589, 1484, 1446, 1406; 1H NMR (500 MHz, DMSO-d6) δ 8.42 (1H, s, H-5), 
7.88 – 7.94 (4H, m, H-3, H-3’, H-4, H-4’), 3.56 – 3.73 (4H, m, H-2), 2.87 – 2.99 (4H, m, H-
1); 13C NMR (125 MHz, DMSO-d6) δ 156.1, 145.0, 137.6, 136.6, 134.9, 134.7, 128.9 (x2), 
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127.1 (x2), 65.8 (x2), 46.4 (x2); Analytical HPLC purity: 100% (CH3CN [0.1% NH3]); 




General procedure C: Using N-methyl-piperazine (0.31 mL, 2.8 mmoles) affording a white 
solid  (17 mg, 5%). Rf 0.41 (EtOAc in Petrol (10/90)); mp: 241-242oC; LCMS (ESI)+ m/z = 
404.1 [M + H]+; UV λmax (EtOH)/nm: 320.0; IR υmax/cm-1 2938, 2846, 2800, 1676, 1582, 
1488, 1453, 1404; 1H NMR (500 MHz, DMSO-d6) δ 8.42 (1H, s, H-5); 7.86 – 7.94 (4H, m, 
H-3, H-3’,H-4, H-4’); 2.95 (4H, br s, H-2), 2.33 – 2.40 (4H, m , H-1), 2.15 (3H, s, -CH3); 13C 
NMR (125 MHz, DMSO-d6) δ 156.1, 144.9, 137.6, 136.6, 135.3, 134.7, 128.7 (x2), 127.0 
(x2), 53.9 (x2), 46.2 (x2), 45.7; Analytical HPLC purity: 100% (CH3CN [0.1% NH3]); 






carboxylate was prepared according to the general procedure (C) using	N-Boc-piperazine 
(0.21 g, 1.12 mmoles) affording a yellow oil (62 mg, 14%). Rf 0.44 (EtOAc in Petrol (10/90); 
LCMS (ESI)+ m/z = 390.1 [M + H - Boc]+; 1H NMR (500 MHz, DMSO-d6) δ 7.91 (1H, s, H-
5), 7.77 – 7.82 (4H, m, H-3, H-3’, H-4, H-4’); 3.46 (4H, t, J = 5.1 Hz, H-2 (x2), H-2’ (x2)); 
2.96 (4H, t, J = 5.1 Hz, H-1 (x2), H-1’ (x2)), 1.35 (9H, s, N-Boc); 13C NMR (125 MHz, 
DMSO-d6) δ 155.9, 154.1, 144.3, 137.0, 136.8, 135.7, 128.4 (x2), 125.6 (x2), 80.5 (x2), 45.9 
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(x2), 28.3 (x3) 
4,5-Dichloro-2-(4-(piperazin-1-ylsulfonyl)phenyl)pyridazin-3(2-H)-one (77) 
 
To a stirred solution of 50 mg of tert-butyl 4-((4-(4,5-dichloro-6-oxopyridazin-1(6-H)-
yl)phenyl)sulfonyl) piperazine-1-carboxylate (0.1 mmoles, 1 equiv.) in dioxane (2 mL) and 
DCM (2 mL) was added 12M HCl (1 mL). The mixture was stirred at room temperature for 
24 hours and then was treated with saturated aqueous solution of NaHCO3, extracted with 
EtOAc (x3), the combined organic extracts were dried (Na2SO4), filtered and evaporated in 
vacuo affording a white solid (17 mg, 35%). Rf 0.71 (EtOAc in Petrol (10/90 + 1 drop of 
NH3)); mp: 236-237oC; LCMS (ESI)+ m/z = 390.1 [M + H]+; UV λmax (EtOH)/nm: 219.0; IR 
υmax/cm-1 3313, 2941, 2903, 2835, 2753, 2317, 1091, 1994, 1918, 1719, 1665, 1586, 1486, 
1449, 1404; 1H NMR (500 MHz, DMSO-d6) δ 8.41 (1H, s, H-5), 7.96 – 7.84 (4H, m, H-3, H-
3’, H-4, H-4’); 3.17 (1H, s, -NH-); 2.85 (4H, t, J = 4.8 Hz, H-2 (x2), H-2’ (x2)); 2.75 (4H, t, J 
= 4.8 Hz, H-1 (x2), H-1’ (x2)); 13C NMR (125 MHz, DMSO-d6) δ 156.1, 144.8, 137.5, 136.6, 
135.1, 134.7, 128.8 (x2), 127.0 (x2), 47.1 (x2), 45.0 (x2); Analytical HPLC purity: 99.4081% 
(CH3CN [0.1% formic acid]); HRMS calc. for C14H14Cl2N4O3S [M+H]+ 389.0236, found 
389.0158 
25.3 Synthesis of (80) and derivatives 








To a solution of (E)-3-(furan-2-yl)acrylic acid (0.8 g, 6 mmol) and anhydrous DMF 
(catalytic) in anhydrous THF (20 mL) was added oxalyl chloride (1.1 mL, 12 mmol) at 0oC. 
The mixture was stirred at room temperature for 16 hours and then was concentrated to half 
its volume by rotary evaporation. The concentrate was added dropwise to a stirred solution of 
methyl 2-aminobenzoate (1.8 g, 6 mmol) and NaHCO3 (3 g, 18 mmol) in THF/H2O (10:1) 
(60 mL). The mixture was stirred for 4 hours at room temperature and then was evaporated in 
vacuo. The crude product was dissolved in EtOAc and washed with saturated aqueous 
solution of NaHCO3, 1 M aqueous HCl, brine and then dried (Na2SO4), filtered and 
evaporated in vacuo affording a pale yellow solid. Chromatography (SP4, silica, EtOAc in 
Petrol, eluting 10%) gave a white solid (28 mg, 2%). Rf 0.42 (EtOAc in Petrol (10/90)); mp: 
224-225oC; UV λmax (EtOH)/nm: 261.3; IR υmax/cm-1 3260, 3131, 2950, 1676, 1588, 1527, 
1434; 1H NMR (500 MHz, DMSO-d6) δ 10.75 (1H, s, -NH-), 8.29 (1H, dd, J = 8.6, 1.2 Hz, 
H-4), 7.92 (1H, dd, J = 8.0, 1.6 Hz, H-1), 7.86 (1H, d, J = 1.7 Hz, H-9), 7.63 (1H, ddd, J = 
8.6, 7.4, 1.6 Hz, H-3), 7.44 (1H, d, J = 15.4 Hz, H-6), 7.22 (1H, ddd, J = 8.0, 7.4, 1.2 Hz, H-
2), 6.94 (1H, d, J = 3.3 Hz, H-7), 6.65 (1H, dd, J = 3.3, 1.7 Hz, H-8), 6.59 (1H, d, J = 15.4 
Hz, H-5), 3.86 (3H, s, -CH3); 13C NMR (125 MHz, DMSO-d6) δ 168.0, 164.0, 151.1, 145.9, 
139.8, 134.2, 130.9, 128.7, 123.9, 122.1, 119.5, 119.0, 115.6, 113.2, 52.9; Analytical HPLC 










General procedure D: Using o-toluidine (820 mg, 5.94 mmoles) affording a pale white solid 
(27 mg, 2%). Rf 0.38 (EtOAc in Petrol (10/90)); mp: 148-149 oC; LCMS (ESI)+ m/z = 228.1 
[M + H]+; UV λmax (EtOH)/nm: 264.5; IR υmax/cm-1 3258, 3214, 3119, 3010, 2948, 2321; 1H 
NMR (500 MHz, Chloroform-d) δ 9.50 (1H, s, -NH-), 7.84 (1H, d, J = 1.8 Hz, H-9), 7.59 
(1H, d, J = 7.8 Hz, H-4), 7.38 (1H, d, J = 15.5 Hz, H-6), 7.23 (1H, d, J = 7.5 Hz, H-1), 7.18 
(1H, td, J = 7.8, 1.5 Hz, H-3), 7.09 (1H, td, J = 7.5, 1.5 Hz, H-2), 6.85 (1H, d, J = 3.3 Hz, H-
7), 6.78 (1H, d, J = 15.5 Hz, H-5), 6.63 (1H, dd, J = 3.3, 1.8 Hz, H-8), 2.24 (3H, s, -CH3); 13C 
NMR (125 MHz, Chloroform-d) δ 164.0, 151.5, 145.5, 136.8, 131.5, 130.8, 127.6, 126.4, 
125.4, 124.9, 119.9, 114.8, 113.0, 18.4; Analytical HPLC purity: 99.5% CH3CN [0.1% 
formic acid]); HRMS calc. for C14H13NO2 [M+H]+ 228.1019, found 228.0979; (lit.,290 mp 
138-140 oC; 13C NMR (400 MHz, Chloroform-d) δ 17.8, 112.2, 114.4, 117.0, 126.7, 130.1, 
130.5, 144.2, 144.5, 151.2, 151.3, 154.0, 166.8) 
(E)-3-(Furan-2-yl)-N-(2-(hydroxymethyl)phenyl)acrylamide (82)
 
General procedure D: Using (2-aminophenyl)methanol (823 mg, 5.96 mmoles) affording a 
pale yellow solid (29 mg, 2%). Rf 0.19 (EtOAc in Petrol (10/90)); mp: 230-231oC; LCMS 
(ESI)+ m/z = 228.1 [M + H]+; UV λmax (EtOH)/nm: 268.0; IR υmax/cm-1 3623, 3038, 2862, 
2322, 2105, 1818, 1660, 1620, 1523, 1452; 1H NMR (500 MHz, DMSO-d6) δ 9.58 (1H, s, -
NH-), 7.89 (1H, d, J = 1.8 Hz, H-9), 7.71 (1H, d, J = 7.7 Hz, H-4), 7.50 (1H, d, J = 7.7 Hz, 
H-1), 7.44 (1H, d, J = 15.5 Hz, H-6), 7.31 (1H, t, J = 7.7, 1.5 Hz, H- 3), 7.26 – 7.19 (1H, m, 
H-2), 6.92 (1H, d, J = 3.4 Hz, H-7), 6.75 (1H, d, J = 15.5 Hz, H-5), 6.69 (1H, dd, J = 3.4, 1.8 
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Hz, H-8), 5.34 (1H, t, J = 5.5 Hz, -OH), 4.59 (1H, d, J = 5.5 Hz, -CH2-); 13C NMR (125 
MHz, DMSO-d6) δ 164.0, 151.4, 145.6, 135.7, 135.2, 127.79, 127.82, 127.4, 125.2, 124.2, 
119.8, 115.0, 113.0, 60.4; Analytical HPLC purity: 98.2% (CH3CN [0.1% formic acid]); 
HRMS (ESI+) calc. for C14H13NO3 [M+H]+ 244.0968, found 244.0909 




To a stirred solution of 1,3-dichloroaniline (3 g, 18.5 mmoles) in conc. HCl (35 mL) was 
added NaNO2 (1.3 g, 18.52 mmoles) in water (5 mL) dropwise at -5oC under N2 atmosphere. 
The mixture was stirred at 0oC for 30 minutes and then SnCl2.(H2O)2 (21.66 g, 96.28 mmoles) 
in conc. HCl (18 mL) was added slowly keeping the reaction mixture below 5oC. The mixture 
was stirred at 0oC for 1 hour and then was filtered through a pad of celite. The filtrate was 
evaporated in vacuo and the residue was suspended in water, 2M aqueous NaOH was added 
and the pH adjusted to 9. The aqueous layer was extracted with EtOAc (x3), the combined 
organic extracts were washed with brine, dried (Na2SO4), filtered and evaporated in vacuo 
affording a yellow oil. Chromatography (SP4, silica, MeOH in DCM, eluting 1-10%) gave a 
colourless oil (1.6 g, 29%). 1H NMR (500 MHz, Chloroform-d) δ 7.19 (1H, s, -NH-), 6.68 
(1H, t, J = 1.8 Hz, H-2), 6.65 (2H, d, J = 1.8 Hz, -H-1), 5.23 (1H, br s, -NH2); 13C NMR (125 
MHz, DMSO-d6) δ 154.1, 134.9 (x2), 116.4, 109.7 (x2) (lit., 1H NMR (400 MHz, 
Chloroform-d) δ 6.75 (t, J = 2.0 Hz, 1H), 6.71 (d, J = 2.0 Hz, 2H), 5.21 (br, 1H) 
2-(4,6-Dichloro-2-methyl-1-H-indol-3-yl)ethan-1-amine (85)  
 
To a stirred solution of (3,5-dichlorophenyl)hydrazine (0.1 g, 0.6 mmoles) in dry ethanol (2 
mL), 5-chloro-2-pentanone (68 µL, 0.6 mmoles) was added dropwise at room temperature 
under N2 atmosphere. The mixture was stirred for 20 minutes and then 0.1 mL of acetic acid 
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was added. The mixture was stirred at 50oC for 16 hours and then was evaporated in vacuo. 
The residue was triturated in DCM, filtered through a sintered funnel and washed with DCM 
affording a pale white solid (53 mg, 39%). Rf 0.44 (CH3CN [0.1% NH3] in water [0.1% NH3] 
(1:1)); UV λmax (EtOH)/nm: 231.4; IR υmax/cm-1 3435, 3284, 2874, 1618, 1552, 1491, 1444; 
mp: 146-147oC; 1H NMR (500 MHz, Methanol-d4) δ 7.25 (1H, d, J = 1.27 Hz, H-1), 7.02 
(1H, d, J = 1.27 Hz, H-2), 3.28 – 3.21 (2H, m, -CH2-3), 3.21 – 3.10 (2H, m, -CH2-4), 2.42 
(3H, s, -CH3);	13C NMR (126 MHz, Methanol-d4) δ 137.2, 135.8, 125.9, 124.1, 123.2, 119.4, 
109.3, 105.1, 41.2, 22.6, 9.7; Analytical HPLC purity: 99.1% (CH3CN [0.1% formic acid]); 
HRMS calc. for C11H12Cl2N2 [M + H]+ 243.0450, found 243.0371 
2-(2,4,6-Trimethyl-1-H-indol-3-yl)ethan-1-amine (87) 
 
To a stirred solution of (3,5-dimethyl)iodobenzene (0.2 g, 0.9 mmoles), tert-butyl carbazate 
(0.14 g, 1 mmol) and caesium carbonate (0.39 g ,1.2 mmoles) in anhydrous DMF (3 mL), CuI 
(8 mg, 0.04 mmoles) was added at room temperature under N2 atmosphere. The mixture was 
stirred at 80oC for 2 hours and then was treated with water and extracted with Et2O (x3), the 
combined organic extracts were washed with brine, dried (Na2SO4), filtered and evaporated 
in vacuo affording a pale brown oil. The crude was dissolved in ethanol (2 mL) and acetic 
acid (2 mL), and then of 5-chloro-2-pentanone (99 µL, 1.7 mmoles) was added dropwise 
under N2 atmosphere. The mixture was stirred at 50oC for 16 hours and then was evaporated 
in vacuo. The residue was triturated in DCM, filtered through a sintered funnel and washed 
with DCM affording a orange oil (14 mg, 8%). Rf 0.29 (CH3CN [0.1% NH3]) in (water [0.1% 
NH3])  (1:1)); UV λmax (EtOH)/nm: 247.0; IR υmax/cm-1 3380, 2916, 2855, 1556, 1439; 1H 
NMR (500 MHz, Methanol-d4) δ 6.87 (1H, s, H-1), 6.54 (1H, s, H-2), 2.94 (2H, t, J = 7.4 Hz, 
-CH2-5), 2.80 (2H, t, J = 7.4 Hz, -CH2-6), 2.59 (3H, s, -CH3-7), 2.34 (3H, s, -CH3-3,4 ); 13C 
NMR (126 MHz, Methanol-d4) δ 136.4, 131.1, 129.3, 128.1, 124.5, 121.8, 108.8, 43.8, 28.4, 
20.1, 19.0, 10.0; Analytical HPLC purity: 96.2% (CH3CN [0.1% formic acid]); HRMS calc. 








To a stirred solution of 3,5-dichlorophenyl)hydrazine (0.125 g, 0.7 mmoles) in acetic acid (2 
mL) anhydrous acetone (52 µL ,0.7 mmoles)  was added at room temperature under N2 
atmosphere. The mixture was stirred at 120oC for 16 hours and then was evaporated in vacuo 
affording a brown oil.  Zinc chloride (0.12 g, 0.84 mmoles) was added to the residue and then 
the mixture was fused at 140oC for 16 hours. The residue was taken up with EtOAc (10 mL), 
treated with ammonium chloride, washed with brine, dried (Na2SO4), filtered and evaporated 
in vacuo affording a dark yellow oil. Chromatography (SP4, silica, EtOAc in Petrol, eluting 
10%) gave a yellow oil (49 mg, 35%). Rf 0.54 (EtOAc in Petrol (5/95)); LCMS (ESI)+ m/z = 
201.1 [M + H]+; 1H NMR (500 MHz, DMSO-d6) δ 7.21 (1H, s, H-1), 6.97 (1H, s, H-2), 6.19 




To a stirred solution of 4,6-dichloro-2-methyl-1-H-indole (49 mg, 0.25 mmoles) in anhydrous 
THF (1 mL) was added NaH (60%) (10 g, 0.27 mmoles) at 0oC under N2 atmosphere. The 
mixture was stirred at 0oC for 30 minutes and then iodomethane (17 µL , 0.27 mmoles) was 
added. The mixture was stirred at 0oC and allowed to warm to room temperature slowly. The 
mixture was stirred at room temperature for 16 hours and then was treated with H2O (3 mL), 
extracted with DCM (x3), the combined organic extracts were washed with brine, dried 
(Na2SO4), filtered and evaporated in vacuo affording a pale yellow oil. Chromatography 
(SP4, silica, EtOAc in Petrol, eluting 1%) gave a pale yellow oil (27 mg, 52%); Rf 0.37 
(EtOAc in Petrol (1/99)); LCMS (ESI)+ m/z = 215.1 [M + H]+; UV λmax (EtOH)/nm: 219.3; IR 
υmax/cm-1 3023, 2935, 2807, 1665, 1642, 1610; 1H NMR (500 MHz, Methanol-d4) δ 7.25 (1H, 
dd, J = 1.6, 1 Hz, H-3), 6.93 (1H, d, J = 1.6 Hz, H-1), 6.20 (1H, p, J = 1 Hz, H-2), 3.60 (3H, 
s, N-CH3), 2.36 (3H, d, J = 1 Hz, -CH3); 13C NMR (126 MHz, Methanol-d4) δ 119.8, 109.0, 
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99.0, 30.1, 11.6; HRMS calc. for C10H9Cl2N [M+H]+ 214.0185, found 214.1468 
4,6-Dichloro-1,2-dimethyl-1-H-indole-3-carbaldehyde (96) 
 
POCl3 was added dropwise to a stirred solution of anhydrous DMF (1 mL) at 0oC under N2 
atmosphere. The mixture was stirred at 0oC for 20 minutes and then 4,6-dichloro-1,2-
dimethyl-1-H-indole (29 mg, 0.14 mmoles) in anhydrous DMF (1 mL) was added dropwise 
at 0oC. The mixture stirred for 1 hour at room temperature and then was treated with aqueous 
2M NaOH and the pH adjusted to 12. The aqueous layer was extracted with EtOAc (x3), the 
combined organic extracts were washed with brine, dried (Na2SO4), filtered and evaporated 
in vacuo affording a pale pink oil (33mg, 99.99%) which was used in the next step without 
further purification due to stability issues. 
4,6-Dichloro-1,2-dimethyl-3-(2-nitrovinyl)-1-H-indole (97) 
 
To a stirred solution of 4,6-dichloro-1,2-dimethyl-1H-indole-3-carbaldehyde (33 mg, 0.14 
mmoles) in CH3NO2 (3 mL) ammonium acetate (37 mg, 0.48 mmoles) was added at room 
temperature. The mixture was stirred at 80oC for 16 hours and then was evaporated in vacuo. 
The residue was taken up with EtOAc, washed with water, brine, dried (Na2SO4), filtered and 
evaporated in vacuo affording an orange oil (39 mg, 99.99%) which was used in the next step 








To a stirred solution of lithium aluminium hydride (20 mg, 0.05 mmoles) in anhydrous THF 
(1.5 mL) was added 4,6-dichloro-1,2-dimethyl-3-(2-nitrovinyl)1-H-indole (39 mg, 0.14 
mmoles) in anhydrous THF (1 mL) dropwise at 0oC under N2 atmosphere. The mixture was 
stirred at room temperature for 16 hours and then was quenched with water, extracted with 
EtOAc (x3), the combined organic extracts were washed with brine, dried (Na2SO4), filtered 
and evaporated in vacuo affording a pale yellow oil. Chromatography (SP4, C18, CH3CN 
[0.1% NH3] in water [0.1% NH3], eluting 33%) gave a colourless oil (1 mg, 3%). Rf 0.41 
(CH3CN [0.1% NH3] in water [0.1% NH3] (1:1)); LCMS (ESI)+ m/z = 258.1 [M + H]+; UV 
λmax (EtOH)/nm: 227.6; 1H NMR (500 MHz, Methanol-d4) δ 7.33 (1H, d, J = 1.7 Hz, H-1), 
7.00 (1H, d, J = 1.7 Hz, H-2), 3.68 (3H, s, N-CH3), 3.13 (2H, t, J = 7.5 Hz, -CH2-4), 2.93 
(2H, t, J = 7.5 Hz, -CH2-3) 2.41 (3H, s, -CH3); 13C NMR (126 MHz, Methanol-d4) δ 139.7, 
138.3, 127.1, 126.1, 124.1, 120.8, 109.1, 108.9, 44.3, 30.2, 28.0, 10.1; Analytical HPLC 




To a stirred solution of 2-(4,6-dichloro-2-methyl-1H-indol-3-yl)ethan-1-amine (93 mg, 0.4 
mmoles) in acetonitrile (2 mL) and anhydrous DMF (1 mL), triethylamine (0.265 mL, 1.9 
mmoles) was added dropwise at room temperature under N2 atmosphere. The mixture was 
stirred at room temperature for 20 minutes and then acetic anhydride (41 µL, 0.43 mmoles) 
was added. The mixture was stirred at room temperature for 16 hours and then was treated 
with saturated aqueous solution of NaHCO3 and extracted with EtOAc (x3), the combined 
organic extracts were washed with brine, dried (Na2SO4), filtered and evaporated in vacuo 
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affording a yellow oil. Chromatography (SP4, silica, EtOAc in Petrol, eluting 45-100%) gave 
a white solid (97 mg, 89%). Rf 0.21 (EtOAc in Petrol (2:1)); UV λmax (EtOH)/nm: 287.0; IR 
υmax/cm-1 3281, 2933, 2400, 1608, 1437; mp: 155-156oC; 1H NMR (500 MHz, Methanol-d4) δ 
8.09 (1H, s, -NH-), 7.17 (1H, d, J = 1.7 Hz, H-1), 6.92 (1H, d, J = 1.7 Hz, H-2), 3.38 (2H, t, J 
= 6.3 Hz, -CH2-4), 3.35 (s, 3H), 3.05 (2H, t, J = 6.3 Hz, CH2-3), 2.34 (3H, s, -CH3), 1.91 (3H, 
s, -C(=O)-CH3); 13C NMR (126 MHz, Methanol-d4) δ 173.2, 138.5, 136.6, 126.7, 126.0, 
125.0, 120.5, 110.3, 109.3, 42.6, 25.5, 22.6, 11.2; Analytical HPLC purity: 99.1% (CH3CN 
[0.1% formic acid]); HRMS calc. for C13H14Cl2N2O [M+H]+ 285.0556, found 285.0477 
N-(2-(4,6-dichloro-2-methyl-1-H-indol-3-yl)ethyl)pivalamide (91)  
 
To a stirred solution of 2-(4,6-dichloro-2-methyl-1-H-indol-3-yl)ethan-1-amine (0.15 g, 0.62 
mmoles) in anhydrous acetonitrile (3 mL) and anhydrous DMF (1 mL), triethylamine (427 
µL, 3.1 mmoles) was added dropwise at room temperature under N2 atmosphere. The mixture 
was stirred at room temperature for 20 minutes and then pivalic anhydride (140 µL, 0.69 
mmoles) was added. The mixture was stirred at room temperature for 16 hours and then was 
treated with saturated aqueous solution of Na2CO3 and extracted with EtOAc (x3), the 
combined organic extracts were washed with brine, dried (Na2SO4), filtered and evaporated 
in vacuo affording a yellow oil. Chromatogrphay (SP4, silica, EtOAc in Petrol, eluting 25-
75%) gave a pale white solid (97 mg, 48%). Rf 0.51 (EtOAc in Petrol (2:1)); UV λmax 
(EtOH)/nm: 287.8; ; IR υmax/cm-1 3447, 3206, 2934, 1639, 1523, 1433; mp: 184-185oC; 1H 
NMR (500 MHz, Chloroform-d) δ 9.30 (1H, s, - NH-C(=O)), 7.14 (1H, d, J = 1.7 Hz, H-1), 
7.00 (1H, d, J = 1.7 Hz, H-2), 3.52 (2H, q, J = 6.9 Hz, -CH2-4), 3.09 (2H, t, J = 6.9 Hz, -CH2-
3), 2.28 (3H, s, -CH3), 1.13 (9H, s, -(CH3)3); 13C NMR (126 MHz, Chloroform-d) δ 179.0, 
136.9, 134.9, 126.1, 124.9, 123.9, 120.4, 109.6, 108.5, 41.4, 38.7, 27.6 (x3), 24.3, 11.6; 
Analytical HPLC purity: 100% (CH3CN [0.1% formic acid]); HRMS calc. for C13H14Cl2N2O 





N-(2-(4,6-dichloro-2-methyl-1-H-indol-3-yl)ethyl)benzamide (92)  
 
To a stirred solution of  2-(4,6-dichloro-2-methyl-1H-indol-3-yl)ethan-1-amine (100 mg, 0.41 
mmoles) in CH3CN/DMF (3:1) (4 mL), triethylamine (0.29 mL, 2 mmoles) was added 
dropwise at room temperature under N2 atmosphere. The mixture was stirred at room 
temperature for 20 minutes and then benzoyl chloride (54 µL, 0.46 mmoles) was added. The 
mixture was stirred at room temperature for 16 hours and then was treated with saturated 
aqueous solution of NaHCO3, extracted with EtOAc (x3), the combinend organic extracts 
were washed with brine, dried (Na2SO4), filtered and evaporated in vacuo affording a yellow 
oil. Chromatography (SP4, silica, EtOAc in Petrol, eluting 15-50%) gave a white solid (10 
mg, 7%). Rf 0.23 (EtOAc in Petrol (1:3)); UV λmax (EtOH)/nm: 235.0; IR υmax/cm-1 3902, 
3869, 3854, 3838, 3748, 3736, 3674, 3649, 3629, 3589, 3566, 1650, 1635, 1541, 1521, 1455, 
1420; mp: 283-284oC; 1H NMR (500 MHz, Methanol-d4) δ 7.80 – 7.75 (2H, m, H-5, H-5’), 
7.56 – 7.49 (1H, m, H-7), 7.47 – 7.41 (2H, m, H-6, H-6’), 7.19 (1H, d, J = 1.7 Hz, H-1), 6.96 
(1H, d, J = 1.7 Hz, H-2), 3.64 (2H, t, J = 7.1 Hz, -CH2-4), 3.22 (2H, t, J = 7.1 Hz, -CH2-3), 
2.33 (3H, s, -CH3); 13C NMR (126 MHz, Methanol-d4) δ 170.3, 138.5, 136.7, 135.9, 132.5, 
129.5 (x2), 128.2 (x2), 126.6, 126.0, 125.1, 120.5, 110.3, 109.4, 43.1, 25.4, 11.3; Analytical 
HPLC purity: 97.9% (CH3CN [0.1% NH3]); HRMS calc. for C18H16Cl2N2O [M+H]+ 
347.0713, found 347.0144 




To a stirred solution of 2-acetyl-pyridine (250 mg, 2 mmol) in 45% hydrobromic acid in 
acetic acid (747 µL, 6.2 mmol) bromine (181 mg, 2.27 mmoles) was added at room 
temperature under N2 atmosphere. The mixture was stirred at room temperature for 16 hours 
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and then treated with Et2O (8 mL). The precipitate formed was filtered through a pad of 
celite, washed with Et2O and the filtrate evaporated in vacuo affording a pale yellow solid 
(702 mg, 85%) which was used in the next step without further purification.; 1H NMR (500 
MHz, Methanol-d4) δ 8.83 (1H, dd, J = 5.8, 1.4 Hz, H-1), 8.75 (1H, td, J = 8.1, 1.4 Hz, H-3), 
8.31 (d, J = 8.1 Hz, H-4), 8.22 – 8.16 (m, H-2), 3.95 (1H, d, J = 11.5 Hz, -CH2-), 3.85 (1H, J 
= 11.5 Hz, -CH2-); 13C NMR (126 MHz, DMSO-d6) δ 200.0, 149.5, 138.5, 128.7, 121.8, 65.6, 
49.1; (lit., 1H NMR (Methanol-d4) δ 8.81 (1H, d, J = 5.4 Hz), 8.73 (1H, t, J = 8.1 Hz), 8.27 




To a stirred solution of 2-bromo-1-(pyridine-2-yl)ethan-1-one (100 mg, 0.5 mmoles) in dry 
EtOH (2 mL) was added thiourea (38 mg, 0.55 mmoles) at room temperature. The mixture 
was stirred at room temperature for 5 hours and then was cooled down to 0oC. The precipitate 
formed was filtered through a sintered funnel and then dissolved in 2M aqueous NaOH (4 
mL) extracted with EtOAc (x3), the combined organic extracts were washed with brine, dried 
(Na2SO4), filtered and evaporated in vacuo affording a pale yellow solid (105 mg, 81%) 
which was used in the next step without further purification. 1H NMR (500 MHz, DMSO-d6) 
δ 8.48 – 8.59 (1H, m, H-1), 7.78 – 7.90 (2H, m, H-4, H-3), 7.24 – 7.37 (2H, m, H-5, H-2), 
7.18 (2H, br s, -NH2); (lit., 1H NMR (600 MHz, Chloroform-d) δ 8.58 (1H, d, J = 4.4 Hz), 
7.88 (1H, d, J = 7.9 Hz), 7.71 (1H, td, J = 7.6, 1.5 Hz), 7.31 (1H, s),  7.18 (1H, ddd, J = 7.3, 





To a stirred solution of 4-(pyridin-2-yl)thiazol-2-amine (50 mg, 0.2 mmoles) and anhydrous 
pyridine (101 µL, 1.25 mmoles) in dioxane (2 mL) was added propionyl chloride (17 µL, 0.2 
mmoles) dropwise at 0oC under N2 atmosphere. The mixture was slowly warmed up to room 
temperature for 30 minutes and stirred for 5 hours. The mixture was treated with saturated 
aqueous solution of NaHCO3 (3 mL), extracted with EtOAc (x3), the combined organic 
extracts were washed with brine, dried (Na2SO4), filtered and evaporated in vacuo affording a 
pale yellow oil. Chromatography (SP4, silica, EtOAc in Petrol, eluting 30-70%) gave a white 
solid (30 mg, 67%). Rf 0.62 (EtOAc in Petrol (1:1)); UV λmax (EtOH)/nm: 234.0, 269; IR 
υmax/cm-1 2982, 2229, 1670, 1501; mp: 226-227oC; 1H NMR (500 MHz, Chloroform-d) δ 
9.51 (1H, br s, -NH-), 8.63 (1H, d, J = 4.6, 1.7 Hz H-1), 7.89 (1H, d, J = 7.8, 1.2 Hz, H-4), 
7.74 (td, J = 7.8, 1.7 Hz, H-3), 7.68 (1H, s, H-5), 7.22 (1H, ddd, J = 7.8, 4.6, 1.2 Hz, H-2), 
2.42 (2H, q, J = 7.6 Hz, -CH2-), 1.22 (3H, t, J = 7.6 Hz, -CH3); 13C NMR (126 MHz, 
Chloroform-d) δ 171.5, 158.2, 152.3, 149.7, 149.4, 136.9, 122.7, 120.5, 112.0, 29.4, 9.0; 
Analytical HPLC purity: 100% (CH3CN [0.1% formic acid]); HRMS calc. for C11H11N3OS 
[M+H]+ 234.0696, found 234.0631 
N-(4-(pyridin-2-yl)thiazol-2-yl)acetamide (104)  
 
To a stirred solution of 4-(pyridin-2-yl)thiazol-2-amine (137 mg, 0.62 mmoles) and 
anhydrous pyridine (252 µL, 3.1 mmoles) in dioxane (2 mL) was added acetic anhydride (66 
µL, 0.7 mmoles) dropwise at room temperature under N2 atmosphere. The mixture was 
stirred at room temperature for 5 hours and then was treated with saturated aqueous solution 
of Na2CO3 (5 mL), extracted with EtOAc (x3), the combined organic extracts were washed 
with brine, dried (Na2SO4), filtered and evaporated in vacuo affording a pale yellow oil. 
Chromatography (SP4, silica, EtOAc in Petrol, eluting 35%) to give a white solid (30 mg, 
67%). Rf 0.55 (EtOAc in Petrol (1:1)); UV λmax (EtOH)/nm: 268.3, 234.6; IR υmax/cm-1 3166, 
3065, 2993, 1639, 1552, 1424; mp: 249-250oC; 1H NMR (500 MHz, DMSO-d6) δ 12.29 (1H, 
s, -NH-), 8.60 (1H, ddd, J = 4.8, 1.8, 1.0 Hz, H-1), 7.93 (dt, J = 7.7, 1.0 Hz, H-4), 7.89 (td, J 
= 7.7, 1.8 Hz, H-3), 7.80 (s, H-5), 7.33 (ddd, J = 7.7, 4.8, 1.0 Hz, H-2), 2.18 (3H, s, -CH3); 
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13C NMR (126 MHz, DMSO-d6) δ 169.2, 158.7, 152.5, 150.0, 149.4, 137.7, 123.3, 120.4, 
111.9, 23.0; Analytical HPLC purity: 100% (CH3CN [0.1% formic acid]); HRMS calc. for 
C10H9N3OS [M+H]+ 220.0539, found 220.0461 
4-(Pyridin-4-yl)thiazol-2-amine294 (111) 
 
To a stirred solution of 2-bromo-1-(pyridin-4-yl)ethan-1-one (0.5 g, 0.85 mmoles) in EtOH 
(10 mL) was added thiourea (71 mg, 0.92 mmoles) portionwise at room temperature under N2 
atmosphere. The mixture was stirred at room temperature for 6 hours and then the precipitate 
formed was filtered through a sintered funnel, dissolved in 2M aqueous NaOH (5 mL), 
extracted with EtOAc (x3), the combined organic extracts were washed with brine, dried 
(Na2SO4), filtered and evaporated in vacuo to afford a white solid (400 mg, 60%) which was 
used in the next step without further purification. m.p. 245-246 ºC; 1H NMR (500 MHz, 
DMSO-d6) δ 8.54 (2H, d, J = 6.1 Hz, H-1, H-1’), 7.72 (d, J = 6.1 Hz, H-2, H-2’), 7.38 – 7.43 
(1H, m, H-3), 7.21 (2H, br s, -NH2); 13C NMR (126 MHz, DMSO-d6) δ 169.0, 150.5 (x2), 
147.9, 141.9, 120.3 (x2), 106.6; (lit., mp 278-282 ºC; 1H NMR (400 MHz, Methanol-d4) δ 




To a stirred solution of 4-(pyridin-4-yl)thiazol-2-amine (75 mg, 0.42 mmoles) and anhydrous 
pyridine (171 µL, 2.1 mmoles) in anhydrous DCM (3 mL) was added propionyl chloride (42 
µL, 0.47 mmoles) dropwise at 0°C  under N2 atmosphere. The mixture was allowed to warm 
to room temperature slowly and stirred at room temperature for 5 hours. The mixture was 
treated with saturated aqueous solution of Na2CO3 (5 mL) and extracted with EtOAc (x3), the 
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combined organic extracts were washed with brine, dried (Na2SO4), filtered and evaporated 
in vacuo to afford a white solid (78 mg, 80%). Rf 0.59 (EtOAc in Petrol (1:1)); UV λmax 
(EtOH)/nm: 280.6, 229.2; IR υmax/cm-1 3166, 3065, 2993, 1639, 1552, 1424; mp: 251-252oC; 
1H NMR (500 MHz, DMSO-d6) δ 12.32 (1H, s, -NH-), 8.62 (2H, d, J = 6.1 Hz, H-1), 7.98 
(1H, d, J = 0.9 Hz, H-3), 7.84 (2H, d, J = 6.1 Hz, H-2), 2.47 (2H, q, J = 7.5 Hz, -CH2-), 1.11 
(3H, t, J = 7.5 Hz, -CH3); 13C NMR (126 MHz, DMSO-d6) δ 173.0, 159.0, 150.7 (x2), 146.7, 
141.5, 120.4 (x2), 112.6, 28.7, 9.6; Analytical HPLC purity: 100% (CH3CN [0.1% formic 
acid]); HRMS calc. for C11H11N3OS [M+H]+ 234.0696, found 234.0618 
4-(p-Tolyl)thiazol-2-amine295 (113) 
 
To a stirred solution of 2-bromo-1-(p-tolyl)ethan-1-one (0.5 g, 2.16 mmoles) in dry EtOH (10 
mL) was added thiourea (181 mg, 2.32 mmoles) portionwise at room temperature under N2 
atmosphere. The mixture was stirred at room temperature under N2 atmosphere for 6 hours, 
then the precipitate formed was filtered through a pad of celite and washed with EtOH. The 
filtrate was evaporated in vacuo. The residue was dissolved in 2M aqueous NaOH (5 mL), 
extracted with EtOAc (x3), the combined organic extratcs were washed with brine, dried 
(Na2SO4), filtered and evaporated in vacuo affording a white solid (210 mg, 44%) which was 
used in the next step without further purification. UV λmax (EtOH)/nm: 212.2; IR υmax/cm-1 
3289, 3174, 3136, 3083, 2999, 2110; 1H NMR (500 MHz, DMSO-d6) δ 8.71 (2H, br s, -NH2), 
7.63 (2H, d, J = 8.0 Hz, H-1, H-1’), 7.30 (d, J = 8.0 Hz, H-2, H-2’), 7.17 (1H, s, H-3), 2.35 
(3H, s, -CH3); 13C NMR (126 MHz, DMSO-d6) δ 170.5, 139.4 (x2), 130.0, 126.2 (x2), 102.2, 
21.3 (2 missing carbon signals); (lit., 1H NMR (DMSO-d6, 400 MHz) δ  8.87 (2H, br s, NH2), 
7.48-7.41 (4H, m, Ar-H), 6.81 (1H, s, -CH), 2.31 (3H, s, Me), 13C NMR (DMSO-d6, 75 








To a stirred solution of 2-bromo-1-(p-tolyl)ethan-1-one (0.2 g, 1.1 mmoles) and anhydrous 
pyridine (170 µL, 2.1 mmoles) in anhydrous DCM (5 mL) was added propionyl chloride (95 
µL ,1.1 mmoles) dropwise at room temperature under N2 atmosphere. The mixture was 
stirred at room temperature for 16 hours, then was treated with saturated aqueous solution of 
Na2CO3 (5 mL) and extracted with EtOAc (x3), the combined organic extracts were washed 
with brine, dried (Na2SO4), filtered and evaporated in vacuo affording a yellow oil. 
Chromatography (SP4, silica EtOAc in Petrol, eluting 40%) gave a white solid (30 mg, 80%). 
Rf 0.62 (EtOAc in Petrol (1:1)); UV λmax (EtOH)/nm: 268.8, 235.8, 210.6; IR υmax/cm-1 3130, 
3023, 2972, 2913, 2872, 1685, 1534; mp: 241-242oC; 1H NMR (500 MHz, Methanol-d4) δ 
7.79 (2H, d, J = 8.0 Hz, H-2), 7.29 (1H, s, H-3), 7.22 (2H, d, J = 8.0 Hz, H-1), 2.52 (2H, q, J 
= 7.6 Hz, -CH2-), 2.37 (3H, s, -CH3-4), 1.25 (3H, t, J = 7.6 Hz, -CH3); 13C NMR (126 MHz, 
Methanol-d4) δ 173.1, 158.0, 149.8, 137.3, 131.9, 128.8 (x2), 125.6 (x2), 106.2, 28.4, 19.8, 
8.2; Analytical HPLC purity: 100% (CH3CN [0.1% formic acid]; HRMS calc. for 
C13H14N2OS [M+H]+ 247.0900, found 247.1830 
4-(Pyridin-3-yl)thiazol-2-amine296(108) 
 
To a stirred solution of 2-bromo-1-(pyridin-3-yl)ethan-1-one (0.5 g, 0.85 mmoles) in dry 
EtOH (10 mL) was added thiourea (71 mg, 0.92 mmoles) portionwise at room temperature 
under N2 atmosphere. The mixture was stirred at room temperature for 6 hours. The 
precipitate formed was filtered through a pad of celite and washed with EtOH. The filtrate 
was evaporated in vacuo and the residue dissolved in 2M NaOH (5 mL), extracted with 
EtOAc (x3), the combined organic extracts were washed with brine, dried (Na2SO4), filtered 
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and evaporated in vacuo affording a white solid (109 mg, 16%) which was used in the next 
step without further purification. 1H NMR (500 MHz, DMSO-d6) δ7.45-9.05 (4H, m, Ar-H-
1), 7.19 (1H, s, H-2), 3.55(2H, s, -NH2); 13C NMR (126 MHz, DMSO-d6) δ 173.0, 149.2, 
148.5, 135.6, 124.0, 105.9; (lit., 1H NMR (DMSO-d6) δ 7.37-9.01 (m, 4H, Ar-H), 7.19 (s, 1H, 
CH of thiazole ring), 3.52 (2H, s, -NH2); 13C NMR (DMSO-d6) δ 169.05, 148.40, 147.28, 




To a stirred solution of 4-(pyridin-3-yl)thiazol-2-amine (0.1 g, 0.56 mmoles) and anhydrous 
pyridine (228 µL, 2.8 mmoles) in anhydrous DCM (3 mL) was added propionyl chloride (56 
µL, 0.6 mmoles) dropwise at room temperature under N2 atmosphere. The mixture was 
stirred at room temperature for 16 hours, then was treated with saturated aqueous solution of 
NaHCO3 (5 mL) and extracted with EtOAc (x3), the combined organic extracts were washed 
with brine, dried (Na2SO4), filtered and evaporated in vacuo affording a yellow oil. 
Chromatography (SP4, silica, EtOAc in Petrol, eluting 35%) gave a white solid (15 mg, 
11%). Rf 0.66 (EtOAc in Petrol (1:1)); UV λmax (EtOH)/nm: 231.2, 269.2; IR υmax/cm-1 3092, 
3054, 2979, 2726, 2106, 1681, 1576, 1505, 1461, 1408; mp: 271-272oC; 1H NMR (500 MHz, 
DMSO-d6) δ 12.28 (1H, s, -NH-), 9.11 (1H, d, J = 2.7 Hz, H-1), 8.53 (dd, J = 4.8, 1.6 Hz, H-
2), 8.23 (dt, J = 8.0, 1.8 Hz, H-4), 7.79 (1H, s, H-5), 7.47 (1H, ddd, J = 8.0, 4.8, 0.7 Hz, H-3), 
2.47 (2H, q, J = 7.5 Hz, -CH2-), 1.11 (3H, t, J = 7.5 Hz, -CH3); 13C NMR (126 MHz, DMSO-
d6) δ 172.9, 159.0, 149.1, 147.4, 146.4, 133.3, 130.5, 124.3, 109.9, 28.7, 9.6; Analytical 
HPLC purity: 98.9% (CH3CN [0.1% formic acid]); HRMS calc. for C11H11N3OS [M+H]+ 
234.0696, found 234.6240 





2-(3-(pyrimidin-4-ylamino)phenyl)acetic acid (115) 
	
To a solution of 4-chloropyrimidine (100 mg, 0.9 mmoles) in anhydrous DMF (4 mL) was 
added 2-(3-aminophenyl) acetic acid (100 mg, 0.66 mmoles). The mixture was stirred at 80oC 
for 3 hours, and then was evaporated in vacuo. Chromatography (SP4, silica, MeOH [0.1% 
AcOH] in DCM, eluting 10%) gave a beige solid (15 mg, 10%). Rf 0.47 (DCM:MeOH:AcOH 
9:1:0.05), IR υmax/cm-1 3045, 2827, 1649, 1580, 1516, 1474; mp 186-187 oC; 1H NMR (500 
MHz, DMSO-d6) δ 12.40 (1H, br s, -CO2H), 9.89 (1H, s, H-1), 8.65 (1H, s, H-2), 8.28 (1H, s, 
H-4), 7.63 (1H, d, J = 7.8 Hz, H-5), 7.53 (1H, s, -NH-), 7.28 (1H, t, J = 7.8 Hz, H-6), 6.95 
(1H, d, J = 7.8 Hz, H-7), 6.85 (1H, d, J = 5.7 Hz, H-3), 3.56 (2H, s, -CH2-8); 13C NMR (500 
MHz, DMSO-d6) δ 159.9, 158.0, 155.1, 139.6, 128.6, 123.5, 120.6, 118.2, 107.2, 41.0 (1 
missing quaternary carbon –CO2H); HRMS calc. for C12H11N3O2 [M + H]+ 230.0924; found 
230.0925 
2-(4-((2-oxo-1,2-dihydropyridin-4-yl)oxy)phenyl)acetic acid (117) 
 
A mixture of 2-(4-((2-methoxypyridine-4-yl)oxy)phenyl)acetate (57 mg, 0.2 mmoles) and 
pyridine hydrochloride (146 mg, 1.2 mmoles) were stirred at 120oC for 24 hours. The mixture 
was allowed to cool to room temperature, and then was evaporated in vacuo. 
Chromatography (SP4, C18, CH3CN in H2O, eluting 10-40%) gave a beige solid (19 mg, 
37%). Rf  0.61 (MeOH/DCM (1:9)), IR υmax/cm-1  3443, 1613, 1216, 1182; mp 260-261 oC; 
1H NMR (500 MHz, DMSO-d6) δ 11.35 (1H, s, -CO2H), 7.36 (1H, d, J = 7.3 Hz, H-3), 7.34 
(2H, d, J = 8.4 Hz, H-5, H-5’), 7.07 (2H, d, J = 8.4 Hz, H-4, H-4’), 5.97 (1H, dd, J = 7.3, 2.5 
Hz, H-2), 5.31 (1H, d, J = 2.5 Hz, H-1), 3.53 (2H, s, -CH2-); 13C NMR (125 MHz, DMSO-d6) 
δ 172.7, 167.7, 163.6, 151.6, 136.7, 132.8, 131.2 (x2), 120.7 (x2), 100.5, 98.6 (1 missing 





To a solution of 6-chloro-2-aminopurine (1g, 2.95 mmoles) in anhydrous DMF (50 mL) was 
added 3,4-dihydropyran (2.7 mL, 29.5 mmoles) followed by the addition of 5.7 M aqueous 
hydrochloric acid (50 µL). The mixture was stirred at 60oC for 2 hours and then was 
evaporated in vacuo. Chromatography (SP4, silica, EtOAc/Petrol (4:6)) to give a yellow oil 
that crystallized upon freezing (1.55 g, 78%). Rf 0.44 (100% EtOAc); m.p. 171-174 °C; IR 
υmax/cm-1 3269, 2940, 2855, 1716, 1614; 1H NMR (500 MHz, DMSO-d6) δ 8.42 (s, 1H), 8.14 
(br s, 1H), 5.53 (d, J = 10.2 Hz, 1H), 5.20-5.12 (m, 1H), 4.02 (d, J = 11.1, 1H), 3.84 (d, J = 
11.1 Hz, 1H), 3.46 (td, J = 2.8, 11.1 Hz, 1 H), 2.21-2.35 (m, 1H), 2.03-1.34 (m, 11H); 13C 
NMR (125 MHz, (CD3)2SO) δ 158.1, 153.7, 150.0, 142.3, 124.7, 81.6, 80.4, 68.2, 66.0, 30.7, 






DABCO (88 mg, 0.59 mmol) was added to a mixture of 6-chloro-N,9-bis(tetrahydro-2H-
pyran-2-yl)-9H-purin-2-amine (100 mg, 0.30 mmol) and anhydrous DMSO (3 mL). The 
mixture was stirred at room temperature for 3 h. The mixture was added to a stirred 
suspension of DBU (49 µL, 0.33 mmol) and methyl 2-(3-hydroxyphenyl)acetate (98 mg, 0.40 
mmol) in anhydrous DMF (2 mL). The mixture was stirred at 65 °C for 72 h. The mixture 
was treated with aqueous saturated sodium bicarbonate (8 mL) and was extracted three times 
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with EtOAc and the combined extracts washed three times with brine, dried over sodium 
sulfate, filtered, and concentrated in vacuo to give the crude product (145 mg) which was 
used as such in the next step without further purification. 
 
2-(3-((2-amino-9H-purin-6-yl)oxy)phenyl)acetic acid (120) 
	
The crude methyl 2-(3-((9-(tetrahydro-2H-pyran-2-yl)-2-((tetrahydro-2H-pyran-2-yl)amino)-
9H-purin-6-yl)oxy)phenyl)acetate (142 mg, 0.3 mmol) was dissolved in THF (5 mL) and 2M 
aqueous HCl (2.5 mL) and stirred at room temperature for 4 h. The mixture was evaporated 
in vacuo purified by chromatography (SP4, C18 silica, H2O:CH3CN:NH4OH 70:30:0.1) gave 
a white powder (8 mg, 10%). Rf 0.18 (DCM/MeOH (9:1)); m.p. 284-285 °C; IR υmax/cm-1  
1233, 1265, 1376, 1568 cm-1; 1H NMR (500 MHz, Methanol-d4) δ 7.97 (1H, s, H-1), 7.38 
(1H, t, J = 8.1 Hz, H-3), 7.27-7.21 (2H, m, H-2, H-5), 7.11 (1H, dd, J = 8.1, 1.1 Hz, H-4), 
3.60 (2H, s, -NH2); 13C NMR (125 MHz, DMSO-d6) δ 173.2, 160.22, 160.18, 153.0, 138.2, 
129.6, 126.5, 122.8, 120.2, 41.9; HRMS calc. for C15H14N3O3 [M + H]+ 286.0935; found 
286.0931  
 
2-(3-(2-amino-9H-purin-6-yl)phenyl)acetic acid (123) 
	
A mixture of 6-chloro-N,9-bis(tetrahydro-2H-pyran-2-yl)-9H-purin-2-amine (100 mg, 0.3 
mmol), potassium carbonate (102 mg, 0.74 mmol), ethyl 2-(3-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)phenyl)acetate (86 mg, 0.3 mmol), 
tetrakis(triphenylphosphine)palladium(0) (17 mg, 0.02 mmol), anhydrous DMF (1.5 mL) and 
deionized water ).5 mL) was stirred at 140 °C for 30 minutes under MW irradiation under N2. 
The mixture was treated with deionized water (5 mL) and extracted EtOAc (x3) and the 
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combined extracts washed with brine, dried (Na2SO4), filtered, and evaporated in vacuo. The 
crude residue was dissolved in THF (5 mL) and 2 M aqueous HCl (2.5 mL) and stirred at 
room temperature for 4 h. The mixture was neutralized with 2 M aqueous NaOH, extracted 
three times with EtOAc, and the combined extracts washed with brine, dried (Na2SO4), 
filtered, and concentrated in vacuo to give a yellow oil which was triturated with anh. 
methanol (5 mL) to afford a white powder (5 mg, 6%). Rf 0.2 (DCM/MeOH (9:1)); m.p. 329-
330 °C; IR υmax/cm-1  3380, 3163, 3041, 2113, 1911, 638; 1H NMR (500 MHz, DMSO-d6) δ 
8.58 (d, J = 7.4 Hz, H-5), 8.50 (br s, H-1), 8.10 (1H, s, H-2), 7.48 (1H, t, J = 7.4 Hz, H-4), 
7.40 (1H, d, J = 7.4 Hz, H-3), 3.69 (2H, s, -CH2-); 13C NMR (125 MHz, DMSO-d6) δ 174.8, 
156.8, 148.6, 137.8, 135.5, 131.7, 130.6, 129.5, 41.5; HRMS calc. for C13H12N5O2 [M + NH4]+ 
287.3025; found 287.1240 




To a solution of (2R)-3-bromo-2-hydroxy-2-methylpropionic acid (0.1 g, 0.49 mmoles) in 
anhydrous THF (2 mL), SOCl2 (0.04 mL, 0.49 mmoles) was added at -5°C under N2 
atmosphere. The mixture was stirred at 0°C for 2 hours and then, 4-nitro-3-
(trifluoromethyl)aniline in THF (2 mL) was added. The mixture was allowed to warm to 
room temperature slowly and stirred for 24 hours and then was evaporated in vacuo. The 
residue was taken up with DCM (10 mL), treated with saturated aqueous solution of 
NaHCO3, extracted with petrol (x3), the combined organic extracts were washed with brine, 
dried (Na2SO4), filetered and evaporated in vacuo affording a yellow oil. Chromatography 
(SP4, silica, EtOAc in Petrol, eluting 5-25%) gave a pale yellow oil (60 mg, 33%). Rf  0.45 
(EtOAc/Petrol (1:2)), mp 105-106 oC; 1H NMR (500 MHz, DMSO-d6) δ 10.59 (1H, s, -NH-
C(=O)), 8.56 (1H, d, J = 2.1 Hz, H-1), 8.36 (1H, dd, J = 9.0, 2.2 Hz, H-3), 8.21 (1H, d, J = 
9.0 Hz, H-2), 6.41 (1H, s, -OH), 3.84 (1H, d, J = 10.4 Hz, H-4a), 3.60 (1H, d, J = 10.4 Hz, H-
4b), 1.50 (s, 3H); (lit., Rf  0.63 (EtOAc/hexanes (1:1));	m.p. 101–102 oC. 1H NMR (DMSO-
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d6) 10.58 (s, N-H), 8.55 (1H, d, J = 2.0 Hz), 8.35 (1H, dd, J = 2.0, 9.0 Hz), 8.19 (1H, d, J = 
9.0 Hz), 6.41 (1H, s), 3.82 (1H, d, J = 10.5 Hz), 3.58 (1H, d, J = 10.5 Hz), 1.49 (3H, s, CH3)) 
(S)-2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)oxirane-2-carboxamide299(126) 
 
To a solution of (R)-3-bromo-2-hydroxy-2-methyl-N-(4-nitro-3-
(trifluoromethyl)phenyl)propanamide (0.23 g, 0.6 mmoles) in anhydrous acetone (5 mL) 
K2CO3 (171 mg, 1.24 mmoles) was added at room temperature. The mixture was stirred at 
60°C for 6 hours and then was treated with water, extracted with EtOAc (x3), the combined 
organic extracts were dried (Na2SO4), filtered and evaporated in vacuo affording a yellow oil. 
Chromatography (SP4, C18, CH3CN [0.1% NH3] in water [0.1% NH3], eluting 10-80%) gave 
a pale yellow oil (320 mg, 68%). mp 88-89 oC; 1H NMR (500 MHz, Methanol-d4) δ 7.95 
(1H, d, J = 9.0 Hz, H-1), 7.03 (1H, d, J = 2.5 Hz, H-2), 6.80 (1H, dd, J = 9.0, 2.5 Hz, H-3), 
2.65 (2H, s, -CH2-), 2.20 (3H, s, -CH3); 13C NMR (126 MHz, Methanol-d4) δ 154.0, 135.3, 
128.8, 123.6, 121.5, 114.2, 69.2, 54.6, 28.2 (2 missing carbon signals); (lit., mp 83-85 oC) 




To a solution of 4-chloro-2-nitrophenol (0.5 g, 2.9 mmoles) and K2CO3 (0.6 g, 4.3 mmoles) 
in anhydrous DMF (10 ml) (80%) propargyl bromide (0.42 mL, 3.8 mmoles) was added 
dropwise at 0°C under N2 atmosphere. The mixture was allowed to warm up to room 
temperature slowly and stirred for 16 hours, then was evaporated in vacuo. The residue was 
dissolved in water (10 mL), extracted with DCM (x3), the combined organic extracts were 
washed with brine, dried (Na2SO4), filtered and evaporated in vacuo affording a brown oil 
(592 mg, 97%) which was used in the next step without further purification. mp 81-82 oC; 
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LCMS (ESI)+ m/z = 210.6 [M + H]+; UV λmax (EtOH)/nm: 219.4; IR υmax/cm-1 3296, 2136, 
2088, 1910, 1773, 1608, 1571, 1511; 1H NMR (500 MHz, Methanol-d4) δ 7.90 (1H, d, J = 
2.6 Hz, H-1), 7.64 (1H, dd, J = 9.0, 2.6 Hz, H-2), 7.42 (1H, d, J = 9.0 Hz, H-3), 4.95 (2H, d, J 
= 2.4 Hz, -CH2-4), 3.12 (1H, t, J = 2.4 Hz, H-5); 13C NMR (126 MHz, Chloroform-d) δ 
150.5, 134.5, 126.6, 126.0, 118.4, 78.53, 78.52, 58.4 (1 missing carbon signal); not found by 
HRMS; (lit., mp 75-77 °C; 1H NMR (300 MHz, Chloroform-d) δ 7.84 (1H, d, J = 2.6 Hz), 
7.52 (1H, dd, J = 9.0, 2.6 Hz), 7.23 (1H, d, J = 9.0 Hz), 4.84 (2H, d, J = 2.4 Hz), 2.61 (1H, t, J 
= 2.4 Hz); 13C NMR (75 MHz, Chloroform-d) δ 149.5, 140.5, 133.8, 126.6, 125.6, 117.1, 
77.54, 76.8, 57.6) 
5-Chloro-2-(prop-2-yn-1-yloxy)aniline (130) 
 
To a solution of 4-chloro-2-nitro-1-(prop-2-yn-1-yloxy)benzene (6 g, 28.4 mmoles) in a 
mixture of dry ethanol (25 mL) and conc. HCl (2 mL) SnCl2.H2O (16 g, 70.9 mmoles) was 
added portionwise at room temperature under N2 atmosphere. The mixture was stirred at 
80oC for 16 hours and then allowed to cool down to room temperature. 2M aqueous NaOH 
solution was added and the pH adjusted to 12. The mixture was extracted with EtOAc (x3), 
the combined organic extracts were dried (Na2SO4), filtered and evaporated in vacuo 
affording a yellow oil which was filtered through an ionic exchange cartridge (SCX-2), 
washed with MeOH and subsequently with MeOH [0.1% NH3] affording a white solid (1.2 g, 
23%) which was used in the next step without further purification. LCMS (ESI)+ m/z = 182.3 
[M + H]+; UV λmax (EtOH)/nm: 243.6, 295.4; IR υmax/cm-1 3427, 3390, 3274, 2114, 1610, 
1492, 1445; 1H NMR (500 MHz, Methanol-d4) δ	6.89 (1H, d, J = 8.5 Hz, H-1), 6.75 (1H, d, J 
= 2.5 Hz, H-3), 6.60 (1H, dd, J = 8.5, 2.5 Hz, H-2), 4.75 (2H, d, J = 2.4 Hz, H-4), 2.98 (1H, t, 
J = 2.4 Hz, H-5); 13C NMR (126 MHz, Chloroform-d) δ 145.4, 140.3, 128.0, 117.8, 115.8, 
114.8, 79.8, 76.9, 57.4; HRMS calc. for C9H8ClNO [M+H]+ 182.0367, found 182.0371 
(lit.,301 IR υmax/cm-1 3472, 3380, 3291, 2122, 1614, 1504; 1H NMR (300 MHz, Chloroform-d) 
δ 6.78 (1H, d, J = 8.5 Hz), 6.68- 6.61 (2H, m), 4.65 (2H, d, J = 2.4 Hz), 3.85 (2H, br s), 2.52 ( 
1H, t, J = 2.4 Hz); 13C NMR (75 MHz, Chloroform-d) δ 143.7, 138.0, 127.1, 117.5, 115.0, 







A solution of 5-chloro-2-(prop-2-yn-1-yloxy)aniline (0.51 g, 2.8 mmoles), 4-chloro-2-methyl 
benzaldehyde (0.43 g, 2.8 mmoles) and ethyl isobutyrylacetate (0.52 g, 2.8 mmoles) in acetic 
acid (5 mL)  was stirred at 110oC for 24 hours. The solvent was evaporated in vacuo and the 
residue was co-evaporated with toluene affording a pale yellow oil. Chromatography (SP4, 
EtOAc in Petrol, eluting 35-90%) gave a brown oil (0.4 g, 31%). Rf 0.44 (silica, EtOAc in 
Petrol (6:4)); LCMS (ESI)+ m/z = 457.1 [M + H]+; UV λmax (EtOH)/nm: 253.0; IR υmax/cm-1 
2972, 2933, 1699, 1650, 1493, 1416; 1H NMR (500 MHz, Methanol-d4) δ 7.20 (1H, dd, J = 
8.9, 2.6 Hz, H-2), 7.06 (1H, d, J = 8.9 Hz, H-3), 7.02 (1H, dd, J = 8.4, 2.1 Hz, H-6), 6.96 (3H, 
m, H-1, H-5, H-7), 6.03 (1H, s, -H (chiral centre)), 4.71 (2H, t, J = 2.3 Hz, -CH2-4), 3.55 (1H, 
p, J = 6.8 Hz, H-8), 2.99 (1H, t, J = 2.3 Hz, H-10), 2.32 (3H, s, -CH3), 1.01 (3H, d, J = 6.8 
Hz, -CH3-9), 0.95 (3H, d, J = 6.8 Hz, -CH3-9); 13C NMR (126 MHz, Methanol-d4) δ 201.7, 
168.6, 158.1, 153.6, 141.2, 135.6, 134.0, 130.8, 130.6, 130.1, 128.2, 127.3, 127.1, 126.8, 
120.6, 115.9, 78.8, 77.9, 58.9, 57.6, 39.0, 19.4, 19.0, 18.1; HRMS calc. for C24H21Cl2NO4 






2-methoxy phenyl hydrazine hydrochloride (1.14 g, 6.6 mmoles) was added portionwise to  a 
stirred solution of 1-(5-chloro-2-(prop-2-yn-1-yloxy)phenyl)-5-(4-chloro-2-methylphenyl)-3-
hydroxy-4-isobutyryl-1,5-dihydro-2H-pyrrol-2-one (0.5 g, 1.1 mmoles) in dry EtOH (10 mL) 
and then a acetic acid (catalytic) was added to the mixture at room temperature under N2 
atmosphere. The mixture was stirred at 130oC for 16 hours and then was evaporated in vacuo 
affording a yellow oil. Chromatography (SP4, EtOAc in Petrol, eluting 1-20%) gave a pale 
yellow oil (480 mg, 79%). Rf 0.51 (silica, EtOAc in Petrol (6:4)); LCMS (ESI)- m/z = 559.1 
[M - H]-; UV λmax (EtOH)/nm: 287.6, 264.6; IR υmax/cm-1 2963, 2926, 2558, 1705, 1485; 1H 
NMR (500 MHz, Methanol-d4) δ 7.54 (1H, dd, J = 7.8, 1.6 Hz, H-2), 7.52 – 7.47 (1H, m, H-
11), 7.38 – 7.07 (7H, m, H-13, H-5, H-1, H-6, H-7, H-12, H-3), 7.05 (1H, d, J = 8.4 Hz, H-
14), 6.46 (1H, s, -H (chiral centre)), 6.27 (0.5H, s, -H (chiral centre)), 4.79 (2H, t, J = 12.0 
Hz, -CH2-4), 3.90 (3H, s, -CH3-15 (due to presence of conformers)), 3.87 (1.4H, s, -CH3-15 
(due to presence of conformers)), 2.92 (1H, hept, J = 7.1 Hz, H-8), 2.35 (3H, s, -CH3 (due to 
presence of conformers)), 2.05 (1.5H, s, (due to presence of conformers)), 1.14 (3H, t, J = 7.0 
Hz, -CH3-9), 0.95 (3H, dd, J = 7.0 Hz, -CH3-9); 13C NMR (126 MHz, Methanol-d4) δ 158.1, 
157.9, 154.0, 153.9, 152.7, 152.6, 152.2, 141.0, 140.7, 140.2, 138.8, 134.6, 133.9, 133.5, 
132.8, 131.9, 131.7, 131.3, 130.3, 130.2, 130.1, 129.93, 129.91, 129.1, 129.0, 128.6, 128.5, 
127.3, 126.8, 126.7, 126.6, 126.5, 126.4, 125.7, 125.50, 125.47, 120.27, 120.25, 114.6, 114.5, 
112.2, 112.1, 77.60, 77.55, 76.59, 76.56, 62.7, 56.5, 56.2, 56.1, 55.2, 55.1, 27.53, 27.47, 21.2, 
21.0, 20.6, 20.6, 17.9, 17.5 







To a stirred solution of 5-(5-chloro-2-(prop-2-yn-1-yloxy)phenyl)-4-(4-chloro-2-
methylphenyl)-3-isopropyl-2-(2-methoxyphenyl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(2H)-
one (10 mg, 0.02 mmoles) and (+)-L-sodium ascorbate (1 mg, catalytic) and copper (I) iodide 
(catalytic) in anhydrous THF (1 mL) 2-(2-(2-azidoethoxy)ethoxy)ethan-1-ol (3 mg, 0.01 
mmoles) in anhydrous THF (0.5 mL) was added at room temperature under N2 atmosphere. 
The mixture was stirred at 110oC for 1 hour under MW irradiation and then was evaporated 
in vacuo affording a yellow oil. Chromatography (SP4, MeOH in DCM, eluting 1-7%) gave a 
yellow oil (10 mg, 77%). Rf 0.42 (silica, MeOH in DCM (1:9)); LCMS (ESI)- m/z = 734.6 [M 
- H]-; UV λmax (EtOH)/nm: 287.2, 265.4; IR υmax/cm-1 3414, 2924, 2869, 2101, 1908, 1704, 
1596, 1559, 1493; 1H NMR (500 MHz, Methanol-d4) δ 8.07 (0.4 H, s, H-16 (due to presence 
of conformers)), 8.03 (0.6 H, s, H-16 (due to presence of conformers)), 7.55 – 7.42 (2H, m, 
H-1, H-11), 7.42 – 6.94 (7H, m, H-13, H-5, H-2, H-6, H-7, H-12, H-3), 6.97 (1H, d, J = 8.4 
Hz, H-14), 6.43 (0.6 H, s, -H-10 (chiral centre)), 6.29 (0.6 H, s, -H-10 (chiral centre)), 5.36 – 
5.03 (2H, m, -CH2-17), 4.61 – 4.45 (2H, m, -CH2-4), 3.88  - 3.80 (2H, m, -CH2-18), 3.79 (3H, 
d, J = 11.8 Hz, -CH3-15), 3.65 - 3.58 (2H, m, -CH2-(linker)), 3.56 – 3.51 (2H, m, -CH2-
(linker), 3.51 – 3.48 (2H, m, -CH2-(linker)), 3.47 – 3.43 (2H, m, -CH2-(linker)), 2.88 (1H, 
heptd, J = 7.0 Hz, -H-8), 2.32 (1.5 H, s, -CH3 (due to presence of conformers)), 1.95 (1.2 H, s, 
-CH3 (due to presence of conformers)), 1.08 (3H, dd, J = 7.0 Hz, -CH3-9 (due to presence of 
conformers)), 0.89 (3H, dd, J = 7.0 Hz, -CH3-9 (due to presence of conformers)); 13C NMR 
(126 MHz, Methanol-d4) δ 159.4, 159.2, 155.3, 154.5, 153.9, 153.5, 143.9, 142.3, 142.0, 
140.2, 138.9, 135.9, 135.2, 134.9, 134.3, 133.4, 133.0, 132.9, 131.6, 131.5, 131.3, 130.4, 
129.92, 129.88, 129.2, 128.7, 128.2, 128.1, 128.0, 127.9, 127.9, 127.2, 126.6, 126.6, 126.4, 
126.3, 121.6, 116.2, 116.1, 113.6, 113.5, 73.6, 71.33, 71.32, 70.2, 63.6, 63.3, 63.1, 62.2, 57.7, 







To a solution of triethyeleneglycol (7.9 g, 53 mmoles) and triethylamine (1.1 mL, 7.9 
mmoles) in anhydrous DCM (10 mL) was added para-toluenesulfonyl chloride (1 g, 5.3 
mmoles) portionwise at 0oC under N2 atmosphere. The mixture was allowed to warm to room 
temperature slowly and stirred for 16 hours and then was washed with saturated aqueous 
solution of NaHCO3, brine, the organic layer separated, dried (Na2SO4), filtered and 
evaporated in vacuo affording a pale yellow oil (1.1 g, 69%) which was used in the next step 
without further purification. 1H NMR (500 MHz, DMSO-d6) δ 7.79 (2H, d, J = 8.2 Hz, H-2, 
H-2’), 7.49 (2H, d, J = 8.2 Hz, H-1, H-1’), 4.57 (1H, br s, -OH-5), 4.16 – 4.06 (2H, m, -CH2-
4), 3.62 – 3.54 (2H, m, -CH2-(linker)), 3.50 – 3.33 (8H, m, -CH2-(linker)), 2.43 (3H, s, -CH3-
3); 13C NMR (126 MHz, DMSO-d6) δ 145.4, 132.9, 130.6 (x2), 128.1 (x2), 72.8, 70.5, 70.2, 
70.1, 68.4, 60.7, 21.6; (lit., 1H NMR (300 MHz, Chloroform-d) δ 7.78 (2H, d, J = 8.2 Hz), 
7.33 (2H, d, J = 8.2 Hz), 4.14-4.16 (2H, m), 3.53-3.70 (10H, m), 2.51 (1H, s, OH), 2.43 (3H, 




To a solution of 2-(2-(2-hydroxyethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (1.1 g, 3.8 
mmoles) in anhydrous DMF (20 mL) was added NaN3 (0.31 g, 4.8 mmoles) at room 
temperature under N2 atmosphere. The mixture was stirred at 100oC for 20 hours and then 
was treated with brine (20 mL), extracted with EtOAc (x3), the combined organic extracts 
were washed with brine (x2), dried (Na2SO4), filtered and evaporated in vacuo affording a 
colourless oil. Chromatography (SP4, EtOAc in Petrol, eluting 40-90%) gave a colourless oil 
(0.4 g, 67%). 1H NMR (500 MHz, Chloroform-d) δ 3.77-3.72 (2H, m, -CH2-1), 3.68 (6H, s, -
CH2-(linker)), 3.64-3.60 (2H, m, -CH2-2), 3.43-3.37 (2H, m, -CH2-3); 13C NMR (125 MHz, 
Chlroroform-d) δ 72.5, 70.6, 70.4, 70.0, 61.7, 50.6; (lit., 1H NMR (250 MHz, Chloroform-d) 
δ: 3.77-3.60 (10H, m), 3.41 (2H, t, J = 5.0 Hz); 13C NMR (63 MHz, Chloroform-d) δ: 72.2, 







3, 6, 9, 12-Tetraoxatetradecane-1,14-di-yl bis(4-methylbenzenesulfonate)304 (138) (n=5) 
 
To a stirred solution of 3,6,9,12-tetraoxatetradecane-1,14-diol (4.11 g, 17.2 mmol) in DCM 
(50 ml) was added para-toluenesulfonyl chloride (6.58g, 34.5 mmol) at 0°C under N2 
atmosphere. KOH (7.69 g, 137 mmol) was ground up and added cautiously to the mixture 
and stirred at 0°C for 3 hours. The mixture was treated with water (50 ml), extracted with 
DCM (x3), the combined organic extracts were washed with brine, dried (Na2SO4), filetered 
and evaporated in vacuo affording a yellow oil (6.4 g, 68%). LCMS (ESI)+ m/z = 547.1 [M + 
H]+; UV λmax (EtOH)/nm: 224.6; IR υmax/cm-1 2869, 1597, 1451; 1H NMR (500 MHz, 
Methanol-d4) δ 7.81 (4H, d, J = 8.2 Hz, H-1, H-1’, H-1’’, H-1’’’) 7.46 (4H, d, J = 8.2 Hz, H-
2, H-2’, H-2’’, H-2’’’), 4.19 – 4.13 (4H, m, -CH2-3 (x2)), 3.68 – 3.65 (4H, m, -CH2-(linker)), 
3.59 (4H, s, -CH2-(linker)), 3.59–3.54 (8H, s, - CH2-(linker)), 2.47 (6H, s, -CH3-4);13C NMR 
(126 MHz, Methanol-d4) δ 145.1 (x2), 133.1 (x2), 129.7 (x4), 127.7 (x4), 70.2 (x4), 70.1 
(x2), 69.6 (x2), 68.3 (x2), 20.3 (x2); (lit., 1H-NMR (400 MHz, Chloroform-d) δ 7.79 (4H, d, J 
= 8.4 Hz), 7.34 (4H, d, J = 8.5 Hz), 4.17 – 4.14 (4H, m), 3.69 – 3.67 (4H, m), 3.60 – 3.58 
(12H, m), 2.44 (6H, s); 13C-NMR (100 MHz, Chloroform-d) δ 145, 133, 130, 128, 70.9, 70.8, 
70.7, 69.4, 68.9, 21.8) 
1,14-Diazido-3,6,9,12-tetraoxatetradecane305 (n=5) (139)  
 
To a stirred solution of 3,6,9,12-tetraoxatetradecane-1,14-diyl bis(4-methylbenzenesulfonate) 
(5.53 g, 10.1 mmol) and tetrabutylammonium iodide (0.187 g, 5 mol%) NaN3 (2.63 g, 40.5 
mmol) was added at room temperature under N2 atmosphere. The mixture stirred at 80°C for 
18 hours and then the precipitated formed was filtered through a sintered funnel and dried in 
vacuo affording a yellow oil (1.83 g, 63%). LCMS (ESI)+ m/z = 289.2 [M + H]+; UV λmax 
(EtOH)/nm: 283.4; IR υmax/cm-1 2865, 2099, 1677; 1H NMR (500 MHz, Methanol-d4) δ 3.70 
(4H, t, J = 4.8 Hz, -CH2-1), 3.68 (12H, s, -CH2-(linker)), 3.40 (4H, t, J = 4.8 Hz, CH2-2); 13C 
NMR (126 MHz, Methanol-d4) δ 70.3 (x4), 70.2 (x2), 69.8 (x2), 50.4 (x2); (lit., 1H NMR 
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(300 MHz, Chloroform-d) δ 3.67 (12H, m), 3.38 (4H, t); 13C NMR (500 MHz, Chloroform-d) 
δ 70.97, 70.97, 70.29, 50.94) 
 14-Azido-3,6,9,12-tetraoxatetradecan-1-amine (n=5) (140)  
 
To a solution of 1,14-diazido-3,6,9,12-tetraoxatetradecane (2.7 g, 9.4 mmol), Et2O (6 ml), 
EtOAc (6 ml) and 2M HCl (9.50 ml), Ph3P (2.45 g, 9.4 mmol) was added at room 
temperature under N2 atmosphere. The mixture was stirred at room temperature for 24 hours 
and then was treated with water, washed with DCM (x3) and the aqueous layer separated, 
treated with 2M aqueous NaOH solution (10 ml) and the pH adjusted to 10. The aqueous 
layer was extracted with DCM (x3), the combined organic extracts were dried (Na2SO4), 
filtered and evaporated in vacuo affording a yellow oil (1.2 g, 49%). LCMS (ESI)+ m/z = 
263.2 [M + H]+; UV λmax (EtOH)/nm: 272.4, 265.6; IR υmax/cm-1 2863, 2097, 1594, 1452, 
1347, 1285; 1H NMR (500 MHz, Methanol-d4) δ 3.71–3.65 (14H, m, -CH2-(linker)), 3.55 
(2H, t, J = 5.3 Hz, -O-CH2-), 3.40 (2H, t, J = 5.3 Hz,  NH2-CH2-), 2.81 (2H, t, J = 5.3 Hz, -
CH2-N3); 13C NMR (126 MHz, Methanol-d4) δ 73.8, 77.42, 72.37 (x4), 72.1, 71.9, 52.6, 42.8; 
(lit.,306 1H NMR (400 MHz, Chloroform-d) δ 3.66-3.61 (16 H, m), 3.48 (2 H, t, J = 5.2 Hz), 
3.37 (2 H, t, J = 5.2 Hz), 2.84 (2 H, br); 13C NMR (100 MHz, Chloroform-d) δ 73.5, 70.7 
(2Χ), 70.6 (3Χ), 70.3, 70.0, 50.8, 42.0) 
 
((Oxybis(ethane-2,1-diyl))bis(oxy))bis(ethane-2,1-diyl) bis(4-methylbenzenesulfonate) 
(n=4) (138)  
 
To a stirred solution of 2,2'-((oxybis(ethane-2,1-diyl))bis(oxy))bis(ethan-1-ol) (10 g, 52  
mmol) in anhydrous DCM (100 mL) para-toluenesulfonyl chloride (19.6 g, 103 mmol) was 
added at 0°C under N2 atmosphere. KOH (23.1 g, 412 mmol) was ground up and added 
cautiously to the mixture and stirred at 0°C for 3 hours. The mixture was treated with water 
(50 mL), extracted with DCM (x3), the combined organic extracts were dried (Na2SO4), 
filtered and evaporated in vacuo affording a pale yellow oil (17.95 g, 69%). LCMS (ESI)+ 
m/z = 503.1 [M + H]+; UV λmax (EtOH)/nm: 224.4; IR υmax/cm-1 2871, 1597, 1451; 1H NMR 
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(500 MHz, Methanol-d4) δ 7.82 (4H, d, J = 8.3 Hz, H-1, H-1’, H-1’’, H-1’’’), 7.46 (4H, d, J = 
8.3 Hz, H-2, H-2’, H-2’’, H-2’’’), 4.17 (4H, t, J = 4.6 Hz, -CH2-3), 3.67 (4H, t, J = 4.6 Hz, -
O-CH2-(linker)), 3.55 (8H, s, -CH2-O-(linker)), 2.47 (6H, s, -CH3-4); 13C NMR (126 MHz, 
Methanol-d4) δ 147.3 (x2), 135.3 (x2), 131.9 (x4), 129.9 (x4), 72.4 (x2), 72.4 (x2), 71.8 (x2), 
70.6 (x2), 22.4 (x2); (lit.,307 1H NMR (400 MHZ, Chloroform-d) δ 7.80 (4H, d, J = 8.2 Hz), 
7.35 (4H, d, J = 8.2 Hz), 4.16 (4H, t, J = 4.7 Hz), 3.68 (4H, t, J = 4.7 Hz), 3.57 (8H, s), 2.45 
(6H, s); 13C NMR (400 MHz, Chloroform-d) δ 144.8, 133.0, 129.8, 128.0, 70.7, 70.5, 69.3, 
68.7, 21.6) 
 
1-Azido-2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethane (n=4) (139)  
 
To a stirred solution of ((oxybis(ethane-2,1-diyl))bis(oxy))bis(ethane-2,1-diyl) bis(4-
methylbenzenesulfonate) (16.33 g, 32.5 mmol) and tetrabutylammonium iodide (0.6 g, 5 
mol%) in anhydrous DMF (60 mL) NaN3 (8.45 g, 130 mmol) was added at room temperature 
under N2 atmosphere. The mixture stirred at 80°C for 18 hours and then, the precipitate 
formed was filtered through a syntered funnel and dried in vacuo affording a yellow oil (6.97 
g, 88%). LCMS (ESI)+ m/z = 245.1 [M + H]+; UV λmax (EtOH)/nm: 283.8; IR υmax/cm-1 2866, 
2091, 1677; 1H NMR (500 MHz, Methanol-d4) δ 3.71–3.67 (12H, m, -O-CH2-(linker)), 3.40 
(4H, t, J = 4.90 Hz, -CH2-1); 13C NMR (126 MHz, Methanol-d4) δ 72.6 (x2), 72.4 (x2), 72.0 
(x2), 52.6 (x2); (lit.,308 1H NMR (400 MHz, Chloroform-d) δ 3.68 (12H, t, J = 6.7 Hz), 3.40 
(4H, t, J = 6.7 Hz). 13C NMR (100 MHz, Chloroform-d) δ 70.9 (x2), 70.2 (x4), 50.8 (x2)) 
(S)-4-(2-Hydroxy-2-methyl-3-((4-nitro-3-(trifluoromethyl)phenyl)amino)-3-
oxopropoxy)benzenaminium 2,2,2-trifluoroacetate (127) 
 
To a solution of (S)-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)oxirane-2-carboxamide 
(200 mg, 0.69 mmoles) in IPA (20 mL) and K2CO3 (238 mg, 1.7 mmoles) N-Boc-4-
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hydroxyaniline (144 mg, 0.69 mmoles) was added at room temperature under N2 atmosphere. 
The mixture was stirred at 80oC for 4 hours and then treated with saturated aqueous solution 
of NaHCO3, extracted with DCM (x3), the combined organic extracts were washed with 
brine, dried (Na2SO4), filtered and evaporated in vacuo affording a yellow oil. 
Chromatography (SP4, MeOH in DCM, eluting 1-10%) gave a pale yellow oil (208 mg, 
60%). LCMS (ESI)+ m/z = 400.1 [M + H]+ Then the oil was dissolved in TFA/DCM (1:1) (4 
mL) and stirred at room temperature for 16 hours, then was evaporated in vacuo affording a 
white solid (90 mg, 54%) that was confirmed by LCMS and used in the next steps without 





To a solution of (S)-3-(4-aminophenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-
(trifluoromethyl)phenyl)propanamide (100 mg, 0.25 mmol) and propiolic acid (26 mg, 0.38 
mmol) in anhydrous THF (2 ml) 4-dimethylaminopyridine (0.3 mg, 1 mol%) was added at 
room temperature. The mixture was stirred for 10 minutes at 0°C and then 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrogen chloride (73 mg, 0.38 mmol) was added. The 
mixture was stirred for 1 hour and then was diluted with DCM and washed with NH4Cl (x3). 
The organic layer was separated, dried (Na2SO4), filtered and evaporated in vacuo affording a 
brown oil (79 mg, 70%). LCMS (ESI)+ m/z = 450.1 [M + H]+; UV λmax (EtOH)/nm: 282.6; IR 
υmax/cm-1 3277, 2929, 2105, 1645, 1596, 1509, 1415; 1H NMR (500 MHz, Methanol-d4) δ 1H 
NMR (500 MHz, Methanol-d4) δ 8.40 (1H, d, J = 2.3 Hz, H-3), 8.21 (1H, dd, J = 9.0, 2.3 Hz, 
H-2), 8.08 (1H, d, J = 9.0 Hz, H-1), 7.49 (2H, d, J = 9.1 Hz, H-6, H-6’), 6.95 (2H, d, J = 9.1 
Hz, H-5, H-5’), 4.34 (1H, d, J = 9.5 Hz, H-4a), 4.05 (1H, d, J = 9.5 Hz, H-4b), 3.76 (1H, ddd, 
J = 6.6, 4.2, 2.5 Hz, -OH), 1.94 – 1.87 (1H, m, H-7), 1.56 (3H, s, -CH3); 13C NMR (126 
MHz, Methanol-d4) δ 210.9, 201.7, 177.0, 175.8, 128.8, 125.1, 123.7 (x2), 116.9 (x2), 77.4, 








To a solution of (S)-3-(4-aminophenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-
(trifluoromethyl)phenyl)propanamide (90 mg, 0.23 mmoles) in THF (1.5 mL) and DIPEA (41 
uL, 0.23 mmoles) chloroacetyl chloride (18 µL, 0.23 mmoles) was added at 0oC under N2 
atmosphere. The mixture was allowed to warm up to room temperature slowly and stirred 
under for 3 hours, then was treated with EtOAc and washed with 2M aqueous HCl solution 
and brine. The organic layer was separated, dried (Na2SO4), filtered and evaporated in vacuo 
affording a yellow oil (107 mg, 99.99%) which was used without further purification. LCMS 





To a solution of (S)-N-(4-(2-hydroxy-2-methyl-3-((4-nitro-3-(trifluoromethyl)phenyl)amino)-
3-oxopropoxy)phenyl)propiolamide (80 mg, 0.17 mmol), 14-azido-3,6,9,12-
tetraoxatetradecan-1-amine (53 mg, 0.2 mmol) in anhydrous DMF (2 ml), K2CO3 (29.2 mg, 
0.21 mmol) was added at room temperature under N2 atmosphere. The mixture was stirred at 
100°C for 3 hours and then was treated with saturated aqueous solution of NaHCO3, 
extracted with DCM (x3), the combined organic extracts were washed with brine, dried 
(Na2SO4), filtered and evaporated in vacuo affording a yellow oil. Chormatography (SP4, 
MeOH in DCM, eluting 1-10%) gave a yellow oil (41 mg, 35%). LCMS (ESI)- m/z = 700.3 
[M - H]-; UV λmax (EtOH)/nm: 250.6; IR υmax/cm-1 3296, 2868, 2100, 1672, 1595, 1509, 
1414; 1H NMR (500 MHz, Methanol-d4) δ 8.40 (1H, d, J = 2.1 Hz, H-3), 8.20 (1H, dd, J = 
8.9, 2.1 Hz, H-2), 8.07 (1H, d, J = 8.9 Hz, H-1), 7.50 (2H, d, J = 9.0 Hz, H-6), 6.94 (2H, d, J 
= 9.0 Hz, H-5), 4.34 (1H, d, J = 9.5 Hz, H-4a), 4.04 (1H, d, J = 9.5 Hz, H-4b), 3.76 (1H, t, J 
= 6.6 Hz, -OH), 3.69 – 3.58 (16H, m, -CH2-(linker)), 3.42 (2H, s, -CH2-7), 3.39 – 3.35 (2H, 
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m, -CH2-8), 2.89 – 2.80 (2H, m, -CH2-9), 1.56 (3H, s, -CH3); 13C NMR (126 MHz, Methanol-
d4) δ 210.9, 177.0, 172.9, 157.8, 144.8, 133.8, 128.8, 123.6 (x2), 120.5, 116.9 (x2), 77.4, 
76.0, 72.5, 72.44, 72.39, 72.36, 72.14, 72.11, 71.9, 69.7, 54.1, 52.6, 50.7, 31.5, 24.0 (2 







To a stirred solution of 5-(5-chloro-2-(prop-2-yn-1-yloxy)phenyl)-4-(4-chloro-2-
methylphenyl)-3-isopropyl-2-(2-methoxyphenyl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(2-H)-
one (24 mg, 0.043 mmol), (+)-L-sodium ascorbate (catalytic) and 1mg of copper (II) sulfate 
pentahydrate (catalytic) in anhydrous THF (1 ml) tris[(1-benzyl-1H-1,2,3-triazol-4-
yl)methyl]amine (2 mg, 0.01 mmol) was added at room temperature under N2 atmosphere. 
The mixture was stirred at 110°C for 1.5 hours under microwave irradiation. Then 1 mg of 
copper (II) sulfate pentahydrate was added and the reaction was re-subjected to the same 
conditions as described before, then the solvent was evaporated in vacuo affording a yellow 
oil. Chromatography (SP4, MeOH in DCM, eluting 1-7%) gave a colourless oil (15 mg, 
25%). Rf 0.58 (silica, MeOH in DCM (1:99)); LCMS (ESI)- m/z = 1260.0 [M - H]-; UV λmax 
(EtOH)/nm: 285.5; IR υmax/cm-1 3308, 3128, 3072, 2920, 2869, 1697, 1595, 1509, 1457, 
1413; 1H NMR (500 MHz, Methanol-d4) δ 8.39 (1H, d, J = 2.1 Hz, H-3), 8.18 (1H, d, J = 8.9 
Hz, H-2), 8.04 (2H, m, H-1, H-10), 7.55 – 7.48 (2H, m, H-13, H-19), 7.47 (2H, d, J = 8.9 Hz, 
H-6, H-6’), 7.42 – 6.96 (7H, m, H-21, H-15, H-12, H-15, H-14, 20, H-11), 6.91 (2H, d, J = 
8.9 Hz, H-5, H-5’), 6.43 (0.6 H, d, J = 73.4 Hz, H-23, 6.29 (0.4 H, d, J = 73.4 Hz, H-23, 5.31 
– 5.13 (2H, m, H-9), 4.45 – 4.58 (2H, m, -CH2-15), 4.33 (1H, d, J = 9.5 Hz, H-4a), 4.02 (1H, 
d, J = 9.5 Hz, H-4b), 3.83 (5H, m, -CH3-24, -CH2-7), 3.70 – 3.37 (16H, m, -CH2-(linker)), 
2.90 (1H, pd, J = 7.0, 3.0 Hz, -H-17), 2.83 (2H, d, J = 5.0 Hz, H-8), 2.12 (d, J = 148.5 Hz, -
CH3), 1.10 (3H, dd, J = 7.0, 1.7 Hz, H-18), 0.96 (2H, dd, J = 7.0 Hz, -CH3-18’), 0.88 (1H, dd, 
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J = 7.0 Hz, -CH3-18’); 13C NMR (126 MHz, Methanol-d4) δ 177.0, 157.8, 156.2, 155.4, 
154.8, 145.1, 141.1, 136.1, 135.8, 135.2, 134.3, 133.8, 132.4, 131.3, 130.8, 129.4, 128.8, 
128.1, 127.5, 126.0, 125.1, 123.6 (x2), 122.5, 120.6, 117.0 (x2), 114.5, 77.4, 76.1, 71.1, 64.2, 
58.6, 57.5, 53.8, 52.3, 29.7, 24.0, 23.3, 22.9, 20.0, 19.6; Analytical HPLC purity: 91.2% 







To a stirred solution of 5-(5-chloro-2-(prop-2-yn-1-yloxy)phenyl)-4-(4-chloro-2-
methylphenyl)-3-isopropyl-2-(2-methoxyphenyl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(2-H)-
one (50 mg, 0.089 mmol) and 1-azido-2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethane (218 
mg, 0.892 mmol), (+)-L-sodium ascorbate (catalytic) and copper (II) sulfate pentahydrate 
(catalytic) in anhydrous THF (1 ml) tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (5 mg, 
0.01 mmol) was added at room temperature under N2 atmosphere. The mixture was stirred at 
110°C for 1 hour under MW irradiation and then filtered through a sintered funnel and dried 
in vacuo affording a yellow oil (50 mg, 69%) which was used for the next step without 
further purification. LCMS (ESI)- m/z = 803.3 [M - H]-; UV λmax (EtOH)/nm: 287.2, 265.8; 
IR υmax/cm-1 2867, 2097, 1710, 1595, 1559, 1493, 1460, 1413; 1H NMR (500 MHz, 
Methanol-d4) δ 8.09 (0.4H, s, H-16), 8.05 (0.6H, s, H-16), 7.57 – 7.46 (2H, m, H-1, H-11), 
7.42 – 7.08 (7H, m, H-13, H-5, H-2, H-6, H-7, H-12, H-3), 7.00 (d, J = 8.3 Hz, H-14), 6.44 
(0.6H, s, H-10), 6.29 (0.4H, s, H-10) 5.34 – 5.17 (2H, m, -CH2-17),  4.64 – 4.51 (2H, m, -
CH2-4), 3.93 – 3.80 (5H, m, -CH2-(linker), -CH3-15), 3.64 – 3.47 (12H, m, -CH2-(linker)), 
3.40 (2H, t, J = 4.9 Hz, -CH2-17), 2.91 (1H, pd, J = 7.0 Hz, H-8), 2.28-1.98 (3H, d, J = 
149.91 Hz, -CH3), 1.12 (3H, dd, J = 7.0 Hz, -CH3-9), 0.93 (3H, dd, J = 7.0 Hz, -CH3-9’); 13C 
NMR (126 MHz, Methanol-d4) δ 158.0, 153.9, 153.2, 152.6, 152.1, 141.0, 140.6, 138.9, 
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134.5, 133.8, 133.6, 133.0, 132.0, 131.7, 131.5, 130.3, 130.1, 130.0, 129.0 (x2), 128.6, 128.5, 
127.3, 126.9, 126.8, 126.7, 126.6, 126.5, 125.8, 125.3, 125.2, 125.2, 120.3 (x2), 114.8, 114.7, 
112.2, 112.1, 70.3, 70.20, 70.17, 70.14, 70.09, 70.0, 69.74, 69.67, 68.9, 62.0, 61.8, 56.4, 







To a stirred solution of 5-(2-((1-(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-
triazol-4-yl)methoxy)-5-chlorophenyl)-4-(4-chloro-2-methylphenyl)-3-isopropyl-2-(2-
methoxyphenyl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(2H)-one (40 mg, 0.05 mmol), (S)-N-(4-
(2-hydroxy-2-methyl-3-((4-nitro-3-(trifluoromethyl)phenyl)amino)-3 
oxopropoxy)phenyl)propiolamide (22 mg, 0.05 mmol), (+)-L-sodium ascorbate (catalytic), 
copper (II) sulfate pentahydrate (catalytic) in THF (1 ml) tris[(1-benzyl-1H-1,2,3-triazol-4-
yl)methyl]amine (3 mg, 0.01 mmol) was added at room temperature under N2 atmosphere. 
The mixture was stirred at 110°C for 1 hour under microwave irradiation and then was 
purified by Semi-Prep HPLC (SCX, Acetonitrile/Water +0.1% formic acid, 5/95 to 100/0) 
affording a dark brown oil (10 mg, 15%). LCMS (ESI)+ m/z = 1255.4 [M + H]+; UV λmax 
(EtOH)/nm: 285.2; IR υmax/cm-1 3345, 3073, 2923, 2867, 2100, 1706, 1596, 1559, 1494, 
1413; 1H NMR (500 MHz, Methanol-d4) 8.47 (1H, d, J = 2.8 Hz, Ar-H), 8.14 (1H, d, J = 9.5 
Hz, Ar-H), 8.02-7.97 (1H, m, Ar-H), 7.59 (1H, d, J = 8.9 Hz, Ar-H), 7.55-7.45 (2H, m, 2×Ar-
H), 7.32-6.95 (10H, m, 10×Ar-H), 6.44-6.28 (1H, m, -C*-H), 5.29-5.12 (2H, m, -O-CH2-
CH2-N), 4.62-4.49 (2H, m, Ar-O-CH2-C-), 4.35 (1H, d, J = 9.5 Hz, -C(Me)(OH)-CH2-O-), 
4.05 (1H, dd, J = 9.5, 1.1 Hz, -C(Me)(OH)-CH2-O-), 3.90-3.80 (5H, m, O-CH2-CH2-N, Ar-
O-CH3), (3.63-3.44 (10H, m, 5×-CH2-), 3.38 (12H, s, 6×-CH2-), 2.91 (1H, h, J = 7.1 Hz, -
CH(Me)2), 2.28-1.97 (3H, m, Ar-CH3), 1.56-1.32 (3H, m, -C*-CH3), (1.13-1.08 (3H, m, -CH-
(CH3)2), 0.98-0.86 (3H, m, -CH-(CH3)2); 13C NMR (126 MHz, Methanol-d4) δ 177.0, 161.2, 
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158.1, 156.2, 155.4, 154.4, 145.1, 144.8, 142.9, 142.3, 141.1, 136.1, 135.8, 135.1, 134.3, 
133.9, 133.5, 132.5, 132.4, 132.2, 131.3, 130.8, 129.5, 129.4, 129.1, 129.0, 128.82, 128.78, 
128.0, 127.5, 127.3, 125.0, 124.4, 122.5, 117.1, 116.9, 114.5, 77.4, 76.0, 72.4, 72.34, 72.30, 
72.26, 72.2, 71.9, 71.12, 71.06, 70.9, 64.2, 57.4, 57.3, 52.6, 52.4, 52.3, 52.3, 29.7, 24.0, 23.4, 
23.2, 22.9, 22.8, 20.0, 19.6; Analytical HPLC purity: 100% (CH3CN [0.1% formic acid]), 






To a stirred solution of 5-(5-chloro-2-((1-(2-(2-(2-hydroxyethoxy)ethoxy)ethyl)-1H-1,2,3-
triazol-4-yl)methoxy)phenyl)-4-(4-chloro-2-methylphenyl)-3-isopropyl-2-(2-
methoxyphenyl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(2H)-one (0.1 g, 0.14 mmoles) in 
anhydrous THF (5 mL) sodium hydride (60%) (3.6 mg, 0.15 mmoles) was added at 0oC 
under N2 atmosphere. The mixture was stirred at 0oC for 30 minutes and then (S)-2-Methyl-
N-(4-nitro-3-(trifluoromethyl)phenyl)oxirane-2-carboxamide (42 mg, 0.14 mmoles) at 0oC 
under N2 atmosphere. Then the mixture was stirred at room temperature for 5 hours and then 
treated with saturated aqueous solution of NaHCO3, extracted with DCM (x3), the combined 
organic extracts were washed with brine, dried (Na2SO4), filtered and evaporated in vacuo 
affording a yellow oil. Chromatography (SP4, MeOH in DCM, eluting 1-10%) gave a pale 
white solid (7 mg, 5%). LCMS (ESI)+ m/z = 1025.3 [M + H]+; UV λmax (EtOH)/nm: 260.8; IR 
υmax/cm-1 728, 800, 834, 919, 1043, 1139, 1249, 1321, 1418, 1476, 1510, 1594, 1672, 2866, 
2923, 3180, 3242, 3317; 1H NMR (500 MHz, Chloroform-d) δ 9.74 (1H, br s, -NH(C=O)), 
8.20 (1H, d, J = 2.0 Hz, H-2), 8.08 (1H, dd, J = 8.9, 2.2 Hz, H-3), 7.96 (1H, d, J = 8.9 Hz, H-
1), 7.90 (1H, s, H-11), 7.59 (1H, dd, J = 7.8, 1.7 Hz, H-18), 7.44 (1H, d, J = 8.2 Hz, H-14), 
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7.38 (1H, td, J = 7.9, 1.7 Hz, H-20), 7.24 (1H, d, J = 2.0 Hz, H-12), 7.20 (1H, dd, J = 8.3, 2.1 
Hz, H-13), 7.09 (1H, td, J = 7.7, 1.2 Hz, H-19), 7.01 – 6.93 (3H, m, H-7, H-21, H-9, H-10 ), 
5.35 (2H, s, -CH2-8), 4.48 (2H, qdd, J = 14.4, 6.1, 4.0 Hz, -CH2-), 3.96 (1H, d, J = 9.8 Hz, H-
4a), 3.85 (2H, dq, J = 10.5, 6.5 Hz, -CH2-), 3.66 (s, 3H, s, -O-CH3-22), 3.64 – 3.53 (2H, m, -
CH2-), 3.50 – 3.44 (4H, m, 2x-CH2-), 3.43 (d, J = 9.7 Hz, H-4b), 2.67 (1H, hept, J = 6.9 Hz, 
H-16), 2.46 (3H, s, H-23), 1.40 (3H, s, -CH3-5), 1.19 (6H, d, J = 6.8 Hz, 2x (-CH3), H-17, H- 
17’); 13C NMR (126 MHz, Methanol-d4) δ 194.0, 174.2, 158.3, 157.4, 152.6, 145.5, 143.3, 
142.1, 140.0, 139.9, 137.9, 131.7, 131.6, 130.1, 129.1, 128.6, 127.1, 126.7, 125.9, 124.3, 
124.0, 122.1, 121.2, 120.4, 119.6, 118.4, 113.1, 111.9, 76.0, 75.9, 71.0, 70.4, 70.3, 70.2, 69.2, 
63.0, 55.6, 50.4, 27.0, 22.9, 22.4, 22.3, 20.3; Analytical HPLC purity: 100% (CH3CN [0.1% 
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